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ABSTRACT 
DESIGN, SYNTHESIS, AND CHARACTERIZATION OF DIMERIC LYSOSOMAL 
INHIBITORS AND THEIR EFFECT ON CANCER BIOLOGY 
Michael C. Nicastri 
Jeffrey D. Winkler 
 When detected early and surgically removed, melanoma has a cure rate greater 
than 90%. However, when the cancer is either unresectable or goes undetected until late-
stage metastases develop, the five-year survival rate drops to 20%. Unfortunately, the 
current standard of care suffers from chemotherapeutic resistance, where the outcome 
results in a high rate of patient mortality. Recent clinical studies have demonstrated 
hydroxychloroquine-mediated inhibition of autophagy presents a promising strategy as an 
adjuvant therapy for melanoma treatment. Regrettably, in clinical trials 
hydroxychloroquine has not demonstrated reliable potency, at the maximum tolerated 
doses, in producing autophagy inhibition. 
 Work by the Winkler and Amaravadi Laboratories has focused on developing a 
series of dimeric chloroquine-based autophagy inhibitors. Our findings encouraged us to 
develop a library of dimeric inhibitors, based on hydroxychloroquine and its congener, 
quinacrine. These not only inhibit autophagy, but also possess single agent anti-cancer 
activity previously unobserved with small-molecule autophagy inhibitors. Through our 
efforts we have designed DQ661, a dimeric quinacrine autophagy inhibitor which 
simultaneously inhibits key drivers of oncogenesis: autophagy, mTOR kinase signaling, 
and macropinocytosis. We have also discovered an analogous dimeric chloroquine 
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inhibitor, DC661, which is a potent inhibitor of autophagy and cancer cell proliferation. 
Utilizing these compounds, we have identified a molecular binding partner for our 
dimeric inhibitors: protein palmitoyl thioesterase 1 (PPT1), a key regulator of 
palmitoylation within the lysosome. We are currently developing chemical tools to study 
the role of PPT1 in cancer biology.   
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CHAPTER 1: STUDY OF AUTOPHAGY INHIBITION IN MELANOMA 
 Malignant melanoma presents a significant challenge to public health. While early 
detection and surgical resection lead to a 90% cure rate, malignancies which cannot be 
removed present a severe health risk. Patients diagnosed with unresectable melanoma 
have a poor prognosis, with a five-year survival rate under 20%. This population of 
melanoma patients performs poorly in a clinical setting, experiencing high rates of 
metastases and acquired chemotherapeutic resistance.1 
Advances in genome sequencing have elucidated specific mutations in regulatory 
pathways which have been found to be pro-tumorigenic. In melanoma, approximately 
52% of malignancies have a mutation in BRAF kinase (V600E).2 BRAF is a 
serine/threonine kinase involved in mitogen activated protein kinase pathway (MAPK) 
signaling, a key regulator of cell growth and proliferation. Aberrant MAPK signaling is 
found in a large number of human cancers.3  The prevalence of mutations in BRAF 
kinase in melanoma has driven multiple small molecule drug discovery efforts aimed at 
modulating the BRAF/MAPK pathways. Specifically, these efforts have led to the 
synthesis, validation, clinical trials, and FDA approval of multiple kinase inhibitors 
which now represent the first course of treatment. MEK, mitogen activated protein 
kinase, is a second kinase which is hyperactive within cancers with aberrant MAPK 
signaling. Clinical trials have demonstrated that patients with BRAF-mutant melanoma 
benefit from treatment with MEK inhibitors.4 The current standard of care for melanoma 
with a BRAF mutation is the combination of dabrafenib and trametinib, kinase inhibitors 
of  BRAF and MEK, respectively.5 Unfortunately, while these treatments can 
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demonstrate immediate efficacy in a clinical setting, they lack durability, with significant 
patient populations acquiring chemotherapeutic resistance. 6  
Immunotherapy has shown significant promise as a new strategy for treating 
metastatic melanoma. PD-1 checkpoint blockade and adoptive T-cell therapy (ACT) have 
been shown to elicit a response in approximately a third of treated patients.7 While 
immunotherapy has shown strong durability in patients with melanoma, only a select 
group among the patient population exhibits a positive response.8,9 The limited success of 
immunotherapy underscores the unmet medical need for further therapeutic strategies for 
melanoma treatment. 
Metastatic melanoma relies heavily on the use of cellular autophagy to further cell 
proliferation and overcome therapeutic induced stress. Autophagy has been found to 
promote acquired drug resistance in melanoma treated with combined BRAF and MEK 
inhibition.10 Macroautophagy (hereafter referred to as autophagy) is a vesicular 
trafficking pathway which maintains cellular homeostasis by facilitating the degradation 
of marked cargo throughout the cellular milieu. The formal discovery of this pathway in 
the 1990’s by Yoshinori Ohsumi was subsequently awarded the Nobel Prize in 
physiology and medicine in 2016. Autophagy is a conserved pathway through eukaryotic 
cells, affecting both normal functioning cells, and cells under metabolic and oxidative 
stress. On an organismal level, the pathway is integral to development and homeostasis. 
11 On an cellular level, the pathway is specifically charged with the degradation of protein 
aggregates, long-lived organelles, and long-lived macromolecules.12 Autophagy is 
marked by the elongation of vesicles (phagophores) which upon maturation become 
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distinct double-membraned vesicles known as autophagosomes. These autophagosomes 
are formed around cargo marked for degradation and are trafficked to the lysosome for 
recycling. Once degraded by the lysosome, the constituent building blocks are released 
back into the cytoplasm, fueling cellular repairs, cell growth, and cell proliferation.12  
In a properly functioning cell, autophagy acts as a cytoprotective and anti-
tumorigenic pathway. In nutrient-replete conditions, autophagy plays an active role in 
cell homeostasis. Specifically, the signaling mechanisms which induce autophagy are 
directly linked to the amino acid-sensing capabilities of the cell. Mammalian target of 
rapamycin (mTOR) acts as the master regulator of eukaryotic cell metabolism, acting as 
both a sensor and a signal relay between the cell’s anabolic and catabolic mechanisms.11 
It is widely accepted that functioning autophagy has a strong correlation with individual 
cell survival. However, the role of autophagy in tumorigenesis is strongly context-
dependent. 11,13,14 In vitro studies have demonstrated that under nutrient-starved 
conditions, similar to those found in solid tumors, inhibition of autophagy increased the 
amount of apoptotic cell death. 15 When pro-apoptotic therapeutics are used against 
cancer cells, upregulated autophagic activity has been shown to blunt drug efficacy. 
Further, when autophagy is inhibited, the efficacy of pro-apoptotic therapies is 
improved.16 
 Autophagy can be viewed in two halves. The first half is early-stage autophagy 
where multiple signaling pathways converge on key signaling loci, inducing the 
elongation of the characteristic double-membraned phagophores. The second half is late-
stage autophagy, marked by the trafficking and eventual vesicular fusion of mature 
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autophagosomes with a lysosome organelle.17,18 Multiple drug discovery efforts have 
tried to inhibit early-stage autophagy. However, these efforts have not led to any 
promising drug leads in the clinic. The cell signaling pathways which comprise early-
stage autophagy contain numerous redundancies which complicate inhibition. Late-stage 
autophagy lacks the same breadth of redundancies. Lysosomal-autophagosomal vesicular 
fusion is required for completion of the recycling pathway. Inhibition of this fusion 
prevents the introduction of lysosomal catabolic enzymes to the substrates within the 
autophagosomes, thus inhibiting the formal act of recycling. The lack of redundancies 
which can take the functional role of the degradative enzymes of the lysosome makes this 
vesicular fusion event a prime target for inhibition of the pathway.  
Chloroquine (CQ, compound 1, Aralen®) has emerged as one of the most 
commonly used inhibitors of late-stage autophagy. Chloroquine is a long standing anti-
malarial compound which was found to be lysosomotropic in eukaryotic cells.19 The 
accumulation of this compound in the lysosome prevents proper function of the 
organelle, including the lysosomal-autophagosomal vesicular fusion event. Clinical trials 
for CQ and hydroxychloroquine (HCQ, compound 4, Plaquenil®), a congener of CQ 1, as 
autophagy inhibitors have shown compelling but unreliable results. CQ/HCQ-mediated 
autophagy inhibition, which is beneficial in cellular models, is not efficiently reproduced 
on an organismal level.10,17,20,21 These results highlight the unmet medical need for potent 
small molecule inhibitors of autophagy. 
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1.1 Detailed Explanation of Autophagy Pathway 
 Significant efforts have been made to characterize the autophagy pathway in 
eukaryotic cells. A family of genes referred to as autophagy related genes (ATG) has been 
identified through significant efforts in yeast, humans, and other organisms.22 The distinct 
steps which bring immature phagophores to autolysosomes can be broken down as 
follows: initiation, nucleation, maturation of autophagic vesicles, and autophagic-
lysosomal vesicle fusion.14 The signaling pathways begin where receptor tyrosine kinases 
(RTKs) initiate a phosphorylation cascade through members of the ATG family. The 
initiation phase involves multiple phosphorylation/dephosphorylation cascades of ATG 
proteins, including ATG1, ATG13, and Ulk1. These proteins make up the Ulk1 complex, 
a key signaling locus in the induction of autophagy. Ulk 1 interacts with the 
phosphoinositide3-kinase (PI3K) class 3 complex of enzymes. This complex of PI3K 
proteins (PI3K-III) contains both Beclin1 and vacuolar protein sorting 34 (Vps34). 
Beclin1 is a critical autophagy gene required for autophagosome formation and apoptosis. 
Vps34 is a kinase which participates in lipid phosphorylation and mTOR signaling.17 The 
Ulk1 complex and the PI3K-III complex act sequentially in the induction of autophagy, 
resulting in the initial formation of the phagophore around cargo marked for degradation. 
Both the Ulk1 complex and the PI3K-III complex have been studied as targets for 
autophagy inhibition.  However, such inhibitors have not achieved efficacy in organismal 
models.23,24 
The maturation of autophagic vesicles is closely associated with the status of light 
chain 3 (LC3), a protein which is integrated into the membrane of mature 
autophagosomes. LC3 is a member of the ATG8 family and is modified via proteolysis 
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by ATG4. This proteolysis event marks the formation of LC3-I, a substrate for lipidation 
with phosphatidylethanolamine. The lipidation of LC3-I forms LC3-II, a protein which 
can be directly correlated to the number of mature autophagic vesicles. 18,25 LC3-II 
directly enables both the elongation of the autophagosomal membranes and the 
recruitment of cargo to be degraded by acting as a recognition point for effector proteins 
such as p62.26 
Mature autophagic vesicles contain cargo marked for degradation.  However, they 
do not contain the catabolic enzymes required for degradation. The vesicles must first 
fuse with the lysosome, the cell organelle which contains catabolic enzymes. The 
vesicular fusion event between the lysosome and a mature autophagosome marks end-
stage autophagy, where the fused vesicles become an autolysosome. The cargo within the 
autolysosome is degraded and redistributed to the cell as building blocks for the 
biosynthesis of new macromolecules. 
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Figure 1.1: A. The autophagy Pathway. Signaling cascades which 
activate the Ulk 1 complex cause a signaling cascade which activates 
the PI3K-III complex. Activation of PI3K-III complex sets in motion 
the nucleation of autophagic vesicles, first as an immature phagophore, 
eventually maturing into an autophagosome. Lysosome-
autophagosome vesical fusion occurs to give an autolysosome, 
allowing degradation to occur. Eventually the autolysosome releases 
the degraded cargo as its constituent macromolecular building blocks.  
B. Light chain 3 (LC3) is a key membrane protein involved in the 
formation of autophagic vesicles (below). LC3 is first proteolyzed by 
ATG4, making it a substrate for lipidation (LC3-I) with 
phosphatidoethanolamine. Lipidation yields a protein (LC3-II) which is 
incorporated into the nucleating immature autophagic vesicle. 
A. 
B. 
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1.2 Small molecule inhibitors of autophagy signaling 
 The inhibition of autophagy is an attractive therapeutic strategy against aggressive 
malignancies because of the ties between autophagy and cancer cell metabolism. The 
most common approach taken by these drug discovery efforts relies on inhibition of early 
autophagic signaling. The two major targets which have recently been pursued in the 
field are Ulk1 and the PI3K-III complex, the inhibition of each of which have been 
successful in cell models.23,24,27 
Multiple strategies for autophagy inhibition have led to the development of anti-
cancer agents with in vitro potency but without comparable effects in organismal models.  
A struggle for the strategy of autophagy inhibition is the ability to translate in vitro 
success to organismal models, let alone to the clinic. Spautin-1, a small molecule kinase 
inhibitor of ubiquitin specific peptidase 10 (USP10) and ubiquitin specific peptidase 13 
(USP13), prevents the deubiquitination of Vps34-containing complexes (PI3K-III), 
resulting in their degradation. The loss of these complexes containing Vps34 results in 
inhibition of early autophagy in mouse embryonic fibroblasts. Despite autophagy being 
inhibited, no anti-cancer activity or organismal model efficacy was demonstrated.27 A 
small molecule inhibitor has been developed for Ulk1, a critical signaling locus for the 
induction of autophagy. SBI-0206965 blocks kinase activity of Ulk1, suppressing the 
phosphorylation of Vps34, thus inhibiting autophagy by slowing the induction of the 
pathway. Egan and coworkers demonstrated that Ulk1 inhibition can be combined with 
mTOR inhibition to result in anti-cancer activity in cellular models.  However, no single-
agent anti-cancer activity was reported for SBI-0206965.23  
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1.3 Efforts exploring CQ and its derivatives for their anti-cancer properties 
 CQ 1 is a quinoline-based anti-malarial therapeutic, first synthesized in 1934. The 
synthesis of this drug was spurred by the need for a synthetic anti-malarial alternative to 
quinine. At the time of its initial synthesis and biological testing, both its structure and 
biological activity were compared to quinacrine (QN, Atabrine®) and Primaquine (PQ, 
Plasmochin®) (Figure 1.2). Before the invention of CQ, QN, and PQ, the front-line anti-
malarial drug was quinine. Extracted as a natural product, the distribution was 
monopolized by the Dutch-East India company.28 As both political and scientific climates 
changed in the mid-1900s, the need for a synthetically derived medicine became 
paramount. This led to CQ 1 becoming the front-line anti-malarial compound both for 
treatment of the disease and as a prophylactic. Due to its long history of medical use, 
chloroquine’s safety profile is also well known.28  
 
In addition to its anti-malarial properties, CQ and its congener HCQ have 
immunosuppressive properties. HCQ, as it is better tolerated than CQ in humans, is FDA-
approved as a treatment for rheumatoid arthritis and lupus erythematosus, two 
autoimmune diseases.29,30 
Figure 1.2: Structures of CQ 1, QN 2, and PQ 3. 
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 Analysis of the structure of chloroquine and its derivatives gives insight as to the 
important structural features required for potency and its predicted biophysical properties. 
Like quinine and its other synthetic congeners, chloroquine contains the bicyclic 
heterocycle, quinoline. Quinolines, by nature of the lone pair of the nitrogen, are weakly 
basic. In general, the pKa of a protonated quinoline heterocycle is approximately 5.0, 
similar but slightly higher than its monocyclic congener pyridine. However, unlike 
quinine, the quinoline in chloroquine contains a 4-amino substitution, which donates 
electron density to the heterocycle, resulting in a significantly increased pKa. This 
increase in pKa has a substantial effect on the biophysical properties of chloroquine, 
because the pKa is raised higher than the pH of the biological milieu (pH 7.2 – 7.6).  
According to the experimentally-determined pKa of chloroquine (8.6 and 9.8) and the 
Henderson-Hasselbach equation, it is predicted that greater than 90% of the inhibitor is 
protonated at physiological pH.31 The necessity of the C-7 chlorine appended to the 
quinoline ring is less understood. Halogens attached to aromatic rings are electron-
withdrawing. The high electronegativity of chlorine increases the pKa, i.e., decreasing the 
basicity, of the 4-aminoquinoline compared to a non-halogenated derivative. The 4-amino 
substituent of CQ is a secondary aniline connected to the C-4 position of a pentyl chain 
which contains a tertiary amine at the C-1 position. The lone methyl group in chloroquine 
generates a stereocenter.  Studies have shown that the absolute configuration does have 
an effect on anti-malarial potency.  However, the stereochemistry appears to affect host 
metabolism and drug clearance rather than target binding.32,33  
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 HCQ is a congener of CQ which only differs by the replacement of one ethyl 
moiety with a hydroxyethyl functionality. The intended purpose of this hydroxyl group is 
to impart more desirable biophysical properties to the inhibitor itself. The hydroxyl 
functional group introduces a new handle for mammalian metabolism. It is this increased 
metabolic lability of HCQ which is thought to impart the decreased toxicity of HCQ 
when compared to CQ.34 
 
 
1.4 CQ/HCQ in Clinical Trials for Cancer 
The path of CQ 1  and HCQ 4 into clinical trials for anti-cancer therapy is 
significantly shorter than that of new drugs due to their long-standing use in modern 
medicine as anti-malarials. 35 Clinical studies have already tested CQ/HCQ 1/4 as 
adjuvants in multiple therapeutic strategies. As of March 23, 2018, 56 clinical trials have 
studied or are studying CQ 1 or HCQ 4 as an adjuvant therapy with other anti-cancer 
Equation 1: The Henderson-Hasselbach Equation 
Figure 1.3: The structures of chloroquine (CQ) 1 and 
hydroxychloroquine (HCQ) 4.  
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strategies (FDA.gov). A Phase 1 clinical trial of HCQ in patients with newly diagnosed 
glioblastoma showed two indicators of autophagy inhibition: a dose-dependent change in 
autophagic vesicle count and an increase in LC3II. When patients were given a daily dose 
of either 600mg or 800 mg of HCQ, tumor biopsies showed an increase in autophagic 
vesicle count and an increase in LC3II. However, at a lower daily dose of 400 mg, only 
20% of patients showed a similar response. 36 Currently, there are no clinical trials of 
non-chloroquine/hydroxychloroquine-mediated autophagy inhibition. 
 
1.5 Derivatives of CQ/HCQ 
 The prevalence of CQ/HCQ use as a primary treatment and prophylactic 
treatment for malaria has led to the evolution of many drug-resistant strains of the 
parasite. One of the many challenges in the field of malaria is countering acquired drug 
resistance.37 As a method of combating the acquired drug resistance, medicinal chemistry 
efforts have produced multitudes of second- and even third-generation chloroquine-
derived anti-malarial therapeutics.38 While most efforts have been unsuccessful, a few 
exceptional analogs have been utilized as frontline therapeutics in certain malaria 
populations.  
Piperaquine 5 is a chloroquine derivative which contains two units of the 7-
chloro-4-aminoquinoline heterocycle (Figure 1.4). However, unlike chloroquine, the 
resulting aniline is tertiary, and is restricted in flexibility by incorporation into a 
piperazine ring. Piperaquine was developed for its use in chloroquine-resistant P. 
falciparum and is currently approved with artemisinin as a combination therapy.39  
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Ferroquine 6 is an analog of chloroquine which has perhaps the most extensive 
structural changes from the parent compound (Figure 1.4). The compound’s name is 
derived from the replacement of two methylenes within the chloroquine butyl linker with 
two carbons of one of the cyclopentadienyl ligands of ferrocene. This incorporation of sp2 
carbons increases the rigidity of the molecule. This rigidity however, is only a biproduct 
of the incorporation of a stable source of iron into the small molecule therapeutic. 
Conceptualization of this inhibitor begins with the proposed mechanism of the anti-
parasitic activity of CQ. In the malaria parasite, CQ is found to accumulate in the 
digestive vacuole and prevent heme crystallization.40 These CQ-heme aggregates are 
unable to be metabolized by the parasite and produce oxidative stress through Fenton-
type oxidation chemistry. Ferroquine incorporates soluble, but indigestible iron to the 
acidic vacuole of the parasite with the purpose of increasing the anti-malarial activity of 
CQ.41 
 
 
Figure 1.4: The structures of Piperaquine (PQ) 5, and Ferroquine (FQ) 6. 
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1.6 The invention of Lys-05, a dimeric lysosomal inhibitor 
Clinical trials utilizing CQ/HCQ have shown some success in utilizing autophagy 
inhibition to improve a cancer patient’s prognosis. However, the intracellular 
concentration required for autophagy inhibition cannot be reliably achieved in a in a 
patient population being given the maximum tolerated dose.20,36 Therefore, the next 
logical extension of these clinical studies is to test a more potent derivative of 
chloroquine which inhibits autophagy more efficiently in organismal models.  
 Over the 50+ years in which CQ has been utilized as a front-line therapeutic for 
malaria, multiple strains of p. falciparum have been discovered to be resistant to CQ 
treatment. The proposed mechanism of CQ toxicity towards the malaria parasite is the 
sequestration of heme resulting in oxidative stress within the digestive vacuole of the 
parasite.40,42 CQ-resistance, which has arisen in multiple strains of malaria, has been 
attributed to the existence of a proteinaceous efflux transporter.43 To circumvent this 
efflux, Roche developed a dimeric CQ inhibitor 7 which is based on 1,2 cyclohexane-
diamine (Figure 1.5).43,44 This molecule was found to have excellent cytotoxicity towards 
the malaria parasite, regardless of the CQ-resistant character of the strain. The authors 
conclude that the increased potency against CQ resistant malaria is due to the efflux 
transporter not removing the dimeric CQ from the digestive vacuole of the parasite. The 
dimeric compound by Roche has not been pursued in the clinic because it was found to 
be too toxic for use in humans.44 The success of this dimeric reporter against CQ-resistant 
strains of malaria led to multiple studies, particularly those by Vennerstrom et. al and 
Girault et. al., both of which have developed multiple dimeric CQ derivatives.43,45,46 It 
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was observed that micromolar quantities of both CQ and bisaminoquinoline dimers are 
required to inhibit heme polymerization in the digestive vacuole. In one of their studies, 
Vennerstrom et. al. utilized a wide series of polyamines as scaffolds to synthesize 
dimeric inhibitors.45 Notably these dimeric inhibitors gave activity comparable to CQ in 
p. falciparum. Girault et. al. later expanded upon this idea, producing dimeric and 
trimeric CQ inhibitors which demonstrated comparable inhibitory activity to CQ in CQ-
resistant p. falciparum. In their work, Girault et. al. observed linear dimers and rigidified 
dimers possess similar anti-parasitic activity, but rigidified dimers possessed less host 
toxicity than the flexible linear dimers.46  
 
 
The identity of the efflux transporter for CQ in the human lysosome is not known. 
The need of a better lysosome-accumulating CQ analog appears to mirror the problem 
which dimeric CQ analogs have overcome in CQ-resistant malaria. Inspired by the results 
of Roche, Vennerstrom et. al., and Girault et. al., the Winkler and Amaravadi 
Laboratories sought to test the autophagy inhibition potency of dimeric CQ derivatives in 
comparison to monomeric CQ. It is known that CQ is highly lysosomotropic.19 Small 
Figure 1.5: Dimeric chloroquine anti-malarials synthesized by Roche (7)44, 
Vennerstrom et. al (8). 43,46 
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molecules which are lipophilic and are weakly basic, like CQ, are known to accumulate 
in the lysosomal compartment. Multiple studies attribute this phenomenon to the pH 
gradient between the cytosol and the lysosomal lumen (pH 7.2 vs pH 4.5).19,47–50 It was 
reasoned that this effect could be magnified by increasing the number of basic nitrogen 
atoms in new derivatives of CQ. The Winkler and Amaravadi Laboratories hypothesized 
that dimeric CQ derivatives which contain a greater number of basic nitrogen atoms 
should accumulate in the lysosome to a greater degree than monomeric CQ. Roche 
reported bisaminoquinoline 7 was photocarcinogenic in cell and mouse models.44 The 
potential carcinogenic properties of bisaminoquinoline 7 make the trans-1,2-
diaminohexane scaffold unattractive to utilize in the synthesis of anti-cancer agents. 
Girault et. al. reported that dimeric inhibitors synthesized from linear polyamines were 
less toxic to human cell cultures than dimers synthesized from rigid cyclic polyamines.46 
The Winkler and Amaravadi Laboratories ruled out the usage of rigid scaffolds for 
diamines due to the toxicities which have precluded their use in humans. When designing 
a dimeric inhibitor, one biophysical factor which was addressed was the increase in 
hydrophobicity of a dimeric inhibitor when compared to CQ. Compounds which have too 
low an aqueous solubility will have low bioavailability. Therefore, the smallest triamine-
based dimeric inhibitor presented by Vennerstrom and Girault, a bis-aminoquinoline 
linked by diethylene triamine, was selected (Figure 1.5, Compound 8). To maintain 
similar functionality to CQ, the internal amine of the linker was methylated, resulting in 
the structure of Lys-05. This compound was also selected for its synthetic ease, as it is 
rapidly synthesized from a commercially available triamine and an aryl halide precursor 
to CQ.    
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A small library of dimeric analogs was synthesized alongside Lys-05 (Fig 1.7.).51 
The library was designed to test the effects of heterocycle dimerization by comparison of 
dimeric Lys-05 with a monomerically-arylated diethylene triamine linker, Lys-02 (Figure 
1.7, Compound 10). Replacement of the C-7 chlorine with a C-7 methoxy group tested 
the importance of the halogen to the chloroquine ring (Lys-03) (Figure 1.7, Compound 
11). The last analog tested the importance of the tertiary amine and the aliphatic linker, 
by replacing the triamine with a triethylene glycol derived diamine(Lys-04). While an 
imperfect control for the presence of a tertiary amine, the diamine precursor was 
commercially available, and maintained the aqueous solubility of the inhibitor. 
 
 
Figure 1.6: Lys-05 9, a dimeric CQ inhibitor studied by the Winkler and Amaravadi 
Laboratories in melanoma.51 
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The mechanism of action of CQ 1 in malaria is presumed to be the prevention of 
heme crystallization. While crystallization of heme correlates with parasite survival, a 
molecular target of CQ 1 has not been established in malaria. The lack of a molecular 
target for chloroquine-mediated autophagy inhibition makes a target-based medicinal 
chemistry effort impossible. In lieu of structural biology or target binding information, a 
phenotypic screening approach was taken, where a cellular or organismal system is used 
to verify the potency and toxicology of a library of inhibitors. The use of a 
cellular/organismal phenotypic approach provides an assay output which combines the 
many factors which contribute to the efficacy of an inhibitor lead. Unlike an in vitro 
assay where the inhibition of an isolated enzyme is tested, changes made to a molecule 
can not be directly attributed to the binding affinity of the inhibitor for a target enzyme. 
Therefore, when applying a phenotypic approach, the assay criteria which is measured to 
interrogate the effectiveness of an inhibitor is critical for the success of the experiment. In 
order to design a more potent CQ 1 derivative which has organismal potency, three 
Figure 1.7: A dimeric inhibitor library based on the dimerization of CQ.51 
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assays were critically important: cell proliferation assays, autophagy inhibition assays, 
and tumor growth suppression in xenograft assays.  
The compounds were first tested as anti-proliferative agents against 1205Lu 
melanoma cells by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay cell proliferation assay. The MTT assay determines whether a cell currently 
is actively metabolizing. An IC50 concentration can then be determined which establishes 
the dosage at which 50% of the cells have active metabolism or cell proliferation. Lys-05 
9 performed significantly better than CQ/HCQ, demonstrating a 6 uM IC50 for single 
agent anticancer activity. While in one cell line it appears that Lys-04 12 also 
demonstrated a significant increase in potency versus CQ 1, Lys-04 12 never showed 
greater potency Lys-05 9. The panel of compounds was also assayed for autophagy 
inhibition by using western blotting to quantify the accumulation of LC3-II, the protein 
corresponding to accumulated mature autophagic vesicles. Lys-05 9 again was observed 
to show greater potency than CQ/HCQ 1/4 and the entire dimeric inhibitor library. Lys-
05 9 was found to not only be a more potent version of CQ/HCQ 1/4, but importantly was 
ten-fold more potent. It appeared that barring a drastic difference in biophysical 
properties between Lys-05 and CQ/HCQ 1/4, the gained increase in potency of Lys-05 9 
could be attributed to a phenomenon more powerful than a simple increase, i.e., doubling, 
in local concentration. These results validate the hypothesis that CQ/HCQ-mediated 
autophagy inhibition could benefit from dimeric chloroquine inhibitors. 
 The invention of Lys-05 9 had a significant impact on the field of autophagy 
inhibition. The inhibitor not only shed light on the structure-activity relationships of 
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chloroquine-mediated autophagy inhibition, but also demonstrated autophagy inhibition 
in an organismal study. Tumor xenografts implanted on the flanks of mice grew at a 
slower rate when treated with Lys-05 9 when compared to HCQ-treated and untreated 
controls. Further, Western blotting of tumor lysate demonstrated greater autophagy 
inhibition in the Lys-05-treated mice when compared to HCQ treated mice. Mice treated 
with Lys-05 9 suffered from bowel obstruction when compared to the untreated control. 
The source of the bowel obstruction was found to be Paneth cell dysfunction, a symptom 
previously reported in autophagy deficient mice. Further, this dysfunction is observed in 
Crohn’s disease patients with a mutation in the autophagy gene ATG16L1.52 This result is 
consistent with autophagy inhibition in an organismal model. While it is encouraging to 
see autophagy inhibition manifest as an organismal phenotype, this result also highlights 
a potential dosing limit, decreasing potential therapeutic windows. 
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CHAPTER 2: THE SECOND GENERATION OF DIMERIC CHLOROQUINE 
INHIBITORS53 
 The small pilot library which was tested during the discovery of Lys-05 gave 
insight into elements which should be conserved in the design of future CQ derivatives. 
We became interested in the importance of linker length, the chain length of the aliphatic 
triamine which forms the scaffold of Lys-05.  From a synthetic perspective, the linker 
length is easily modified by starting from triamines comprised of different aliphatic chain 
lengths. Buchwald-Hartwig arylation utilizing Pd(OAc)2 and BINAP as the catalyst 
system is selective for primary amine arylation over secondary amine arylation (Figure 
2.1). We turned to the literature to identify known triamines which could be used as 
scaffolds for new dimeric inhibitors. Spermidine 16 is a triamine natural product found in 
eukaryotic cells and is commercially available. Spermidine 16 differs from diethylene 
triamine in that it has an unsymmetrical number of carbons between the nitrogen atoms of 
the triamine, and it is three atoms longer (Figure 2.1). The additional carbons add more 
hydrophobic character to the structure of the inhibitor, but also increase the flexibility of 
the molecule. Without a validated cellular target, the active conformation of Lys-05 9 is 
unknown; it was hypothesized that a more flexible molecule would allow a dimer to 
sample more potential binding conformations with each CQ heterocycle.  
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It should be noted that compound 17 had been previously synthesized in malaria 
studies via SNAr reaction between spermidine and 4,7-dichloroquinoline.
46 Synthesis of 
17 is improved by Buchwald-Hartwig arylation (Figure 2.1). The use of 17 as a dimeric 
autophagy inhibitor is a novel application of the small molecule.53  
 In a head-to-head comparison, 17, Lys-05 9, and CQ 1 were compared in two 
different cell viability assays (Figure 2.2). The first, an MTT assay, is a short duration 
single dose assay, which indicates the effect of the inhibitor on immediate cell 
proliferation. The second is a long-term colony formation assay, where cancer cells are 
treated once with the inhibitor, but are allowed to continue proliferating for two weeks 
post treatment. In MTT assays, both 17 and Lys-05 9 perform significantly better than 
Figure 2.1: A. Gram-scale synthesis of Lys-05 9. B. Synthesis of 17 via 
Buchwald-Hartwig arylation of spermidine with 4-bromo-7-chloroquinoline 13. 
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CQ but are not significantly different. However, in the long-term colony formation assay, 
17 demonstrates significantly better anti-proliferative activity than Lys-05 9. These 
results sparked a more thorough exploration of the role which the triamine linker plays in 
the potency of dimeric chloroquine inhibitors (Figure 2.3). 
 
 
A second area that we explored was the role of the substitution of the central 
nitrogen of the triamine linker. The success of DC340 17 made apparent that secondary 
amines could be tolerated within triamine linked dimeric chloroquine inhibitors. When 
Figure 2.2: Comparison of Lys-05 9 and DC340 17 in two-week colony formation 
assays and MTT cell proliferation assays (A375P melanoma). Reproduced from 
Rebecca et. al.53 
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comparing the computed biophysical properties, it became obvious that central nitrogen 
methylation increased the hydrophobicity of the designed inhibitor. However, perhaps 
less obvious is the negligible change in the calculated of pKa the amine (17 pKa = 9.59, 
18 pKa = 9.54). While it is well accepted that tertiary amines are significantly more basic 
than their primary amine counterparts, the difference between secondary amines and 
tertiary amines is not as significant. Tertiary amines do gain electron density from their 
alkyl substituents; however, they also gain a significant steric penalty when completely 
substituted. In most acyclic cases, these two effects balance themselves out. Therefore, 
differences in the properties of secondary amine or tertiary amine linked dimers will 
more likely reflect the difference in the hydrophobicity of the drug, steric contribution to 
a binding interaction, and/or potential cell metabolism. 
 
2.1 The second generation of dimeric lysosomal inhibitors – dimeric quinacrine 
The invention of Lys-05 9 produced structure activity relationship data which 
highlighted the importance of the C-7 chlorine on the quinoline.51 However, this study 
did not comprehensively study the importance of heterocycle identity. In the field of anti-
Figure 2.3: Structures of DC340 17 and DC341 18: dimeric chloroquine inhibitors 
differing by central nitrogen alkylation. For each inhibitor cLogP and pKa was 
calculated utilizing Chemdraw. 
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malarial therapeutics, multiple quinoline based heterocycles exist as substitutes for 
chloroquine. Quinacrine 2 (QN, Atabrine®), primaquine (PQ, Primaquine®) 3, and 
mefloquine (MQ, Lariam®) 19 have been used as anti-malarial medicines. Working with 
Dr. Noel McLaughlin, we derived three new classes of dimeric autophagy inhibitors from 
these existing anti-malarial therapeutics. We wanted to test the hypothesis that dimeric 
inhibitors synthesized from these heterocycles could be used as anti-cancer agents. As a 
later independent effort, I designed and synthesized a series of inhibitors based on 
piperaquine, the only clinically used dimeric chloroquine anti-malarial (Chapter 2, 
Synthesis of Piperaquine Derivatives). We also synthesized dimeric forms of ferroquine, 
a newly emerging anti-malarial compound which has demonstrated anti-proliferative 
activity in cancer (Chapter 2, Synthesis of Ferroquine Derivatives).54 
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We designed a specific nomenclature to refer to dimeric inhibitors derived from 
existing anti-malarial heterocycles. Dimeric inhibitors are described first by a two-letter 
code, “D” for dimeric, followed by the first letter of the anti-malarial heterocycle. (DC 
for dimeric chloroquine). Following the two-letter code is a three-digit number, where the 
first digit corresponds to the length of the first alkyl chain of the triamine, followed by a 
second digit corresponding to the length of the second alkyl chain of the triamine. The 
final digit corresponds to whether the central nitrogen of the triamine is a secondary 
amine (0) or a methylated tertiary amine (1). Utilizing this new nomenclature, Lys-05 9 is 
Figure 2.4: Structures of commercially available anti-malarial compounds. 
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defined as DC221 (Figure 2.5). 
 
 
Spermidine was selected as a triamine scaffold to test the effect of dimerization on 
the other heterocycles. The first three aryl halides were synthesized by Dr. Noel 
McLaughlin according to literature precedent, each corresponding to either QN 2, PQ 3, 
or MQ 19 (Figure 2.6). The acridine precursor of dimeric quinacrine inhibitors (DQ) was 
synthesized as a 6,9-dichloro-2-methoxyacridine. Compound 22 was synthesized by an 
Ullman coupling of p-anisidine 21 (Acros Organics) and 2,4-dichlorobenzoic acid 20 
(Acros Organics). Ullman couplings are known to be directed and significantly 
accelerated by an ortho-carboxylic acid moiety, which enabled the product 22 to be 
isolated as a single isomer. The benzoic acid 22 derivative was then cyclized by Friedel-
Crafts acylation and chlorinated in situ with neat phosphorus(V) oxychloride, heated to 
reflux, to afford 23. The resulting phenol 23 was chlorinated in situ to afford the 6,9-
dichloro-2-methoxyacridine, 24. 55 The primaquine (DP) aryl chloride precursor, 26, was 
Figure 2.5: Key for the nomenclature for identifying dimeric inhibitors 
derived from antimalarial therapeutics. 
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synthesized according to the method of  Childers and coworkers.56 The heterocyclic 
precursor of dimeric mefloquine (DM) was synthesized first from the 
condensation/cyclization reaction of 2-trifluoromethyl aniline (Sigma Aldrich) and ethyl 
4,4,4-trifluoro-3-oxobutanoate (Oakwood Chemical) in polyphosphoric acid, resulting in 
29.57 4-hydroxyquinoline, 29 was chlorinated by phosphorus(V) oxychloride to give 
compound 30.58 
 
Palladium-catalyzed C-N arylation was then used to synthesize dimers from 
commercially available spermidine as a linker. Spermidine 16 (Acros Organics) was 
selected as a linker for this second-generation library because of its success in the case of 
DC340 17. The Pd(OAc)2/BINAP catalyst system is compatible with spermidine, which 
contains both primary amine and secondary amine functionality, due to the significantly 
slower rate of the arylation of acyclic secondary amines compared to primary amines. 
Figure 2.6: Synthesis of aryl halide precursors to dimeric lysosomal inhibitors. 
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The Pd(OAc)2/BINAP catalyst in combination with potassium phosphate tribasic as a 
base yields DC340 17 with excellent chemoselectivity. Dimeric forms of quinacrine 31 
(DQ340) and mefloquine (DM340) 33 were synthesized in reasonable yields, 
demonstrating the toleration of aryl chlorides by this catalyst system. Dimeric primaquine 
(DP340) 32 was synthesized in only trace quantities using these reaction conditions. 
Analysis of the crude reaction mixture by proton nuclear magnetic resonance (1H NMR) 
showed the starting materials did not decompose. The base utilized in the reaction was 
switched from potassium phosphate tribasic (K3PO4) anhydrous to anhydrous sodium 
tert-butoxide (NaOtBu), a stronger base. The source of palladium was also changed to 
Pd2(dba)3. These new reaction conditions afforded DP340 32 in 83% yield.   
 
 
The compounds were first subjected to MTT anti-proliferative assays in A375P 
BRAF mutant melanoma cells. In these assays, the new dimeric inhibitors were compared 
Figure 2.7: Synthesis of dimeric inhibitors with other anti-malarial 
heterocycles. 
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to their respective parent monomeric anti-malarial and to Lys-05, the state of the art in 
dimeric autophagy inhibitors. As previously observed in MTT assays, cells treated with 
DC340 17 exhibited reduced cell proliferation compared to cells treated with either Lys-
05 9 or CQ 1. DM340 33 treated cells exhibited reduced cell proliferation compared to 
cells treated with the parent mefloquine 19 (MQ), with activity comparable to Lys-05. 
DP340 32 treated cells exhibited reduced cell proliferation compared to cells treated with 
the parent primaquine 3 (PQ), with activity comparable to Lys-05 9. Cells treated with 
DQ340 31 exhibited reduced cell proliferation when compared to QN 2, and also relative 
to Lys-05 9. When compared as a ratio of dimeric/monomeric, cells treated with DQ 
exhibited the greatest decrease in cell proliferation. From this result we inferred that 
DQ340 31 was the most promising lead molecule tested (Figure 2.8.). 
 
Informed by these MTT results, a library of dimeric quinacrine inhibitors was 
synthesized in collaboration with Dr. Noel McLaughlin, a postdoctoral researcher in the 
Winkler Laboratory. The library was designed to explore two structural features of the 
Figure 2.8: MTT assay results for dimeric inhibitors derived from other 
commercially available anti-malarial compounds.  
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linker region of each dimeric inhibitor: the length of the aliphatic chains linking the 
nitrogen atoms of the triamine, and the substitution of the nitrogen in the center of the 
linker. The library was synthesized by arylation of various triamines with 6,9-dichloro-2-
methoxyacridine. For each triamine linker, K3PO4 was found to be an adequate base in 
combination with the Pd(OAc)2/BINAP catalyst system, suggesting that the previously 
observed difference in reactivity between 8-chloro-6-methoxyquinoline and 6,9-dichloro-
2-methoxyacridine lies in the substitution of the aryl halide. Many of the triamines 
utilized in this library were commercially available (2/2, 3/3, 3/4, and 6/6) or were 
previously synthesized (4/4, 5/5). However, the remaining triamines (7/7, 8/8, and 11/11) 
were not known and required the development of a synthetic strategy. 
2.2 Synthesis of a DQ library 
Triamines based on heptyl and octyl aliphatic chains were prepared from 
commercially available dibromoalkanes (1,7-dibromoheptane 34 and 1,8-dibromooctane 
35). Sodium azide was selected as a protected nitrogen source because of its greater 
reactivity as a SN2 nucleophile when compared to potassium phthalimide. Both 1,7-
dibromoheptane 34 and 1,8-dibromooctane 35 were subjected to SN2 reaction with 
sodium azide in dimethylsulfoxide (DMSO) at room temperature (23 °C). Use of the 
dibromoalkanes in excess (2.2 equiv.) allowed for minimization of bis-SN2 product and 
afforded the mono-substitution product 37 in reasonable yield. Benzylamine was selected 
as a divalent nitrogen source to link the protected triamine. SN2 alkylation of 
benzylamine with 37 in n-butanol afforded product 39 in serviceable yields. The azides 
can be converted to primary amines 41 with simultaneous debenzylation of the interior 
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tertiary amine via hydrogenolysis catalyzed by 10 mol% palladium (0) on carbon support 
(Pd/C) in methanol/ethyl acetate. The triamine products were then utilized in the 
palladium catalyzed arylation reactions. (Figure 2.9) 
 
 The 11/11 linker was synthesized from 11-aminoundecanoic acid 42, a natural 
product isolated from castor oil (Arkema). First, 11-aminoundecanoic acid 42 was 
converted into 11-aminoundecanol 43 by lithium aluminum hydride reduction in 
tetrahydrofuran (THF), upon heating the reaction to reflux. The resulting aminoalcohol 
43 was protected by acylation with benzyl chloroformate to yield the Cbz-protected 
aminoalcohol 44. Previous results demonstrated alkylation of benzylamine with alkyl 
bromides was poor yielding. Fortunately, the existing alcohol functionality makes 
oxidation followed by reductive alkylation of benzylamine to be step economical. 
Therefore, alcohol 44 was oxidized under Swern conditions to yield 45. Benzylamine was 
then reductively alkylated twice with the aldehyde, using sodium triacetoxyborohydride 
as a reducing agent, to synthesize compound 46. We attributed the improved efficiency of 
this transformation to the elimination of over alkylation. In contrast, SN2 alkylation of 
primary amines often results in the production of tetraalkylammonium species in addition 
to or to the exclusion of tertiary amines. Unlike sodium borohydride, the three acetoxy 
substituents of this borohydride derivative reduce the hydridic character of the boron-
Figure 2.9: Synthesis of an 8/8 triamine linker 41 
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hydrogen bonds, making the reduction selective for iminium ion intermediates formed in 
the reductive alkylation reaction. (Figure 2.10) 
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The resulting protected triamine precursor, 46, was then deprotected in one step 
utilizing hydrogenolysis in the presence of catalytic Pd/C. The reaction required 30 mol% 
of catalyst for any consumption of starting material to occur. No consumption of starting 
material was observed when using 10 mol% of Pd/C, even with prolonged reaction times. 
Additionally, 1.2 equivalents of hydrochloric acid (HCl) were added in an attempt to 
activate the benzylic amine toward hydrogenolysis.  However still no starting material 
was consumed in 24 hours. The protected triamine precursor was successfully 
deprotected upon hydrogenolysis in the presence of 30 mol% Pd/C, rapidly affording the 
product in good yield 47 (Figure 2.10). With the library of triamine precursors in hand, 
palladium catalyzed arylation was utilized to synthesize the library of dimeric quinacrine 
compounds (Figure 2.11). 
 
 
 
Figure 2.10: Synthesis of an 11/11 triamine linker 
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Inhibitor Yield Compound. 
DQ221 33% 52 
DQ330 56% 53 
DQ340 56% 31 
DQ440 39% 54 
DQ550 83% 55 
DQ660 68% 56 
DQ770 38% 57 
DQ880 33% 58 
DQ11110 30% 59 
 
In Lys-05 9 the amine comprising the center of the linker is a methylated tertiary 
amine. DC340 17 established the dimeric inhibitors containing secondary amines can also 
be potent anti-cancer agents. A side-by-side comparison of secondary versus tertiary 
amine-containing inhibitors was not yet available to establish the role of the alkylation of 
this nitrogen in the potency of the inhibitors. Both previous work in our laboratory and 
other studies have established that the aminoquinoline nitrogen in CQ 1 and our dimeric 
lysosomal inhibitors to be a much weaker nucleophile than the linker central secondary 
amine. Despite the presence of more than ten-fold molar excess of formaldehyde and 
sodium triacetoxyborohydride, only the central linker amine is methylated at room 
temperature (23 °C). This sequence allowed for the synthesis of both secondary and 
tertiary amine linked dimers to proceed through the same common intermediates.  
Figure 2.11: Synthesis of a library of secondary 
amine linked DQ inhibitors 
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Reactions of aqueous formaldehyde, dimeric quinacrine inhibitor, and sodium 
triacetoxyborohydride produced a heterogeneous mixture and required long reaction 
times. This heterogeneous mixture prevented complete consumption of starting material, 
thereby complicating product purification. As an alternative, Eschweiler-Clarke 
methylation conditions were explored for the synthesis of tertiary amine-linked dimeric 
quinacrine compounds. Secondary amine-linked dimeric quinacrine compounds were 
soluble in aqueous formic acid. The methylation reaction using aqueous formaldehyde in 
formic acid, which was heated to reflux, furnished tertiary amine linked compounds in a 
shorter and more consistent reaction time (approximately 4 hours). Reductive 
methylation of dimeric inhibitors afforded good yields of the tertiary amine products and 
allowed for gram-scale synthesis of DQ661 64.  
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Inhibitor DQ331 DQ341 DQ441 DQ551 DQ661 DQ771 DQ881 DQ11111 
Compound 60 61 62 63 64 65 66 67 
Yield 86%B 94%A 83%A 50%A 91%B 74%B 72%B 75%B 
 
 
2.3 Assessment of DQ Biological Activity 
We worked in collaboration with Dr. Vito Rebecca of the Amaravadi Laboratory 
to explore the biological activity of DQ compounds. The dimeric inhibitors were first 
assessed for their anti-proliferative activity by MTT assay in two cell lines known to have 
upregulated autophagy: A375P melanoma cells and PANC1 pancreatic cancer cells. 
These inhibitors were compared to early-stage autophagy inhibitors Spautin-1 and SBI-
0206965.23,59 In melanoma, compounds with linkers containing aliphatic regions between 
Figure 2.12: Synthesis of N-methylated DQ inhibitors by sodium triacetoxyborohydride 
reductive alkylation, or Eschweiler-Clarke reaction. Superscript on yield indicates the 
synthesis method used. 
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three and six carbons in length were significantly more potent than the parent monomeric 
inhibitor QN 2 and Lys-05 9 (Figure: 2.13). Longer linked dimeric inhibitors, with linkers 
containing aliphatic regions seven carbons and longer, were significantly less potent. We 
hypothesized that the compounds lost potency due to increased hydrophobic properties 
imparted by the longer linker. We anticipated that hydrophobicity would reach a 
threshold which was detrimental to subcellular localization, aqueous solubility, and/or 
cell penetration of the inhibitor. The utilization of in cell assays rather than enzymatic in 
vitro assays for developing a structure activity relationship allowed us to combine 
biophysical properties, drug transport, subcellular localization, and potential target 
binding into one output.  
 
One result which caught our attention was the modest potency of DQ221 52 in 
MTT cell proliferation assays. Despite being a dimeric inhibitor, and the quinacrine 
Figure 2.13: MTT assay results for the DQ inhibitor library compared to QN, 
CQ, Lys-05, and known early autophagy inhibitors, Spautin-1 (Vps-34 
inhibitor) and SBI-0206965 (ULK1 Inhibitor).8,9  
Cell Viability Assays for Dimeric Quinacrine Inhibitors 
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congener of the potent dimeric inhibitor Lys-05, DQ221 52 was found not to be more 
potent than its monomeric parent anti-malarial QN 2. Structurally, DQ221 52 and Lys-05 
9 contain the same exact triamine linker, only differing in the structures of the 
heterocycles. The success of Lys-05 9 establishes that 4-N-Methyl-diethylenetriamine 14 
is a linker capable of generating potent dimeric inhibitors from CQ 1. However, the result 
for DQ221 52 suggested that the alteration of the heterocyclic ring system has changed 
the requirements of the triamine linker region for effective biological activity. Acridines 
are approximately 50% larger than quinoline rings, by nature of being tricyclic rather 
than bicyclic aromatic systems. This fact, coupled to the performance of DQ221 52 in 
MTT assays, indicates that longer linker lengths are necessary for the more sterically 
demanding tricyclic acridine-based dimers. Increasing the linker length to a three-carbon 
linker, dipropylenetriamine, produced the expected result, a dramatic increase in inhibitor 
potency when compared to the parent monomeric compound, QN 2. DQ221 52, DQ330 
53, and DQ331 60 do not appear to differ significantly in their aqueous solubility. A 
fragment-based approach utilized to compute theoretical pKa values for the internal 
nitrogen indicates that Lys-05 9 and DQ221 52 should have reduced basicity in 
comparison to CQ 1, QN 2, DQ330 53, and DQ331 60. However, structurally it is not 
obvious why this effect would affect the observed potency of DQ221 52 more than that 
of Lys-05 9 (Figure 2.14).  
40 
 
 
 
Pancreatic cancer is an example of another type of cancer which is highly reliant 
on the autophagy pathway.60 In a pancreatic cancer cell line, PANC1, MTT assays 
revealed smaller derivatives DQ330 53, DQ331 60, DQ340 31, and DQ341 61 are the 
most potent compounds in the dimeric quinacrine library. PANC1 cells were also utilized 
in a two-week colony formation assay to assess the long-term effect of a subset of the DQ 
library on PANC1 cell proliferation (Figure 2.14). Fascinatingly, some of the dimeric 
Figure 2.14: The structures of CQ 1, QN 2, Lys-05 9, DQ221 52, DQ330 53, and 
DQ331 60. Their calculated (Chemdraw) LogP and pKa values. 
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quinacrines possess potency in suppression of long term cell proliferation at doses as low 
as 30 nM. As in melanoma, DQ221 52 again lacks the same degree of potency in MTT 
and long-term colony formation assays for cell proliferation, suggesting the lack of 
potency is due to the structure of DQ221 52. 
 
Apoptosis is a form of programmed cell death which is induced in response to 
cellular stress in multi-cellular organisms.61,62 In properly functioning apoptosis, cells 
which experience stress undergo programmed cell death by the activation of proteolytic 
enzymes which recycle the contents of the cell. In cancer, however, apoptosis is often 
functioning incorrectly, leading to further cancer cell proliferation. Anti-cancer 
therapeutics which induce apoptosis can be used as a means of both stopping cancer cell 
proliferation and shrinking tumors.62 PANC1 cells treated with the DQ library were 
assayed for apoptosis, where DQ660 56 and DQ661 64 were the best performing pro-
apoptotic compounds at a dose of 3 uM in a 24-hour assay (Figure 2.16). DQ compounds 
produced significantly larger amounts of apoptosis than Lys-05 9, marking a significant 
Figure 2.15: MTT and long-term colony formation assays for DQ inhibitors in the 
PANC1 pancreatic cancer cell line.53 
42 
 
improvement over the first-generation autophagy inhibitors. Early-stage autophagy 
inhibitors Spautin-1 and SBI-0206965, do not induce significant amounts of apoptosis 
compared to dimeric quinacrine compounds.23,27 The result underscores the inability of 
early-stage autophagy inhibition to prevent cancer cell proliferation. 
 
Next, the DQ library was assayed for its effects on the autophagy pathway. 
Western blotting for LC3 allowed for a relative quantification of the accumulation of its 
two forms, LC3-I and LC3-II. The relative accumulation of LC3-II to LC3-I is directly 
correlated to the accumulation of mature autophagosomes. A subset of the DQ library 
was assayed, and a peculiar pattern emerged. The compounds containing a methylated 
tertiary amine performed as hypothesized, where treatment of melanoma cells with 
inhibitors resulted in substantial autophagy inhibition. However, when cells were treated 
with the secondary amine linked dimers, LC3 was found to accumulate to a significantly 
smaller degree. (Figure 2.17) 
Figure 2.16: Annexin V assay for apoptosis. PANC1 cells treated with 3 uM DQ 
compound at a time of 24 hours.53 
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In autophagy, inhibition of lysosomal-autophagosomal vesicle fusion creates the 
expected increase of the LC3-II to LC3-I ratio. Unfortunately, induction of the autophagy 
pathway will also cause an increase in autophagosomes and thus both LC3-I and LC3-II, 
which can complicate a semi-quantitative technique such as Western blotting. The 
bafilomycin clamp assay has been developed which eliminates vesicle fusion by 
inhibition of the lysosome prior to treatment with an autophagy inhibitor. The name of 
the assay is derived from Bafilomycin A1 (Baf), an inhibitor of the vacuolar ATPase, the 
main proton pump maintaining the lysosomal pH gradient. Treatment of a cell with Baf 
causes lysosomes to deacidify and halts lysosomal vesicle fusion. In the Baf-clamp assay, 
cells are pre-treated with Baf, then treated with the inhibitor of interest. Any subsequent 
increase in the production of either LC3-I or LC3-II must be attributed to the induction of 
autophagy. When assayed by Baf-clamp, the unmethylated secondary amines increased 
the production of LC3-B, indicating the induction of autophagy, while the methylated 
tertiary amines do not induce autophagy. 
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Another marker for autophagic activity is the adaptor protein p62. In autophagy, 
the adaptor protein p62 marks cargo for degradation and facilitates the recruitment of the 
cargo to the forming autophagosomes. After lysosomal vesical fusion with the 
autophagosome, p62 itself becomes degraded. In cases where autophagy is inhibited, the 
Bafilomycin A1 Clamp Experiment 
LC3B Accumulation- Autophagy Inhibition 
Figure 2.17: A. Western blotting for protein markers of autophagy inhibition, LC3B. B. The 
average accumulation of LC3-II vs LC3-I in methylated and unmethylated DQ inhibitors. C. 
Western blotting for protein markers of autophagy inhibition, LC3B, in a Bafilomycin 
clamp experiment. D. The average accumulation of LC3-II vs LC3-I in methylated and 
unmethylated DQ inhibitors in a Bafilomycin clamp experiment.53 
A. 
C. 
B. 
D. 
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p62 adaptor protein accumulates because the degradative machinery is sequestered from 
the autophagosomes containing the p62. PANC1 cells showed a striking difference in 
levels of p62 when treated with DQ inhibitors. Western blotting of treated cells showed 
unmethylated DQ compounds allowed p62 degradation, whereas methylated DQ 
inhibitors caused the accumulation of p62. These experiments further support the idea 
that methylated DQ compounds inhibit autophagy, while unmethylated compounds 
induce autophagy (Figure 2.18). NBR1 is a receptor protein which is associated with 
recruitment of cargo for autophagic degradation. NBR1 is degraded upon lysosomal-
autophagosomal vesicle fusion. Following the same trend as p62, NBR1 was found to be 
degraded in cells treated with secondary amine linked DQ compounds, indicating active 
autophagy (Figure 2.18). 
 
P62 & NBR1 Accumulation- Autophagy 
Figure 2.18: A. Western blot analysis for p62 and NBR1 accumulation in cells treated 
with DQ compounds. B. The average accumulation of p62 in methylated and 
unmethylated DQ. Accumulated p62 or NBR1 indicates inhibited autophagy, where 
lack of these proteins indicates active autophagy.53 
A. B. 
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To understand the striking contrast between the DQ inhibitors, we attempted to 
identify potential stressors which could be inducing autophagy. Dr. Vito Rebecca 
recognized that DNA damage is an inducer of autophagy, and therefore cells treated with 
DQ compounds were assayed for DNA damage. DNA damage is known to induce 
autophagy through a signaling cascade which engages two key autophagy signaling loci, 
the Ulk1 complex and the beclin1-Vps34 complex. Through these complexes, autophagy 
is induced which can lead to DNA damage repair, autophagic cell death, or senescence 
followed by an immune response. 63 QN is known as a potent DNA intercalator.  
Therefore it is a reasonable hypothesis that DQ compounds are potent intercalators as 
well.64 DNA intercalation is known to cause the DNA processing machinery to stall when 
scanning the phosphate backbone of DNA, resulting in double stranded nicks in the DNA 
backbone. These breaks are identified by DNA damage response (DDR) machinery of the 
cell and labeled by histone phosphorylation. When small molecules are intercalated into 
DNA, topoisomerase inhibition causes the phosphorylation of histone 2A (pH2AX), a 
marker which can be observed by Western blotting or by immunofluorscence. 65 
Immunofluoresence (IF) imaging of pH2AX was performed on A375P melanoma 
cells. Cells treated with unmethylated inhibitors were found to have significantly more 
DNA damage than their methylated counterparts (Figure 2.19). Further, as the linker 
lengths of the DQ compounds increased, the differential amount of DNA damage 
between methylated and unmethylated inhibitors increased. This result is consistent with 
the hypothesis that DQ compounds which induce autophagy do so through induction of 
the cellular DDR.  
47 
 
 
The subcellular localization of the DQ compounds was assessed using 
spectroscopic measurements. Acridines, like quinolines, can absorb a photon of light. 
When the correct wavelength of light is absorbed, the resulting excited molecule can 
relax back to the ground state by the emission of a photon. Most quinoline based 
molecules fluoresce when they absorb UV irradiation. Fortunately, with the increased 
size of the aromatic system comes the red shifting of both absorption and fluorescence 
emission of the molecule. Quinacrine has long been known to absorb light at 
approximately 425 nm and fluoresce at approximately 500 nm. One of the first uses of 
quinacrine was the fluorescent staining of DNA chromosomes for karyotyping.64,66 We 
Immunofluorescence imaging of pH2AX - Indicator of 
DNA Damage 
Figure 2.19: A. Immunofluorescence microscopy 
observing phosphorylated histone 2A, a marker for 
DNA damage. Unmethylated DQ inhibitors induce 
significantly greater amounts of DNA damage. DAPI is 
a fluorescent dye which labels the nuclei of cells 
regardless of drug treatment. B. The quantification of 
the fluorescence signal which indicates 
phosphorylation of histone 2A.53 
A. 
B. 
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investigated the spectroscopic properties of the DQ library by UV-Vis absorbance 
spectroscopy and fluorescence spectroscopy. The compounds were found to absorb 
strongly at 424 nm and 440 nm. Each compound had a fluorescence emission maximum 
at approximately 500 nm. Unsurprisingly, the spectroscopic properties of the DQ 
compounds varied with the pH of the aqueous medium. Lowering of the pH of the 
medium (1N HCl) caused a partial quenching of the fluorescence emission, and, 
surprisingly, the appearance of a secondary fluorescence emission peak. Compounds 
which have longer linkers were found to have slightly higher fluorescence emission 
intensities in both peaks. 
Using fluorescence microscopy, DQ compounds can be seen to enter the cell and 
localize primarily in two places: the nucleus and the lysosome. The subcellular 
localization of the drug was not entirely surprising due to the knowledge of the DNA 
intercalating ability of quinacrine, and the propensity of weakly basic molecules, 
including CQ, to localize to the acidic lysosomal compartment.19,47,50,64  
Differential subcellular localization was hypothesized as a potential factor for the 
observed DNA damage or autophagy inhibition, respectively. Microscopy shows a more 
pronounced lysosomal presence for the methylated DQ inhibitors. However, the 
experiments done were not quantitative. Therefore, a concerted effort was made to 
understand where the different classes of DQ compounds were localizing sub-cellularly. 
A375P melanoma cells were treated with DQ660 56 or DQ661 64. The cells were then 
fractionated into lysosomal and whole cell fractions. Fluorescence spectroscopy was used 
to quantify the amount of each DQ compound in the respective compartment after the 
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fractions were normalized for protein concentration. We elected to compare DQ660 56 
accumulation versus DQ661 64 accumulation as a ratiometric measurement. DQ661 64 
was found to significantly accumulate in the lysosome (36 uM) relative to the whole cell 
(16 uM). In contrast, DQ660 56 barely accumulates in the lysosome (10 uM) versus the 
whole cell (7 uM).   
The same experiment was performed on isolated nuclear compartments from 
A375P melanoma cells. When compared to the remainder of the cell, both drugs are 
trafficked to the nucleus to the same extent. DQ660 56 treated cells exhibit significantly 
greater DNA damage compared to DQ661 treated cells. However, DQ660 56 and DQ661 
64 localized to the nucleus to the same extent. Therefore, subcellular localization cannot 
be the direct cause for the difference in DNA damage induction between the methylated 
and unmethylated DQ inhibitors. Further study into the DNA damaging ability of DQ660 
56 is ongoing in collaboration with the Maity Laboratory in the Radiology Department at 
the University of Pennsylvania Medical School. In preliminary organismal studies, 
DQ660 56 induced DNA damage potentiates radiation therapy in cancer xenograft 
experiments. 
One proposed mechanism of lysosomal inhibition is the induction of lysosomal 
membrane permeabilization (LMP). Recently, a marker for this phenomenon has been 
discovered. Lectin galactoside binding soluble 3 (LGAL3) or galectin-3 has been found 
to swiftly localize to damaged lysosomal membranes.67 IF microscopy can be used to 
observe the localization of galectin-3 into puncta when LMP is induced. Melanoma 
A375P cells were treated with DQ compound or positive LMP control leucine 
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methylester hydrobromide (LloMe) and compared to an untreated control. IF imaging 
revealed a diffuse staining of galectin-3 in cells treated with the unmethylated inhibitors, 
QN, and the non-potent DQ221 52. Small puncta were imaged in cells treated with the 
positive control LloMe and the methylated DQ compounds with linkers greater in size 
than DQ221 52. DQ661 64 was found to most significantly induce LMP in melanoma 
cells. Notably, DQ221 52 is the lone methylated DQ inhibitor tested which does not 
induce LMP (Figure 2.20). 
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Lysosomal Membrane Permeabilization 
Figure 2.20: IF microscopy which assays the propensity for DQ inhibitors to cause 
LMP. Antibodies for galectin-3 image the enzyme in the cytosol. When LMP is 
induced galectin-3 localized to the damaged membrane. In methylated inhibitors 
which are longer in length than DQ221, significant LMP is observed by the 
appearance of puncta within the cell. 53 
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To further understand the degree of DQ661 64-induced LMP, Western blotting 
was performed to observe the subcellular localization of the lysosomal protease cathepsin 
D (CTSD). Upon maturation of the enzyme, it is transported to the lysosomal 
compartment, where it acts as one of the main degradative enzymes within the 
lysosome.68 Cells treated with either DQ660 56 or DQ661 64 were fractionated into a 
lysosome enriched fragment and a whole cell fragment. The degree of lysosomal 
enrichment is measured by Western blotting for lysosomal membrane associated protein 
2 (LAMP2), a lysosomal membrane protein. Western blotting for CTSD shows cells 
treated with DQ661 64 have CTSD in both the whole cell and the lysosome containing 
fractions, despite having efficiently separated the lysosome containing fraction from the 
whole cell fraction. This result demonstrates that the lysosomal membrane integrity is 
being damaged by DQ661 64. Both untreated and DQ660 56 treated cells have CTSD 
only in the lysosome-enriched fragment (Figure 2.21).  
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The most potent dimeric autophagy inhibitor DQ661 64 was also one of the most 
potent anti-proliferative agents, having caused the largest amount of apoptosis and the 
largest accumulation of LC3B and p62. These qualities made DQ661 64 the best 
candidate for studying the mechanism of action of DQ inhibitors. To elucidate the 
mechanism, high-throughput experimentation was utilized in a reverse phase protein 
array (RPPA). Through a collaboration with MD Anderson Cancer Center at the 
University of Texas, melanoma cells treated with DQ661 64 were subjected to RPPA. 
This assay screens the expression levels of >290 proteins involved in signaling pathways 
commonly misregulated in cancer. Treatment with DQ661 64 had a strong, reproducible 
impact on protein levels of autophagy-related proteins, apoptosis-related proteins, and 
mTOR-signaling proteins. Western blotting for protein levels present in the mTOR 
Figure 2.21: Western blot analysis of cells treated with DQ660 and DQ661. Cells 
were separated into lysosome-enriched fragments and blotted for cathepsin D a 
lysosomally localized protein.53 
CTSD 
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pathway confirmed that DQ661 was indeed causing mTOR inhibition, a phenotype 
previously not observed in cells treated with Lys-05 9.  
MTORC1 is a master regulator of cellular metabolism, extensively regulating 
autophagy and macropinocytosis.11,69 The mTORC1-signaling pathway involves multiple 
enzymes which sense the levels of specific amino acids. When amino acids are present, 
the regulatory proteins, Rag GTPases, recruit mTORC1 to the surface of the lysosome. 
Residing on the surface of the lysosome are the proteins which comprise the Ragulator 
complex and Rheb, the master activator of mTOR kinase activity. When mTORC1 is 
recruited to the lysosomal surface, it binds to the Ragulator, which allows for the 
localization of Rheb on the lysosomal membrane to the Ragulator complex. When Rheb 
encounters mTOR bound to the Ragulator complex, mTORC1 is phosphorylated, 
activating its kinase activity. MTORC1 kinase activity is a suppressor of autophagy and 
micropinocytosis, two compensatory pathways which a cell can utilize to scavenge 
nutrients. 
Three cell lines (BRAF mutant, NRAS mutant, and WT/WT) were treated with 
DQ661 64, and then analyzed by Western blot to determine the extent of the mTOR 
inhibition. DQ661 64 demonstrated the ability to inhibit mTOR signaling in all three cell 
lines. S6K is a protein which is phosphorylated by mTOR signaling. Treatment with 
DQ661 64 reduced SK6 phosphorylation, indicating mTOR was inhibited. 4E_BP1 is 
also a protein which is phosphorylated by mTOR signaling. Again, treatment of A375P 
melanoma cells with DQ661 64 significantly reduces the phosphorylation of 4E_BP1. S6 
is another phosphorylated protein in the mTOR signaling pathway. The phosphorylation 
55 
 
of S6, another protein that is phosphorylated in the mTOR signaling pathway, is also 
inhibited on treatment of A375P melanoma cells with DQ661 64. Finally, the three cell 
lines were also blotted for the apoptosis marker caspase-7, a protein which is cleaved 
when a cell undergoes apoptosis. Cleaved caspase-7 was observed in all cell lines. 
However, the amount of cleaved caspase7 in both mutant melanomas was significantly 
greater than in WM3918 (WT) melanoma (Figure 2.22, A). 
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For each of these markers, a kinetic experiment was performed in BRAF mutant 
melanoma, where time points were taken between zero and twenty-four hours. In cells 
treated with 3 uM DQ661 64, accumulation of LC3B began at approximately one hour. In 
two hours, the amount of phosphorylated S6K and phosphorylated 4E-BP1 decreased. In 
six hours, significant amounts of p62 were observed to accumulate, indicating autophagy 
Western Blotting for mTOR Substrates 
Figure 2.22: A. Western blotting for mTOR kinase substrates (S6K, 4E-BP1, and S6), LC3B, and 
a marker of apoptosis (caspase-7) in mutants of melanoma. Increased phosphorylation of 
mTOR kinase substrates indicates mTOR activity. Cleavage of caspase 7 indicates the 
induction of apoptosis. B. A 24-hour time course measuring mTOR kinase substrates (S6K, 
4E-BP1, and S6), LC3B, and caspase-7 in A375P melanoma.53 
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was inhibited. In six hours, when both autophagy and mTOR are inhibited, the cells 
began to undergo a significant degree of apoptosis, marked by cleaved caspase-7 (Figure 
2.22, B).  
These results raised the interesting question of whether this type of mTOR 
signaling inhibition is present when melanoma is treated with other lysosomal inhibitors. 
Untreated melanoma cells were compared to cells treated with a panel of lysosomal 
inhibitors, utilizing serum starvation as a positive control for mTOR signaling 
suppression. Pepstatin A is an aspartyl protease inhibitor which inhibits cathepsin D 
activity in the lysosome. E64 is a covalent cysteine protease inhibitor, containing an 
epoxide warhead. Combinations of pepstatin A and E64 can be used to significantly 
suppress lysosomal degradation. Siramesine, a small molecule inhibitor of sigma-2 
receptor, was originally developed as an anti-depressant. Recent studies of siramesine as 
an anti-cancer therapeutic have established that it leads to inhibition of lysosomal 
function through inhibition of acid sphingomyelinase and the induction of LMP.70 PET 
and PES are two inhibitors of HSP90 designed by the Murphy Laboratory at the Wistar 
Institute. Hsp90 is known to aid in protein folding and the maintenance of protein 
homeostasis. One function of autophagy is the degradation of protein aggregates, and 
therefore we were interested in whether these compounds altered mTOR kinase activity 
autophagy. These inhibitors alone and in combination were tested in melanoma cells to 
determine whether they could also impact the mTOR signaling pathway in a similar 
fashion to DQ661 64. DQ661 64 was found to be the only compound which inhibited 
lysosomal function and prevented mTOR signaling, as indicated by the phosphorylation 
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of S6K and 4E-BP1. Only serum starvation, the removal of required nutrients, was able 
to induce a comparable suppression in mTOR activity. Further, RPPA analysis of DQ660 
56 and QN 2 treated melanoma cells showed the impact on mTOR signaling to be unique 
to DQ661 64 (Figure 2.23).  
 
 
To become activated, mTOR must localize to the lysosomal surface guided by 
RagGTPases. These enzymes allow mTOR to bind the Ragulator complex on the surface 
of the lysosome, fixing the location of mTOR. Rheb, the master activator of mTOR, is a 
kinase which is present on the lysosomal surface. When Rheb encounters mTOR bound 
Figure 2.23: A 375P melanoma cells were treated with a panel of compounds. 
Western blot analysis of mTOR kinase substrates and LC3B. Phosphorylation of 
mTOR substrates indicates functioning mTOR signaling. Accumulation of LC3-II 
when compared to LC3-I indicates inhibited autophagy.53 
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to the Ragulator complex, Rheb phosphorylates mTOR, turning on mTOR kinase 
activity. In collaboration with the Zoncu Laboratory at UC Berkeley, we explored the 
localization of mTOR and its recruiting enzymes through IF imaging. Fascinatingly, 
DQ661 64 treatment inhibits the lysosomal localization of RagC, a recruiting GTPase, 
and mTORC1. A proximity ligation assay was utilized to determine the degree of 
colocalization of mTORC1 and RagC. Utilization of specially modified antibody-DNA 
conjugates allows for the fluorescent labeling of a protein-protein interaction.53,71 When 
A375P melanoma cells were treated with DQ661 64, the Rheb and the Ragulator 
complex showed nearly zero co-localization, as observed by IF microscopy, unlike the 
untreated control. The same assay was conducted utilizing antibodies for mTORC1 and 
Rheb, the master activator for mTOR, and imaged by IF microscopy. Untreated 
melanoma cells showed significant colocalization of these two enzymes. Rapamycin, an 
mTOR inhibitor, Torin, an mTOR kinase inhibitor, Bafilomycin A1, lysosomal VATPase 
inhibitor, and siramesine, an inducer of LMP, were tested in the proximity ligation assay. 
In each case, mTOR and Rheb were found to have a degree of interaction similar to the 
control, suggesting the inhibitors do not affect the activation of mTOR by Rheb. Further, 
siramesine, which causes LMP, did not inhibit mTOR in the same manner. These results 
demonstrate that loss of mTOR localization to the surface was not merely an artifact of 
disrupting membrane integrity. Treatment of A375P cells with DQ661 64 completely 
abolished the interaction between mTOR and Rheb, thus inhibiting mTOR activation. 
MTOR inhibition has not led to significant success  in clinical studies.14,72 MTOR 
suppression activates the Ulk1 complex, which upregulates autophagy. It has been 
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hypothesized that this is an effort by the cells to recycle internal cargo and make amino 
acid building blocks available, which in cancer cells allows for the continuation of cell 
proliferation. MTOR suppression is also known to increase cellular macropinocytosis 
which allows for Ras-driven cancers to continue their cell proliferation.11 
Macropinocytosis is an endocytic process where cells envelop extracellular proteins 
which are trafficked to the lysosome. In the lysosome, the proteins are broken down to 
their constituent amino acids and released into the cell as metabolic building blocks. 
Thompson and coworkers have demonstrated that tumor regions which are under 
metabolic stress by growing beyond their amino acid supply can activate 
macropinocytosis when mTOR is inhibited and continue further cell proliferation.73 The 
engagement of macropinocytosis allows cancer cells to paradoxically continue cell 
proliferation even when faced with mTOR suppression. The engagement of 
macropinocytosis is another hypothesis which could explain the lack of efficacy of 
mTOR suppression in clinical trials. To explore the effect of DQ661 64 on 
macropinocytosis, pancreatic cancer cells were grown under nutrient starved conditions 
with a fluorescently labeled bovine serum albumin derivative added to the medium. The 
BSA is labeled with such a high density of dye that fluorescence is significantly 
quenched. When the protein is degraded, fluorescence increases due to dissociation of the 
labeled amino acids. When macropinocytosis is engaged, uptake and degradation of the 
labeled BSA is observed. Cells treated with DQ661 64 or torin-1, an mTOR kinase 
inhibitor, both engaged in the macropinocytotic uptake of labeled BSA. Cells treated with 
torin-1 showed significant degradation of the labeled BSA. In contrast, while the labeled 
BSA was taken up by cells treated with DQ661 64, the protein was not degraded by the 
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lysosome, suggesting DQ661-mediated lysosomal impairment prevents macropinocytosis 
from circumventing mTOR inhibition. DQ661 64 therefore represents a new strategy 
which suppresses mTOR signaling in cancer cells but is not circumvented by either the 
autophagy pathway or macropinocytosis. 
  Collaboration with the Rabinowitz Laboratory at Princeton University allowed 
for the quantification of the effect of DQ661 64 on extracellular protein uptake. In this 
experiment, cancer cells are grown in an isotopically labeled medium containing 13C 
enriched amino acids. The isotopically-labeled cells are then grown in amino acid starved 
media with standard BSA supplemented as the only protein source. If BSA is taken up 
and broken down via macropinocytosis, the incorporation of the light, 12C only, amino 
acids into cellular proteins can be quantified versus an untreated control. Due to the 
sequence specificity of BSA, the amino acid profile which would be incorporated 
provides a unique signature, and therefore is easily quantified as the source of scavenged 
amino acids. When comparing cells treated with DQ661 64 to an untreated control, the 
amount of amino acid scavenging was significantly suppressed. This result confirms the 
ability of DQ661 64 to inhibit macropinocytosis.  
In vivo study of DQ compounds in mouse tumor xenograft models produced 
positive anti-cancer results. BRAF mutant and HCQ resistant melanoma cells, 1205Lu, 
were implanted in the flank of NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. These 
tumors were allowed to grow for a period of one to two weeks, until the tumors were 
palpable. Treatment, either vehicle control, DQ661 64, DQ660 56, or QN 2, was given to 
the mouse through an intraperitoneal (IP) injection. The mice were treated with a regimen 
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which did not drastically decrease the weight of the subject. Subjects treated with QN 2 
were found not to differ from control at a dose of 8mg/kg. However, at this dose DQ660 
56 demonstrated significant potency, along with DQ661 64. When comparing the two 
DQ inhibitors, DQ661 64 performed significantly better than its unmethylated 
counterpart, yielding further evidence for the importance of a tertiary amine within the 
linker of DQ inhibitors (Figure 2.24, A). When the rate of growth was calculated for the 
xenograft experiment, only DQ661 64 was able to produce a 0% growth rate at 8 mg/kg 
(Figure 2.24, B).  
 
 
Figure 2.24: A. Mice were treated first at 8mg/kg with QC 2, DQ660 56, or DQ661 62. 
Mice were euthanized at 16 days due to lethargy when treated with DQ661. B. The 
tumor growth rate plotted for each drug treatment. C. A second experiment was run 
where mice were given 2mg/kg DQ661, and tumor growth rate was suppressed over the 
course of 22 days. D. The tumor growth rate plotted for each drug treatment 
condition.53 
A. 
B. 
C. 
D. 
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To understand the mechanism of action of these inhibitors in the xenograft 
experiment, tumor biopsies were taken. The biopsies were analyzed by 
immunohistochemistry for pH2AX and it was found that only DQ660 56 produced 
significant histone phosphorylation, indicating DNA damage occurred. When examined 
for autophagic vesicle accumulation, DQ661-treated tumors showed significant vesicle 
accumulation, whereas DQ660-treated tumors did not. In our first experiments, doses of 
DQ661 64 at 8mg/kg caused significant weight loss (greater than 10% of body weight) in 
mouse subjects. After one week, mice treated with these large doses experienced lethargy 
and distended bowels. Autopsy and subsequent histological analysis revealed significant 
Paneth cell dysfunction akin to that reported in the in vivo investigation of Lys-05 9. The 
Paneth cell dysfunction is a hallmark of autophagy dysfunction, confirming again that 
DQ661 64 is inhibiting autophagy in vivo.52 
2.4 Second Generation of DC Inhibitors 
 Encouraged by the successful study of the DQ library, we sought to synthesize the 
analogous DC library analogs. In a combined effort with Dr. Noel McLaughlin, the 
analogous library was created to mirror the DQ library. Dr. McLaughlin synthesized 
DC440, DC441, DC550, DC551, in addition to a number of other dimeric compounds 
which are not linked via simple triamine linkers. Dr. McLaughlin prepared the first 
samples of DC660 and DC661, and I led subsequent efforts to translate these preparations 
to multi-gram syntheses for animal studies. We were also interested in determining 
whether DC inhibitors lost potency at linker lengths greater than 6/6, and therefore 
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synthesized the following new dimers: DC770, DC771, DC880, DC881, DC11110, and 
DC11111. 
 We next wanted to understand whether the bishexamethylene triamine linker of 
DQ661 64 imparted the same biological activity to DC inhibitors. DC661 69 was 
synthesized by Buchwald-Hartwig C-N arylation of bishexamethylene triamine 51, 
followed by Eschweiler-Clarke reaction to methylate the internal nitrogen of the linker 
(Figure 2.25). DQ661 64 was tested for its anti-proliferative activity by two-week colony 
formation assay and autophagy inhibition activity by Western blotting. DC661 69 
possesses superior potency in both autophagy inhibition and anti-cancer activity when 
compared to HCQ 4 and Lys-05 9 (Figure 2.26). 
 
 We next chose to assay DC661 for the induction of LMP via the galectin-3 IF 
microscopy assay, where galectin-3 localizes in puncta where LMP occurs on the 
lysosomal membrane. DC661 69 causes significant LMP, where Lys-05 9 and HCQ 4 do 
not (Figure 2.27). The three compounds were then tested in three cell lines for their 
Figure 2.25: The gram-scale synthesis of 
DC661 69.  
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ability to induce apoptosis. Compared to untreated control, dabrafenib (BRAF inhibitor), 
trametinib (MEK inhibitor), and the combination of dabrafenib and trametinib (standard 
of care for BRAF mutant melanoma), DC661 69 produced significantly more apoptosis 
in all three cell lines. 
 
 
Figure 2.26: The structures of HCQ, Lys-05, and DQ661. Assays for anti-cancer activity 
(colony formation), and autophagy inhibition (LC3B accumulation). 
69 
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DC661 69 was tested in tumor xenograft experiments with 1205Lu melanoma in 
NSG mice. Tumors were grown on the flanks of mice until palpable, after which DC661 
was administered via IP injection at a dose of 3mg/kg. DC661 69 treatment halted tumor 
growth over the course of a 15-day experiment (Figure 2.28).  
Figure 2.27: A. IF 
microscopy images 
indicating that DC661 
induces significant amounts 
of LMP in melanoma cells 
(A375P, 451Lu, and 
WM983B).  
B. Annexin V assay 
demonstrates that 
melanoma treated with 
DC661 undergoes 
significantly more apoptosis 
than treatment with the 
standard of care, 
dabrafenib(Dab) and 
trametinib(Tra) 
combination therapy. 
A. 
B. 
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2.5 Synthesis of longer linked DC inhibitors 
 We synthesized DC11110 71 via Buchwald-Hartwig arylation conditions utilizing 
our synthesized 11/11 triamine 47. The resulting inhibitor was methylated using 
formaldehyde and sodium triacetoxyborohydride in CH2Cl2 to give 72. We began with 
the synthesis of DC880 from 4-bromo-7-chloroquinoline 13, and our 8/8 triamine 41 
linker using a Pd(OAc)2/BINAP catalyst system with K3PO4 in dioxane. Unfortunately, 
no product was observed in the reaction. We had previously taken note of the decreased 
yields in arylation reactions of triamines with increasing linker length when synthesizing 
the DQ library. This result suggested that altered arylation conditions would be required 
to synthesize DC880. We screened different reaction conditions where solvent, base, 
ligand and palladium sources were changed. However, no product was observed in the 
reactions. In reactions where the catalyst system was altered, only starting material 13 
Figure 2.28: Mice were treated daily with DC661 (3mg/kg) or water via IP injection. A. 
Tumor volume measured in DC661 treated mice and untreated control mice. B. 
Tumor growth rate plotted for untreated control and DC661 treated mice. 
A. B. 
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was observed via 1H NMR analysis of the reaction mixture. We attempted to utilize the 
more efficient Buchwald-Hartwig pre-catalyst which is recommended for primary amine 
arylation, although no product was observed. The base was changed to NaOtBu in 
combination with our existing catalyst system Pd(OAc)2/BINAP. However, the outcome 
of the reaction did not improve when compared to K3PO4. When attempting a solvent 
screen, we noticed that the 8/8 triamine 41 was sparingly soluble in dioxane and most 
non-alcohol organic solvents. Tert-butanol was screened for its ability to solubilize the 
8/8 triamine 41, as it has been utilized with NaOtBu in arylation reactions. However, the 
compound was still sparingly soluble. We had previously observed that DC and DQ 
inhibitors with tertiary amines were much more soluble in organic solvent than their 
secondary amine-linked counterparts.  
 Simultaneously with our screen of arylation conditions, we explored utilizing the 
8/8 triamine with the internal amine protected 73 (Figure 2.29). Staudinger reduction of 
the 8/8 bisazide 39 yielded a triamine where the central nitrogen of the triamine was a 
benzylated tertiary amine 73. We next attempted to arylate the triamine utilizing our 
original arylation conditions: Pd(OAc)2/BINAP and K3PO4 in 1,4-dioxane heated to 
reflux. The reaction produced good yields of dimeric chloroquine compound where the 
linker amine was a tertiary benzylamine 74. We next explored methods of removing the 
benzyl protecting group from the internal nitrogen. However, hydrogenolysis conditions 
reductively cleaved the chlorines from the quinoline rings of the inhibitor. We next 
attempted to remove the benzyl group under SN2 conditions with hydrobromic acid. 
However, this reaction proved to be unsuccessful. Next, we attempted to acylate the 
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tertiary amine utilizing methyl chloroformate. Previous work by our laboratory 
demonstrated that chloroformates can be utilized to deprotect benzylic tertiary amines.74 
However, in the presence of the aminoquinoline rings the reaction did not produce any 
debenzylated product. As a control reaction we proved the benzylamine of the 8/8 
bisazide 39 could be acylated and debenzylated by methyl chloroformate in good yield to 
give compound 75. With this compound in hand we elected to reduce the azides via a 
Staudinger reduction and assess the compatibility of the methyl carbamate protecting 
group with our arylation conditions. Buchwald-Hartwig arylation of the diamine 76 
provided an 8/8 dimeric chloroquine analog 77 where the internal amine was protected 
with a methyl carbamate. The carbamate was successfully deprotected by reaction with 
HBr (33% v/v in AcOH) at 100 °C to give DC880 78. The resulting DC880 78 inhibitor 
was then methylated with formaldehyde and sodium triacetoxyborohydride in CH2Cl2 to 
give DC881 79.  
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 We next set out to synthesize both DC770 85 and DC771 86 (Figure 2.30). 
However, we wanted to explore whether utilization of a nitrogen source other than 
benzylamine could improve the synthesis of dimeric inhibitors. We selected 2,4-
dimethyoxybenzylamine as a nitrogen source to synthesize a protected triamine 
precursor, because we believed under acidic deprotection conditions the protecting group 
could be removed. 7-azidoheptanol 80 was oxidized to 7-azidoheptanal via Swern 
conditions, which was concentrated to a crude dilute solution due to safety concerns 
regarding low-molecular weight azides. The crude aldehyde-containing solution was then 
used to reductively alkylate 2,4-dimethoxybenzylamine 81 in serviceable yield over 2 
Figure 2.29: Synthesis of 8/8 DC inhibitors 78 and 79. 
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steps to give bis-azide 82. The resulting bis-azide 82 was then reduced via Staudinger 
reduction to afford a triamine 83 in good yield. The resulting triamine was then arylated 
with 13 using Pd(OAc)2/BINAP and K3PO4 in 1,4-dioxane heated to reflux. The resulting 
dimethoxybenzyl protected DC77 inhibitor 84 was then deprotected in neat trifluoracetic 
acid with water and triisopropylsilane by heating to 130 °C under microwave irradiation 
to yield DC770 85. The internal linker nitrogen of 85 was then methylated using 
formaldehyde and sodium triacetoxyborohydride in CH2Cl2 to yield DC771 86.  
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 We compared the anti-cancer activity of DC770 85 and DC771 86 to their 6/6 
congeners, DC660 68 and DC661 69. Interestingly, both DC770 85 and DC771 86 appear 
to be comparably potent in anti-cancer activity (Figure 2.31). This result contrasts with 
the DQ series of inhibitors. We had previously hypothesized that longer linked dimers 
eventually become hydrophobic to an extent that is detrimental to their anti-cancer 
activity. While DQ inhibitors 57, 58, 59, 65, 66, and 67 (Figure 2.10 and Figure 2.11) lost 
potency, DC770 85 and DC771 86 appear to inhibit cell proliferation to a greater extent 
than DC660 and DC661. We had hypothesized that linkers longer than 7 carbons in the 
aliphatic chain were too hydrophobic to utilize as dimeric inhibitors. However, in the 
Figure 2.30: Synthesis of 7/7 DC inhibitors. 
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case of DC compounds, it appears that 41 is not too hydrophobic to generate a potent 
inhibitor. Further study into the activity of longer linked DC inhibitors is required.  
 
 
2.6 Preparation for the Third Generation of Dimeric Chloroquine Inhibitors 
 Our studies of the second generation of dimeric lysosomal inhibitors 
demonstrated the importance of the identity of the triamine linker from which the 
inhibitor is synthesized. In the absence of a target, we became interested in how the 
distance between heterocycles effects the potency of a dimeric inhibitor. Unfortunately, 
increasing the length of the aliphatic chains which comprise the triamine linker also 
results in a significant increase in hydrophobicity. To separate hydrophobicity and 
distance as factors, we elected to synthesize dimeric inhibitors derived from less 
hydrophobic linkers. We wanted to determine whether making single heteroatom 
substitutions in the aliphatic regions of dimeric inhibitors could improve their potency as 
Figure 2.31: MTT and colony formation assay comparing DC66 inhibitors to DC77 
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autophagy inhibitors by improving their biophysical properties. We identified PEG linked 
dimers to be a sterically conservative modification of the aliphatic linked dimers, while 
drastically reducing the inhibitors hydrophobicity. 
 We planned to use the strategy applied to the synthesis of DC880 and DC881 to 
synthesize PEG linked dimeric inhibitors. We selected two lengths of PEG, diethylene 
glycol and tetraethylene glycol, as scaffolds to mimic DC inhibitors with triamine linkers 
of length 5/5 and 11/11 (Figure 2.32). The resulting azides, 87 and 89, were converted to 
the corresponding alkyl bromides by Appel reaction, 88 and 90.75,76 The alkyl bromides 
were used to alkylate benzylamine via SN2 yielding 91 and 92. In the case of PEG-based 
alkyl bromides, we observed an increase in yield of the SN2 reaction when compared to 
the aliphatic alkyl bromides. Further, the significant weight added by the bromine atom to 
the diethylene glycol chains gave us confidence in our ability to isolate pure azide-
containing material in a safe manner. The resulting bisazide 91 was then acylated with 
methyl chloroformate and deprotected in toluene at 85 °C to yield 93.  Compound 93 was 
reduced via a Staudinger reduction to afford compound 95. The resulting diamine 95 was 
then arylated with 13 utilizing Pd(OAc)2/BINAP and K3PO4 in 1,4-dioxane heated to 
reflux to yield compound 97. The resulting carbamate-containing derivatives were then 
deprotected utilizing either KOH in ethanol (compound 99), heated to reflux, or 
trimethylsilyl iodide in CHCl3 (compound 100). The resulting secondary amine-
containing inhibitors were methylated utilizing CH2O and sodium triacetoxyborohydride 
in CH2Cl2 to afford compounds 101 and 102.  
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 We next wanted to determine whether the addition of amines to the linker would 
improve the potency of dimeric chloroquine inhibitors. We began our synthesis from a 
protected pentaamine, 103,  reported by Jahromi and coworkers, where the three internal 
nitrogen atoms were Boc protected.77 The primary amines are arylated with 13 utilizing 
Pd(OAc)2/BINAP and K3PO4 in 1,4-dioxane heated to reflux to yield a DC inhibitor of 
5/5 in length with three Boc-protected amines, compound 104. The Boc protecting groups 
are then removed by reaction with trifluoroacetic acid in CH2Cl2. The resulting DC 
inhibitor, 105, was methylated with Eschweiler-Clarke conditions in reasonable yield to 
afford compound 106. We were pleased to observe product without observation of any 
cyclic aminal intermediates (Figure 2.32).  
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Figure 2.32: Synthesis of PEG2 linked DC inhibitors and pentaamine linked DC inhibitors 
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2.7 Synthesis of Piperaquine Derivatives 
 Piperaquine (PQ) 5 is a commercially available anti-malarial derivative of CQ 1 
(Figure 2.33). The inhibitor is the only commercially available dimeric anti-malarial CQ 
derivative. Currently, a combination therapy of artusunate (artemisinin methyl ester) and 
piperaquine is one of the standards of care for malaria in east Asia. PQ 5 differs from CQ 
1 in that the aminoquinoline moiety is a tertiary amine rather than a secondary amine and 
is constrained into a piperazine ring. The dimer is formed by linking two CQ-piperazine 
halves of PQ by a propyl linker. We hypothesized that perhaps PQ could possess unique 
anti-cancer activity akin to Lys-05 9 by nature of its dimeric structure. We also 
hypothesized that if the propyl linker were extended, by spacing the CQ rings an 
equivalent distance to DC661 69, that the anti-cancer properties of the two molecules 
would be similar in nature. 
 
 
 We began our synthesis by reacting 4,7-dichloroquinoline with an excess of 
piperazine in ethanol at 135 °C under microwave irradiation.78 The resulting SNAr 
reaction produces a CQ-piperazine, 107, in good yield. Three derivatives of piperaquine 
were derived from three dibromoalkanes: 1,2-dibromoethane 108, 1,7-dibromoheptane 
Figure 2.33: The structure of piperaquine (PQ). 
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34, and 1,8-dibromooctane 35. The SN2 reactions were performed by heating in DMF to 
120 °C in a sealed vessel (Figure 2.34). The resulting dimers, 109, 110, and 111, will be 
tested for their anti-cancer activity by MTT proliferation assay. 
 
 
2.8 Synthesis of Ferroquine Derivatives 
 Recently, a new chloroquine analog has demonstrated significant success in anti-
malarial studies.79,80 Ferroquine 6 is a chloroquine-based antimalarial which utilizes 
ferrocene as a stable iron source in place of two methylenes of the linker between the 
Figure 2.34: Synthesis of dimeric PQ analogs of various linker lengths 
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heterocycle and the tertiary amine (Figure 2.35). In malaria it is hypothesized that CQ 
resistance can be overcome by compounds which accumulate to a greater extent in the 
digestive vacuole. Work by Biot et. al. has demonstrated that FQ 6 is potent in CQ-
resistant malaria.80 A recent study by Kondratskyi and coworkers has observed ferroquine 
to be potent when assayed for its anti-cancer activity.54  
 We hypothesized that perhaps the addition of a second CQ heterocycle to the 
ferroquine skeleton could improve the potency of ferroquine as an anti-cancer agent, just 
as Lys-05 improved the potency of CQ. We started by purchasing commercially available 
ferroquine and synthesized the tetraalkyl ammonium salt 112 following the studies of Li 
and coworkers.81 We synthesized two secondary amine containing monomeric 
chloroquine analogs 107 and 114 for the derivatization of FQ. First, piperazine was 
reacted in excess with 4,7-dichloroquinoline in ethanol at 135 °C under microwave 
irradiation.78 The resulting secondary amine, 104, was utilized to synthesize compound 
113. We next synthesized 7-chloro-N-(piperidin-4-yl)quinolin-4-amine, 114, previously 
synthesized by Madrid et. al.82 We again used the tetraalkyl FQ salt 112 as an 
electrophile in a SN2 reaction with excess 114 to afford dimeric FQ2, 115. (Figure 2.35) 
These reactions proceeded in modest yield at 40 °C over four days. We believe the yield 
could be improved by screening reaction conditions.  
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 In a pilot biological experiment, the MTT antiproliferation potency of our two 
new ferroquine derivatives (FQ1 and FQ2) were assayed in comparison to commercial 
FQ (6). Interestingly, the FQ2 (115) was more potent than FQ (6) and FQ1 (113), 
indicating that the formation of a dimeric species did improve the anti-proliferative 
activity of FQ (6). FQ1 (113) which has a tertiary amino-quinoline instead of a secondary 
aminoquinoline performed worse than FQ (6). These results could be attributed to the 
importance of the flexibility of CQ heterocycles in dimeric inhibitors to populate 
different conformations and the requirement for the CQ heterocycle to contain a 
secondary aniline. (Figure 2.36) 
Figure 2.35: The synthesis of dimeric FQ derivatives, FQ1 113 and FQ2 115. 
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 Currently, further study of the biological activity of dimeric ferroquine 
compounds is underway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.36: MTT proliferation assay results for FQ 
derivatives in A375P melanoma. The more flexible FQ2 
115 is more potent than the parent ferroquine (FQ) 6. 
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Chapter 3: Determination of the mechanism of action of dimeric chloroquine and 
quinacrine lysosomal inhibitors. 
In modern day medicinal chemistry, most drug discovery efforts start with a 
biological target. In most cases, a medicinal chemistry effort will target a specific enzyme 
either directly involved in an enzymatic transformation, an enzymatic process upstream 
of the target transformation which will regulate the target event, or an enzymatic process 
downstream which will induce a feedback loop effecting the target enzymatic process. 
Often a high-throughput screen is used to identify chemical structures which are most 
effective at inhibition of the target enzyme. If the enzymatic target responsible for a 
biological transformation is unknown, the process of intelligent inhibitor design becomes 
significantly more empirical.  
 CQ was designed as an anti-malarial therapeutic. However, due to multiple 
toxicities and resistant malaria strains, the use of CQ as a standard of care has been 
reduced.37 An off-target effect of CQ is the inhibition of lysosomal vesicle fusion in the 
autophagy pathway. The use of CQ as an inhibitor of late stage autophagy is the result of 
a serendipitous observation rather than rational target-focused design (Chapter 1). 
3.1 The Justification of a Protein Target for DQ and DC Inhibitors. 
The lysosomotropic nature of CQ is directly correlated to autophagy inhibition, 
where inhibition of the lysosome prevents lysosomal-autophagosomal vesicle fusion. CQ 
is a dibasic inhibitor (pKa 8.6 and 9.8), causing the molecule to be protonated in acidic 
compartments of the cell.31 Dating back to the work of de Duve studying the lysosome, 
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CQ was observed to significantly accumulate in the lysosome and other acidic vesicles.19 
It is well known that the lysosome requires an acidic pH to maintain proper function. 
Therefore, it has been widely hypothesized that the ability of CQ to deacidify the 
lysosome is the mechanism of action of CQ-mediated autophagy inhibition. However, no 
direct evidence is available that this lysosomal buffering capacity is solely responsible for 
CQ-mediated autophagy inhibition. Treatment of eukaryotic cells with millimolar 
quantities of ammonium chloride will deacidify the lysosome as well.83 A simple analysis 
of the pKa of CQ and HCQ would suggest the inhibitors have a similar buffering capacity 
to that of ammonium chloride (pKa ~9). However, CQ and HCQ are both more potent 
autophagy inhibitors than ammonium chloride.  
CQ has also been documented to accumulate to a greater extent than a simple 
analysis of pKa would infer. In a scenario where only the pH gradient governs the 
accumulation of CQ within a vesicle, it is expected that the ability of the lysosome to 
accumulate CQ would be directly proportional to the pH gradient between the lysosomal 
lumen and the cytosol. As the pH gradient approaches zero from accumulated compound 
buffering, the rate at which CQ accumulates should approach zero as well. Previous 
workers have postulated that the lipophilicity of CQ allows for more efficient 
accumulation via partitioning with hydrophobic lipids and proteins within the 
lysosome.19,84 This partitioning could allow for a reservoir of CQ and thus a buffering 
capacity beyond what an initial analysis of pKa would allow. The ability of a hydrophobic 
molecule to better pass through a membrane compared to ammonium chloride may be an 
explanation for the observed differences in potency. 
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Our studies of Lys-05 9 suggest that dimeric chloroquine (DC) inhibitors are 
acting not only as a lipophilic weak bases. Lys-05 is more than an order of magnitude 
more potent than CQ as an anti-proliferative agent and as an inhibitor of autophagy. More 
importantly, Lys-05 derivatives (Lys-02 10, Lys-03 11, and Lys-04 12), which are 
similarly hydrophobic as Lys-05 9, are no more potent than CQ 1 (Figure 3.1). One could 
argue the increase in potency is derived from the tribasic nature of Lys-05 9 compared to 
the dibasic nature of CQ 1. However, this is not consistent with our studies. Other tribasic 
analogs 10 & 11 of Lys-05 9 were tested and were found to be equipotent with CQ 1 in 
autophagy inhibition assays. Replacement of the C-7 chlorine on the aminoquinoline ring 
with a methoxy substituent also decreases activity of the inhibitor 11. The SAR study 
during the development of Lys-05 indicated small structural changes which do not greatly 
alter the biophysical properties of the Lys-05 derivatives do have a significant impact on 
the potency of the resulting inhibitor (Chapter 2). The exchange of C-7 chlorine in 
compound 9 for a C-7 methoxy substituent should produce an inhibitor with a more basic 
aminoquinoline ring. It is a reasonable hypothesis that increasing the pKa of the 
aminoquinoline would improve the efficacy of the inhibitor, however this is not reflected 
in the experiments reported by our Laboratory.85 
85 
 
 
The SAR observed in our study of DQ lysosomal inhibitors is in accord with this 
hypothesis. DQ221 52 is significantly less potent than other DQ analogs in MTT anti-
proliferation assays. A375P melanoma cells treated with DQ221 52 exhibited cell 
proliferation comparable to melanoma cells treated with monomeric QN. DQ331 60, the 
linker of which is two atoms longer, was among the most potent anti-proliferative DQ 
compounds (Chapter 2). This small structural difference between DQ221 52 and DQ331 
60 supports the hypothesis of a mechanism more complicated than these compounds 
simply acting as lipophilic buffering agents. The tricyclic fused ring system of the 
dimeric quinacrines is ~50% larger than the aminoquinoline of CQ and DC inhibitors. 
We hypothesized that the increased steric demand of the QN heterocycles necessitated an 
increase in linker length of the dimeric inhibitors in order to enjoy an increase in potency 
from dimerization relative to the monomeric heterocycle. The distance between the 
heterocycles and the tertiary amine of the linker could influence the pKa of the linker 
Figure 3.1: The structure of Lys-05 and other dimeric chloroquine inhibitors. 
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tertiary amine through inductive effects. Lys-05 9 should have been equally influenced 
by inductive effects as DQ221 52. However, Lys-05 was more potent than the parent 
monomeric CQ (Figure 3.2). This SAR data set suggests that inductive effects of the 
heterocycle on the linker tertiary amine pKa were not the cause of the lack of potency of 
DQ221 52. 
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 One plausible hypothesis which would explain the differences in activity across 
monomeric CQ 1, monomeric QN 2, DC, and DQ compounds is the existence of a 
protein binding partner. If these molecules were able to inhibit an enzymatic reaction 
within the lysosome, perhaps an increase in enzyme binding affinity correlating with anti-
Figure 3.2: CQ, QN, DQ221, DQ331, and Lys-05 structures. The calculated pKa from 
chemdraw are reported for each structure. The experimental values for pKa are 
reported for CQ 1. 
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proliferative activity could explain the observed differences in the biological activity of 
the dimeric inhibitors.  
3.2 Determining a protein target of a small molecule inhibitor 
The sequencing of the human genome in the early 2000s has catalyzed a new 
approach towards understanding and managing disease pathology. Following the central 
dogma of biology, where the DNA in a cell contains the sequences of the constituent 
enzymes of an organism, a non-infectious disease phenotype must be the result of the 
improper regulation or improper expression of a specific enzyme or enzymes. Therefore, 
if a gene can be identified in a disease phenotype, one can design and target the enzyme 
resulting from this gene with a small molecule therapeutic. In parallel with the advances 
in genome sequencing technology, advancements in mass spectrometry (MS) have led to 
a rapidly expanding field of proteomics, where differentially expressed or modified 
proteins can be identified from exceedingly complex biological mixtures. These advances 
have led to the rapidly expanding field of chemical proteomics, where the molecular 
target of a small molecule can now be identified using a phenotypic screening 
approach.86–89 
 The rapid advancement in MS technology has helped birth the ever-growing field 
of proteomics. While full length proteins can be difficult to observe by electrospray 
ionization mass spectrometry, improvements in both liquid chromatography (LC) and MS 
detection have allowed for the rapid identification of peptides in a complex mixture. In 
general, proteases, enzymes which cleave the peptide backbone of a protein, have 
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exquisite selectivity and cleave the protein after specific amino acid residues in 
polypeptide sequence. Therefore, the peptide products of enzyme-catalyzed proteolysis 
can be predicted accurately with prior knowledge of the sequence of a protein. These 
predicted peptides can be thought of as a fingerprint for a specific protein. Sequencing of 
the human genome has made obtaining sequence information for human proteins 
significantly more accessible. Combining genome sequencing data, with mass 
spectrometry identification of peptide mixtures, one can accurately pick out the 
constituent proteins which comprise a complex mixture.  
Often, when a small molecule is biologically active it binds an enzyme or another 
bio-macromolecule. If the binding interaction of a small molecule to the target protein is 
tight enough (usually nM affinity), then fixing the small molecule to a solid support 
would allow for affinity chromatography purification of the target protein.90 This concept 
was first employed to isolate proteins from their natural sources by Leonard Lerhman in 
the early 1950s.91 Later, this approach was utilized by the McCormick Laboratory in 
1964 to purify liver flavokinase.92 This approach was also utilized by the Anfinsen 
Laboratory in 1968 to purify staphylococcal nuclease, α-carboxypeptidase, and 
chymotrypsin.93 In theory, this idea of small molecule affinity chromatography could be 
utilized to purify and identify the binding partner for a drug-like small molecule inhibitor. 
Two of the most well-known examples come from the Schreiber Laboratory which 
utilized this technique to identify the targets of previously discovered drug-like natural 
products in their study of the binding partners for immunosuppressants and histone 
deacetylases.94–96 This strategy should be applicable with any small molecule inhibitor. 
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However, the effectiveness of this approach is significantly affected by the relative 
abundance of the target protein, the background noise of non-specific binding, and the 
off-rate of the inhibitor (koff, time at which half of the protein-ligand complex has 
dissociated).97 In cases where a non-covalent adduct does not bind its target tightly 
enough to employ affinity chromatography, the introduction of a covalent linkage could 
negate the issue of inhibitor off-rate and low binding affinity. 
 A second strategy for identifying binding partners for biologically active 
molecules is utilization of a covalent inhibitor for an enzyme or enzyme class, and the 
subsequent MS identification of the bioconjugate or purification of the complex through a 
known affinity-tag, such as biotin. The earliest example was demonstrated by Glynn and 
coworkers in their identification of a new serine protease using biotinylated 
organophosphorus compounds.98 More recent work by the Cravatt Laboratory at the 
Scripps Research Institute has expanded on this idea to discover binding partners of drug-
like small molecules and to discover new proteins within a class of enzymes. This field, 
now referred to as activity-based protein profiling (ABPP) is defined as a methodology 
which broadly profiles the activity of an enzyme in a biological organism through the 
utilization of a reactive functional group.99 This reactive functional group forms a 
covalent linkage between the protein and small molecule ligand, allowing for isolation of 
a bioconjugate. A phenotypic screen can be interrogated by ABPP through the design and 
synthesis of probe analogs of a lead molecule. At the cornerstone of a chemocentric 
ABPP approach is the utilization of a reactive functional group which is specifically 
reactive towards a class of enzymes, or the utilization of a small molecule warhead which 
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binds a protein tightly and specifically enough to confer specificity to the reactive 
functional group. This covalent adduct can be visualized by fluorescent labeling or 
enriched with affinity chromatography. Analysis of these protein profiles identifies the 
binding partners of the inhibitor in question, allowing for biological validation of the 
mechanistically relevant binding partner. Unfortunately, most drug-like small molecule 
inhibitors are not covalent inhibitors of enzymes, preventing the utilization of this 
approach to binding target identification. Photoaffinity labeling (PAL) is a technique 
which has been used in biochemistry and chemical biology dating back to the 1960s. The 
Westheimer Laboratory introduced this concept in a fundamental contribution to the 
intersecting fields of organic photochemistry and biochemistry. 
 The seminal work by Westheimer and coworkers outlined a strategy of forming 
small molecule-protein covalent adducts through photolysis of a small molecule.100 Their 
studies utilized the reactivity of chymotrypsin towards p-nitrophenolate esters 116 to 
covalently modify the enzyme active site. Acetylation of chymotrypsin prevents the 
native activity of the enzyme. Reaction of acetylchymotrypsin with hydroxylamine 
cleaves the acetylation site, recovering the native activity of the enzyme. Unlike previous 
acetylations of chymotrypsin, Westheimer and coworkers modified the active site with a 
p-nitrophenyl diazoester 117. Photoirradiation of the protein conjugate 118 reduced the 
activity of the enzyme by 25%. This reactivity loss was not recovered by the reaction of 
the protein conjugate with hydroxylamine, indicating that a new non-acyl bond 120 must 
have been formed with chymotrypsin. (Figure 
3.3)
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 This example of the compatibility of organic photochemistry with a biological 
macromolecule has set the foundation of many contributions to modern chemical biology. 
In their work, Westheimer and coworkers postulated that if the chromophore of the small 
molecule absorbs at a longer wavelength than the protein in question, organic 
photochemical reactions can be used to map the molecular contacts of the active site of a 
protein.100 Today, the concepts put forth by Westheimer and coworkers have been 
extrapolated to form a field known as photocrosslinking, where two molecules in a 
biological context can be chemically linked utilizing photoirradiation. 
 As stated by the original Westheimer hypothesis, photolysis leads to a reactive 
intermediate which enables bioconjugation. The tremendous reactivity of the photolyzed 
intermediate comes with a complete lack of specificity in what the intermediate reacts 
Figure 3.3: The experiment by Westheimer and coworkers utilized a p-nitrophenyl 
diazoester to first covalently modify chymotrypsin. Photolysis of this bioconjugate with 
UV light results in a reactive carbene. In a productive photocrosslinking reaction the 
carbene can insert into a C-H bond of the enzyme, or a H-heteroatom bond to form a 
covalent linkage. 
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with. In the case of diazoesters, a reactive carbene is formed. When the carbene is solvent 
exposed, reaction occurs to a substantial degree with bulk solvent, a non-productive side 
product of the bioconjugation reaction. To bias the photoinduced bioconjugation reaction 
towards productive reactivity with chymotrypsin, Westheimer and coworkers attached the 
photolabel covalently to an active site residue of the protein prior to photolysis. This 
covalent adduct makes the resulting photolabeling reaction intramolecular; improving the 
selectivity of the carbene insertion for the target protein. This strategy is often not 
applicable in the realm of medicinal chemistry. The vast majority of medicinal chemistry 
compounds are non-covalent inhibitors of enzymatic activity. However, because of the 
kinetics of photoexcitation and reactivity, covalently linking a photolyzable functional 
group and a non-covalent inhibitor imparts specificity to the reactivity of the typically 
non-specific photoreactive functional group. 
After the introduction of photoaffinity labeling by Westheimer and coworkers, 
work by the Knowles Laboratory published pioneering work utilizing PAL to map active 
site residues of proteins.101 With the advances in proteomic capabilities, proteins can now 
be identified from PAL reactions after isolation from the biological milieu and MS 
analysis. Advances in these techniques have led to the rapid expansion of the field. 
Taunton and coworker published an excellent summary which details a protocol for the 
selection of a PAL reactive group, and the subsequent techniques which allow for target 
identification.90 In modern chemical biology, three photolyzable functional groups 
dominate the field: aryl ketones 121, aryl azides 124, and diazirines 127 (Figure 3.4). 
Each photolyzable group differs in its excited state reactivity, imparting slight differences 
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in photolabeling outcomes. Excitation of aryl ketones 121 promotes the molecule to the 
first singlet excited state. Intersystem crossing to the triplet state results in the ketone 
having more diradical character than carbonyl character 122. This diradical 122 can relax 
back to the ground state 121, making the photoexcitation of aryl ketones reversible, or the 
diradical can abstract a hydrogen atom from a biological molecule resulting in radical 
recombination and carbon-carbon bond formation 123. This reversibility sets the 
reactivity of aryl ketones apart from the other photolyzable functional groups. The high 
homolytic bond dissociation of water makes this functional group unreactive towards the 
bulk solvent, conferring high selectivity to the labeling reaction. Light excitation of aryl 
azides 124 causes the loss of nitrogen gas, yielding a nitrene intermediate 125.102 The aryl 
nitrene 125 can react with organic molecules in several ways: aziridine formation with 
alkenes, C-H insertion reactions 126, C-N insertion reactions, or ring expansion followed 
by conjugation to a nucleophile. The last crosslinking functional group is the excitation of 
diazirines 127. These functional groups represent the most synthetically complex 
photoaffinity labels. Once excited, these molecules lose nitrogen gas yielding a carbene 
intermediate 128. The carbene is then able to either react with solvent and act as an 
electrophile, undergo H-heteroatom insertion reactions, or undergo C-H insertion 
reactions 129.103 
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 In an ideal scenario, the photolabeling of a protein could be identified through the 
use of a positive control and a negative control for photoirradiation, where MS analysis 
could observe a new photoproduct mass for Target + Probe. However, the sheer 
complexity of the biological milieu results in tremendous background signal making this 
approach quite challenging. Instead, if an investigator considers that their photo-affinity 
probe is now a covalent inhibitor of the protein binding partner, then the principles of 
competitive ABPP can be applied. Small lipophilic molecules have an intrinsic affinity 
for protein when compared to the bulk solvent, water. Thus, an investigator would expect 
a certain level of non-specific covalent bonding of the photoprobe, but the expected level 
and identity of the background will be unknown. In a PAL pulldown, comparing 
experiments with and without competition answers this question. A specific binding 
Figure 3.4: Modern photolyzable functional groups utilized in photocrosslinking: aryl 
ketones, aryl azides, and diazirines. When excited by UV light these groups form reactive 
intermediates which can form covalent bonds with biomolecules, making small-molecule 
bioconjugates. 
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partner of the parent drug should be enriched through chemical reactivity of the 
photoprobe. However, in the presence of the non-covalent competition, the signal should 
be significantly decreased or not observed. This result indicates the protein is making a 
specific interaction with the inhibitor warhead from which the pulldown probe was 
derived. 
3.3 Design and synthesis of a photoaffinity analog from an inhibitor lead 
To perform a photo-affinity pulldown experiment, the photo-affinity analog of the 
parent inhibitor must be designed with significant preexisting SAR knowledge. The point 
of attachment for the photocrosslinker and the affinity handle must conserve the 
selectivity of the parent molecule for the target. To achieve this, we designed a 
photoaffinity probe by the addition of a photoaffinty label and a biotin handle to our most 
potent inhibitors. The SAR of dimeric chloroquine (DC) and dimeric quinacrine (DQ) 
inhibitors indicated that inhibitors containing a 6/6 triamine linker are the most potent 
inhibitors of autophagy and the most potent anti-cancer agents. SAR studies of both 
classes molecules identified the importance of the basic nitrogen atom within the linker 
of the dimeric compound. The linker size and the presence of a tertiary amine was to be 
maintained in the photoaffinity analog. Studies of DQ inhibitors established the central 
nitrogen atom alkylation governs whether a molecule induces or inhibits autophagy. We 
identified that alkylation of the central nitrogen of our triamine linker could serve as an 
attachment point for the required PAL functional groups. We used these criteria to design 
a series of photoaffinity probes to identify the target of tertiary amine containing DQ and 
DC inhibitors.  
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 A linear synthetic strategy was chosen (Fig 3.5, A), where a photocrosslinker 
could be attached to the DC660 68 (Figure 3.5, B) inhibitor through a flexible linker via 
alkylation of the central linker nitrogen. The attached photoaffinity moiety would contain 
an alkyne handle where click chemistry could be used either synthetically to attach an 
affinity handle or in situ utilizing biorthogonal click chemistry. Benzophenone was 
selected as the first choice for a photoreactive functional group because of the synthetic 
ease of its incorporation and its specificity in photolabeling reactions (Figure 3.5, C).  
 Biotin is a natural product ubiquitous in biological systems and is commonly used 
as a handle in affinity chromatography. Multiple homologs of biotin-binding proteins 
exist which form extremely tight non-covalent binding interactions. The interaction 
Figure 3.5: (A) A linear scheme for the construction of a photoaffinity probe. (B) a DC 
inhibitor warhead. (C) Benzophenone, the photocrosslinking functional group chosen for 
our photoaffinity probe. (D) Two affinity handles which can be used to pulldown proteins 
from the biological milieu.  
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between biotin and streptavidin, a common biotin-binding protein, is non-covalent. The 
tight binding affinity of this interaction allows for solid-supported streptavidin to rapidly 
bind biotinylated molecules in solution. The non-covalent interaction between biotin and 
a biotin binding protein is strong enough that the supernatant can be removed from a 
mixture of lysate and solid support without breaking the interaction. Further, washing the 
solid support with detergent will not break the biotin-enzyme interaction. Desthiobiotin is 
an analog of biotin which maintains a significant binding interaction with biotin-binding 
enzymes. However, additional biotin can be utilized to displace desthiobiotin from biotin 
binding proteins (Figure 3.5, D). The advantages of using a biotin analog become 
apparent when separating biotin labeled targets from native biotinylated molecules. 
 Polyethylene glycol (PEG) was selected as a linker between each component of 
the photo-affinity probe. With binding conformation of the parent inhibitor unknown, a 
flexible linker was chosen to maximize the likelihood of crosslinking. PEG specifically 
was chosen as the linker because of its lower cLogP value when compared to an aliphatic 
linker of similar length (Fig 3.6). The addition of benzophenone adds a significant 
amount of hydrophobic surface area to the probe; therefore, the addition of the 
hydrophilic PEG chain was designed to maintain the aqueous solubility of the molecule. 
Tetraethylene glycol was selected as the PEG linker for multiple reasons: first, PEG 
linkers between two and four monomer units are commodity chemicals; second, 
tetraethylene glycol afforded a significant amount of hydrophilic surface area to help 
solubilize the large probe molecule; third, the increased flexibility of the extended linker 
would maximize the chances of photocrosslinking success, even if the inhibitor warhead 
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was buried deep within the protein of interest; fourth, the longer linker was selected to 
space the benzophenone far enough away from the parent warhead so as to not influence 
the binding mode of the probe molecule. 
 
 
 With advances in the sensitivity of mass spectrometry, it is becoming increasingly 
possible to generate large profiles of data for multiple photocrosslinking probes. If the 
number and cost of biological experiments were not a factor, each photoreactive 
functional group would be combined with each length of spacer. A protein pulled down 
most often among all analogs would be the most attractive putative target. However, in a 
case where three photoreactive chemistries are available and three linkers are considered, 
nine biological experiments would be required prior to the reproduction of the results. 
Each biological experiment consists of one set of experimental conditions and two 
controls, which would result in 27 proteomic profiles for analysis of each inhibitor 
warhead. Such efforts were beyond the scope of our capabilities, and therefore we 
proceeded with inhibitors utilizing one PEG length and one photoaffinity probe per 
inhibitor warhead.  
Figure 3.6: The structures of PEG chains and the corresponding aliphatic diols of equal 
length. 
100 
 
 With the design of a photoaffinity probe in hand, the synthetic effort focused on 
the synthesis of three separate regions. The dimeric inhibitor was synthesized as the 
secondary amine-linked analog, which would allow for the attachment of a PEG chain via 
reductive amination. The benzophenone could be attached to a PEG chain, which could 
be used to alkylate the inhibitor. The other side of benzophenone could contain a 
propargyl group which could facilitate the attachment of biotin via click chemistry. 
 
 
Figure 3.7: A. General structure of a DC photoaffinity pulldown analog. Key synthetic 
disconnections are noted by dotted lines. B. Retrosynthesis of a photoaffinity analog of 
DC661. 
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 Tetraethylene glycol was mono-tosylated using p-toluene sulfonyl chloride as the 
limiting reagent in the presence of pyridine to yield compound 143.104 4,4-
dihydroxybenzophenone was monoalkylated with propargyl bromide in ethanol heated to 
reflux using potassium carbonate as a base to yield 142.105 4-propargyloxy-4-
hydroxybenzophenone 142 was deprotonated by potassium carbonate in ethanol, and the 
resulting phenolate was then alkylated with tosylate 143 to give 141. Compound 141 was 
oxidized by Swern conditions yielding an aldehyde, 144. Aldehyde 144 was used in 
slight excess, without purification, in the subsequent reductive alkylation of the 
secondary amine containing DC660 68 with sodium triacetoxyborohydride in CH2Cl2 
(Figure 3.8). 
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 The affinity handle for the probe was synthesized starting from the bis-mesylation 
of tetraethylene glycol in methylene chloride, using triethylamine as a base. The crude 
mesylate was then reacted with sodium azide in situ using a mixture of water and ethanol 
heated to reflux.105 Monoreduction of the bisazide was facilitated by Staudinger reduction 
using triphenylphosphine in a biphasic solvent system of diethyl ether and 0.9 M 
phosphoric acid (1:1, 50% v/v) to give compound 147.105 The resulting primary amine 
147 was then coupled to desthiobiotin 131 via a peptide coupling reaction using TBTU 
and Hünig’s base in DMF to give 140.105 (Figure 3.9) 
Figure 3.8: Synthesis of DC661, Lys05, and DQ661 benzophenone-containing analogs. 
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 The alkyne-containing photoprobes 139, 145, and 146 were then linked to the 
desthiobiotin affinity handle 140 by click chemistry using copper (II) sulfate and sodium 
ascorbate in a methanol and water solvent system. Click chemistry was selected as the 
final synthetic step due to its broad functional group compatibility. The click reaction 
yielded photoaffinity compounds 139, 148, and 149 in serviceable yield. (Figure 3.10). 
Figure 3.9: Synthesis of Desthiobiotin Azide 140 
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 CQ 1 and HCQ 4 have structural differences in the linker region when compared 
to DC inhibitors, specifically a methyl group and a diethylamine (Figure 3.11).  Both CQ 
1 and HCQ 4 are similarly effective in inhibiting autophagy, and thus we hypothesized 
the hydroxyl of HCQ 4 was not necessary and could be utilized as a handle to attach 
photoaffinity functional groups to commercial HCQ 4. We envisioned the construction of 
a photoaffinity analog for CQ/HCQ 1/4 would contain a PEG chain linked to the tertiary 
amine found in the linker of CQ/HCQ 1/4 (Figure 3.12). Multiple attempts were made to 
utilize the hydroxyl of HCQ 4 as a free nucleophile in the SN2 alkylation of a tosylated 
PEG derivative. Each of these attempts proved unsuccessful, where no alkylated product 
Figure 3.10: Click ligation of desthiobiotin azide and the alkyne-containing DC analogs. 
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was observed. We attempted to reverse the polarity of the SN2 reaction by exchanging the 
hydroxyl of HCQ 4 with a leaving group via synthesis of the mesylate and the bromide. 
TLC analysis of both reactions indicated a consumption of starting material; however, a 
baseline spot was observed which was found to be immobile on silica. We hypothesized 
that either the molecule is undergoing a decomposition reaction with the unprotected 
aminoquinoline acting as a nucleophile, or that the tertiary amine could be contributing to 
the premature ejection of the new leaving group via aziridinium formation. 
Unfortunately, any attempts to trap the electrophile with triethylene glycol proved to be 
unsuccessful. This reaction should be studied in future derivatizations of chloroquine. 
However, in the interest of synthetic ease we pivoted our design strategy to synthesize a 
CQ 1 derivative de novo.  
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 In 1946 Professor Marvin Carmack and coworkers synthesized monoalkylated 
versions of CQ.106 In their paper they described a compound which was referred to as 
desethyl chloroquine, a chloroquine analog containing a secondary amine rather than the 
standard tertiary amine. This led us to hypothesize that by accessing this chloroquine 
derivative, we could apply the same chemistry we had utilized to functionalize secondary 
amine containing DC inhibitors. The route published by Carmack and coworkers 
contained no spectroscopic data for the compounds and required high pressure reductions 
Figure 3.11: A. A structural comparison of CQ and HCQ. B. Retrosynthesis of a chloroquine 
photoaffinity analog. The synthesis proceeds through a secondary amine containing CQ 
analog which is synthesized de novo. 
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and extremely low-pressure distillations. Therefore, we proposed to improve the route 
through the utilization of modern organic chemical methods. 
 We envisioned synthesizing desethyl chloroquine by first synthesizing an amino 
alcohol and arylating the nitrogen via Buchwald-Hartwig conditions. We elected to 
arylate prior to synthesizing the diamine because we feared the length of the carbon 
linker (four) would make any attempts to synthesize the diamine prone to cyclization. We 
hypothesized that arylation of the primary amine of the amino alcohol 153 with the 
electron withdrawing chloroquine ring would help prevent the cyclization from 
occurring.   
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 We began by synthesizing 4-nitropentanoate, 154, from nitroethane and ethyl 
acrylate, according to literature precedent.107 Ester 154 was then reduced with lithium 
aluminum hydride to afford the 4-amino-1-pentanol 153 in good yield. Buchwald-
Hartwig arylation of amino alcohol 153 produced the arylated product 152 in serviceable 
yield. Alcohol 152 was then oxidized to aldehyde 155 using Swern conditions. Initial 
experiments which used CH2Cl2 as a solvent were unsuccessful. Changing the solvent to 
THF proved critical to the success of the Swern oxidation. Aldehyde 155 was found to 
decompose on purification. Therefore, the crude aldehyde was reacted without 
Figure 3.12: The synthesis of a chloroquine pulldown molecule 156. 
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purification in a reductive amination reaction with ethylamine and sodium 
triacetoxyborohydride to yield desethyl chloroquine, 151. Compound 151 was 
reductively alkylated with aldehyde 144 using sodium triacetoxyborohydride in CH2Cl2. 
Alkyne 150 analog was then ligated to desthiobiotin azide 140 via click chemistry, 
yielding the final CQ-P 156. 
 
  
For a pulldown probe to be successfully utilized in a competitive 
photocrosslinking experiment, it must mimic the in vivo activity of the inhibitor analog 
from which it was derived. We assayed A375P melanoma cells treated with each of the 
photoaffinity pulldown molecules to determine whether autophagy was inhibited 
similarly to A375P melanoma cells treated with the parent inhibitors. DC661-P, (Figure 
3.10, 138) caused the accumulation of LC3-B at doses as low as 0.3 nM. DC221-P, 148, 
and CQ-P, 156, both lost significant potency in comparison to their parent inhibitors 
(Figure 3.13). However, inhibition of autophagy at high micromolar doses demonstrated 
that the molecules were still functional, and that the molecules still caused autophagy 
Figure 3.13: Western blots of LC3B for DC inhibitors. DC661-P (pulldown) was observed to 
significantly inhibit autophagy. Lys05 and CQ-P also inhibited autophagy, although, 
significantly less potently than their parent inhibitors.  
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inhibition. This indicated to us that they would be acceptable molecules for a competitive 
PAL experiment. 
 
 
3.4 Implementation of a photoaffinity pulldown probe 
In our studies of DQ inhibitors, we observed inhibited cell proliferation, inhibited 
autophagy, and blocked mTOR signaling in DQ661 treated melanoma cells. The DQ661-
P, 149, treated cells were assayed for autophagy inhibition and mTOR signaling. 
Treatment of melanoma cells with DQ661-P 149 caused the accumulation of LC3B, 
which indicated that autophagy was inhibited. Western blotting for 4E-BP1 and S6 
demonstrated that phosphorylation was decreased upon treatment of A375P melanoma 
cells with 149, indicating that mTOR activity was suppressed. Therefore, we reasoned 
that 149 would be effective in competitive PAL experiments. 
Figure 3.14: Western blot assaying autophagy inhibition (LC3B) and mTOR signaling 
(p4E-BP1 and pS6) in DQ661-P 149 treated cells. Decreased p4E-BP1 and pS6 indicates 
inhibition of mTOR signaling. 
DQ661-P 149 (uM) 
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 Doses for the pulldown assay were determined with maximum target capture in 
mind, while minimizing background non-specific binding. In a standard model for 
protein-substrate binding, the affinity of an enzyme for a substrate or inhibitor can be 
quantified in terms of the dissociation constant (Kd) of the ligand, defined by the 
concentration of free enzyme and free ligand divided the concentration of enzyme-ligand 
complex. Utilizing this metric, a smaller numerical value indicates a tighter binding 
interaction. The amount of inhibitor present at concentrations below the Kd is rapidly 
complexed with enzyme. Enzymes quickly reach a point of saturation where no further 
ligand is bound after the dissociation constant is reached (Figure 3.15). Inhibitor added 
beyond the enzyme saturation point will have a greater contribution to unwanted 
background signal than increased target binding. We hypothesized that for a phenotype to 
be induced, significant quantities of the target enzyme must be bound. Therefore, a dose 
of 200 nM was selected, because at this dose LC3B is observed to accumulate, indicating 
autophagy inhibition. From this result we hypothesized that a significant quantity of the 
putative target must be bound to cause the autophagy inhibition phenotype. Our proposed 
proteomic analysis was used only for protein identification purposes, and therefore we 
valued background signal reduction greater than increased target binding.  
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 The experimental controls are critical to the successful design of a pulldown 
experiment. At its core, the goal of a photoaffinity pulldown is to make an unbiased 
crosslink between the photoreactive functional group and the nearest protein to the probe. 
In all cases, addition of the probe functionality to parent warhead inherently will add 
significant non-specific binding, because desthiobiotin will be bound by native biotin 
binding proteins and benzophenone will make non-specific hydrophobic interactions with 
proteins. Further, it is expected that all small molecule therapeutics have non-specific 
protein binding due to the drug partitioning between the aqueous solvent and the more 
hydrophobic macromolecules of the cell. 
 The experimental setup becomes a balancing act of generating and isolating as 
many crosslinked potential targets as possible, while discerning which of those crosslinks 
are specific and which are non-specific. We utilized three controls for every probe tested. 
Figure 3.15: A representation of a dissociation constant with an indication of enzyme saturation, 
where additional ligand would bind background non-specific binding rather than the target 
protein. 
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This first control was a negative control in which cells were treated with the photoaffinity 
probe but were not exposed to UV irradiation. Proteins identified should not be covalent 
adducts and were regarded as nonspecific binding. In the next experiment, the cells were 
treated with the photoaffinity probe and irradiated with UV light.  The benzophenone and 
the affinity handle will generate false targets which bind the photoaffinity probe but 
would not have significant affinity for the parent inhibitor. In order to separate these false 
positive results from the true potential targets, a competition control was utilized. We 
hypothesized that the mechanistic target of dimeric lysosomal inhibitors will bind equally 
or more potently to the parent inhibitor than the photoaffinity probe. This hypothesis was 
based on the observation that neither benzophenone nor biotin/desthiobiotin have been 
reported as inhibitors of autophagy. We hypothesized that the administration of a 
competition dose of tenfold greater magnitude than the photoaffinity probe would 
displace the photoaffinity probe from the putative protein target.  This decrease in signal 
for proteins would indicate that their crosslinking was conferred by a specific binding 
affinity between the inhibitor warhead and the protein. The crosslinking of proteins 
which non-specifically bind the benzophenone or affinity handle should not be 
significantly altered by the competition dose.  
Once cells were either irradiated or not irradiated, they were immediately 
harvested and lysed. The cell lysate was frozen at -80 °C in the presence of broad 
spectrum protease inhibitors until affinity purification. To facilitate affinity 
chromatography, a streptavidin protein conjugated to polymer support was required. 
Neutravidin (Thermo Scientific), a bioengineered homolog of avidin and streptavidin, 
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was chosen for our experiment. Neutravidin binds biotin as tightly as both avidin and 
streptavidin, but the surface of the protein is mutated to maximally reduce non-specific 
protein binding to the resin. The protein is conjugated to agarose as a solid support. The 
neutravidin resin was equilibrated with cell lysis buffer containing protease inhibitors, 
and was mixed with cell lysate for a period of 12-16 hours at 4 °C. The resin was then 
separated via centrifugation and washed with a series of NP-40-containing buffers to 
remove cell debris and non-specifically bound proteins. The washes were analyzed via 
SDS-PAGE to determine whether further washing was required.   
The use of desthiobiotin as an affinity handle facilitated a non-denaturing elution 
step, yielding a cleaner elution from the resin. Desthiobiotin 131 (Figure 3.5) is an analog 
of biotin 130 (Figure 3.5), where the sulfur atom is removed from the 
tetrahydrothiophene ring, leaving only the cyclic urea of the fused ring system. Multiple 
orthogonal elution methods based on chemical linkers which are labile to bioorthogonal 
chemistry have been invented.108 We elected to utilize desthiobiotin because of synthetic 
ease and the predefined protocols for elution from avidin resins. 
Desthiobiotin binds avidin/streptavidin with a Kd of ~10
-13 versus the Kd of 
biotin~10-15. The difference of two order of magnitude allows for elution of 
desthiobiotinylated molecules via incubation with a biotin-containing buffer. A 15-
minute incubation of the solid supported neutravidin resin in a 4 mM biotin buffer 
produced proteomic profiles which were analyzed by trypsin digest LC-MS/MS to 
identify the proteins which were pulled down. 
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3.5 Selection and Validation of the Putative Protein Targets 
The proteomic profiles were analyzed with two metrics. First, the abundance of a 
protein was scored by viewing the positive experimental condition (+UV) divided by the 
negative control (-UV). A higher score in this metric demonstrates an enrichment via the 
UV-irradiation induced crosslinking process, separating a pulled down protein from 
background noise. Second, the protein abundance was scored by viewing the positive 
experimental condition (+UV) divided by the competition control (+UV+Comp). A 
higher score in this metric is indicative of the degree of specificity of the interaction of 
the drug, and its ability to impart specificity to the non-specific crosslinking reaction.  
 
The protein profile of DQ661-P 149 was analyzed with the two metrics, revealing 
a number of potential protein candidates. The best proteins judged by these metrics were 
DC661-P DQ661-P
Figure 3.16: Proteomic profiles of DC661-P 138 and DQ661-P 149 (best performing 
candidates were highlighted). CTSD and PPT1 are the best protein candidates which are 
known lysosomal enzymes. 
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then cross-referenced with their association with the lysosome and autophagy. Filtering 
by protein association revealed three promising lysosomal targets: PPT1, cathepsin D, 
and LGALS3 (Galectin-3) (Figure 3.16). When interrogating the proteins by their 
abundance across all photoaffinity probe synthesized, PPT1 and cathepsin D stood out as 
the two best candidates. LGALS3 is a protein known to localize to the lysosome after 
permeation of the lysosomal membrane occurs. Therefore, this protein was discounted as 
a mechanistically relevant target.67 
 
 
Cathepsin D, while significantly pulled down in every experiment, was not 
competed off effectively (Figure 3.16). From this result, we concluded that the natural 
abundance of cathepsin D (CTSD) in the lysosome made the protein a non-specific 
binder of the dimeric inhibitors. CTSD is an aspartyl protease, acting as one of the major 
proteolytic enzymes in the lysosome. Therefore, we sought to determine whether CTSD 
activity was inhibited by DC/DQ in activity assays. However, CTSD activity from neither 
in vitro nor cell lysate was affected by treatment with DQ or DC inhibitors (Figure 3.17). 
Figure 3.17: Cathepsin activity in 
melanoma cells treated with DQ 
inhibitors at a concentration of 3 uM 
for 3 hours. 
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The combination of poor competition efficiency in the pulldown assay, inability for 
DC/DQ inhibitors to affect CTSD activity, and the lack of literature support for CTSD 
producing the observed phenotype led to the exclusion of CTSD from the likely target 
list. 
 
 
 
 
 
 
 
Figure 3.18: Western blotting for PPT1 reveals specific binding by the DC, DQ, and CQ 
inhibitors. A. Western blot for PPT1 in a pulldown experiment (DC661-P, 138), where three 
conditions were assayed (+UV, -UV, and +UV +competition). B. Western blot for PPT1 in a 
pulldown experiment (DC221-P, 148), where three conditions were assayed (+UV, -UV, and 
+UV +competition). C. Western blot for PPT1 in a pulldown experiment (CQ-P, 156), where 
three conditions were assayed (+UV, -UV, and +UV +competition). D. Silver stain SDS-PAGE of 
a pulldown experiment for DQ661-P 149 treated A375P melanoma cells. E. Western blot for 
PPT1 and CTSD in a pulldown experiment (DQ661-P, 149), where three conditions were 
assayed (+UV, -UV, and +UV +competition). 
A. B. C. 
D. E. 
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The next most prominent lysosomal protein pulled down by DQ and DC 
photoaffinity probes was protein palmitoyl thioesterase 1 (PPT1). PPT1 scored highly in 
the selectivity metric for proteomic analysis, meaning the competition experiment 
indicated DQ/DC inhibitors make a specific interaction with PPT1. PPT1 is a member of 
the serine hydrolase family of enzymes.109 The enzyme is known to reside within the 
lysosome of the cell.110 The function of PPT1 is to help maintain dynamic lipid signaling 
on the surface of proteins, in addition to removing S-acyl fatty acids from substrates it 
encounters in the lysosomal compartment. PPT1 was originally observed as a protein 
bound to the kinase H-Ras, an important enzyme in oncogenesis.111 Biochemical studies 
of PPT1 have defined a wide substrate scope for the enzyme including palmitoyl-CoA, 
myristoyl-CoA, and palmitoylated thio-glucoside.111–113 It is hypothesized that PPT1 
recognizes the fatty-acid and hydrolyzes the labile acyl bond, regardless of the molecule 
which is acylated.114 It has been proposed that PPT1 is responsible for cleaving palmitate 
from proteins which have been trafficked to the lysosome for degradation. The activity of 
PPT1 has been monitored using both small molecule cleavage assays and fatty acid 
labeled proteins.112,113 
 
Figure 3.19: Native activity of PPT1 cleaves thioester derivatives of fatty acids in the lysosome 
of the cell.  
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PPT1 is most well-known for the role it plays in infantile neuronal ceroid 
lipofuscinoses (INCL). INCL is a subset of Batten disease, a fatal lysosomal storage 
disorder which effects the nervous system of human patients.115 In these patients, 
lysosomal activity is significantly reduced, resulting in the build-up of toxic lipidated 
species. The buildup of these toxic species manifests itself in multiple neurological 
disorders including retinal toxicity, resulting in the patients’ loss of vision. Perhaps most 
interesting is the observed retinal toxicity in patients who have taken extended courses of 
CQ 1.116 While this result may be anecdotal, it is consistent with the observation that 
PPT1 dysfunction can perturb lysosomal functional on an organismal level. We 
hypothesized that extended CQ usage could result in tremendously high doses 
accumulated in the lysosomes of patients, resulting in a toxicity similar to that 
experienced by INCL patients. 
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 To explore whether the catalytic activity of PPT1 was affected by treatment with 
dimeric lysosomal inhibitors, we adopted a fluorescence assay described by van Diggilen 
et. al.112 This assay leverages the agnosticism of PPT1 toward the identity of the 
palmitoylated substrate by building the reporter 157 from a thioglucose scaffold. The 
reporter molecule 158 contains a primary thiol which is palmitoylated. At the anomeric 
position of the sugar is a coumarin, which is non-fluorescent when the oxygen is 
alkylated. In order to release the fluorescent coumarin, β-glucosidase is required to cleave 
the anomeric sugar bond. When the sugar is palmitoylated, β-glucosidase is unable to 
cleave the fluorescent coumarin, resulting in a quenched fluorescence signal. However, 
when PPT1 is present, it rapidly cleaves the palmitoyl chain from the thioglucose 
reporter, yielding compound 158. This allows for efficient release of the fluorescent 
Figure 3.20: Mechanism of PPT1 reactivity. 
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coumarin 159 by β-glucosidase. The assay is designed with beta-glucosidase in excess, 
forcing the rate determining step of the reaction to be the enzymatic activity of PPT1. 
Thus, the increase in coumarin fluorescence is directly correlated to the activity of PPT1. 
 
We adapted the reported assay by utilizing homogenized melanoma cell cultures 
treated with different inhibitors. The cell culture conditions were assayed by dose and 
treatment duration with DC/DQ inhibitors to understand the effects of our inhibitors on 
PPT1 activity. Once the treatment period had elapsed, the cultures were homogenized 
using mechanical and osmotic stress to lyse the cells, as per the van Diggelin protocol. 
The cell homogenates were then normalized for their protein content as a method of 
maintaining the same amount of PPT1 across the reactions. The normalized homogenates 
were then mixed with an assay cocktail containing the reporter and exogenous beta-
glucosidase and reacted for one hour at 37 °C. The results of DC661-mediated 69 PPT1 
inhibition were the most striking (Figure 3.23). Cells treated with escalating doses of 
Figure 3.21: The assay described by van Diggilen et. al. for measuring PPT1 activity.  
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DC661 69 for 3 hours were found to have significantly diminished PPT1 activity. 
DQ661-treated melanoma cells were also found to have decreased PPT1 activity. In an 
effort to validate PPT1 as a target across chloroquine-based molecules, Lys 05 9 and 
HCQ were also tested for their ability to inhibit PPT1. Gratifyingly, Lys-05 demonstrated 
inhibitory activity against PPT1. Cells treated with higher doses of HCQ 4 also 
demonstrated some inhibition of PPT1 (~50% activity), supporting the hypothesis that 
PPT1 is also a target of the parent monomeric heterocycle chloroquine.  
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Figure 3.22: A. The dose-dependent inhibition of PPT1 by cells treated with DC661. The 
activity of PPT1 was measured by a fluorogenic reporter assay. B. HCQ, Lys 05 also inhibit 
PPT1 in melanoma cell culture when cells were assayed with the same fluorogenic 
reporter assay. 
B. 
A. 
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With cellular data in hand we wanted to determine if PPT1 could be inhibited by the 
dimeric compounds in vitro. The Arrowsmith Laboratory had previously solved the 
crystal structure of a PPT1 construct which was expressed in insect cells (SF9) via 
infection with baculovirus (PDB: 3GRO). The construct for the insect cell expression was 
made available for purchase through Addgene. PPT1 contains post-translational 
modifications, N-linked glycosylation, which are required for the proper function of the 
enzyme. Unfortunately, E. coli, the standard organism used for recombinant protein 
expression, does not glycosylate expressed proteins. In collaboration with Dr. Julie 
Rotenberg-Barber in the Marmorstein Laboratory at the University of Pennsylvania, we 
acquired and expressed the in vitro construct of PPT1 in SF9 insect cells. During the 
initial purification we identified that the protein was being excreted into the medium, 
requiring ammonium sulfate precipitation and resuspension in new buffer to facilitate 
His-tag/nickel-NTA purification.53 
To correlate the recombinant enzymatic activity to the fluorescence emission of 
the van Diggelin assay, the linear activity range of the protein was established.112 
According to Michaelis-Menten kinetics, when a protein catalyzes a reaction in a range 
where the correlation between signal and concentration of the substrate is linear, then the 
rate of the reaction is directly dependent on the binding interaction between the protein 
and the substrate. We hoped to observe whether DC or DQ compounds function as 
competitive inhibitors of PPT1 catalytic activity. Recombinant PPT1 was subjected to the 
van Diggelin assay conditions, where 50 nM PPT1 was found to react linearly over 
twenty minutes with 640 uM thioglucoside substrate.  
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Once the linear range of the enzyme was established, the assay was set up by 
charging each reaction vessel with recombinant protein (50 nM) and inhibitor (20 uM) in 
a pH 5.0 citric acid/sodium phosphate buffer. The protein and inhibitor samples were 
incubated for 90 minutes at 37 °C to allow time for any potential binding interactions to 
occur. A separate reaction cocktail was created containing the standard van Diggelin 
assay components. The cocktail was then added to the protein-containing reaction vessels 
and mixed with a pipet. The reactions were incubated at 37 °C and the fluorescence was 
read via a fluorescent plate reader. Unfortunately, no concentration of DC661 in vitro 
could replicate the inhibition of PPT1 which was observed in vivo. (Figure 3.24) 
Figure 3.23: Recombinant PPT1 (50 nM) reaction kinetics with 640 uM of assay 
substrate with or without DC661 present. 
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To confirm that a binding interaction exists between PPT1 and the DC/DQ 
inhibitors, we again turned to our collaboration with the Marmorstein Laboratory. 
Differential scanning calorimetry (DSC) is a method that detects the heat at which a 
protein begins to melt and unfold. The fold of a protein is the summation of numerous 
favorable interactions which cooperatively lend stability to the tertiary structure of the 
protein. When enough heat is added, the protein absorbs enough energy to transition from 
the folded to the unfolded state. This point is defined as the melting temperature (Tm). 
Theoretically a molecule which binds a folded protein can either increase the stability of 
the fold by buttressing a cleft which is normally occupied by solvent and providing 
favorable bonding interactions, or the binding molecule could lower the activation barrier 
to unfolding and destabilize the fold of the protein. Dr. Julie Rotenburg-Barber conducted 
the DSC experiments in the presence of DQ661 64, DC661 69, Lys-05 9, and HCQ 4. 
Each inhibitor was found to interact with recombinant PPT1. DC661 69, Lys-05 9, HCQ 
4, and DQ661 64 all cause a decrease in the melting temperature of the protein by a 
significant value compared to PPT1 without an inhibitor present. We have concluded 
from this decrease in melting temperature that PPT1 is bound by each inhibitor and is 
destabilized by the interaction with the inhibitors. 
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 Work by Dr. Vito Rebecca of the Amaravadi Laboratory monitored the 
effectiveness of PPT1 depalmitoylation in A375P melanoma cells via the use of a biotin-
acyl exchange assay. In this assay, cell lysate is harvested from melanoma cells treated 
with DQ661 64 or from an untreated control. The free cysteines in the lysate are first 
alkylated via maleimide chemistry, then the palmitoylations are removed by the addition 
of hydroxylamine. Maleimide biotin was then added to the lysate to label the proteins 
which had existing palmitoylations. These palmitoylations prevented reaction with the 
initial maleimide treatment. The biotinylated proteins were pulled down with avidin resin 
and analyzed by Western blotting. CD44 is a protein which is well documented to be 
palmitoylated.117 Western blotting for CD44 in the acyl biotin exchange assay revealed 
that treatment with DQ661 64 resulted in the increase in palmitoylated CD44, 
demonstrating PPT1 inhibition in vivo (Figure 3.25, A.).  
Figure 3.24: Differential scanning calorimetry for PPT1 in the presence and absence of DC 
and DQ inhibitors. On the Y-axis is the heat capacity of the protein and on the X-axis is 
the temperature each measurement was recorded. 
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 PPT1 was knocked down in melanoma cells utilizing siRNA (siPPT1). Cells 
which were treated with siPPT1 showed inhibited autophagy by the accumulation of 
LC3B and p62. Phosphorylation of S6 substrates decreased over time with siPPT1, 
indicating mTOR inhibition. These results demonstrate that PPT1 suppression mimics 
DQ661 treatment in melanoma cells (Figure 3.25, B.).  N-tert-butyl hydroxylamine 
(NTBHA) is a derivative of hydroxylamine which is less toxic to human cells. A study by 
the Mukherjee Laboratory has utilized NTBHA to mimic PPT1 activity in cells with 
deficient PPT1.118 Our studies found that melanoma cells treated with DQ661 64 and 
Figure 3.25: A. A375P cells were treated with DQ661 (0–240 minutes, 3 μmol/L). CD44 
palmitoylation was measured using the acyl biotin exchange assay. The appearance of 
CD44 indicates protein which is palmitoylated in the cell lysate. Samples not treated with 
hydroxylamine (−HAM) were used as a negative control. B. Western blot analysis for 
autophagy inhibition, PPT1 expression, mTor signaling, and apoptosis in A375P melanoma 
cells treated with DQ661. C. Western blot analysis for mTOR signaling (S6K and S6) and 
autophagy inhibition (LC3-B) in cells treated with either DQ661 or DQ661 and NTBHA 
(PPT1 activity mimetic). 
A. B. C. 
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NTBHA showed blunted autophagy inhibition and blunted mTOR inhibition. (Figure 
3.25, C.) 
 A375P Melanoma cells were treated with DC661 to examine the effect on global 
palmitoylation. CD44 was enriched via the acyl-biotin exchange assay, indicating that 
DC661 69 treatment suppressed the depalmitoylation activity of PPT1. HCQ 4 treatment 
also resulted in the accumulation of CD44 as observed by the acyl-biotin exchange assay, 
indicating that PPT1 activity was suppressed. Finally, NTBHA was utilized in 
combination with HCQ 4, Lys-05 9, and DC661 69, to observe the effect of the 
combinations on autophagy inhibition. Western blotting for LC3B indicated that 
autophagy inhibition was blunted by the co-treatment of HCQ 4 and DC inhibitors with 
NTBHA. This result suggests that compensation for the activity of PPT1 blunts 
autophagy inhibition via HCQ 4, Lys-05 9, and DC661 69.  
 
Figure 3.26: A. A375P melanoma cells treated with DC inhibitors or HCQ. CD44 
palmitoylation was assayed via the acyl biotin exchange assay and Western blotting for 
CD44. Cells treated without hydroxylamine were utilized as a control. CD44 observed on 
the Western blot is palm B. A375P melanoma cells treated with DC inhibitors or HCQ. The 
cells were treated with or without NTBHA treatment (PPT1 activity mimetic). The 
autophagy inhibition in cells was measured by Western blotting for LC3-B. 
A. B. 
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3.6 The effect of PPT1 inhibition on mTOR kinase function 
 To understand how inhibition of PPT1 could inhibit lysosomal functional, we 
surveyed the literature for connections between PPT1 and our observed phenotypes. 
Reports by Bagh et. al. recently reported that a specific subunit of the VATPase is 
palmitoylated. They determined that, when PPT1 is dysfunctional in cells, subunits of the 
VATPase do not correctly localize to the lysosomal membrane. This in turn prevents 
proper VATPase function and contributes to the deacidification of the lysosomal 
compartment. In addition, Zoncu et. al. reported that the VATPase is critical for mTOR 
localization to the lysosome. The VATPase interacts with the Ragulator complex on the 
surface of the lysosome. When the VATPase is not functional, the Ragulator complex 
cannot effectively bind mTOR and lead to activation of the kinase. We have proposed a 
mechanism of action for DQ661-mediated mTOR inhibition, whereby inhibition of PPT1 
function and the lysosomal localization of VATPase subunits are disrupted. This in turn 
results in dysfunctional mTOR signaling, resulting in the inhibition we have observed. 
Consistent with this hypothesis, Dr. Vito Rebecca observed mislocalization of the 
VATPase subunit which was reported to require PPT1 function for its correct localization 
(Figure 3.27). 
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3.7 Precedent for Aberrant Behavior of Recombinant PPT1 
We were interested in why PPT1 in melanoma cells was inhibited by DC/DQ 
treatment, whereas recombinant PPT1 is not inhibited. We considered that the lysosomal 
environment could be critical for the inhibition of PPT1 activity. There have been studies 
of PPT1 which suggest that recombinantly expressed PPT1 does not behave in the same 
manner as endogenous PPT1.119 Work by Lyly et. al. demonstrated that recombinantly 
expressed PPT1 was catalytically active. However, when overexpressed within 
fibroblasts or neuronal cells, the protein was found to localize differently than the 
endogenously expressed PPT1. In non-neuronal cells, PPT1 is transported to the 
lysosomal compartment. Overexpression, however, resulted in the improper localization 
of the enzyme to non-lysosomal vesicle structures within the cell. Further biochemical 
studies were performed to identify activity differences between endogenous PPT1 and 
Figure 3.27: Western blot of A375P 
melanoma cells (wild type and PPT1 
siRNA knockout) analyzing the localization 
of subunits of the VATPase. Loss of signal 
for V1A indicates that the VATPase 
subunit required for proper mTOR 
localization is not present in the 
membrane fraction compared to the wild 
type control. 
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recombinant PPT1. In a fascinating experiment, PPT1 was overexpressed as a fusion 
protein with eGFP as an affinity handle and label for co-immunoprecipitation. This 
experiment should only pulldown PPT1-eGFP fusion. However, when the co-
immunoprecipitation fractions were analyzed by Western blot, both eGFP-PPT1 and 
endogenous PPT1 were detected. This experiment establishes the previously unreported 
ability of PPT1 to homo-oligomerize. Lysosomes were enriched and separated by size-
exclusion chromatography, where PPT1 was observed to elute during the gradient 
corresponding to proteins with a molecular weight >100 kDa (3-fold the molecular 
weight for the enzyme). To quantify this oligomerization affinity, PPT1 was assayed by 
surface plasmon resonance. In this technique, labeled PPT1 was fixed to a surface, and 
recombinant PPT1 was flowed over the PPT1-containing surface. If a binding interaction 
occurs, the detector should be reflected by a plasmon resonance in the surface, indicating 
a binding event. Strikingly, in this experiment using only recombinant PPT1, no binding 
event was observable by surface plasmon resonance. This result gives biochemical proof 
that endogenous PPT1 and recombinantly expressed PPT1 behave differently in a series 
of different assays.  
With these results in mind, we propose that studying the extra-lysosomal activity 
of PPT1 is not an accurate model of DQ/DC-mediated PPT1 inhibition in vivo. Therefore, 
future efforts will focus on the use of techniques that can better monitor the effect of 
DQ/DC inhibitors in a live cell context. 
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Chapter 4: Design, Synthesis, and Application of a Fluorogenic Substrate for 
Monitoring PPT1 Activity In Vivo. 
4.1 The Need for a Live Cell Reporter for PPT1 activity 
 Having identified protein palmitoyl thioesterase 1 (PPT1) as a specific binding 
partner of the dimeric lysosomal inhibitors, we tested the effect of DC/DQ compounds on 
the catalytic activity of PPT1. These experiments were conducted both in vivo, utilizing 
cultured melanoma cells, and in vitro, with recombinantly expressed PPT1. During these 
studies we observed that endogenous PPT1 activity was inhibited, while the activity of 
exogeneous, recombinantly expressed, PPT1 was not inhibited (Chapter 3, Selection and 
Validation of the Putative Protein Targets). 
Previous workers have also observed different activities with  recombinant PPT1 
and endogenous PPT1 in multiple assays (Chapter 3, Precedent for Aberrant Behavior of 
Recombinant PPT1).119  We hypothesize that the lysosome is a privileged environment 
which cannot be adequately recapitulated in vitro. It appears that endogenous PPT1 is 
required to study the interaction of the enzyme with DC/DQ inhibitors. Existing reporters 
for PPT1 activity require cell lysis. Lysis of the cell necessarily disrupts the lysosomal 
environment. For these reasons, the development of a live cell probe for PPT1 activity, 
which represents an unmet need in the study of palmitoylation regulation in cancer 
biology, became the next goal for our studies. 
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4.2 Existing Applications of Fluorescence Reporters 
The successful application of bioorthogonal fluorescence in living systems has 
fundamentally changed the biological and life sciences. The discovery and application of 
green fluorescent protein was recognized with the Nobel Prize in 2008, marking the 
tremendous impact which bioorthogonal fluorescence has had on biology and the life 
sciences. In addition to genetically encoded fluorescent reporters, it has become common 
place to design experiments which utilize fluorescent dyes which have bioorthogonal 
fluorescence (fluorescence emission red-shifted beyond the fluorescence emission of 
nucleotides and aromatic amino acids) to monitor biological processes both in vivo and in 
vitro. Multiple efforts have successfully harnessed the sensitivity of fluorescence 
emission to design molecules which can be used to sense ionic analytes in human 
cells.120–124 In a similar manner, reactive molecules have been detected in cellular 
environments.125 Small molecule and polypeptide substrates have also been utilized to 
monitor the activity of different enzymes in vivo and in vitro.126–129 
4.3 Fluorescent Properties of Small-Molecule Dyes 
 Fluorescence emission is extremely sensitive to both the electronic structure of a 
fluorophore and the environment of the fluorophore. For fluorescence emission to occur, 
a molecule must first absorb a photon of high energy light. This excitation promotes an 
electron to the first singlet excited state. In order to relax back to the ground state, the 
molecule can emit a photon of light corresponding to the gap between the ground state 
and the first singlet excited state. (Figure 4.1) In many cases, non-radiative relaxations 
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are also available to molecules in the form of internal conversion, vibrational relaxation, 
rotational relaxation, electron transfer, and chemical reactivity.130,131 Both the intrinsic 
energetics of a fluorophore and the surrounding environment can shift the balance 
between radiative and non-radiative relaxations. Therefore, in select cases the bias of a 
molecule towards fluorescence emission can be correlated to a chemical event. 
 
A chemical understanding of the photophysics of the fluorophore affords the 
capability to harness fluorescence emission as a sensor by biasing the molecule into 
either a radiative or non-radiative state through molecular design. When designing a 
sensor or a probe from a fluorophore, the on-state and off-state can be assigned to either a 
fluorescence emission (on) or lack thereof (off). These states can be extrapolated and 
applied to any system where the chemical reactivity being observed will bias a molecule 
towards either of these two states. By leveraging predictable electronic effects, these 
environmentally sensitive biases can be engineered into a molecular probe. (Figure 4.2) 
Figure 4.1: A Jablonski diagram depicting excitation of a molecule from the ground state 
(S0) to the first singlet excited state (S1) through the absorption of a photon of light. To the 
right a radiative relaxation is depicted where the excited molecule relaxes to the ground 
state through the emission of a photon of light. 
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 A fluorophore has multiple measurable spectroscopic properties that impact the 
translation of excitation light into fluorescence emission. The absorption of excitation 
light by the fluorophore is linearly correlated to the intensity of fluorescence emission. 
The molar extinction coefficient of the fluorophore describes how efficiently a molecule 
absorbs a photon of light. This efficiency is directly correlated to the ability of the 
molecule to enter an excited state. The intensity of the fluorescence emission is 
dependent on another intrinsic quality of the fluorophore known as the quantum yield. 
This factor is defined in a range between zero and one and can be referred to as the 
Figure 4.2: A. Jablonski diagram defining non-radiative relaxations of a molecule and 
radiative relaxations of an excited state molecule. B. Assignment of non-radiative 
relaxations to the off-state, where relaxation produces no light. The on-state is assigned 
to radiative relaxations, where relaxation of the excited state molecule produces the 
emission of light. 
A. 
B. 
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efficiency in which a fluorophore converts the energy of absorbed light into emitted 
radiation. The wavelength of the emission corresponds directly to the HOMO-LUMO 
energy gap. Alteration of electronic effects of a fluorophore pi-system directly affects this 
energetic gap, and thus the fluorescence emission. Often, the energy of the light absorbed 
is higher than that of the resulting fluorescence emission. This absorption of a photon 
promotes a chromophore to a higher state than the first singlet excited state. This 
energetic difference in absorption versus fluorescence emission is due to differences in 
torsional energies, vibrational energies, or solvation energies between the ground state 
and the excited state of the fluorophore. This causes a fluorophore to undergo a non-
radiative relaxation to enter the first singlet excited state prior to emitting a photon of 
light. This difference in the excitation versus the resulting fluorescence emission is 
known as the Stokes shift of a fluorophore. Each of these characteristics are directly tied 
to the chemical structure of the fluorophore and can be synthetically engineered.130,132 
 The design and synthesis of cyanine dyes represents an example of modulating 
the wavelength to a more efficient absorption maximum of light.  The absorption 
maximum of cyanine dyes is easily tuned by synthetically increasing or decreasing the 
number of methine bridges between the two nitrogen atoms of the fluorophore. Cyanine 3 
160 has an absorption maximum at approximately 550 nm. Synthetic modifications 
which insert two methines, or one alkene, to the bridge region yield a dye with an 
absorption maximum at approximately 650 nm, known as cyanine 5 161 A near-infrared 
absorbing, ca. 750 nm, cyanine analog can be synthesized by the addition of one more 
alkene to the bridge region, to yield cyanine 7 162.133,134 (Figure 4.3) 
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The quantum yield of a molecule is also tied to structural features of a 
fluorophore. While predicting the quantum yield of a dye is quite difficult, many dyes 
have been developed that use well-known molecular mechanisms which decrease 
fluorescence emission.132 In the case of fluorescein, the chemical reactivity of the phenol 
is directly tied to the quantum yield of the dye. When fluorescein 163 is deprotonated at 
the phenolic position, the resulting phenolate 164 can collapse to a carbonyl, fully 
aromatize the xanthene skeleton, and liberate the carboxylate from the tricyclic skeleton 
of the dye. This causes a dramatic increase in the quantum yield of the dye, effectively 
turning on its fluorescent properties 165 (Figure 4.4). In acidic media, activation of the 
carbonyl induces cyclization of the carboxylate onto the xanthene skeleton. This 
cyclization results in a dramatic decrease in the quantum yield of the dye, effectively 
turning off the fluorescence emission. 
Figure 4.3: The structure of multiple cyanine dyes, where extension of the alkene 
linkages between the indolenine fragments increases the wavelength of the absorption 
maximum for the fluorophore. 
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4.4 Translating Fluorescence Spectroscopy to Monitoring a Chemical Event 
Correlating the fluorescence properties of a molecule to a chemical event can be 
abstractly assigned to a two-state problem. These states are most easily assigned to the 
magnitude of fluorescence emission of a dye, where increased fluorescence emission 
represents the on-state, and the lack of fluorescence emission represents the off-state. 
These states are assigned by the investigator through selection of the excitation and 
emission wavelengths for observation via fluorescence spectroscopy. To apply this two-
state system to monitoring a chemical event, the spectroscopic output from the two states 
must be understood in order to correctly frame the excitation and emission wavelengths. 
The previously described spectroscopic properties of a molecule can affect 
whether an interrogated state appears to be on or off. From the perspective of the 
Figure 4.4: The pH dependence of fluorescein fluorescence emission. Deprotonation of 
the phenol allows for resonance delocalization of the resulting phenolate into the 
conjugated pi system, resulting in tautomerization which liberates the carboxylate 
functionality; thereby extending the conjugated pi system. 
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observer, a change in quantum yield will result in a change in fluorescence intensity 
easily correlating to pushing a switch from one state to the other. (Figure 4.5 C&D). 
Often, the making or breaking of a covalent or transient chemical bond induces a 
shift of the HOMO and LUMO of the fluorophore. This in turn shifts the absorption 
maxima and emission maxima either higher or lower in energy, presenting a more 
complex signal to parse into a two-state problem. However, when taking precise single 
point fluorescence emission measurements, a change in the absorption and emission 
maxima will fundamentally mimic a change in quantum yield from the perspective of the 
observer. (Fig 4.5 E & F).  
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Figure 4.5: A. Typical absorption and fluorescence emission spectra. The gap between 
the maxima in each spectrum is known as the Stokes shift. B. Jablonski plot which 
indicates the cause of the stokes shift. C. An absorption spectrum and two fluorescence 
emission spectra, where turn on of fluorescence is observed. D. Jablonski plot of 
fluorescence emission, where a radiative and non-radiative pathway are in competition. 
The equilibrium between these events yields the intensity of the turn-on in 
fluorescence. E. An absorption spectrum and a fluorescence emission spectrum which 
depicts a molecule where the HOMO-LUMO gap changes. F. Jablonski diagram which 
depicts a change in the HOMO-LUMO gap, resulting in a change in the energy difference 
between S0 and S1. 
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4.5 Fluorophore Choice for a Fluorogenic PPT1 Substrate 
The most common classes of fluorophore utilized for emitting light in the visible 
range are: xanthene dyes (fluorescein, rhodamine, rhodol, etc.), cyanine dyes (Cy3, Cy5, 
Cy7, etc.), coumarin dyes (4-methylumbelliferone 159, and more), and BODIPY dyes 
167. Each class of dye has found different applications in chemical biology, depending 
on the photophysical requirements of the study. (Figure 4.6) 
 
 In many fluorogenic substrates dyes which have reactive heteroatoms are utilized. 
These heteroatoms are used to either form covalent bond which can be cleaved or altered 
by the targeted enzyme. In the PPT1 fluorogenic assay designed by van Diggelin et. al. 
the fluorescence emission of 159 is greatly diminished, and blue-shifted, when the phenol 
oxygen is substituted.  In this assay, the 4-MU is linked to the anomeric position of a 
Figure 4.6: Common dye classes and fluorophores  
143 
 
glucose derivative 158, which contains a palmitoylated thiol as a substrate for PPT1. This 
linkage is stable to biological conditions and prevents phenolate formation (Chapter 3, 
Figure 3.21). Thus, the glycosidic bond biases the 4-MU 159 into the off state. The 
cleavage of this bond with beta-glucosidase, and subsequent raising the buffer pH causes 
4-MU 159 to predominantly exist as the phenolate (the on-state), resulting in a large 
increase in observed fluorescence emission (Figure 4.7). A second example is the use of 
acylated fluorescein-type dyes as substrates for esterases.135 Xanthene based dyes, such 
as rhodol 169, exhibit a very high quantum yield, (Fluorescein QY = 0.95), and a well 
understood mechanism for internal quenching.132 However, when the phenol oxygen is 
protonated or substituted by chemical modification 170, such as acetylation, the phenyl 
ring containing the phenol exists as an aromatic system more closely related to benzene. 
This causes the free carboxylic acid to attach to the electropositive carbon resulting in a 
pentacyclic structure which has broken the conjugation of the aromatic xanthene ring. 
The broken conjugation and resulting orthogonal pi system result in a dramatic decrease 
in the fluorescence emission of the dye. When the dye is deacylated, the lone pairs of the 
oxygen can form a carbonyl through resonance, delocalizing across the large xanthene 
conjugated system and restoring the quantum yield of fluorescence (Figure 4.7). 
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4.6 Conceptualizing a PPT1 Fluorogenic Substrate 
 In order for a fluorescent probe to be used to monitor PPT1 activity, it must 
contain a palmitoylated substrate for PPT1, a reactive linkage which will bias the state of 
a fluorophore, and it must be capable of traveling to the lysosomal compartment. 
Conceptually, we envisioned that such a PPT1 probe could be realized by chemically 
linking each of the different functional groups which serve each listed purpose above. 
PPT1 is a catabolic enzyme in the class of serine hydrolases.109 We envisioned using a 
probe where a bond cleaved by PPT1 either alters the fluorescence of the probe molecule 
or induces further reactivity which influences the fluorescence of the probe. We 
hypothesized that a probe can fundamentally be broken down into four parts: the PPT1 
Figure 4.7: A. A common strategy for defining the fluorophore 4-MU into a two-state 
system. B. depicts the adaptation of rhodol to a two-state system via acylation of the 
phenolic oxygen. 
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substrate, the fluorophore, the lysosome localizing tag, and the labile chemical linkage 
which biases the state of the fluorophore. (Figure 4.8) 
 
4.7 Assigning a PPT1 Substrate for a Fluorogenic Probe 
To adapt strategies which are used in modern fluorogenic substrates to design a 
PPT1 probe, we first considered the native substrates for PPT1. The palmitoylation of 
proteins most commonly occurs by acylation of a free thiol of cysteine residues.110 We 
therefore elected to use cysteine as the scaffold for our fluorogenic probe. Our previous 
unsuccessful efforts to demonstrate dimeric lysosomal inhibition, in vitro, heavily 
influenced this choice of scaffold. (Chapter 3) We hypothesize that while the identity of 
the substrate is not important for PPT1 catalytic activity (thioester hydrolysis), perhaps 
DC/DQ-mediated PPT1 inhibition only occurs when PPT1 encounters specific substrates.  
Figure 4.8: A scheme of the construction of a PPT1 probe. The 
green represents a lysosomal localizing functional group, the 
blue represents a fluorophore, the red is a PPT1 substrate, and 
the arrow points to a labile linkage between the substrate and 
the dye. The labile linkage will be used to bias the state of the 
fluorophore. 
146 
 
Our inability to recapitulate DC/DQ-mediated PPT1 inhibition in vitro with 
recombinant PPT1 was a significant cause for concern. We hypothesized that in addition 
to the lysosome being a privileged environment, the thioglycoside which was utilized as a 
palmitoylated substrate was too far removed from the intended substrate of the enzyme. 
Work by the Crews laboratory established that the didemnin series of natural products are 
uncompetitive inhibitors of PPT1.113 (Figure 4.9) An uncompetitive inhibitor is a binder 
of the enzyme substrate complex, not the unbound enzyme active site. We viewed this 
work as further evidence that when interrogating inhibition of the enzyme, perhaps 
substrate binding is also important in defining a context for DC/DQ mediated PPT1 
inhibition. We hypothesized that the design of a probe more closely related to the native 
substrate would give a more accurate representation of in vivo activity.  
 
Figure 4.9: The uncompetitive inhibition of PPT1 by the didemnin series of natural products. 
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4.8 Selection of a Lysosomal Localizing Tag 
For the probe to function properly, the molecule must localize to the lysosomal 
compartment of the cell. Lysosomotropism has been observed in molecules dating back 
to the discovery of the lysosome as an organelle.19 In his contributions to modeling 
lysosomotropism, de Duve described a scenario where charged molecules were less likely 
to pass through a membrane than neutral, hydrophobic small molecules. Therefore, 
molecules which become protonated in the lysosomal compartment, and become 
positively charged, accumulate at a faster rate than their diffusion out of the lysosome. 
These molecules accumulate as a function of the pH gradient between the cytosol (pH 
7.4) and lysosome (pH 4.5 – 5.5). Since de Duve’s original hypothesis, the lysosomal 
concentration has been spectroscopically measured for multiple kinase inhibitors which 
contain weakly basic nitrogen atoms, and the anti-malarial chloroquine.50This work 
established that molecules with nitrogen atoms possessing a higher pKa than the 
lysosomal lumen pH were able to accumulate in the lysosome preferentially and supports 
the hypothesis put forth by DeDuve, where basicity is the driving force for localization. 
However, drug phase partitioning between lipid/protein bound inhibitor and solid 
precipitation also plays a significant factor in the extent that a small molecule 
accumulates in the lysosome. We envisioned that a lysosomotropic probe could be 
synthesized by incorporating basic nitrogen atoms within the fluorogenic probe. Our 
results with dimeric lysosomal inhibitors supports these observations.53  
An added benefit of the incorporation of basic nitrogen atoms is their contribution 
to added aqueous solubility. Tertiary amine incorporation within the molecule will yield 
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nitrogen atoms that have a conjugate acid pKa greater than seven, thus making them 
protonated at physiological pH. Protonation of the molecules will aid in the aqueous 
solubility of the resulting fluorescent probe. Furthermore, molecules with a significant 
degree of positive charge are known to associate with the negatively charged cell 
membrane.136 This association with the membrane increases the likelihood for 
hydrophobic molecules to either pass successfully into the cell or be taken up by 
endocytosis and potentially ending up in the lysosome.137 
4.9 Selection of a NIR fluorophore: CyOH 
For the fluorogenic probe to be used in cells in the presence of dimeric lysosomal 
inhibitor, we required a fluorophore with minimal spectral overlap with our library of 
compounds. DQ absorption is strong between 350 nm and 450 nm, yielding a 
fluorescence emission maximum at 490 nm. However, at high concentrations of inhibitor, 
excitation of the DQ inhibitors results in a broad emission band that stretches beyond 600 
nm. With the degree of concentration of the DQ inhibitor within the lysosome both 
unknown and uncontrollable, we chose to pursue the application of near-infrared 
radiation (NIR) dyes (excitation >600 nm and emission >650 nm). (Figure 4.10) 
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Cyanine, BODIPY, and xanthene derived NIR dyes exist. Cyanine dyes commonly 
exhibit fluorescence in the red to NIR range. However, by their nature they lack a 
reactive handle from which to effectively make a standard fluorogenic probe. BODIPY 
dyes have also been synthesized which extend their fluorescence into the NIR range. 
However, these dyes similarly lack a reactive handle by which to modulate their 
fluorescent properties. Xanthene dyes have been synthesized which extend into the far-
red to NIR range.  However, their fluorescence is quenched by low pH.  With the 
lysosomal pH being between 4.5-5.5, quenching in an acidic environment is likely to be 
problematic for lysosomal imaging. Further, NIR analogs of xanthene dyes present 
significant synthetic challenges, including the requirement of a large number of linear 
synthetic steps.138 
Figure 4.10: The normalized fluorescence emission spectrum of DQ661, excitation at 400 
nm. 
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 Work by Yuan and coworkers disclosed a series of NIR dyes which structurally 
are reminiscent of both cyanine and xanthene dyes.139 In these molecules the indolenine 
scaffold is tethered to a xanthene ring through an alkene linkage. The new dye, referred 
to as CyOH 173, is strongly red-shifted like the parent cyanine. However, more akin to 
the xanthene class of dyes, a free phenol strongly modifies the fluorescent properties of 
the dye based on its substitution. 
 
 
The dyes are derived by the degradation of existing NIR dye, 171, by resorcinol 
172 in the presence of a base (Figure 4.12). Proceeding first through an addition 
elimination mechanism 174, a chlorine from the NIR dye is displaced by resorcinol 175. 
Figure 4.11: Original Synthesis of CyOH 173 by Yuan et. al. Depicted left are fluorescein 
and cyanine dyes. Depicted right is CyOH 173, a NIR dye which combines the structural 
features of both cyanine dyes and xanthene type dyes. 
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In the presence of trace water and heat, the dye undergoes retro-Knovenagel reaction 
resulting in a free aldehyde 176. Addition of the phenol to the aldehyde 177, followed by 
rearomatization, results in the CyOH 173 dye scaffold. Cy7 171 is both commercially 
available on a gram scale and is easily synthesized in two steps. (Figure 4.11) 
 
 
Upon their initial disclosure of the dye, Yuan and coworkers also investigated the 
spectroscopic properties of the substitution state of the terminal phenolic oxygen. To 
prevent phenolate ionization, the authors synthesized two O-alkylated derivatives, and 
compared these controls to the phenol bearing CyOH 173. The O-alkylated derivative 
Figure 4.12: Mechanism of resorcinol degradation of cyanine 7 to yield CyOH. 
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exhibits a blue-shifted absorption spectrum, with the maximum absorbance shifting from 
690 nm to 608 nm. CyOH 173 has two fluorescence emission peaks, 690 nm and 715 nm. 
O-alkylation of CyOH blue shifts the emission maximum to 675 nm. The reported 
quantum yield of CyOH 173 drops from 0.36 to 0.006 when the oxygen is alkylated. 139 
These results establish that substitution of the phenolic oxygen shifts the fluorophore into 
the off-state, making CyOH an excellent candidate for a fluorogenic probe. The authors 
also applied CyOH to two small molecule fluorogenic sensors, a sensor for hydrogen 
peroxide (H2O2), compound 178, and a sensor for thiol detection (R-SH), compound 179. 
Encouragingly, both applications showed significant turn-on in fluorescence at 700 nm. 
(Figure 4.13) 
 
Figure 4.13: Hydrogen peroxide and thiol reactive sensor derivatives of CyOH. Both have 
significant turn on in fluorescence. 
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4.10 Utilization of a Lysosomotropic Analog of CyOH 
On consulting the literature for further applications of this dye scaffold in the 
context of the lysosome, we found that Wan et. al. prepared a morpholine-containing 
derivative of CyOH to probe lysosomal pH.140 Lyso-CyOH 187 maintains its 
fluorescence even in the acidic environment of the lysosomal compartment (Figure 4.16). 
Corresponding with the work of Yuan and coworkers, Wan and coworkers also saw 
significant increase in fluorescence at 708 nm upon increasing the pH from 5.0 to 7.4. 
This result, where fluorescence emission increases with pH, demonstrates that 187 is not 
sufficiently quenched by the tertiary amine to not make the dye useful. Further elaborated 
in the work by Wan and coworkers,187 maintains an inflection point in its fluorescence 
emission spectrum at 670 nm, allowing for pH insensitive fluorescence emission 
measurements. Their work demonstrated 187 can accurately probe the pH of the 
lysosomal compartment by comparing the emission ratio of 708 nm with 670 nm when 
excited at 635 nm.140  These results confirmed that the fluorophore is functional at 
lysosomal pH, as well as at neutral pH. We therefore hypothesized that utilization of 187 
would allow for the incorporation of the two functionalities required of a PPT1 probe, the 
fluorophore and the lysosome localizing tag, via the incorporation of one molecule. 
4.11 State of the Art in Palmitoylation Probes 
While we were considering these dye attachment/release methods for our 
fluorogenic probe, the Dickinson Laboratory at the University of Chicago published an 
analogous probe 180 for monitoring palmitoylation of acyl protein thioesterase 1 (APT1), 
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a cytosolic homolog of PPT1.141 APT1 is responsible for regulating the palmitoylation of 
proteins within the cytosolic compartment of the cell.110 The technology disclosed in the 
paper leverages the nucleophilicity of free thiols, where acyl transfer can occur through a 
5-membered transition state. Free thiols, under the correct conditions, are able to 
nucleophilically attack amide, carbamate, and ester carbonyls. Under aqueous conditions, 
the resultant tetrahedral intermediate can lead to the transfer of the acyl group to the thiol 
sidechain. Naturally occurring enzymes known as inteins also rely on thiol-mediated 
peptide-bond cleavage to facilitate protein splicing.142,143 Without the aid of enzymatic 
catalysis, this process is thermodynamically uphill, forcing the equilibrium significantly 
towards amide, carbamate, or ester. However, in the case of N-carbamoyl cysteine the 
release of the phenol allows for the dissociation of the molecule into two halves, driving 
the cleavage reaction to completion. Multiple small molecule probes have utilized a 
similar system of thiol-mediate acyl cleavage.  However, the Dickinson APT1 probe 180 
represents the first translation of this molecular strategy directly to a cysteine residue 
bearing a N-terminal carbamate141,144 (Figure 4.14) 
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The probe developed by the Dickinson Laboratory utilizes the fluorophore rhodol 
169 (Figure 4.14), a derivative of fluorescein. Rhodol contains a reactive phenol and a 
tertiary amine moiety, the latter which is present in the more red-shifted rhodamine 
family of xanthene dyes. While the use of the Dickinson fluorescent probe piqued our 
interest, we hypothesized the probe would be inadequate for our observation of PPT1 
activity for two reasons: first, the molecule possesses no driving force for lysosomal 
localization, making the differentiation of PPT1 activity from APT1 activity a significant 
challenge; and second, the fluorescence emission of rhodol shares spectral overlap with 
the DQ library of compounds. Therefore, we elected to take the insights gleaned from the 
Dickinson fluorogenic probe in designing our own PPT1 targeted fluorogenic probe. 
Figure 4.14: The structure and proposed reactivity of the palmitoylation probe disclosed 
by the Dickinson laboratory at the University of Chicago. 
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4.12 Design of a CyOH-Fluorogenic PPT1 Probe 
 
We envisioned that a small molecule probe 185, which represents the union of a 
CyOH reactive probe and the technology described the Dickinson laboratory 180, would 
be ideal for studying PPT1 activity in cells (Figure 4.15). The NIR fluorescence 
properties of CyOH 173 would allow for studying of PPT1 activity in the context of DQ 
mediated autophagy inhibition. The technology of thiol-mediated carbamate cleavage 
would also allow for a substrate that is closer to the native substrate for PPT1 than non-
endogenous thio-glucose. 
The union of these technologies required that the labile linkage between substrate 
and dye modify the intrinsic spectroscopic properties of the fluorophore. We reasoned 
that acylation of the phenolic oxygen would suppress resonance delocalization of the 
Figure 4.15: The Dickinson APT1 palmitoylation probe 180 compared to the PPT1 probe 
proposed by the Winkler Laboratory 185. 
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phenol oxygen into the keto-form. This in turn would induce the same suppression in 
fluorescence emission, between 690 and 710 nm, that alkylation of the phenolic oxygen 
did in the work of Yuan and coworkers.139 Therefore, we believed this strategy would 
accomplish the incorporation of all four required elements for a probe: a lysosomal 
localizing tag, a PPT1 substrate, a labile linkage of the scaffold and dye, and a DQ and 
lysosome-compatible fluorophore (Figure 4.15). 
4.13 Chemical Synthesis of a 1st Generation PPT1 Fluorogenic Probe 
We set out initially to take advantage of the lysosomal analog of CyOH 187 
disclosed by Wan et. al (Figure 4.16).140 We believed that lysosomal localization of the 
probe could be accomplished by the presence of the morpholine functionality on 187. 
This construction strategy would also allow for the dye to be constructed in two linear 
steps from commercial Cyanine 7 dye, maintaining the step economy advantage of CyOH 
derivatives. 
187 was synthesized by reacting 186 with of a commercially available Cy 7 
derivative 171, as described by Wan et. al.140 Next, we chose to elaborate a cysteine 
scaffold, modeled after the work of Dickinson and coworkers, where a N-methyl cysteine 
derivative will be linked to the dye through a stable tertiary carbamate linkage. Initially 
we prepared the same cysteine derivative utilized in the Dickinson synthesis (Figure 
4.16).141 
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Next, we chose to couple 187 to 191 in a similar fashion to the work by the 
Dickinson laboratory.141 We hypothesized that both 187 and rhodol 169 (Figure 4.14) 
would have similar reactivity because of their similarly acidic phenols (pKa rhodol 169 = 
5.5, pKa CyOH 173 = 5.0). In the work by Dickinson and coworkers, triphosgene is first 
reacted with the free phenol of rhodol at 0 °C, presumably forming a chloroformate in 
situ. The crude chloroformate is then used, without purification, to acylate the secondary 
amine of the cysteine scaffold.141  
 However, when we attempted to repeat the chloroformate synthesis with 187, no 
product was observed by mass spectrometry analysis of the crude reaction mixture. We 
then attempted to trap a chloroformate by reaction of an aliquot with excess morpholine. 
However, no product was observed in this reaction. From these results we hypothesized 
that the chloroformate intermediate derived from 187 was either not stable under the 
reaction conditions, or was not forming with triphosgene. The reaction was set up 
Figure 4.16: Synthesis of Lyso-CyOH by Wan and Coworkers. Synthesis of the Dickinson 
peptide substrate for probing APT1 activity. 
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according to the protocol of Kathayat et. al., where 187 (pKa = 5.0) is deprotonated first 
by triethylamine (pKa = ~10) in THF.140,141 However, 187 is only sparingly soluble in 
THF. Chloroformates have previously been synthesized by the reaction of phenols in 
CH2Cl2, a solvent in which 187 exhibited significant solubility. The reactants are mixed 
by slow addition of the solution of 187 and triethylamine in CH2Cl2 to the reaction vessel 
containing a chilled solution of triphosgene in CH2Cl2. Upon addition of a blue solution 
of 187 to the triphosgene solution, a purple color evolves but quickly changes back to 
blue within minutes. This result suggests an intermediate species is forming in the 
reaction mixture but is being consumed prior to the end of the reaction. 
Based on the experimental results from our attempts to acylate 187, we believed 
that the ortho benzylic morpholine substituent could lead to decomposition of any dye-
triphosgene adduct formed in situ. As a control we wanted to react triphosgene with 
CyOH 173, a dye lacking the ortho amine functionality. First, CyOH 173 was synthesized 
according to the conditions by Yuan et al. and Ma et al.139,145 Through our efforts we 
found that the utilization of inorganic bases furnished better yield in the CyOH 173 
forming reaction when compared to the use of organic tertiary amine bases. Gratifyingly, 
we also found the yield of this reaction to be substantially better than the synthesis of the 
Lyso-CyOH 187, enabling multi-gram scale synthesis of CyOH 173. (Figure 4.17) 
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 With CyOH 173 in hand, we explored the formation of CyOH-chloroformate 192, 
derived from the reaction of 173 with triphosgene. A solution of deprotonated dye, in 
CH2Cl2, was introduced to the reaction vessel containing triphosgene in CH2Cl2 at 0 °C, 
in the same manner as the previous attempts with 187. Slow addition of the 173 solution 
causes the rapid formation of a purple color which persists over the course of the 
addition, unlike attempts with 187. TLC analysis of the crude mixture instantaneously 
showed the appearance of a baseline spot, purple in color, which was not observed in the 
reaction of 187 with triphosgene. 
 Encouraged by these results we analyzed the mixture by 1H NMR, observing a 
down-field shift of the methine protons of the alkene, indicating the reaction of 173. An 
aliquot of the crude reaction was reacted with excess methanol and analyzed by LC-MS, 
Figure 4.17: Synthesis of CyOH 173 via degradation of Cy7 with resorcinol. Proposed 
synthesis of a CyOH-chloroformate 192 
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where the CyOH starting material 173 and two carbonyl containing species were 
observed: the methyl-CyOH carbonate 193 and the bis-CyOH carbonate 194.  
 
 Due to the presence of symmetrical 194, we hypothesized that the rate of addition 
of 173 was too fast for the reactivity of the derived chloroformate intermediate at 0°C. To 
test this hypothesis, we chose to analyze the reaction via UV/Vis-LC-MS at 0 °C and 
after warming to 25 °C. At 0 °C the reaction was significantly retarded, where, after 
quenching with excess methanol, large quantities of the phenol 173 were present in 
comparison to a mixture of 193 and 194. Warming of the reaction to room temperature 
causes the reaction to proceed directly to a mixture of only 193 and 194 as observed by 
LC-MS. 
Figure 4.18: CyOH reacting with triphosgene produces predominantly two species in solution, 
a dimeric carbonate, and a chloroformate. Reaction with excess methanol allows for easy 
observation of the reactive chloroformate via LC-MS. 
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 The reaction was run at ambient temperature (23 °C), and despite slow addition of 
a solution of 173 in CH2Cl2, over the course of one hour, the reaction still yielded a 
mixture of the two carbonate species 193 and 194 upon reaction with methanol (Figure 
4.18). The crude reaction mixture was analyzed after adding 0.08 molar equivalents of 
173 with respect to triphosgene. LC-MS analysis found 194 carbonate was still observed, 
suggesting that the rate of addition was not causing the formation of the carbonate. We 
next attempted to see if the mixture composition could have been biased by the change of 
the reaction solvent from the literature precedent, THF, to CH2Cl2. THF, with either 50% 
or 10% CH2Cl2 (v/v) as a co-solvent, utilized to solubilize the starting dye, was tested as 
Figure 4.19: Proposed mechanism of the formation of bis-CyOH carbonate 194 via the 
reaction of CyOH 173 and triphosgene. 
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a reaction solvent. With a 1:1 mixture of THF and CH2Cl2 as the reaction solvent, the 
reaction proceeded to completion after 2 hours at 23 °C. Reaction of an aliquot with 
excess methanol and UV/Vis-LC-MS analysis showed an improved ratio of 193 to the 
carbonate 194 but did not inhibit the formation of the side product.  With 10% CH2Cl2 in 
THF the reaction never fully consumed the starting CyOH phenol during 24 hours at 23 
°C. 
 In parallel, we tested whether 194 could be used as a CyOH acylation reagent. 
Due to the extensive delocalization of the resulting phenolate anion, we hypothesized that 
173 could be a comparable leaving group to chloride anion in CH2Cl2. Therefore, we 
hypothesized 194 could be cleaved by an amine to yield the desired carbamate. Reaction 
of the crude triphosgene reaction mixture with excess N-Boc-piperazine 196 in CH2Cl2 
gave the desired product 197 as observed via LC-MS, consuming both the 193 and the 
194. (Figure 4.20) 
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With evidence that 171, could be accessed through reaction with 194 or 192 we 
concluded that our inability to utilize 187 to synthesize carbamates was due to the 
presence of the ortho-morpholine substituent. We altered our fluorophore selection from 
187 to 173. In doing this, we lost the ability to append our lysosomal localizing tag to the 
fluorophore itself. The work by the Dickinson laboratory indicates that the enzyme-
substrate compatibility is maintained in APT1 when the C-terminal position of the 
cysteine residue is substituted with multiple R groups, including the amino acid lysine.141 
This result mirrors similar observations made in the literature about PPT1 substrate 
flexibility. PPT1 is well documented to hydrolyze palmitate chains from large proteins 
such as H-Ras.114 Alternatively, multiple studies also describe the ability of PPT1 to 
hydrolyze palmitate thioesters appended to other non-protein substrates.112–114 
Figure 4.20: Reaction of 1-N-Boc piperazine with a crude mixture of 193 and 194, resulting in 
the LC-MS observation of 197. 
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To test our hypothesis, we altered our probe design to move the lysosomal tag 
from the dye to the peptide scaffold 198 (Figure 4.21). We determined that the design of 
a diamine which contains a morpholine and a primary amine could be used as the second 
residue in our peptide scaffold and as a lysosomal tag. We decided to use the known 
diamine 204.146 We first synthesized a phthalimide protected aminopropanol 201 by 
reaction of 3-aminopropan-1-ol 200 and phthalic anhydride 199 neat at elevated 
temperature.147 Alcohol 201 was oxidized by Swern oxidation to aldehyde 202 and 
reductively aminated with morpholine to yield 203.148,149 The phthalimide protecting 
group was removed from 203 by reaction of hydrazine in ethanol, heated to reflux, to 
give compound 204.146 Primary amine 204 was coupled to 189 (Figure 4.16) utilizing 
EDC/HOBt in DMF to yield 205. The Boc protecting group was removed from 205 with 
TFA to yield secondary amine 206 (Figure 4.22). 
Figure 4.21: The design of the 1st generation PPT1 fluorogenic probe. The structure of the 1st 
generation of a fluorogenic PPT1 probe. In this figure blue corresponds to the NIR dye, red 
to the cysteine based PPT1 substrate, and green to the lysosomal localizing tag. 
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 We elected to complete the synthesis of the first-generation probe utilizing the 
crude reaction mixture of 192 and 194 to acylate our cysteine scaffold. Secondary amine 
206 (Figure 4.22) was dissolved in CH2Cl2 with triethylamine. The amine containing 
solution was reacted with the crude reaction mixture of 192 and 194, with 206 as the 
limiting reagent. The acylation reaction proceeded to completion as observed by LC-MS. 
We proceeded to remove the trityl protecting group from the cysteine thiol 207 via 
reaction with TFA and triisoproylsilane in CH2Cl2. Removal of the solvent followed by 
acylation with palmitoyl chloride yielded the product, compound 198, which was isolated 
by reverse phase HPLC in 20% yield with respect to 206 over the 3 steps. 
Figure 4.22: Synthesis of the peptide fragment for the 1st generation PPT1 probe. 
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 The probe molecule was found to be soluble at concentrations of 100 uM in both 
PBS (pH 7.4, physiological pH) and acetate buffer (pH 5.0, simulated lysosomal pH). 
The absorbance and fluorescence spectra of the probe were then measured and compared 
with those of the starting dye, 173. The UV-Vis absorption spectra of both 173 and the 
PPT1 probe 198were measured in PBS at pH 7.4. We observed a blue-shift of the 
absorption spectrum of the probe relative to free dye 173. We were optimistic about these 
results, as they were quite similar to those reported by Yuan and coworkers in the O-
alkylated and sulfonated CyOH derivatives (Figure 4.13, 178 & 179).139 
Figure 4.23: Synthesis of the 1st-generation PPT1 probe. Products not isolated until 
compound 198. 
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 Next, the fluorescent properties of the probe 198 and CyOH 173 (100 μM) were 
examined at pH 7.4. Preliminary results were promising, where substantially increased 
fluorescence was observed at 708 nm when comparing CyOH 173 to the PPT1 probe 
198. After extended periods of time, the probe was found to precipitate irreversibly from 
pH 7.4 PBS. To address this issue, Triton-X100 was added to the buffers at 0.1% (w/v). 
Previous fluorescent assays which contain palmitoylated substrates utilize this 
surfactant.112,141 We hypothesized that the palmitoylated probe could aggregate at high 
concentrations in solution due to the hydrophobic nature of the palmitate chain. 
Fluorescent molecules which aggregate at high concentrations are known to have 
intermolecular interactions which quench the fluorescence emission.150 In our case, we 
hypothesized that the observed turn-on in fluorescence between CyOH 173 and the 
Figure 4.24: UV/Vis absorbance spectra for the 1st-generation PPT1 probe 198 and the 
free dye CyOH 173. 
CyOH 173 
PPT1 Probe 
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palmitoylated probe 198 could be artificial, and therefore needed to be measured again in 
the presence of the surfactant.  
 
 
 In the presence of a surfactant, an approximately four-fold turn on in fluorescence 
between compounds 173 and 198 was observed at lysosomal pH. In our previous studies 
without surfactant compounds 173 and 198 exhibited 100-fold turn-on, where 173 was 
significantly more fluorescent. Previous studies which reported fluorescence emission 
differences between O-substituted derivatives of CyOH reported significantly larger 
increases in fluorescence emission. O-alkylated derivatives presented by Yuan et. al. 
show a 50-fold difference in fluorescence emission turn-on when the phenol oxygen is 
Figure 4.25: Fluorescence intensity measured at 690 nm. The 1st-generation probe was 
assayed in comparison to CyOH (free dye) across a selection of buffers with increasing 
pH. Triton-X100 was utilized to prevent self-quenching of the probe due to small 
molecule aggregation in situ. 
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unsubstituted.139 Previous applications of CyOH 173 as a fluorogenic substrate in living 
systems utilized derivatives which had significantly greater turn on in fluorescence.139 
Further, the probe applied by the Dickinson Laboratory claimed a turn-on of fluorescence 
significantly greater than 100-fold.141 
 Based on these data we determined that while the first-generation probe 198 could 
be studied in cells utilizing a four-fold fluorescence turn-on to observe depalmitoylation 
by PPT, analysis would be greatly simplified by reducing the background noise from the 
unreacted fluorescent probe. Therefore, we elected to design a second-generation probe 
which would exhibit a significantly greater turn-on of fluorescence when cleaved by 
PPT1. 
4.14 Design, Chemical Synthesis, and Characterization of a 2nd Generation PPT1 
Fluorogenic Probe 
One method of increasing the turn-on sensitivity of a fluorescent probe would be 
reducing the background signal due to imperfect quenching of the unreacted PPT1 probe. 
Unlike xanthene dyes such as rhodol 169 or fluorescein 165, CyOH 173 does not have a 
defined chemical mechanism for fluorescence quenching. Yuan and coworkers reported 
that alkylation of the phenolic oxygen with methyl or ethyl iodide substantially decreases 
the quantum yield from 0.36 to 0.007.139 However, according to our observations 
acylation of the free phenol with a carbamate did not adequately quench the fluorescence 
of CyOH 173. To reduce the quantum yield of fluorescence for the unreacted probe we 
derived two possible chemical strategies: the first would involve the incorporation of a 
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quenching functional group on the peptide substrate scaffold, and the second would be 
the alteration of the carbamate linkage to the dye to incorporate a labile alkylation 
between the carbamate and the dye. We elected to proceed with the incorporation of a 
known quencher to the peptide scaffold because we hypothesized this strategy was the 
most likely to be effective, as well as being the most conservative by not altering the 
chemistry of the dye release mechanism. 
 
To design a molecule which had lower fluorescence in the uncleaved form, we 
needed to reduce the intrinsic fluorescence emission of the probe through the 
incorporation of a quenching functional group. In fluorescence spectroscopy two general 
strategies are utilized to quench fluorescence: 1) the incorporation of a PET quencher, or 
2) the incorporation of a FRET quencher. A PET quencher, or photoinduced electron 
transfer quencher, is a functional group which can either accept an electron from or 
donate an electron to the photoexcited fluorophore. This electron transfer then inhibits the 
Figure 4.26: A mechanism of photoinduced electron transfer quenching (PET), where an 
excited state dye can undergo electron transfer to a PET quenching functional group. The 
electron transfers to a lower energy state and relaxes through a non-radiative transition 
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ability of the fluorophore to relax to the ground state by the emission of a photon. A 
FRET quencher utilizes Forster resonance energy transfer, where a second dye can 
couple to the excited state of the original fluorophore. This coupling allows for a non-
radiative energy transfer between the dyes, where the second dye can either relax in a 
non-radiative fashion or emit light which is further red-shifted than the original 
chromophore. 
 Two examples of PET quenching functional groups are tertiary amines and 
thioamides.151,152 A tertiary amine was not an option as a PET quencher in this case 
because the first-generation probe contains a tertiary amine as the lysosomal localizing 
tag and still possesses too strong a fluorescence emission. Initial attempts to induce 
intermolecular quenching via a PET mechanism proved unsuccessful. Incubation of the 
first-generation probe in a buffer containing 10 mM thioacetamide produced no change in 
fluorescence emission when compared to a buffer without thioacetamide. At this juncture 
Figure 4.27: A mechanism for FRET quenching. When a dye is excited to the singlet 
excited state, an acceptor dye can couple to the excited state of the donor dye and be 
promoted to the excited state. The acceptor dye can then either emit a red-shifted 
fluorescence emission or undergo through non-radiative relaxations via internal 
conversion. 
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we abandoned the strategy of adding a small functional group which could quench our 
CyOH fluorophore 173. 
We next consulted the literature for the identification of a FRET quencher that 
would be compatible with CyOH 173. In the NIR range, fewer options exist for 
quenchers outside the use of the black hole series of quenchers. Comparison of the 
emission spectrum of the first-generation probe with the absorption spectra of the black 
hole series of quenchers indicated that black hole quencher 3 (BHQ3) would be the 
optimal choice for incorporation.  
 
Figure 4.28: The UV-Vis absorbance of the 1st-generation PPT1 probe, the fluorescence 
emission spectrum resulting from excitation at the absorption maximum for the 1st 
generation PPT1 probe. Also plotted is the UV-Vis absorption spectrum for black hole 
quencher 3. Black hole quencher 3 has significant overlap with both the absorption and 
emission of the 1st generation PPT1 probe. 
198 
198 
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We envisioned that BHQ3 would be an ideal FRET partner for the first-generation 
probe because of the documented spectral overlap. With the first-generation probe 
containing both a labile thioester and the exceptional leaving group capability of CyOH, 
we sought benign conditions for the incorporation of BHQ3. Fortuitously, an azide 
containing analog of BHQ3(Figure 4.32, 219) had been described by Chevalier et. al.153  
 
The incorporation of an alkyne handle into the peptide scaffold for click 
chemistry required an alteration of the lysosomal tag region of the first-generation probe. 
We envisioned a linear scheme for the synthesis of the probe where the dye was 
connected to the peptide substrate in the same manner as the first-generation probe, 
followed by introduction of a lysosomal tag which contains an alkyne. In a final step this 
alkyne-containing first generation probe could be clicked to the azide containing BHQ3 
yielding the proposed structure 209 (Fig 4.29).  This synthetic sequence would add 
Figure 4.29: The design of a second generation of a PPT1 probe. Right, depicts the 
structure of the second generation PPT1 probe with key synthetic disconnections 
labeled. 
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potential for chemical diversity in quencher incorporation in the event that a different 
quenching molecule was required.  
The diamine scaffold was redesigned to incorporate a propargyl amine 
functionality by changing the original morpholine from the first-generation probe to a 
piperazine ring. Starting from 3-amino-1-propanol and phthalic anhydride, compound 
201 was synthesized by heating the reagents neat (Figure 4.22).147 The resulting alcohol 
201 was then oxidized to the corresponding aldehyde 202 by Swern oxidation (Figure 
4.22).148 N-propargyl piperazine 211 was synthesized by alkylation of N-Boc-piperazine 
196 with propargyl bromide in THF under microwave irradiation, followed by 
deprotection of the resulting N-propargylated carbamate 210 using a 1:1 mixture of 
TFA:CH2Cl2, to yield 211 in good yield.154,155 Aldehyde 202 and amine 211 were 
reductively aminated using sodium triacetoxyborohydride to furnish 212 in good yield. 
The phthalimide protecting group was removed from 212 by reaction with hydrazine in 
ethanol heated to reflux to yield 213. Compound 189 was then coupled to triamine 213 
via peptide coupling conditions using EDC and HOBt in dimethylformamide.141 The 
resulting peptide 214 was then deprotected using a 1:1 mixture of TFA:CH2Cl2 to afford 
215. 
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CyOH 173 was deprotonated with triethylamine and reacted with triphosgene in a 
1:1 mixture of CH2Cl2:THF to synthesize the previously described mixture of the 
chloroformate 192 and symmetrical carbonate of CyOH 194 (Figure 4.19). The peptide 
substrate 215 was then added to the CyOH chloroformate 192 (Figure 4.19) to acylate the 
N-terminus of the cysteine substrate. Once the peptide starting material was consumed, 
the trityl protecting group was removed in situ by first switching the solvent to CH2Cl2, 
followed by the addition of TFA and triisopropylsilane. The resulting thiol was acylated 
by reaction in neat palmitoyl chloride, and isolated by preparative HPLC to give 218 in 
19 % yield over three steps from the peptide scaffold 215.  
Figure 4.30 Synthesis of peptide for 2nd generation PPT1 fluorogenic probe 
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 Chevalier and coworkers published a two-step synthetic route to an azide 
containing analog of BHQ3 221.153 The derivative of BHQ3 was synthesized through a 
diazo coupling between  a tertiary aniline 220 and the diazonium salt of Methylene Violet 
3RAX 219. The resulting azide can be purified by reverse phase HPLC and isolated as a 
blue solid. The synthesized azide and alkyne coupling partners were joined through 
copper catalyzed click chemistry using Cu(II)SO4 and sodium ascorbate in a solvent 
system of water and DMSO to give 222. 
 
 
Figure 4.31: Synthesis of the alkyne-containing 2nd-generation PPT1 probe. Products not 
isolated until compound 218. 
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 First, the resulting second-generation probe 218 and the probe attached to BHQ3 
222 were tested for solubility. Both molecules were found to be soluble at 100 μM in 
PBS (pH 7.4) and acetate buffer (pH 5.0). Buffered solutions containing Triton-X100 
maintain colored solutions for multiple hours with no obvious precipitation. In order to 
apply the second-generation probe as an effective sensor for PPT1 activity, the 
spectroscopic properties of the probe must be characterized, followed by its validation as 
a substrate for recombinant PPT1. First, the alkyne, azide, and final clicked probe were 
analyzed by UV-Vis absorption spectroscopy to determine the absorption maxima and 
extinction coefficient of each component (Figure 4.33).
Figure 4.32: A. Synthesis of BHQ3-Azide 221 according to Chevalier et. al. B. The click 
ligation of BHQ3-Azide 221 and the propargylated probe G2 218 to give the final probe 
222. 
A. 
B. 
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Figure 4.33: A. Structures of probes (198, 218, 221, 173, 222) which were observed by 
UV-Vis absorption spectroscopy. B. The UV-Vis absorption spectra for both generations 
of PPT1 probes (Figure 4.23, 198 & Figure 4.31, 218), black hole quencher 3 (BHQ3) 
(Figure 4.32, 221), CyOH (Figure 4.31, 173), and the second-generation probe attached 
to black hole quencher 3 (Probe G2/BHQ3) (222) 
A. 
B. 
218 
198 
221 
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 Next the probe (Figure 4.33, 222) was analyzed by fluorescence spectroscopy 
utilizing two excitation wavelengths taken from the results of our study of the visible 
light absorption, 600 nm and 675 nm, of the molecules. Excitation of the molecules at 
either wavelength produced the same fluorescence emission spectra. This result 
demonstrated that excitation of these molecules at either wavelength caused similar 
fluorescence emission spectra.  In order to translate these spectroscopic properties to an 
assay for enzymatic activity, we needed to correlate probe reactivity to fluorescence 
emission. (Figure 4.34) 
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Figure 4.34: The fluorescence emission spectra of the PPT1 probe compounds 
(Structures in Figure 4.33) (150 uM, in pH 5.0 Acetate Buffer). The compounds were 
excited at 600 nm and 675 nm the two absorbance maxima for CyOH 173. For structures 
of probes see Figure 4.33 
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 The probe 222 (Figure 4.33) was designed to degrade under aqueous conditions 
when the palmitoyl chain is removed from the thiol. The free thiol, through a five-
membered transition state, will attack the carbonyl of the tertiary carbamate, and collapse 
of the tetrahedral intermediate will result in the loss of CyOH 173. Therefore, the 
increase in CyOH 173 concentration would be reflected in increased fluorescence 
emission and correlate to enzymatic activity. With the spectroscopic properties of the free 
dye and unreacted probe characterized, we next chose to validate the reactivity of the 
probe towards recombinant PPT1. The probe was dissolved in acetate buffer (pH 5.0, 150 
mM NaCl, 0.1% Triton-X100) at a concentration of 100 μM. Recombinantly expressed 
PPT1 was then added to the reaction vessel to give an enzyme concentration of 50 nM, 
and the reaction was incubated at 37 °C. After 15 minutes, the appearance of free dye can 
be observed by LC-MS, along with another compound, the mass of which corresponds to 
the quencher-cysteine containing fragment of the probe. After 60 minutes, the reaction 
contains no starting probe, and significant quantities of both CyOH and the quencher-
cysteine fragment. These results confirm that PPT1 can catalyze the removal of palmitate 
from the PPT1 probe, and once depalmitoylated, the thiol-mediate carbamate cleavage 
occurs at pH 5.0. (Figure 4.35, bottom) 
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Figure 4.35: Two chromatograms observed by UV-Vis absorbance at 650 nm. The 
identity of the peaks was determined by mass spectrometry analysis of each peak. The 
observed molecular ions are indicated on the figure for each species. The top 
chromatogram is a negative control displaying only the PPT1 2nd-generation 
fluorogenic probe 222. The bottom chromatogram displays a reaction at 60 min where 
only the cleaved fragments of the probe are observed. 
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 With these results in hand we chose to monitor the evolution of CyOH 173, as 
catalyzed by the PPT1-mediated decomposition of the probe molecule 222, by 
fluorescence emission at 700 nm (excitation at 675 nm). An excitation wavelength of 675 
nm was chosen because this is the strongest absorption band for the CyOH at pH5. 
Further, unreacted probe-G2-BHQ3 222 begins to decrease rapidly in absorptivity 
beyond 650 nm. Due to the inherent sensitivity of fluorescence spectroscopy, we were 
able to dramatically decrease the scale and concentration of the substrate in each of these 
reactions, compared to assays observed via LC-MS (UV-Vis). Each reaction, for 
monitoring via fluorescence emission, contained 500 nM PPT1, and 10 μM PPT1-probe. 
The concentration of the enzyme was increased to increase the rate of reaction for 
efficient measuring of the reactions kinetics. The reactions were run in a fluorescence 
plate reader warmed to 37 °C, where measurements of the fluorescence emission at 700 
nm were observed every three minutes. Gratifyingly, under these conditions we observed 
rapid consumption of the probe molecule, where the entirety of the substrate was 
consumed after 20 minutes. (Figure 4.36).  
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 We are currently exploring the cell permeability, cytotoxicity, and PPT-mediated 
degradation of the 2nd generation probe 222 in live melanoma cell cultures. Future work 
will describe the reactivity of the probe in A375 melanoma cells and PPT1 CRISPR 
knockout melanoma cells. Further, HDSF will be used as a positive control to chemically 
knockdown PPT1 as a positive control. 
Figure 4.36: The fluorescence emission observed from the reaction of 2nd generation 
probe-BHQ3 with PPT1 222 in a pH 5.0 Acetate buffer (+0.1% triton X-100). Below the 
graph is a scheme depicting the chemical reaction being catalyzed by PPT1 and the 
resulting fluorescence emission. 
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Biological Methods: 
Chapter 2: 
All biological assays were performed as described by Rebecca et. al.53 
Chapter 3: 
MTT assay, and autophagy inhibition assays were performed as described by Rebecca et. 
al.53 
Pulldown Methodology: 
A375P melanoma cells were grown to confluency in 15 cm diameter culture 
dishes (~20 million cells per dish). For each experimental condition, the cultures were 
grown in quadruplicate. The cell cultures were treated with the photoaffinity compound 
(400 nm) for 24 hours. For each compound, three conditions were tested: 1) photoaffinity 
probe without UV irradiation, 2) photoaffinity probe with a 30-min UV irradiation, and 
3) photoaffinity probe with 1 hour of parental inhibitor competition, followed by UV 
irradiation (Spectroline transilluminator 365 nm, 15 watts)(Cultures were placed on a 
sheet of aluminum foil and the transilluminator was held above the culture dishes). 
Inhibitor competition was assayed by treatment of a culture after the 24-hour 
photoaffinity probe treatment, with the inhibitor warhead for 1 hour at a 10-fold dose 
compared to the photoaffinity probe. The culture was then irradiated with UV light for 30 
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min. After irradiation was performed the cell cultures were then lysed using RIPA buffer 
(4 mL/culture dish). The RIPA buffered lysate was then frozen at -80 °C.  
Next, while the cell lysate was thawed on ice, Neutravidin resin (Avidin on 
agarose, high capacity, Thermo Scientific. Cat. No. 29204) was aliquoted into a 50 mL 
falcon tube. The resin, packaged in a 1:1 slurry, was aliquoted where 1 mL of packed 
resin was used per experimental condition.  The buffer was exchanged to the cell lysis 
buffer (RIPA buffer containing protease inhibitor tablets, Roche) by first pelleting the 
resin via centrifugate 1 minute (1500 x G), discarding the supernatant, and resuspension 
of the resin in cell lysis buffer. This process was repeated three times to fully exchange 
the buffer. To each sample of cell lysate, 2 mL of 1:1 resin:buffer slurry, was added. The 
resin was nutated with cell lysate for 16 hours at 4 °C. The resin-lysate mixture was 
pelleted for 1 minute via centrifugation (1500 X G). The lysate was removed, with 200 
uL of supernatant saved as the flow-through. The packed bed of resin was then rigorously 
washed with 0.1% NP-40 followed by buffer exchanging into PBS. One wash consists 
resuspending packed resin in a volume of wash buffer, pelleting the resin via 
centrifugation (1500 x G), and removal of the supernatant, leaving packed resin. The 
resin for each condition was washed with 0.1% NP-40 (7 x 30 mL) and exchanged into 
PBS by washing (3 x 30 mL). The packed resin was transferred into 1.5 mL Eppendorf 
tubes by repeated resuspension in PBS followed by pelleting via centrifugation (1500 x 
G), and removal of the PBS supernatant. The pelleted resin was dehydrated with a gel 
loading pipet tip to remove the retention volume of the resin. The resin was then 
resuspended in 300 uL of elution buffer (4 mM biotin in PBS) and incubated at 37 °C. 
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After 5 minutes, then resin was agitated by repeated shaking of the Eppendorf tube. This 
process was repeated until 15 min has elapsed. The 300 uL elution buffer was removed 
and placed into an Eppendorf tube. The elution process was repeated twice more, 
yielding three total elutions. 
Proteomic analysis: 
Trypsin digest LC-MS/MS analysis was performed by the Speicher Laboratory at the 
Wistar Institute as described by Rebecca et. al.53 
Fluorogenic PPT1 assay 
Melanoma cell cultures were treated with the specified dose of inhibitor for 3 hours. The 
cells were lysed by osmotic and mechanical stress in milli-Q water. The cell lysates were 
adjusted to an equal protein concentration of 0.1 ug/ uL. The cell lysates were used a 
source of PPT1 and assayed according to the methodology described by Van Diggelin et. 
al.112  
Recombinant PPT1 Expression 
Recombinant expression of PPT1 was performed in SF9 cells and purified by nickel-
NTA/his-tag purification. The protein was expressed and purified by Dr. Julie Rotenburg-
Barber as described by Rebecca et. al.53 
CD-44/Acyl biotin exchange assay 
The assay was performed as described by Rebecca et. al.53 
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Differential Scanning Calorimetry 
DSC assays were performed by Dr. Julie Rotenburg-Barber as described by Rebecca et. 
al.53 
Chapter 4 Assay Methods 
Spectroscopic characterization 
Small molecule fluorescence and absorption properties were observed on a Tecan 
M1000 fluorescent plate reader. UV-Vis spectroscopy was collected in triplicate and 420 
nm was found to be the average most red shifted absorption across the library of dimeric 
quinacrines. Emission spectra were collected for each compound at 1 μM solutions, 
which was confirmed to be in the linear range of fluorescence. Solutions of pH 7.4 and 1 
N HCl, were used to bias the degree of protonation of the heterocycles. Emission data 
was processed with a five-point floating average to reduce instrument noise. The data was 
then normalized to the fluorescence maximum of the library, DQ 661.  
Expression of PPT1 was performed as described above in chapter 3. 
LC-MS observation of PPT1-mediated degradation of the second generation PPT1 probe 
The probe was dissolved in acetate buffer (pH 5.0, 150 mM NaCl, 0.1% Triton-
X100) at a concentration of 100 uM. Recombinantly expressed PPT1 was then added to 
the reaction vessel to give an enzyme concentration of 50 nM, and the reaction was 
incubated at 37 °C. The reaction was monitored by injection into a Waters UPLC-MS 
with UV-Vis absorbance detection. The probe was identified by monitoring absorption at 
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650 nm. The molecular identity of the reaction products were identified by mass 
spectrometry. 
Fluorogenic Assay for PPT1-mediated degradation of the second generation PPT1 probe 
The fluorescence assay was conducted in a Tecan M1000 fluorescent plate reader 
heated to 37 °C. Each 50 uL reaction contained 500 nM PPT1, and 10 μM PPT1-probe, 
dissolved in acetate buffer (pH 5.0, 150 mM NaCl, 0.1% Triton-X100). The reactions 
were monitored by fluorescence emission (ex. 675, em. 700 nm) every three minutes. The 
data shown is an average of 9 experiments, where the error was calculated as the standard 
deviation of fluorescence emission. 
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APPENDIX  
Synthetic Methods 
General Synthetic Methods 
Solvents used for extraction and purification were HPLC grade from Fisher Scientific. 
Unless otherwise indicated, all reactions were run under an inert atmosphere of argon. 
Anhydrous tetrahydrofuran, ethyl ether and methylene chloride were obtained via 
passage through an activated alumina column. Commercial reagents were used as 
received. VWR pre-coated silica gel plates (250 m, 60 F254) were used for analytical 
TLC. Spots were visualized using 254 nm ultraviolet light or with potassium 
permanganate if no chromophore was available. Chromatographic purifications were 
performed on Sorbent Technologies silica gel (particle size 32-63 microns). 1H and 13C 
NMR spectra were recorded at 500 MHz and 125 MHz, respectively in CDCl3, CD3OD, 
or DMSO-d6, on a Bruker AM-500 or DRX-500 spectrometer. Chemical shifts are 
reported relative to internal chloroform ( = 7.26 for 1H,  = 77.00 for 13C), methanol ( 
= 3.31 for 1H,  = 49.00 for 13C), or DMSO ( = 2.50 for 1H,  = 39.00 for 13C). HPLC 
purification was performed utilizing a Shimadzu HPLC (Water [0.1% TFA v/v, MeCN]) 
with reverse phase columns from Waters (Analytical X-Select, C18, 5 um pore size, 
column dimensions 4.6 mm x 250 mm; Preparative X-Select, C18, 5 um pore size, column 
dimensions 19 mm x 250 mm). Infrared spectra were recorded on a NaCl plate using a 
Perkin-Elmer 1600 series Fourier transform spectrometer. Melting points were obtained 
on a Thomas Hoover capillary melting point apparatus and are uncorrected. Accurate 
mass measurement analyses were conducted on either a Waters GCT Premier, time-of-
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flight, GCMS with electron ionization (EI), or an LCT Premier XE, time-of-flight, LCMS 
with electrospray ionization (ESI).  Samples were taken up in a suitable solvent for 
analysis.  The signals were mass measured against an internal lock mass reference of 
perfluorotributylamine (PFTBA) for EI-GCMS, and leucine enkephalin for ESI-
LCMS.  Waters software calibrates the instruments, and reports measurements, by use of 
neutral atomic masses. The mass of the electron is not included. We thank Dr. Charles W. 
Ross III and Joo Myung Jun for their measurement and analysis of compound accurate 
mass. 
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Chapter 2: Synthetic Methods 
Synthesis of Dimeric Chloroquine Inhibitors 
 
DC220-3HCl 
To a flame-dried round bottom flask, the triamine linker (14), (TCI America) (1.9 
mL, 17.6 mmol, 1.0 eq.), 4-bromo-7-chloroquinoline156 (13) (9.00g, 37.0 mmol, 2.2 eq.), 
Pd(OAc)2 (Strem Chemicals) (160mg, 0.71mmol, 0.04 eq.), (±)-2,2′-
bis(diphenylphosphino)-1,1′-binaphthalene (BINAP) (Strem Chemicals) (880mg, 1.41 
mmol, 0.08 eq.), K3PO4 (Acros Organics)(11.27g, 52.9 mmol, 3.0 eq.) were added at 
25oC. The reagents were placed under an argon atmosphere and dissolved in 1,4-dioxane 
(44mL, 0.4 M). The reaction was then heated to 105 °C under a reflux condenser. The 
reaction was monitored by 1H NMR (CDCl3) where the disappearance of the primary 
amine linker marks consumption of the limiting reagent (peak at δ ~2.7 ppm). The 
reaction was then cooled to 23 °C and filtered through Celite™ using 300 mL of a 2:1 
mixture of CHCl3:MeOH. The resulting solution was concentrated under reduced 
pressure to afford a yellow solid (15.0g). The solid was triturated three times with boiling 
CH2Cl2 (100 mL) to afford a crude white solid (9.75 g) which was collected via vacuum 
filtration. The solid was purified by salt formation (recrystallization in 1N HCl; 700 mL), 
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yielding a white solid (15) (5.72g, 61%), the structure of which was confirmed by 1H 
NMR. TLC (Rf = 0.2, 10:89:1; MeOH:CH2Cl2:NH4OH). Melting point (mp) (H2O) = 
>240 °C (decomposition). 1H NMR (500 MHz, DMSO-d6): δ 9.89 (s, 2H), 9.81 – 9.74 
(m, 2H), 8.82 (d, J = 9.2 Hz, 2H), 8.63 (d, J = 7.1 Hz, 2H), 8.08 (d, J = 2.1 Hz, 2H), 7.77 
(dd, J = 9.1, 2.1 Hz, 2H), 7.05 (d, J = 7.1 Hz, 2H), 3.97 (q, J = 5.8 Hz, 4H), 3.41 (t, J = 
6.0 Hz, 4H). 13C NMR (126 MHz, D2O): δ 155.64, 142.67, 139.69, 137.26, 127.73, 
123.73, 118.82, 114.77, 98.48, 44.59, 39.15. FTIR (thin film) λ (cm-1):  3021.73, 
2920.36, 2783.11, 1626.95, 1611.13, 1584.16, 1550.07, 1451.45, 1365.71, 1343.21, 
1228.39, 1210.89. HRMS (ESI) C22H24Cl5N5: Calculated for [M+H-3HCl] C22H22N5Cl2, 
426.1252; found: 426.1247. 
  
Lys 05 (DC221) 85 
DC220-3HCl (15) (5.00 g, 9.3 mmol, 1.0 eq) was added to a two-neck round 
bottom flask with a stir bar. A septum was placed in one neck, while a reflux condenser 
was placed over the other neck. The entire apparatus was placed under an atmosphere of 
argon. Formic acid (HCOOH) (Acros Organics) (31 mL) was added to the reaction vessel 
via a syringe, resulting in a 0.3M solution. Formaldehyde (CH2O) (Fisher Scientific) (1.2 
mL, 13.6 mmol, 1.45 eq.) was added as a solution (37% w/w aqueous) via a syringe to 
the reaction vessel. The reaction was heated to reflux with an oil bath preset to 105 °C. 
The reaction was monitored via TLC, whereby consumption of the starting material 
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DC220 (Rf = 0.2, 10:90:1, MeOH:CH2Cl2:NH4OH) and appearance of the product as a 
UV 254 nm active spot (purple in color, Rf = 0.45, 10:90:1, MeOH:CH2Cl2:NH4OH) 
indicated completion of the reaction.   The resulting mixture was then cooled to 23 °C 
and poured onto 200 mL of ice water. More ice was added to a final volume of 300 mL, 
and the pH of the solution brought to 12 with concentrated NH4OH (ca. 60 mL) at which 
point a white solid precipitated. The solid was collected via vacuum filtration (3.5g). 
Further purification was affected by recrystallization from hot ethyl acetate (EtOAc), 
which on cooling to -20°C resulted in the formation of small off-white needles whose 
structure was confirmed by 1H NMR. The product was collected via vacuum filtration 
(2.41g, 59%) and washed with cold EtOAc (-20 °C). The structure of the resulting 
product was confirmed by 1H NMR, and found to match literature precedent (9).85  1H 
NMR (500 MHz, CDCl3): δ 8.53 (2H, d, J = 5.5 Hz) ppm, 7.94 (2H, d, J = 2.0 Hz), 7.41 
(2H, d, J = 9.0 Hz), 6.99 (2H, dd, J = 9.0, 2.0 Hz), 6.38 (2H, d, J = 5.5 Hz), 5.45 (2H, 
s(br)), 3.40 (4H, quart., J = 5.0 Hz), 2.89 (4H, t, J = 6.0 Hz), 2.46 (3H, s). 
 
Lys 05 (Water Soluble Salt) 
Synthesis of Lys 05 the water-soluble salt of DC221, was performed according to 
literature precedent. NMR of the water-soluble salt was found to match the reported 
literature precedent.85 1H NMR (500 MHz, D2O): δ 8.26 (d, J = 6.9 Hz, 2H), 7.86 (d, J = 
9.0 Hz, 2H), 7.71 (d, J = 2.2 Hz, 2H), 7.36 – 7.42 (m, 2H), 6.75 (d, J = 7.0 Hz, 2H), 4.01 
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(s, 4H), 3.76 (s, 4H), 3.23 (s, 3H). 13C NMR (126 MHz, D2O): δ 155.43, 142.80, 140.01, 
136.94, 127.86, 123.86, 118.78, 114.49, 98.68, 52.91, 42.65, 38.15. Purity of the final 
compound was determined by UPLC-MS analysis. Lys05 was found to be a single peak, 
with a mass corresponding to the reported literature precedent, [M+2H-3HCl]/2 = 220.8 
 
 
1 –Bromo-7-Azidoheptane 
1,7-Dibromoheptane 34 (959 mg, 3.81 mmol, 2.0 equiv.) was weighed into a 
round bottom flask. The flask was placed under an argon atmosphere, and DMSO (4mL) 
was added via a syringe to the reaction vessel. Sodium azide (124 mg, 1.90 mmol, 1.0 
equiv.) was added, and allowed to stir for five hours at room temperature. Upon 
completion, the reaction was diluted with water (40mL), and extracted with diethyl ether 
(3x25 mL). The organic layer was washed with brine, and dried over sodium sulfate. 
Concentration yielded a clear oil (1.00g), which was purified by column chromatography 
(30mm x 150mm, 10:1 Hexanes: Ethyl Acetate) to yield a clear oil 36 (264mg, 63%), the 
structure of which was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) δ 3.41 (t, J = 
6.8 Hz, 2H), 3.26 (t, J = 6.9 Hz, 2H), 1.90 – 1.81 (m, 2H), 1.64 – 1.57 (m, 2H), 1.50 – 
1.30 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 51.41, 33.96, 32.81, 28.92, 28.47, 28.16, 
26.72. FTIR (thin film) λ (cm-1): 2932, 2857, 2095. HRMS (ESI) C7H14N3Br: Calculated 
for [M+H] C7H15N3Br, 220.0449; found: 220.0420. 
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1 –Bromo-8-Azidooctane 
Synthesized by the general procedure used for 1-Bromo-7-Azidoheptane 36. 
Product (37) isolated as an oil (1.07g, 60%) the structure of which was verified by 1H 
NMR. 1H NMR (500 MHz, CDCl3) δ 3.41 (t, J = 9.8, 4.1 Hz, 2H), 3.26 (t, J = 8.1, 5.8 
Hz, 2H), 1.86 (m, 2H), 1.60 (m, 2H), 1.48 – 1.42 (m, 2H), 1.40 – 1.31 (m, 6H). 13C NMR 
(126 MHz, CDCl3) δ 51.34, 33.78, 32.64, 28.85, 28.70, 28.50, 27.94, 26.51. FTIR (thin 
film) λ (cm-1): 2931, 2857, 2095. HRMS (ESI) C7H14N3Br: Calculated for [M-N2] 
C8H16NBr, 206.0544; found: 206.0624. 
 
 
7-azido-N-(7-azidoheptyl)-N-benzylheptan-1-amine 
1 –Bromo-7-Azidoheptane (36) (1.577g, 7.17 mmol, 2.2 equiv.), potassium 
carbonate (1.348g, 9.77 mmol), and potassium iodide (108 mg, 0.65 mmol, 0.2 equiv.) 
were added to a round bottom flask. After placing the reaction under argon gas, n-butanol 
(14 mL) was added and heated to 115 ˚C. Benzylamine (360 uL, 3.26 mmol, 1.0 equiv.) 
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was added via a syringe, and the reaction was stirred at reflux for 16 hours. The reaction 
was dissolved in diethyl ether (60 mL), filtered through Celite™, and concentrated to a 
yellow oil (1.61g). The crude material was purified by column chromatography (dry 
loaded onto 2g SiO2, then eluted on a 40mm x 150 mm column with 5:1 Hexanes:Ethyl 
Acetate), yielding a yellow oil (38) (435mg , 35%), the structure of which was verified by 
1H NMR. 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.25(m, 5H), 3.58 (s, 2H), 3.28 (t, J = 7.0 
Hz, 4H), 2.47 – 2.40 (m, 4H), 1.61 (q, J = 7.2 Hz, 4H), 1.55 – 1.47 (m, 4H), 1.43 – 1.27 
(m, 12H). 13C NMR (126 MHz, CDCl3) δ 140.16, 128.97, 128.20, 126.81, 58.79 , 53.84 , 
51.58 , 29.15 , 28.92 , 27.35 , 27.02, 26.83. FTIR (thin film) λ (cm-1): 2932, 2857, 2797, 
2094. HRMS (ESI) C21H35N7: Calculated for [M+H] C21H36N7, 386.3032; found: 
386.3012. 
 
 
8-azido-N-(8-azidoheptyl)-N-benzyloctan-1-amine 
Synthesized by the general procedure used for 7-azido-N-(7-azidoheptyl)-N-
benzylheptan-1-amine (38). The product 39 was isolated as a golden oil (310 mg, 39%), 
the structure of which was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) δ 7.37 – 
7.22 (m, 5H), 3.56 (s, 2H), 3.28 (t, J = 6.8 Hz, 4H), 2.42 (t, J = 7.5 Hz, 4H), 1.62 (p, J = 
7.1 Hz, 4H), 1.48 (s, 4H), 1.34 (d, J = 42.1 Hz, 14H). 13C NMR (126 MHz, CDCl3) δ 
128.79, 128.04, 126.58, 124.56, 58.67, 53.84, 51.50, 29.39, 29.15, 28.83, 27.32, 27.03, 
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26.70. FTIR (thin film) λ (cm-1): 2932, 2857, 2797, 2094. HRMS (ESI) C23H39N7: 
Calculated for [M+H] C23H40N7, 414.3278; found: 414.3301. 
 
 
N1-7(-aminoheptyl)heptane-1,7-diamine 
 7-azido-N-(7-azidoheptyl)-N-benzylheptan-1-amine (38) (435mg, 1.12 mmol, 1.0 
equiv.) was added to a round bottom flask and dissolved in methanol. The reaction was 
degassed by bubbling argon gas through the mixture for ten minutes. To this palladium 
on carbon (356 mg of 10 weight %, 0.34 mmol, 0.3 equiv.) was added and the reaction 
sealed with a septum. Using a balloon and needle, hydrogen gas was bubbled through the 
reaction for fifteen minutes. Then placed under a balloon of hydrogen at one atmosphere 
for 6 hours. Upon completion, argon gas was bubbled through the reaction mixture for 
fifteen minutes, sonicated in methanol, and filtered through a pad of Celite™. 
Concentration of this reaction mixture gave a white solid (40) (235 mg, 86%) the 
structure of which was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) δ 2.61 (h, J = 
7.9, 6.8 Hz, 4H), 2.53 (q, J = 7.4, 6.1 Hz, 4H), 1.78 – 1.73 (m, 9H), 1.45 – 1.34 (m, 11H), 
1.33 – 1.17 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 50.19, 42.32, 33.86, 30.21, 29.53, 
27.50, 26.95. FTIR (thin film) λ (cm-1): 2923, 2851. HRMS (ESI) C14H33N3: Calculated 
for [M+H] C14H34N3, 244.2753; found: 244.2755. 
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N1-(8-aminooctyl)octane-1,8-diamine 
The same general synthesis as N1-7(-aminoheptyl)heptane-1,7-diamine (40)  was 
used. The product was isolated as an off-white paste (41) (160 mg, 79%), the structure of 
which was verified by 1H NMR.  1H NMR (500 MHz, CDCl3) δ 2.69 – 2.61 (m, 4H), 2.55 
(td, J = 7.5, 2.8 Hz, 5H), 1.65 (bs, 8H), 1.48 – 1.37 (m, 11H), 1.28 (d, J = 5.7 Hz, 19H). 
13C NMR (126 MHz, CDCl3) δ50.28, 42.30, 33.85, 30.19, 29.65, 29.54, 27.47, 26.94. 
FTIR (thin film) λ (cm-1): 2923, 2851. HRMS (ESI) C16H37N3: Calculated for [M+H] 
C16H38N3, 272.3066; found: 272.3063. 
 
Benzyl (11-hydroxyundecyl)carbamate 
To a reaction vessel 11-aminoundecanol157 43 (466mg, 2.49 mmol, 1.0 equiv.) 
was added, placed under a positive pressure of argon gas, and dissolved in 
tetrahydrofuran (8mL). Triethylamine (800 ul, 5.73 mmol, 2.3 equiv.) was added to the 
reaction mixture via a syringe, and the reaction was cooled to 0 ˚C. While stirring, benzyl 
chloroformate (400 ul, 2.74 mmol, 1.1 equiv.) was added slowly via a syringe. The 
reaction was allowed to stir 6 hours at 55 ˚C till completion. The reaction was filtered 
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through Celite™ and concentrated to a yellow-white solid 800 mg. The solid was purified 
on by column chromatography (SiO2, 30 mm x 150 mm, 3% MeOH: CH2Cl2). Collect 
463 mg of product (44) 58% yield, the structure of which was confirmed by 1H NMR. 
MP = 66-69 ˚C. 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H), 5.08 (s, 2H), 4.88 – 
4.78 (m, 1H), 3.62 (t, J = 6.7 Hz, 2H), 3.17 (q, J = 6.8 Hz, 2H), 1.64 (s, 1H), 1.55 (p, J = 
6.8 Hz, 2H), 1.47 (q, J = 7.1 Hz, 2H), 1.36 – 1.20 (m, 14H). 13C NMR (126 MHz, CDCl3) 
δ 156.54, 136.77, 128.61, 128.22, 128.18, 66.68, 63.09, 41.22, 32.90, 30.05, 29.66, 29.60, 
29.57, 29.52, 29.35, 26.83, 25.85. HRMS (ESI) C19H31NO3: Calculated for [M+H] 
C19H31NO3, 188.2104; found: 188.2005. FTIR (thin film) λ (cm
-1): 3346, 2922, 2852, 
1685, 1531, 1267, 1245. 
 
benzyl (11-oxoundecyl)carbamate 
To a flame dried round bottom flask, CH2Cl2 (83 ml) was added followed by 
distilled oxalyl chloride (960 ul, 11.2 mmol, 1.2 equiv.). The reaction vessel was cooled 
to -78 ˚C and stirred under a positive pressure of argon gas. DMSO (1.59 ml, 22.4 mmol, 
2.4 equiv.) was added via a syringe, and allowed to stir 45 min until the reaction ceases 
bubbling. In a solution of CH2Cl2 (10 ml) Benzyl (11-hydroxyundecyl)carbamate (44) 
(3.00g, 9.33 mmol, 1.0 equiv.) was added to the reaction mixture, and allowed to stir for 
30 minutes. Triethylamine (6.5 ml, 46.7 mmol) was added and the reaction was stirred 60 
min warming to room temperature until the oxidation was complete. Upon completion, 
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the reaction was washed 3 x 20 mL with a saturated NH4Cl solution, washed with brine, 
and the organic layer was dried over sodium sulfate. Concentration of the organic layer 
yielded a paste, which was dissolved in toluene and evaporated till a white solid (45) 
(2.8g, 94 %) forms. 1H NMR (500 MHz, CDCl3) δ 9.71 (s, 1H), 7.29 (dd, J = 20.5, 4.4 
Hz, 5H), 5.05 (s, 2H), 4.96 (t, J = 6.1 Hz, 1H), 3.14 (q, J = 6.7 Hz, 2H), 2.37 (td, J = 7.3, 
1.8 Hz, 2H), 1.59 (q, J = 7.2 Hz, 2H), 1.45 (p, J = 7.2 Hz, 2H), 1.36 – 1.17 (m, 13H). 13C 
NMR (126 MHz, CDCl3) δ 202.97, 156.43, 136.73, 128.47, 128.05, 128.01, 66.46, 43.87, 
41.08, 29.93, 29.43, 29.31, 29.30, 29.22, 29.12, 29.11, 26.71, 22.04. FTIR (thin film) λ 
(cm-1): 3325, 2922, 2851, 1688, 1634, 1556, 1469. 
 
 
dibenzyl((benzylazanediyl)bis(undecane-11,1-diyl))dicarbamate 
To a round bottom flask, compound (45) (2.8g, 8.8 mmol, 2.2 equiv.) was added 
and placed under a positive pressure of argon gas. CH2Cl2 was added (80 ml), then 
benzyl amine (435 ul, 3.98 mmol, 1.0 equiv.) was added via a syringe. Once the reaction 
becomes homogenous, sodium triacetoxyborohydride was added (4.24 g, 20 mmol, 5.0 
equiv.). Upon completion, the reaction was diluted by half and excess sodium 
triacetoxyborohydride was quenched by reaction with an equal volume of 2N aqueous 
sodium hydroxide for 1 hour. The organic layer was separated, washed with brine, dried 
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over sodium sulfate, and concentrated under reduced pressure. The crude material was 
purified by column chromatography (SiO2, 45 mm x 150 mm, 3:1 Hexanes:THF). Yield a 
white solid (46) (2.33g, 82%).  1H NMR (500 MHz, CDCl3) δ 7.39 – 7.27 (m, 15H), 7.24 
– 7.20 (m, 1H), 5.10 (s, 4H), 4.85 (s, 1H), 3.54 (s, 2H), 3.17 (t, J = 7.0 Hz, 4H), 2.39 (t, 
4H), 1.52 – 1.41 (m, 8H), 1.34 – 1.19 (m, 32H). 13C NMR (126 MHz, CDCl3) δ 156.46, 
140.41, 136.80, 128.91, 128.59, 128.20, 128.15, 128.12, 126.65, 66.62, 58.72, 53.92, 
41.22, 41.09, 30.05, 29.73, 29.68, 29.66, 29.65, 29.40, 27.56, 27.12, 26.86. FTIR (thin 
film) λ (cm-1): 2923, 2852, 1685, 1531. HRMS (ESI) C45H67N3O3: Calculated for 
[M+Na] C45H67N3O4Na, 736.5032; found: 736.5029. 
 
 
 
N1-(11-aminoundecyl)undecane-1,11-diamine 
To a round bottom flask, compound 46 (800mg, 1.12 mmol, 1.0 equiv.) was 
added, and dissolved in MeOH (12.5 ml). The reaction was then degassed by bubbling 
argon gas through the solution for 10 minutes. Palladium on carbon (10% by weight, 367 
mg, 0.34 mmol, 0.3 equiv.) was added to the reaction mixture, and while stirring, 
hydrogen gas was bubbled through the reaction mixture for 15 minutes. The reaction was 
then placed under a balloon of hydrogen, and stirred till the starting material was 
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consumed. Upon completion the reaction was degassed by bubbling argon gas through 
the reaction for 15 minutes. Then, the reaction was sonicated and filtered through 
Celite™ using methanol. The methanol was concentrated yielding compound 47 (360 
mg, 91%), as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.67 (t, J = 7.0 Hz, 4H), 2.58 
(t, 3H), 1.45 – 1.39 (m, 1H), 1.35 – 1.22 (m, 34H). 13C NMR (126 MHz, CDCl3) δ 50.20 
42.44, 34.01, 30.16, 29.78, 29.74, 29.72, 29.67(2C), 27.58, 27.07 HRMS (ESI) C22H49N3: 
Calculated for [M+H] C22H50N3, 188.2104; found: 188.2005. FTIR (thin film) λ (cm
-1): 
2925, 2850, 2812.  
 
General procedure for Buchwald-Hartwig amination 
To a vial, triamine (1.0 Eq), Arylhalide (2.2 eq)55,56,156, Pd(OAc)2 (0.05 eq), 
racemic BINAP (0.10 eq), and K3PO4 (3.0 eq) were added. The reaction vessel was 
sealed, evacuated, and placed under an argon atmosphere. To the vial, a solution of 10:1 
1,4-dioxane:water (degassed by freeze-pump-thaw method) was added(0.4M final 
reaction concentration), and the reaction was heated to 120°C. Upon completion, the 
reaction was allowed to cool to 23°C and filtered through Celite™™ using either CHCl3 
(DC compounds) or CH2Cl2 (DQ compounds) and concentrated under reduced pressure. 
The compounds were then dissolved in a minimum amount of either CHCl3 (DC 
compounds), or CH2Cl2 (DQ compounds). The HCl salt was formed by added 3.0 eq of 
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HCl in diethyl ether. The precipitate was filtered and collected via vacuum filtration. The 
organic layer is washed 3 x with H2O. The precipitate was dissolved in H2O unless 
specified. The H2O layer was then washed once with CH2Cl2. Following the organic 
wash, the pH of the aqueous layer was adjusted to 12 by the addition of aqueous 
ammonium hydroxide. The aqueous layer was then extracted with 25% 2-propanol in 
CHCl3 and dried over anhydrous sodium sulfate. The organic reaction was concentrated 
to a solid or film yielding the dimeric inhibitor. Further purification used when specified. 
 
DC340 
DC340 (17) was synthesized and isolated by the general procedure above. The 
product as a white solid (785 mg, 91% yield), the structure of which was verified by 1H 
NMR to match literature precedent.46 Rf = 0.10 (EtOAc:MeOH:TEA; 80:15:5); 
1H NMR 
(500 MHz, CD3OD) δ 8.34 (t, J = 5.4 Hz, 2H), 8.07 (dd, J = 12.3, 9.0 Hz, 2H), 7.90 (d, J 
= 0.8 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.38 (ddd, J = 8.7, 6.1, 2.2 Hz, 2H), 6.52 (t, J = 
6.3 Hz, 2H), 3.40 (dt, J = 17.8, 7.0 Hz, 4H), 2.76 (t, J = 7.1 Hz, 2H), 2.69 (t, J = 7.5 Hz, 
2H), 1.94 (p, J = 7.0 Hz, 2H), 1.79 (p, J = 7.2 Hz, 2H), 1.69 (q, J = 7.6 Hz, 2H). 
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DM 340 (33) – Dr. Noel McLaughlin 
To a vial was added 3-Chloro-2,8-bis(trifluoromethyl)quinoline58 (558.00 mg, 
1.86 mmol, 2.40 equiv.), BINAP (72.00 mg, 0.12 mmol, 0.15 equiv.), Pd(OAc)2 (14.00 
mg, 0.06 mmol, 0.075 equiv.), finely ground K3PO4 (659.00 mg, 3.10 mmol, 4.00 equiv.) 
and spermidine (120.0 uL, 0.78 mmol, 1.00 equiv.). The reagents were placed under a 
blanket of Argon; then a mixture of degassed dioxane and water (3 mL, 10:1) was added. 
The reaction vial was sealed and heated to 120 ˚C for 12 hours. The reaction was then 
cooled to room temperature and filtered on a pad of Celite™; washing with chloroform (3 
× 10 mL). Combined organic layers were acidified to pH 1 using 1M aqueous HCl 
solution (4.7 mL, 4.66 mmol, 6.00 equiv.) and diluted with water (20 mL). The resulting 
biphasic mixture was separated, and the water layer was washed with chloroform (2 × 15 
mL). The pH of the aqueous layer was adjusted to 11 using ammonium hydroxide. The 
now alkaline mixture was washed with chloroform (3 × 20 mL). These 3 chloroform 
extracts were combined, washed with brine, dried over Na2SO4 and concentrated which 
afforded the product as an off-white foam (33) (243.00 mg, 50% yield). The purity of this 
material was calculated to be ≥ 95% which negated the need for further purification. Rf = 
0.25 (CCl3:MeOH:TEA; 85:10:5); Mp = 84 – 87 ˚C. 
1H NMR (500 MHz, DMSO) 1.55 – 
1.60 (2H, m, CH2), 1.70 – 1.75 (2H, m ,CH2), 1.79 – 1.85 (2H, m, CH2), 2.58 (2H, t, J = 
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7.0 Hz, CH2), 2.65 (2H, t, J = 6.0 Hz, CH2), 3.39 – 3.43 (4H, m, CH2), 6.86 (2H, d, J = 
7.5 Hz, ArH), 7.59 – 7.66 (2H, m, ArH), 8.03 (1H, s(br), NH), 8.08 (1H, d, J = 7.0 Hz, 
ArH), 8.12 (1H, d, J = 7.0 Hz, ArH), 8.26 (1H, s(br), NH), 8.53 (1H, d, J = 8.5 Hz, ArH), 
8.61 (1H, d, J = 8.5 Hz, ArH) ppm. 13C (125 MHz, DMSO) 25.9, 27.3, 28.0, 41.6, 42.8, 
47.5, 49.4, 94.4, 119.7, 119.7, 120.9, 123.1, 124.8 (d), 126.6, 126.8, 127.2, 127.3, 129.3 
(br), 144.17, 144.23, 152.7, 152.8 ppm. FTIR (thin film) λ (cm-1): 3406, 3020, 2976, 
1523, 1215, 771. HRMS (ESI) C29H26F12N5: Calculated for [M+H] C29H27F12N5, 
672.1997; found: 672.2033. 
 
DP340 
To a vial was added 8-Chloro-6-methoxyquinoline56 (26)(193.0 mg, 1.0 mmol, 
2.20 equiv,), BINAP (45.00 mg, 0.072 mmol, 0.16 equiv.), Pd2(dba)3 (33.00 mg, 0.036 
mmol, 0.08 equiv.), NaOtBu (130.0 mg, 1.37 mmol, 3.0 equiv) and spermidine (71.0 uL, 
0.46 mmol, 1.00 equiv.). The reagents were placed under a blanket of Argon; then 1 mL 
of dioxane was added. The reaction vial 26and filtered on a pad of Celite™; washing 
with chloroform (3 × 10 mL). The filtrate was concentrated and dissolved with methanol 
and dichloromethane and adsorbed onto 400 mg of SiO2. These materials were separated 
via flash column chromatography (EtOAc:MeOH:TEA; 90:9:1) to afford the product as a 
red brown paste (32) (173 mg, 83%), the structure of which was confirmed by 1H NMR.  
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1H NMR (500 MHz, CDCl3) δ 8.54 – 8.50 (m, 2H), 7.91 (ddd, J = 8.1, 4.0, 1.7 Hz, 2H), 
7.29 (d, J = 1.3 Hz, 2H), 6.37 – 6.27 (m, 5H), 6.14 (s, 1H), 3.88 (d, J = 1.3 Hz, 6H), 3.35 
(t, J = 6.9 Hz, 2H), 3.28 (q, J = 6.2 Hz, 2H), 2.82 (td, J = 6.9, 1.4 Hz, 2H), 2.75 – 2.67 
(m, 2H), 2.00 – 1.93 (m, 2H), 1.84 – 1.76 (m, 2H), 1.74 – 1.65 (m, 2H). 13C (125 MHz, 
CDCl3) 26.2 (2C’s), 29.6, 40.8, 42.7, 46.3, 47.9, 55.1 (2C’s), 92.2, 92.6, 96.8, 97.1, 
121.75, 121.81, 129.60, 129.61, 134.6, 135.17, 135.19, 144.3, 144.5, 145.3, 145.5, 159.2, 
159.3 ppm. FTIR (thin film) λ (cm-1): 2936, 1617, 1522, 1458, 1422, 1388, 1214, 1154, 
1050, 821, 791. HRMS (ESI) C27H34N5O2: Calculated for [M+H] C27H35N5O2, 460.2713; 
found: 460.2707. 
 
DQ 221 – Dr. Noel McLaughlin 
DQ 221 (52) was prepared by the above general procedure. Required flash 
column chromatography (EtOAc:MeOH:TEA; 90:9:1) to afford the product as a red solid 
(240.00 mg, 33%). Rf = 0.15 (EtOAc:MeOH:TEA; 92:7:1); Mp = 163 – 164 ˚C; 
1H NMR 
(500 MHz, CDCl3) 2.45 (3H, s, CH3), 2.88 (4H, t, J = 6.0 Hz, CH2), 3.73 (6H, s, CH3), 
3.85 (4H, t, J = 6.0 Hz, CH2), 5.65 (2H, s(br), NH), 7.16 (2H, d, J = 9.0 Hz, ArH), 7.21 
(2H, d, J = 2.5 Hz, ArH), 7.32 (2H, d, J = 8.5 Hz, ArH), 7.95 (2H, d, J = 9.0 Hz, ArH), 
8.01 – 8.07 (4H, m, ArH) ppm. 13C NMR (125 MHz, CDCl3) 42.0, 47.4, 55.4, 57.9, 99.5, 
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115.5, 117.8, 124.3, 124.4, 127.5, 130.8, 135.1, 145.9, 147.8, 149.9, 156.1 ppm. FTIR 
(thin film) λ (cm-1): 3688, 3619, 3019, 1219, 929. HRMS (ESI) C33H32Cl2N5O2: 
Calculated for [M+H] C33H32Cl2N5O2, 600.1933; found:600.1935.2707.  
 
DQ 330 
DQ 330 (53) was prepared by the above general procedure. The workup was altered from 
the general procedure as follows. After formation of the HCl salt, and following the 
standard workup showed little product moved into the aqueous layer, therefore the 
collected precipitate (380mg) was recrystallized from methanol yielding (229 mg). The 
HCl salt solubilized in a solution of a 1:1 mixture of dichloromethane to basic methanol. 
The residue was dissolved in dichloromethane, washed with water (2x20 mL) then 
washed with brine and dried over Na2SO4. Concentration of the organic phase yielded an 
orange solid (172 mg, 56%). Mp = 122 – 124 ˚C 1H NMR (500 MHz, CDCl3) δ 8.01 – 
7.96 (m, 2H), 7.92 (d, J = 9.3 Hz, 4H), 7.33 (dd, J = 9.4, 2.7 Hz, 2H), 7.21 (d, J = 2.7 Hz, 
2H), 7.10 (dd, J = 9.2, 2.2 Hz, 2H), 6.01 (s, 2H), 3.83 – 3.75 (m, 10H), 3.49 (s, 1H), 2.82 
(t, J = 6.3 Hz, 4H), 1.89 (p, J = 6.4 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 155.56, 
149.93, 134.72, 124.37, 123.86, 123.72, 117.50, 115.26, 100.41, 55.52, 49.90, 30.87, 
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25.41. FTIR (thin film) λ (cm-1): 2925, 2853, 1631, 1562, 1466, 1238. HRMS (ESI) 
C34H34Cl2N5O2: Calculated for [M+H] C34H35Cl2N5O2, 614.2090; found: 614.2088. 
 
 
DQ 340 – Dr. Noel McLaughlin 
DQ 340 (31) was prepared by the above general procedure. The isolated materials were 
separated via flash column chromatography (EtOAc:MeOH:TEA; 84:16:1) to afford the 
product as a red solid (160.00 mg, 56%). Rf = 0.10 (EtOAc:MeOH:TEA; 84:15:1). Mp = 
115 – 118 ˚C. 1H NMR (500 MHz, CDCl3) 1.68 – 1.74 (2H, m, CH2), 1.80 – 1.86 (2H, m, 
CH2), 1.88 – 1.92 (2H, m, CH2), 2.73 (2H, t, J = 7.0 Hz, CH2), 2.89 (2H, t, J = 7.0 Hz, 
CH2), 3.74 (2H, t, J = 7.0 Hz, ArH), 3.87 (3H, s, CH3), 3.89 – 3.92 (5H, m, CH3, and 
CH2), 7.11 – 7.24 (3H, m, ArH), 7.31 – 7.39 (3H, m, ArH), 7.95 – 8.04 (6H, m, ArH) 
ppm. 13C NMR (125 MHz, CDCl3) 27.2, 29.5, 30.1, 49.0, 49.7, 50.5, 50.8, 55.6 (2C), 
99.5, 101.3, 117.9, 118.4, 118.5, 120.6, 123.5, 123.6, 124.1, 124.4, 124.5, 124.8, 134.9, 
135.2, 148.2, 149.7, 150.8, 155.4, 156.0 ppm. FTIR (thin film) λ (cm-1): 3435, 3019, 
1635, 1216, 929. HRMS (ESI) C35H36Cl2N5O2: Calculated for [M+H] C35H37Cl2N5O2, 
628.2246; found:628.2247. 
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DQ 440 – Dr. Noel McLaughlin 
DQ 440 (54) was prepared by the above general procedure yielding the product as an 
orange foam (0.35 g, 39% yield). Rf = 0.25 (EtOAc:MeOH:TEA; 80:15:5). Mp = 58 – 62 
˚C; 1H NMR (500 MHz, CDCl3) 1.55 – 1.61 (4H, m, CH2), 1.72 – 1.78 (4H, m, CH2), 
2.60 (4H, t, J = 7.0 Hz, CH2), 3.68 – 3.71 (4H, m, CH2), 3.92 (6H, s, CH3), 7.23 (2H, d, J 
= 2.5 Hz, ArH), 7.26 (2H, dd, J = 2.0, 9.0 Hz, ArH), 7.40 (2H, dd, J = 2.5, 9.5 Hz, ArH), 
7.98 – 8.00 (4H, m, ArH), 8.05 (2H, d, J = 1.5 Hz, ArH) ppm.13C NMR (125 MHz, 
CDCl3) 27.5, 29.5, 49.3, 50.6, 55.6, 67.1, 99.6, 115.9, 117.9, 124.1, 124.2, 124.4, 128.3, 
131.6, 134.7, 146.9, 148.4, 149.8, 155.9 ppm. FTIR (thin film) λ (cm-1): 3943, 3688, 
3054, 2987, 2685, 1631, 1559, 1528, 1421, 1264, 1032, 896. HRMS (ESI) 
C36H38Cl2N5O2: Calculated for [M+H] C36H39Cl2N5O2, 642.2403; found: 642.2402. 
 
 
DQ 550 – Dr. Noel McLaughlin 
212 
 
DQ 550 (55) was prepared by the above general procedure yielding the product as an 
orange solid (0.73 g, 83% yield). Rf = 0.15 (EtOAc:MeOH:TEA; 84:15:1). Mp = 52 – 54 
˚C. 1H NMR (500 MHz, CDCl3) 1.47 (8H, s(br), CH2), 1.73 – 1.75 (4H, m, CH2), 2.51 – 
2.53 (4H, m, CH2), 3.65 – 3.66 (4H, m, CH2), 3.93 (6H, s, CH3), 7.19 (2H, s(br), ArH), 
7.25 (2H, s(br), ArH), 7.38 – 7.40 (2H, m, ArH), 7.96 – 7.98 (4H, m, ArH), 8.04 (2H, 
s(br), ArH) ppm. 13C NMR (125 MHz, CDCl3) 24.7, 29.7, 31.6, 49.7, 50.5, 55.5, 99.3, 
115.8, 117.9, 124.0, 124.4 (2C), 128.1, 131.4, 134.8, 146.6, 148.3, 149.7, 156.0 ppm. 
FTIR (thin film) λ (cm-1): 3943, 3692, 3054, 2987, 2934, 2858, 2685, 1631, 1560, 1519, 
1421, 1265, 896. HRMS (ESI) C38H42Cl2N5O2: Calculated for [M+H] C38H43Cl2N5O2, 
670.2716; found: 670.2715. 
 
DQ 660 
DQ 660 (56) was prepared by the above general procedure. This compound, the 
precipitated HCl salt was recrystallized in MeOH, and then solubilized in a solution of a 
1:1 mixture of CH2Cl2 and MeOH. Ammonium hydroxide was added until the solid 
completely dissolved. The residue was concentrated under reduced pressure to remove 
MeOH. The residue was dissolved in CH2Cl2, washed with water (2 x 20 mL) then 
washed with brine and dried over Na2SO4. Evaporation yielded an orange solid (4.28g, 
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68%). Rf = 0.30 (EtOAc:MeOH:TEA; 80:15:5). Mp = 52 – 54 ˚C; 
1H NMR (500 MHz, 
CDCl3) δ 1.31 – 1.36 (4H, m, CH2), 1.40 – 1.47 (8H, m, CH2), 1.71 – 1.77 (4H, m, CH2), 
2.51 (4H, t, J = 7.0 Hz, CH2), 3.69 (4H, t, J = 7.0 Hz, CH2), 3.95 (6H, s, CH3), 7.20 (2H, 
d, J = 2.5 Hz, ArH), 7.30 (2H, dd, J = 2.0, 9.5 Hz, ArH), 7.42 (2H, dd, J = 2.5, 9.5 Hz, 
ArH), 8.00 (2H, dd, J = 3.0. 9.5 Hz, ArH), 8.06 (2H, d, J = 2.0 Hz, ArH) ppm; 13C NMR 
(125 MHz, CDCl3) δ 26.8, 27.1, 31.8, 49.9, 50.7, 55.6, 99.1, 115.9, 118.0, 124.0, 124.5, 
124.6, 128.4, 131.6, 134.8, 146.3, 149.0, 149.7, 156.0 ppm. FTIR (thin film) λ (cm-1): 
3943, 3692, 3054, 2987, 1560, 1421, 1265, 896. HRMS (ESI) C40H46Cl2N5O2: Calculated 
for [M+H] C40H47Cl2N5O2, 698.3029; found: 698.3029. 
 
DQ 770 
DQ 770 (57) was prepared by the above general procedure. Solid HCl salt was 
recrystallized from EtOH yielding 331 mg. This solid was converted to its free base form 
by dissolution in a one to one mixture of aqueous ammonium hydroxide and 25% 2-
propanol/75% CHCl3 yielding an orange foam (145 mg, 38%). 
1H NMR (500 MHz, 
CDCl3) δ 8.07 (d, J = 2.1 Hz, 2H, ArH), 8.00 (dd, 4H, ArH), 7.42 (dd, J = 9.4, 2.7 Hz, 
2H, ArH), 7.30 (dd, J = 9.2, 2.1 Hz, 2H, ArH), 7.20 (d, J = 2.7 Hz, 2H, ArH), 4.67 (t, J = 
5.9 Hz, 2H, NH), 3.96 (s, 6H), 3.68 (q, 4H, CH2), 2.54 (t, J = 8.1, 7.4 Hz, 4H, CH2), 1.74 
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(p, J = 7.3 Hz, 4H, CH2), 1.48 – 1.37 (m, 8H, CH2), 1.36 – 1.25 (m, 10H, CH2). 
13C NMR 
(126 MHz, CDCl3) δ 156.04, 149.87, 148.43, 146.80, 134.85, 131.53, 128.27, 124.56, 
124.53, 124.18, 117.96, 115.87, 99.30, 77.39, 55.64, 50.78, 50.14, 31.84, 30.11, 29.36, 
27.37, 26.95. FTIR (thin film) λ (cm-1): 2927, 2853, 2358, 2330, 1558, 1507. HRMS 
(ESI) C42H49Cl2N5O2: Calculated for [M+H] C42H50Cl2N5O2, 725.3263; found: 725.3339. 
 
DQ 880 
DQ 880 (58) was prepared by the above general procedure. The product required 
recrystallization from methanol, and flash column chromatography (Ethyl Acetate with 
5% Triethylamine). Yielded an orange paste (125 mg, 33%). 1H NMR (500 MHz, CDCl3) 
δ 8.07 (d, J = 2.1 Hz, 2H, ArH), 8.04 – 7.97 (m, 4H, ArH), 7.42 (dd, J = 9.4, 2.7 Hz, 2H, 
ArH), 7.34 – 7.24 (m, 7H, ArH), 7.21 (d, J = 2.7 Hz, 2H, ArH), 4.68 (bs, 2H, N-H), 3.97 
(d, J = 2.7 Hz, 6H, CH3), 3.69 (t, 4H, CH2), 2.55 (t, J = 7.2 Hz, 4H, CH2), 1.78 – 1.71 (m, 
4H, CH2), 1.44 (t, J = 7.0 Hz, 8H, CH2), 1.36 – 1.23 (m, 12H, CH2). 13C NMR (126 MHz, 
CDCl3) δ 155.98, 149.72, 148.44, 146.88, 134.70, 131.64, 128.38, 124.51, 124.41, 
123.98, 117.96, 115.91, 99.16, 55.52, 50.77, 50.15, 31.81, 30.19, 29.43, 29.26, 27.28, 
26.86. FTIR (thin film) λ (cm-1): 3292, 2927, 2854, 2359, 2341, 1632, 1559, 1434, 1336, 
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924. HRMS (ESI) C44H53Cl2N5O2: Calculated for [M+H] C44H54Cl2N5O2, 753.3576; 
found: 753.3510. 
 
DQ 11110 
DQ 11110 (59) was prepared by the above general procedure except for purification. The 
reaction, post Celite™ filtration is adsorbed onto silica, and purified by flash 
chromatography (20 mm x 150 mm, 4% MeOH, 25% ethyl acetate, 1% triethylamine, 
and 70% CH2Cl2) to yield an orange paste (95 mg, 30%). 
1H NMR (500 MHz, 
Chloroform-d) δ 8.07 – 7.91 (m, 6H), 7.41 (dd, J = 9.4, 2.7 Hz, 2H), 7.29 (dd, J = 9.3, 2.2 
Hz, 2H), 7.21 (d, J = 2.8 Hz, 2H), 3.96 (s, 6H), 3.70 (t, J = 7.2 Hz, 4H), 2.61 (t, J = 7.4 
Hz, 4H), 1.78 – 1.70 (m, 4H), 1.50 (d, J = 7.7 Hz, 4H), 1.46 – 1.37 (m, 4H), 1.25 (d, J = 
16.7 Hz, 28H). 13C NMR (126 MHz, CDCl3) δ 156.15, 149.97, 148.50, 146.88, 134.94, 
131.65, 128.39, 124.66, 124.60, 124.19, 118.06, 115.99, 99.38, 55.70, 50.93, 50.21, 
31.96, 30.12, 29.69, 29.66, 29.63, 29.59, 29.47, 27.54, 27.08. 
 FTIR (thin film) λ (cm-1): 3302, 2925, 2852, 2360, 2341,1631, 1561, 1518, 1465, 1434, 
1235. HRMS (ESI) C50H64Cl2N5O2: Calculated for [M+H] C50H64Cl2N5O2, 838.4515; 
found: 838.4574. 
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General reductive alkylation procedure 
Method 1: Reductive alkylation with sodium triacetoxyborohydride 
Dimeric inhibitor was added to a flask and dissolved in CH2Cl2, to give a final reaction 
concentration of 0.3M. Aqueous formaldehyde (37% w/v) (2.0 equiv.) was added to the 
reaction and allowed to stir for 15 minutes. Once the reaction becomes homogenous, 
sodium triacetoxyborohydride was added (4 equiv.). Upon disappearance of the starting 
DQ compound as observed by TLC, approximately 16 hours, the reaction was diluted by 
half with CH2Cl2 and the excess sodium triacetoxyborohydride was quenched by reaction 
with a volume of 2N aqueous sodium hydroxide, equal to the CH2Cl2, for 1 hour at 23°C. 
To the dichloromethane solution was added 1 Maq HCl solution. The mixture was stirred 
vigorously at room temperature for 1 hour, resulting in the formation of a water-soluble 
salt of the desired product. Both layers were separated. The aqueous layer was further 
washed with CHCl3 (2 × 15 mL) and combined chloroform washings were discarded at 
this point. Using NH4·OH, the pH of the aqueous layer was adjusted to 11, resulting in 
the liberation of the free base of the product. The product was extracted into a solvent 
mixture of CHCl3 and i-PrOH (4:1). These combined extracts were washed with brine 
and dried over Na2SO4. The combined organic layers were concentrated under reduced 
pressure to afford a pure product unless specified. 
 
Method 2: Eschweiler-Clarke Methylation 
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The dimeric inhibitor was added to a flask under an atmosphere of argon and dissolved in 
88% formic acid (to give a reaction concentration of 0.5M). Aqueous formaldehyde was 
added to the reaction (3 equiv.), and then heated to reflux at 105 °C till consumption of 
the starting material is observed by TLC. Upon completion, between one and three hours, 
the reaction was poured over water, resulting in a twofold dilution. The pH of the 
aqueous layer was adjusted to pH 12 by addition of aqueous ammonium hydroxide. 
When a precipitate formed, it was dissolved in a solution of 50:50 MeOH:CH2Cl2. To this 
solution aqueous ammonium hydroxide was added. The solution was then concentrated 
under reduced pressure to near dryness and dissolved in both CH2Cl2 and water. The 
organic layer was separated, and the aqueous layer was then extracted three times 
CH2Cl2. The combined organic layer was then dried over sodium sulfate and 
concentrated under reduced pressure to yield the methylated inhibitor. The compound 
required no further purification unless specified. 
 
DQ 331 
DQ 331 (60) was synthesized by general method 2. The product was isolated as an 
orange film (21mg, 86%). Mp = 62 – 65 ˚C. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 
2.1 Hz, 2H, ArH), 7.89 (dd, J = 19.6, 9.3 Hz, 4H, ArH), 7.32 (dd, J = 9.4, 2.7 Hz, 2H, 
218 
 
ArH), 7.15 – 7.09 (m, 4H, ArH), 3.78 (s, 6H, CH3), 3.76 (t, J = 6.4 Hz, 4H, CH2), 2.56 (t, 
J = 6.3 Hz, 4H, CH2), 2.35 (s, 3H, CH3), 1.88 (p, J = 6.4 Hz, 4H, CH2). 13C NMR (126 
MHz, CDCl3) δ 155.71, 149.84, 148.64, 146.92, 134.78, 131.59, 128.38, 124.21, 124.13, 
123.93, 117.51, 115.37, 100.20, 57.06, 55.61, 50.10, 42.91, 28.34. FTIR (thin film) λ 
(cm-1): 3254, 295, 2926, 2359, 2341, 1633, 1236. HRMS (ESI) C35H35Cl2N5O2: 
Calculated for [M+H] C35H36Cl2N5O2, 628.2246; found: 628.2244. 
 
DQ 341 – Dr. Noel McLaughlin 
DQ 341 (61) was prepared by the general method 2. The product as a dark-red solid (34.0 
mg, 94% yield). Mp = 61 – 66 ˚C. 1H NMR (500 MHz, CD2Cl2) 1.61 – 1.67 (4H, m, 
CH2), 1.84 (2H, pent, J = 5.5 Hz, CH2), 2.32 (3H, s, CH3), 2.44 (2H, t, J = 7.0 Hz, CH2), 
2.57 (2H, t, J = 7.0 Hz, CH2), 3.67 (2H, t, J = 6.5 Hz, CH2), 3.83 (3H, s, CH3), 3.86 (3H, 
s, CH3), 3.89 (2H, t, J = 4.5 Hz, CH2), 7.07 – 7.14 (4H, m, ArH, NH), 7.24 (1H, d, J = 2.5 
Hz, ArH), 7.30 – 7.34 (3H, m, ArH), 7.86 (2H, dd, J = 3.5, 9.5 Hz, ArH), 7.92 (3H, d, J = 
9.5 Hz, ArH), 8.02 (1H, d, J = 9.5 Hz, ArH) ppm. 13C NMR (125 MHz, CD2Cl2) 25.1, 
27.7, 30.4, 43.0, 51.0, 51.7, 56.0, 56.1, 57.8, 58.7, 99.7, 101.3, 115.0, 116.4, 117.2, 118.4, 
123.5, 124.0, 124.7 (2C), 124.8, 125.6, 128.4, 128.7, 131.7, 132.0, 134.9 (2C), 148.8, 
149.2 (2C), 150.0, 150.9, 155.8, 156.5. FTIR (thin film) λ (cm-1): 3434, 1653, 1213, 929. 
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HRMS (ESI) C36H37Cl2N5O2: Calculated for [M+H] C36H38Cl2N5O2, 642.2403; found: 
642.2398. 
 
DQ 441 – Dr. Noel McLaughlin 
DQ 441 (62) was synthesized by general method 1. Filtration followed by solvent 
evaporation afforded the product as a red solid (0.13 g, 83% yield). Rf = 0.55 
(EtOAc:MeOH:TEA; 80:15:5); Mp = 60 – 62 ˚C. 1H NMR (500 MHz, CDCl3) 1.52 – 
1.58 (4H, m, CH2), 1.67 – 1.83 (4H, m, CH2), 2.15 (3H, s, CH3), 2.30 (4H, t, J = 7.0 Hz, 
CH2), 3.68 (4H, t, J = 6.5 Hz, CH2), 3.91 (6H, s, CH3), 5.06 (2H, s(br), NH), 7.22 (2H, d, 
J = 2.5 Hz, ArH), 7.24 (1H, d, J = 2.0 Hz, ArH), 7.26 (1H, s(br), ArH), 7.39 (2H, dd, J = 
2.5, 9.5 Hz, ArH), 7.97 – 7.99 (4H, m, ArH), 8.04 (2H, d, J = 2.0 Hz, ArH) ppm. 13C 
NMR (125 MHz, CDCl3) 24.6, 29.6, 42.2, 50.5, 55.6, 57.0, 99.6, 115.8, 117.9, 124.1, 
124.2, 124.4, 128.3, 131.6, 134.7, 146.8, 148.4, 149.9, 155.9 ppm. FTIR (thin film) λ 
(cm-1): 3054, 2987, 1559, 1422, 1265, 896. HRMS (ESI) C37H40Cl2N5O2: Calculated for 
[M+H] C36H41Cl2N5O2, 656.2559; found: 656.2565. 
220 
 
 
DQ 551 – Dr. Noel McLaughlin 
DQ 551 (63) was synthesized by general method 1. The product was isolated as a red 
foam (0.30 g, 50% yield). Mp = 48 – 52 ˚C. 1H NMR (500 MHz, CD2Cl3) 1.45 (8H, 
s(br), CH2), 1.78 (4H, s(br), CH2), 2.12 (3H, s, CH3), 2.26 (4H, s(br), CH2), 3.73 (4H, t, J 
= 6.5 Hz, CH2), 3.98 (6H, s, CH3), 7.31 – 7.34 (4H, m, ArH), 7.41 – 7.45 (2H, m, ArH), 
7.96 – 7.98 (2H, m, ArH), 8.03 (2H, s, ArH), 8.10 (2H, d, J = 8.0 Hz, ArH) ppm. 13C 
NMR (125 MHz, CD2Cl3) 24.7, 26.9, 31.5, 41.8, 50.6, 55.5, 57.4, 99.3, 115.7, 117.8, 
124.0, 124.3, 124.5, 128.0, 131.4, 134.4, 146.7, 148.4, 149.8, 155.9 ppm. FTIR (thin 
film) λ (cm-1): 3944, 3692, 3054, 2987, 1631, 1560, 1422, 1262, 896. HRMS (ESI) 
C39H43Cl2N5O2: Calculated for [M+H] C39H44Cl2N5O2, 684.2872; found: 684.2897.  
 
DQ 661 
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DQ 661 (64) was synthesized by general method 2. The product was isolated as a brown 
orange solid/foam (2.98g, 91%). IR λ (neat/cm
-1) 3293, 2934, 2854,1687, 1657, 1235, 
925, 829 1H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 2.1 Hz, 2H, ArH), 8.02 (t, J = 8.9 Hz, 
4H, ArH), 7.43 (dd, J = 9.4, 2.7 Hz, 2H, ArH), 7.32 (dd, J = 9.3, 2.1 Hz, 1H, ArH), 7.23 
(d, J = 2.7 Hz, 2H, ArH), 4.75 (s, 2H, NH), 3.97 (d, J = 2.9 Hz, 6H, CH3), 3.70 (s, 4H, 
CH2), 2.25 (t, J = 7.6 Hz, 4H, CH2), 2.17 (s, 3H, CH3), 1.75 (p, J = 7.5 Hz, 4H, CH2), 
1.43 (d, J = 7.6 Hz, 8H, CH2), 1.32 (m, 4H, CH2).
13C NMR (126 MHz, CDCl3) δ 155.98, 
150.00, 148.06, 146.29, 134.97, 131.02, 127.80, 124.55, 24.36, 124.30, 117.74, 115.56, 
99.48, 57.73, 55.63, 50.57, 42.30, 31.74, 27.32, 27.24, 26.93. FTIR (thin film) λ (cm-1): 
3293, 2934, 2854,1687, 1657, 1235, 925, 829. HRMS (ESI) C41H47Cl2N5O2: Calculated 
for [M+H] C41H48Cl2N5O2, 712.3185; found: 712.3164. 
 
DQ 771 
DQ 771 (65) was synthesized by general method 2. The product was isolated as a 
black/orange solid film. (31mg, 74%). 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 2.1 Hz, 
2H), 8.00 (dd, J = 9.3, 5.4 Hz, 4H), 7.42 (dd, J = 9.4, 2.7 Hz, 2H), 7.31 (dd, J = 9.2, 2.1 
Hz, 2H), 7.21 (d, J = 2.7 Hz, 2H), 3.96 (s, 6H), 3.69 (t, J = 7.2 Hz, 4H), 2.27 (t, J = 7.6 
Hz, 3H), 2.17 (s, 2H), 1.74 (p, J = 7.3 Hz, 4H), 1.47 – 1.22 (m, 16H). 13C NMR (126 
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MHz, CDCl3) δ 156.19, 149.93, 148.54, 146.94, 134.94, 131.75, 128.49, 124.73, 124.60, 
124.15, 118.13, 116.07, 99.39, 57.95, 55.72, 50.92, 42.42, 31.92, 29.45, 27.60, 27.35, 
27.07. FTIR (thin film) λ (cm-1): 3302, 2930, 2854, 2793, 2359, 2341, 1632, 1559, 1236. 
HRMS (ESI) C43H51Cl2N5O2: Calculated for [M+H] C41H52Cl2N5O2, 739.3420; found: 
739.3522. 
 
DQ 881 
DQ 881 (66) was synthesized by general method 2. The product was isolated as a red 
orange film (15 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 8.06 (s, 2H, ArH), 8.03 – 7.97 
(m, 4H, ArH), 7.42 (dd, J = 9.4, 2.9 Hz, 2H, ArH), 7.30 (dd, J = 9.2, 3.4, 2.1 Hz, 2H, 
ArH), 7.21 (d, J = 2.8 Hz, 2H, ArH), 4.72 (s, 2H, NH), 3.96 (d, J = 4.6 Hz, 6H, CH3), 
3.68 (t, J = 7.1 Hz, 4H, CH2), 2.27 (dd, J = 8.9, 6.2 Hz, 4H, CH2), 2.18 (d, J = 3.5 Hz, 
3H, CH3), 1.73 (p, J = 7.5 Hz, 4H, CH2), 1.49 – 1.19 (m, 24H, CH2). 13C NMR (126 
MHz, CDCl3) δ 156.17, 149.93, 148.57, 146.99, 134.91, 131.77, 128.51, 124.71, 124.59, 
124.15, 118.13, 116.08, 99.36, 58.06, 55.71, 50.95, 42.48, 31.98, 29.64, 29.47, 27.63, 
27.47, 27.05. FTIR (thin film) λ (cm-1): 2930, 2854, 2359, 1632, 1559,1236. HRMS 
(ESI) C45H55Cl2N5O2: Calculated for [M+H] C45H56Cl2N5O2, 767.3733; found: 767.3719. 
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DQ 11111 
DQ 11111 (67) was synthesized by general method 2. The product was isolated as a red 
orange paste (53mg, 75%). 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 2.1 Hz, 2H, ArH), 
7.98 (dd, J = 9.4, 2.3 Hz, 4H, ArH), 7.40 (dd, J = 9.4, 2.7 Hz, 2H, ArH), 7.30 – 7.26 (m, 
4H, ArH), 7.18 (d, J = 2.7 Hz, 2H, ArH), 3.94 (s, 6H, CH3), 3.66 (t, J = 7.2 Hz, 4H, CH2), 
2.31 – 2.24 (m, 4H, CH2), 2.19 (s, 3H, CH3), 1.72 (p, J = 7.3 Hz, 4H, CH2), 1.46 – 1.36 
(m, 8H, CH2), 1.34 – 1.15 (m, 30H, CH2). 
13C NMR (126 MHz, CDCl3) δ 156.09, 149.90, 
148.54, 146.95, 134.85, 131.67, 128.41, 124.59, 124.56, 124.16, 118.03, 115.97, 99.31, 
58.13, 55.64, 50.90, 42.52, 31.95, 29.76, 29.70, 29.64, 29.61, 29.47, 27.77, 27.52, 27.06. 
FTIR (thin film) λ (cm-1): 2925, 2852, 2793, 1631, 1465, 1236. HRMS (ESI) 
C51H68Cl2N5O2: Calculated for [M+H] C45H69Cl2N5O2, 852.4672; found: 852.4634. 
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Synthesis of longer linked dimeric chloroquine 
inhibitors
 
DC660 
To a flame-dried round bottom flask, bishexamethylene triamine (TCI America) 
(51) (3.799 g, 17.64 mmol, 1.0 eq.), 4-bromo-7-chloroquinoline156 (13) (9.43, 38.8 mmol, 
2.2 eq.), Pd(OAc)2 (199mg, 0.71 mmol, 0.05 eq.), BINAP (1098 mg, 1.41 mmol, 0.1 eq.), 
K3PO4 (11.27g, 52.9 mmol, 3.0 eq.) was added. The reagents were placed under an argon 
atmosphere and dissolved in 1,4-dioxane (44mL) to give a 0.4M reaction concentration. 
The reaction was then heated in an oil bath preset to 105 °C under a reflux condenser. 
The reaction was monitored by 1H NMR (CDCl3) where the consumption of primary 
amine-containing linker marks complete consumption of the limiting reagent (peak at 
~2.7 ppm). The reaction was then cooled to 23 °C and filtered through Celite™ using 300 
mL of a 4:1 mixture of CHCl3:MeOH. The solution was concentrated under reduced 
pressure to afford an orange-yellow solid (13.37 g), which was recrystallized from 
CH2Cl2 (heated to reflux and then cooled to -20 °C) to afford a white solid (8.516 g, 
90%), the structure (68) of which was verified by 1H NMR. TLC (Rf = 0.25, 90:10:1, 
CH2Cl2, MeOH, NH4OH). Melting point (mp) = 100 – 102 ˚C; 
1H NMR (500 MHz, 
CD3OD): δ 1.38 – 1.55 (12H, m), 1.73 – 1.78 (4H, m), 2.55 (4H, t, J = 7.5 Hz), 3.36 (4H, 
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t, J = 7.0 Hz), 6.50 (2H, d, J = 5.5 Hz), 7.38 (2H, dd, J = 2.0, 9.0 Hz), 7.76 (2H, d, J = 2.0 
Hz), 8.09 (2H, d, J = 9.0 Hz), 8.34 (2H, d, J = 5.5 Hz). 13C NMR (125 MHz, CD3OD): δ 
26.7 (2C), 27.9, 28.8, 42.5, 49.1, 98.2, 117.4, 122.9, 124.5, 126.2, 134.8, 148.3, 151.0 
(2C). FTIR (thin film) λ (cm-1):  3054, 1420, 1265, 896. HRMS (ESI) C30H37Cl2N5: 
Calculated for [M+H] C30H38Cl2N5, 538.2507; found: 538.2509.  
 
 
DC661 
Compound 68 (7.02 g, 13.0 mmol, 1.0 eq.) was added to a round bottom flask, 
under a reflux condenser and placed under an atmosphere of argon. Formic acid 
(HCOOH, 19.3 mL) was added to the reaction vessel to give a 0.3M reaction 
concentration. While stirring, aqueous formaldehyde (37 % w/w) (0.95 mL, 12.75 mmol, 
2.2 eq.) was added to the reaction vessel via a syringe. The reaction was then heated to 
reflux in an oil bath preset to 105 °C. The reaction was stirred at reflux until the starting 
material (68) was observed by TLC (90:10:1, CH2Cl2, MeOH, NH4OH, Rf = 0.25) to be 
consumed. The formic acid was diluted with water (300 mL) resulting in a black aqueous 
solution. The pH of the solution was brought to 12 using concentrated NH4OH (50 mL), 
and then extracted with CHCl3 (3 x 100 mL). Upon extraction, a gray precipitate forms 
which was identified by 1H NMR to be mostly product. The solid (1.1g) was collected via 
vacuum filtration of the remaining aqueous layer. The combined organic layers were 
226 
 
dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford a 
gray-brown foam (5.4g). The foam was dissolved in CH2Cl2, and stirred with 
decolorizing carbon (2.0 g) for 45 min. The carbon was then removed by filtration 
through a plug of Celite™, using CH2Cl2 (100 mL). The gray solid was dissolved in a 4:1 
mixture of CHCl3:MeOH (100 mL) and stirred with decolorizing carbon (1.0 g) for 45 
min. The carbon was them removed by filtration through a plug of Celite™. The filtered 
carbon was washed using CH2Cl2 (100 mL). The combined filtrates were then 
concentrated under reduced pressure to afford a beige-white crude solid. Purification was 
affected by recrystallization from a three-solvent system, where boiling CH2Cl2 yields a 
slightly cloudy solution, which was not clarified by the addition of more boiling CH2Cl2. 
To this solution methanol was added dropwise stirring until the boiling solution clarifies. 
The solution was then cooled to 20 °C, diethyl ether was then added until a droplet 
caused the solution to turn cloudy. The solution was cooled to -20°C for 24 hours to yield 
white circular crystals which were collected via vacuum filtration (4.508g, 63%), the 
structure (69) of which was verified by 1H NMR. TLC (Rf = 0.35 (EtOAc:MeOH:TEA; 
80:15:5)). MP (CH2Cl2/Et2O): 58 – 60 ˚C. 
1H NMR (500 MHz, CD3OD): δ 1.35 – 1.47 
(12H, m, CH2), 1.69 – 1.73 (4H, m, CH2), 2.17 (3H, s, CH3), 2.29 – 2.31 (4H, m, CH2), 
3.30 (4H, s(br), CH2), 6.45 (2H, s(br), ArH), 7.34 – 7.37 (2H, m, ArH), 7.75 (2H, s, 
ArH), 8.06 – 8.08 (2H, m, ArH), 8.32 (2H, s(br), ArH). 13C NMR (125 MHz, CD3OD): δ 
26.2, 26.6, 27.0, 27.9, 41.0, 42.5, 57.1, 98.2, 117.4, 122.9, 124.5, 126.2, 134.8, 148.3, 
151.0, 151.3. FTIR (thin film) λ (cm-1): 3683, 3455, 3019, 2936, 2859, 1582, 1215, 852. 
HRMS (ESI) C31H39Cl2N5: Calculated for [M+H] C31H40N5Cl2, 552.2655; found: 
552.2654. 
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DC661 (Water Soluble Salt) 
DC661 (69) (126 mg, 0.23 mmol, 1.0 eq) was added to a round bottom flask. MeOH (3 
mL) was added to dissolve DC661, and the solution was stirred at 23 °C. A solution of 
HCl in methanol (3 mL, 0.25 M) was added to the reaction vessel, and the resulting 
solution was stirred for 1 hour at 23 °C. The solvent and excess HCl was removed by 
concentration under reduced pressure to afford a yellow foam (150 mg, 99%). The foam 
was found to be a hygroscopic solid, which must be stored under a dry inert atmosphere. 
Attempts to determine a melting point result in phase transition of the foam to a paste. 1H 
NMR (500 MHz, CD3OD) δ 8.45 (d, J = 9.1 Hz, 2H), 8.35 (d, J = 7.1 Hz, 2H), 7.83 (d, J 
= 2.1 Hz, 2H), 7.60 (dd, J = 9.1, 2.1 Hz, 2H), 6.86 (d, J = 7.2 Hz, 2H), 3.58 (t, J = 7.3 Hz, 
4H), 3.25 – 3.02 (m, 4H), 2.83 (s, 3H), 1.87 – 1.70 (m, 8H), 1.57 – 1.40 (m, 8H). 13C 
NMR (126 MHz, CD3OD) δ 157.47, 143.64, 140.84, 139.91, 128.53, 126.26, 120.18, 
116.83, 99.81, 57.23, 44.69, 40.44, 28.80, 27.35, 27.16, 25.08. FTIR (thin film) λ (cm-1):  
3220, 3020, 2938, 2729, 1612, 1591, 1453, 1212. HRMS (ESI) C31H42Cl5N5: Calculated 
for [M+H-3HCl] C31H40N5Cl2, 552.2661; found: 552.2656. Purity of the final compound 
was determined by UPLC-MS analysis. DC661-3HCl was found to be a single peak, with 
a mass corresponding to the reported literature precedent, [M+2H-3HCl]/2 = 277.8. 
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To a screw cap vial, 11,11 triamine (47) (178mg, 0.5 mmol, 1.0 eq.) was added, followed 
by 4-bromo-7chloroquinoline156 (13) (267 mg, 1.1 mmol, 2.2 eq.), Pd(OAc)2 (6 mg, 0.03 
mmol, 0.05 eq.), BINAP (32mg, 0.05mmol, 0.1 eq.) and K3PO4 (320 mg, 1.5 mmol, 3.0 
eq.). The reaction is placed under an atmosphere of argon and 1,4-dioxane (1.25 mL) was 
added. The vial was sealed and heated to 120 °C until the reaction was complete. The 
reaction was deemed complete when the all the primary amine starting material was 
consumed as observed by 1H NMR (~2.7 ppm). The reaction was cooled to room 
temperature and filtered through a pad of Celite™ with a mixture of 1:1 CHCl3:MeOH 
(ca. 50 mL). The filtrated was concentrated under reduced pressure to afford a crude 
paste (250 mg) which was purified by column chromatography (SiO2; dry load on 300mg 
SiO2, 25 mm x 15 mm; 5:2:93, MeOH:TEA:EtOAc) to afford an off-white solid (69) (52 
mg, 16%). The structure of the product was verified by 1H NMR. TLC (Rf = 0.45, 
10:90:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 5.3 Hz, 
2H), 7.94 (d, J = 2.2 Hz, 2H), 7.67 (d, J = 9.0 Hz, 2H), 7.34 (dd, J = 8.9, 2.2 Hz, 2H), 
6.40 (d, J = 5.4 Hz, 2H), 5.07 (d, J = 5.4 Hz, 2H), 3.29 (td, J = 7.2, 5.1 Hz, 4H), 2.61 (t, J 
= 7.4 Hz, 4H), 1.74 (p, J = 7.3 Hz, 4H), 1.55 – 1.19 (m, 36H). 13C NMR (126 MHz, 
CDCl3) δ 152.19, 149.93, 149.30, 134.98, 128.95, 125.38, 121.07, 117.31, 99.23, 50.10, 
43.45, 29.91, 29.65, 29.63, 29.62, 29.47, 29.04, 27.50, 27.28. FTIR (thin film) λ (cm-1): 
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3277, 2924, 2851, 1611, 1578, 1536, 1456, 1373, 1135. HRMS (ESI) C40H57Cl2N5: 
Calculated for [M+H] C40H58Cl2N5, 678.4069; found: 678.4076. 
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11111 
 
DC11110 (71) (25 mg, 0.037 mmol, 1.0 equiv.) is added to a round bottom flask and 
placed under an atmosphere of argon. The flask contents were dissolved in CH2Cl2 (750 
uL). Aqueous formaldehyde is added and the reaction is stirred at 23 °C. Sodium 
triacetoxyborohydride (78 mg, 0.37, 10.0 equiv.) was added to the flask in one portion, 
and the reaction was stirred until the starting inhibitor was consumed as observed via 
TLC (Rf = 0.45, 10:90:1, MeOH:CH2Cl2:NH4OH). The reaction was quenched by first 
dilution with CH2Cl2 (5 mL) and 2N NaOH (5 mL). The reaction was stirred for 60 
minutes to quench any excess reducing agent. The layers of the resulting biphasic mixture 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over anhydrous sodium sulfate and concentrated to a 
film on a vial (72) (19 mg, 74%). The structure of the product was verified by 1H NMR. 
TLC (Rf = 0.70, 10:90:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.52 
(d, J = 5.3 Hz, 2H), 7.95 (d, J = 2.2 Hz, 2H), 7.65 (d, J = 8.9 Hz, 2H), 7.35 (dd, J = 8.9, 
2.2 Hz, 2H), 6.40 (d, J = 5.4 Hz, 2H), 5.00 (s, 2H), 3.29 (td, J = 7.2, 5.2 Hz, 4H), 2.34 – 
2.27 (m, 4H), 2.21 (s, 3H), 1.79 – 1.70 (m, 4H), 1.51 – 1.40 (m, 8H), 1.40 – 1.22 (m, 
23H). 13C NMR (126 MHz, CDCl3) δ 152.21, 149.82, 149.28, 134.92, 129.00, 125.36, 
120.93, 117.23, 99.20, 58.05, 53.57, 43.42, 42.45, 29.74, 29.69, 29.64, 29.48, 29.03, 
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27.75, 27.43, 27.27. FTIR (thin film) λ (cm-1):3273, 2924, 2851, 1578, 1540, 1456, 1364, 
1126. HRMS (ESI) C41H59Cl2N5: Calculated for [M+H] C41H60Cl2N5, 692.4226; found: 
692.4242. 
 
 
 The bisazide (39) (920 mg, 2.2 mmol, 1.0 eq.) was added to a round bottom flask 
and dissolved in THF (4 mL). Water (500 uL, mmol, eq.) was added via a syringe, and 
the reaction was heated in an oil bath at 50 °C for 16 hours. The reaction was observed to 
be complete by LC-MS, where no bis- or mono-azide was found. The reaction was then 
stirred with 2N HCl (5 mL) to form the ammonium salt of the product. The layers of the 
biphasic mixture were separated. The resulting organic layer was extracted with 0.5 N 
HCl (3 x 10 mL). The combined aqueous layers were extracted with CH2Cl2 (2 x 30 mL) 
to remove all traces of triphenylphosphine oxide in the aqueous layer. The aqueous layer 
was saturated with solid NaCl, and the pH brought to 12 by the addition of NH4OH (ca. 
10 mL). The aqueous layer was then extracted with CH2Cl2 (3 x 30 mL). The resulting 
organic layers were combined, dried over anhydrous sodium sulfate, and concentrated 
under reduced pressure to afford an off white waxy solid (73) (679 mg, 85%). The 
structure of the resulting product was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) δ 
7.26 – 7.19 (m, 4H), 7.15 (d, J = 6.8 Hz, 1H), 3.46 (s, 2H), 3.35 (d, J = 2.7 Hz, 4H), 2.60 
(t, J = 7.1 Hz, 4H), 2.35 – 2.25 (m, 4H), 2.10 (s, 6H), 1.37 (d, J = 7.8 Hz, 8H), 1.28 – 
1.13 (m, 16H). 13C NMR (126 MHz, CDCl3) δ 140.27, 128.93, 128.12, 126.67, 58.73, 
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53.90, 50.17, 42.15, 33.54, 29.62, 29.55, 27.49, 27.06, 26.93. IR (thin film) λ (cm-1): 
2927, 2851, 2360, 1604, 1468. HRMS (ESI) C23H43N3: Calculated for [M+H] C23H44N3, 
362.3535; found: 362.3516. 
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To a screw cap vial, diamine (73) (99mg, 0.3 mmol, 1.0 eq.) was added, followed 
by 4-bromo-7chloroquinoline (13) (160mg, 0.66 mmol, 2.2 eq.), Pd(OAc)2 (97mg, 0.03 
mmol, 0.05 eq.), BINAP (38mg, 0.06mmol, 0.1 eq.) and K3PO4 (192 mg, 0.9 mmol, 3.0 
eq.). The reaction is placed under an atmosphere of argon and 1,4-dioxane (0.75 mL) was 
added. The vial was sealed and heated to 105 °C for 8 hours until the reaction was 
complete. The reaction was deemed complete when the all the primary amine starting 
material was consumed as observed by 1H NMR. The reaction was cooled to room 
temperature and filtered through a pad of Celite™ with CH2Cl2 (3 mL). The filtrated was 
concentrated under reduced pressure to afford a crude paste (270 mg). The crude product 
was purified by column chromatography (SiO2; 25 mm x 15 mm; 2:98:1, 
MeOH:CH2Cl2:NH4OH) to afford an off-white solid (74) (107 mg, 65%). The structure 
of the product was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 5.4 
Hz, 2H), 7.96 (d, J = 2.2 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.40 – 7.27 (m, 6H), 7.25 – 
7.21 (m, 2H), 6.40 (d, J = 5.5 Hz, 2H), 5.13 (s, 2H), 3.59 (s, 2H), 3.30 (td, J = 7.2, 5.2 
Hz, 4H), 2.50 – 2.38 (m, 4H), 1.72 (q, J = 7.4 Hz, 11H), 1.55 – 1.22 (m, 22H). 13C NMR 
(126 MHz, CDCl3) δ 152.24, 149.87, 149.36, 140.45, 134.98, 129.06, 128.95, 128.21, 
126.78, 125.41, 120.99, 117.30, 99.24, 58.83, 54.00, 43.43, 29.58, 29.48, 29.03, 27.49, 
27.25, 27.23. IR (thin film) λ (cm-1):2925, 1577, 1541, 1456, 1366. HRMS (ESI) 
C41H51Cl2N3: Calculated for [M+H] C41H52Cl2N3, 684.3600; found: 684.3591. 
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 The bisazide (39) (208 mg, 0.5 mmol, 1.0 eq.) was to a screwcap vial, followed 
by NaHCO3 (21 mg, 0.6 mmol, 1.0 eq.) and toluene (700 uL). Methyl chloroformate was 
added to the reaction, and the vial was sealed under an atmosphere of argon. The reaction 
was heated to 85 °C in an oil bath for 36 hours, until the reaction was complete. The 
reaction was observed to be complete by the loss of UV active starting material, as 
observed by TLC (Rf = 0.3; 8:1, Hex:EtOAc). The reaction was then concentrated under 
reduced pressure to afford a crude paste which was purified by column chromatography 
(SiO2; 25 mm x 110 mm; 6:1, Hex:EtOAc). The product was isolated as an oil (75) (187 
mg, 97%), the structure of which was verified by 1H NMR. The 13C NMR contains a 
mixture of two rotamers which have split the signal of two methylenes. 1H NMR (500 
MHz, CDCl3) δ 3.68 (s, 3H), 3.26 (t, J = 6.8 Hz, 4H), 3.19 (s, 4H), 1.59 (h, J = 6.7 Hz, 
4H), 1.56 – 1.47 (m, 4H), 1.44 – 1.22 (m, 16H). 13C NMR (126 MHz, CDCl3) δ 157.00, 
52.44, 51.61, 47.60, 47.02, 29.38, 29.23, 28.97, 28.73, 28.28, 26.86, 26.80. FTIR (thin 
film) λ (cm-1): 2929, 2857, 2090, 1699, 1477, 1438, 1408, 1350, 1253, 1191, 1134, 1090, 
1035. HRMS (ESI) C18H35N7O2: Calculated for [M+H] C18H36N7O2, 382.2930; found: 
382.2190. 
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 Bisazide (75) (210 mg, 0.55 mmol, 1.0 eq.) was added to a round bottom flask 
and dissolved in THF (1 mL). Triphenylphosphine (286 mg, 1.1 mmol, 2.0 eq.) was 
added to the solution in two portions, and gas evolution was observed after each addition. 
Water (400 uL) was added to the reaction via a syringe and the reaction was stirred at 23 
°C for 2.5 hours, until the starting bis-azide was observed to be consumed by LC-MS. 
The reaction was concentrated under reduced pressure to remove THF. The crude paste 
was then dissolved in CH2Cl2 (10 mL) and extracted with 0.2 N HCl (2 x 5 mL). The 
combined organic layers were then washed with CH2Cl2 (2 x 10 mL) to ensure the 
removal of triphenylphosphine oxide. The aqueous layer was saturated with NaCl and the 
pH was raised to 12 by the addition of concentrated NH4OH (ca. 3 mL). The basic 
aqueous solution was then extracted with CHCl3 (3 x 5 mL) and the combined organic 
layers were dried over anhydrous sodium sulfate. The dried organic fraction was 
concentrated under reduced pressure to afford the product as a paste (76) (154 mg, 86%), 
the structure of which was verified by 1H NMR. The 13C NMR contains a mixture of two 
rotamers which have split the signal of two methylenes. 1H NMR (500 MHz, CDCl3) δ 
3.65 (s, 3H), 3.22 – 3.09 (m, 4H), 2.66 (t, J = 7.0 Hz, 4H), 1.54 – 1.19 (m, 30H). 13C 
NMR (126 MHz, CDCl3) δ 157.02, 52.43, 47.64, 47.06, 42.38, 33.93, 29.58, 29.53, 
28.75, 28.30, 26.99, 26.94. IR (thin film) λ (cm-1): 3362, 2925, 2854, 1704, 1575, 1478, 
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1408, 1309, 1305, 1196, 1092. HRMS (ESI) C18H39N3O2: Calculated for [M+H] 
C18H40N3O2, 330.3121; found: 330.3112.  
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To a screw cap vial, diamine (76) (99mg, 0.3 mmol, 1.0 eq.) was added, followed 
by 4-bromo-7-chloroquinoline 13 (160mg, 0.66 mmol, 2.2 eq.), Pd(OAc)2 (97mg, 0.03 
mmol, 0.05 eq.), BINAP (38mg, 0.06mmol, 0.1 eq.) and K3PO4 (192 mg, 0.9 mmol, 3.0 
eq.). The reaction is placed under an atmosphere of argon and 1,4-dioxane (0.75 mL) was 
added. The vial was sealed and heated to 105 °C for 8 hours until the reaction was 
complete. The reaction was deemed complete when the all the primary amine starting 
material was consumed as observed by 1H NMR. The reaction was cooled to room 
temperature and filtered through a pad of Celite™ with CH2Cl2 (3 mL). The filtrated was 
concentrated under reduced pressure to afford a crude paste (270 mg). The crude product 
was purified by column chromatography (SiO2; 25 mm x 15 mm; 2:98:1, 
MeOH:CH2Cl2:NH4OH) to afford an off-white foam (77) (107 mg, 65%). The structure 
of the product was verified by 1H NMR.  The 13C NMR was observed to contain a 
mixture of rotamers which suppressed the signal of two methylenes. 1H NMR (CDCl3) δ 
8.52 (d, J = 5.3 Hz, 2H), 7.97 (d, J = 2.2 Hz, 2H), 7.68 (d, J = 8.9 Hz, 2H), 7.35 (dd, J = 
8.9, 2.2 Hz, 2H), 6.41 (d, J = 5.3 Hz, 2H), 5.07 (s, 2H), 3.67 (s, 3H), 3.32 (q, J = 6.5 Hz, 
4H), 3.20 (t, J = 7.5 Hz, 4H), 1.76 (p, J = 7.3 Hz, 4H), 1.60 – 1.22 (m, 20H). 13C NMR 
(126 MHz, CDCl3) δ 157.07, 151.96, 150.05, 149.08, 135.12, 128.80, 125.47, 121.15, 
117.28, 99.20, 52.52, 43.42, 29.39, 28.98, 27.20, 26.85. FTIR (thin film) λ (cm-1): 2915, 
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1693, 1581, 1479, 1452, 1122. HRMS (ESI) C36H47Cl2N5O2: Calculated for [M+H] 
C36H48Cl2N5O2, 652.3185; found: 652.3173. 
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 The carbamate (77) (108 mg, 0.165 mmol, 1.0 eq.) was added to a round bottom 
flask and dissolved in HBr/AcOH (33% HBr) (v/v) (500 uL). The reaction was heated at 
reflux until the starting material was consumed as observed by TLC (starting material Rf 
= 0.25; 2:98:1, MeOH:CH2Cl2:NH4OH). The reaction was complete at 45 minutes and 
allowed to cool to room temperature. The reaction was then poured onto 0.1N NH4OH 
(20 mL) to deprotonate the product. The aqueous phase was then extracted with a mixture 
of CHCl3 and MeOH (3:1, 3 x 10 mL). The combined organic layers were washed once 
with brine (30 mL) and dried over anhydrous sodium sulfate. The resulting organic layer 
was decanted and concentrated under reduced pressure to afford a crude paste. The crude 
material was then purified by column chromatography (SiO2; 20 mm x 200 mm; 7:92:1, 
MeOH: CH2Cl2:NH4OH) yielding a tan-white solid (47 mg, 48%). The structure of the 
isolated product (78) was verified 1H NMR. 1H NMR (500 MHz, CDCl3) δ 8.51 (d, J = 
5.3 Hz, 2H), 7.94 (d, J = 2.2 Hz, 2H), 7.67 (d, J = 8.9 Hz, 2H), 7.33 (dd, J = 8.9, 2.2 Hz, 
2H), 6.39 (d, J = 5.4 Hz, 2H), 5.08 (t, J = 5.2 Hz, 2H), 3.27 (td, J = 7.2, 5.1 Hz, 4H), 2.59 
(t, J = 7.3 Hz, 4H), 1.73 (p, J = 7.3 Hz, 4H), 1.54 – 1.27 (m, 21H). 13C NMR (126 MHz, 
CDCl3) δ 152.22, 149.89, 149.34, 134.94, 129.00, 125.36, 121.06, 117.31, 99.23, 50.20, 
43.41, 30.14, 29.56, 29.40, 29.01, 27.44, 27.21. FTIR (thin film) λ (cm-1): 2926, 2853, 
240 
 
1610, 1578, 1541, 1451, 1367, 1331, 1281, 1135, 1079. HRMS (ESI) C34H45Cl2N5: 
Calculated for [M+H] C34H46Cl2N5, 594.3130; found: 594.3149. 
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  DC880 (78) (24 mg, 0.04 mmol, 1.0 eq) was added to a screwcap vial followed 
by HCOOH (270 uL) and CH2O (10 uL, 37% aqueous, 0.12 mmol, 3.0 eq.). The reaction 
was sealed and heated to reflux in an oil bath, preset to 105 °C, until the starting material 
is observed to be consumed by TLC (DC880 Rf = 0.5; 7:92:1, MeOH:CH2Cl2:NH4OH). 
The reaction was cooled to room temperature and diluted with CHCl3 (1 mL) and 2 N 
NaOH (500 uL). The reaction was stirred for 60 minutes at room temperature to quench 
excess sodium triacetoxyborohydride. The resulting biphasic mixture was separated, and 
the aqueous layer was extracted with CHCl3 (3 x 1 mL). The combined organic layers 
were dried over anhydrous sodium sulfate, decanted, and concentrated under reduced 
pressure to afford a crude paste. The resulting crude product was purified by filtration 
through a plug of silica, first with CH2Cl2 (5 mL), followed by an elution gradient of (2 
mL each: 7:93:1, MeOH:CH2Cl2:NH4OH; 10:90:1, MeOH:CH2Cl2:NH4OH; 15:85:1, 
MeOH:CH2Cl2:NH4OH). The product was isolated as a translucent film on a vial (79) (36 
mg, 76%). The structure of the product was verified by 1H NMR. 1H NMR (500 MHz, 
CDCl3) δ 8.52 (d, J = 5.4 Hz, 2H), 7.95 (d, J = 2.2 Hz, 2H), 7.65 (d, J = 8.9 Hz, 2H), 7.34 
(dd, J = 8.9, 2.3 Hz, 2H), 6.40 (d, J = 5.4 Hz, 2H), 5.01 (t, J = 5.3 Hz, 2H), 3.28 (td, J = 
7.3, 5.1 Hz, 4H), 2.30 (dd, J = 8.8, 6.4 Hz, 4H), 2.20 (s, 3H), 1.73 (p, J = 7.4 Hz, 4H), 
1.51 – 1.20 (m, 22H). 13C NMR (126 MHz, CDCl3) δ 152.26, 149.86, 149.37, 134.97, 
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129.08, 125.40, 120.98, 117.31, 99.25, 58.06, 43.44, 42.50, 29.65, 29.46, 29.05, 27.67, 
27.48, 27.25. FTIR (thin film) λ (cm-1): 3264, 2928, 2853, 1611, 1579, 1541, 1452, 1428, 
1368, 1331, 1282, 1247, 1202, 1135, 1080. 
HRMS (ESI) C35H47Cl2N5: Calculated for [M+H] C35H48Cl2N5, 608.3287; found: 
608.3287. 
 
 
 
In a flame-dried round bottom flask under an argon atmosphere, a solution of 
freshly distilled oxalyl chloride (2.0 mL, 23.0 mmol, 1.2 eq.) in CH2Cl2 (95 mL), was 
cooled to -78°C. DMSO (3.25 mL, 45.8 mmol, 2.4 eq.) was added to the flask, causing 
the evolution of gas. The reaction mixture was stirred for 30 min at -78°C, then a solution 
of 7-azidoheptanol158 (80) (3.00 g, 19.1 mmol, 1.0 eq.) in EtOAc was added slowly. The 
resulting solution was stirred at -78°C for 1 hour, at which time freshly distilled 
triethylamine (13.3 mL, 96.0 mmol, 5.0 eq.) was added to the reaction. The resulting 
mixture was slowly warmed to 23 °C and stirred at 23 °C for 16 hours. The progress of 
the reaction was determined via TLC by consumption of the starting alcohol (TLC Rf = 
0.5, EtOAc) and the appearance of a new TLC spot for the aldehyde product (Rf =0.8, 
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EtOAc). The reaction mixture was then washed with saturated aqueous NH4Cl (3 x 20 
mL), brine (1 x 20 mL), and the resulting organic solution dried over anhydrous Na2SO4. 
The filtrate was concentrated under reduced pressure yielding a crude oil, the structure of 
the product was verified by 1H NMR. Due to stability concerns, the crude aldehyde was 
used without further purification in the next reaction. 
A solution of the resulting 7-azidoheptanal (2.3 g, 14.2 mmol, 1.2 eq.) in CH2Cl2 (35 mL) 
was added to a round bottom flask. The solution was stirred under an atmosphere of 
argon and 2,4-dimethoxybenzylamine 81 (1.1 mL, 7.0 mmol, 1.0 eq.) was added to the 
reaction via a syringe. The reaction was stirred for 10 minutes to allow imine 
intermediates to form. Sodium triacetoxyborohydride was added in one portion and the 
reaction was stirred at 23 °C until the starting aldehyde was consumed as observed by 
TLC (Rf = 0.8, EtOAc). The reaction was then quenched by dilution with CH2Cl2 (30 
mL), followed by the addition of 2N NaOH (30 mL). The reaction was stirred for 60 min. 
The layers of the biphasic mixture were separated, and the aqueous layer was extracted 
with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over sodium sulfate, 
concentrated under reduced pressure, and purified by column chromatography (SiO2, 45 
mm x 150 mm, 1:1 Hexanes:EtOAc). Purification yields a golden oil (82) (1.25 g, 39%), 
the structure of which was verified by 1H NMR. TLC (Rf = 0.3, 1:1 Hex:EtOAc).  
1H 
NMR (500 MHz, CDCl3) δ 7.26 (t, J = 4.1 Hz, 1H), 6.51 – 6.41 (m, 2H), 3.79 (d, J = 8.3 
Hz, 6H), 3.50 (s, 2H), 3.24 (t, J = 7.0 Hz, 4H), 2.45 – 2.36 (m, 4H), 1.58 (p, J = 7.0 Hz, 
4H), 1.47 (p, J = 7.2 Hz, 4H), 1.41 – 1.23 (m, 12H). 13C NMR (126 MHz, CDCl3) δ 
159.71, 158.80, 130.88, 103.99, 98.42 (2C), 55.49, 55.47, 54.09, 51.62, 51.59, 29.26, 
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28.96, 27.52, 27.12, 26.89. FTIR (thin film) λ (cm-1): 2931, 2855, 2094, 1612, 1588, 
1506, 1464, 1289, 1259, 1207, 1156, 1039. 
HRMS (ESI) C23H39N7O2: Calculated for [M+H] C23H40N7O2, 446.3243; found: 
446.3228. 
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 Bisazide (82) (1.00g, 2.25 mmol, 1.0 equiv.) was added to a round bottom flask 
and dissolved in THF (4.5 mL). Next, triphenylphosphine (1.18 g, 4.5 mmol, 2.0 equiv.) 
was added to the round bottom flask in one portion, and gas evolution from the solution 
was observed. The solution was heated under an atmosphere of argon to 50 °C, and water 
(1.2 ml, 68 mmol, 30 equiv.) was added to the reaction vessel via a syringe. The reaction 
was heated for 16 hours until complete, where no bis- or mono-azide was observed via 
LC-MS of the crude reaction mixture. The reaction was concentrated under reduced 
pressure and the resulting oil was dissolved in EtOAc (25 mL). Water was added to the 
solution causing a biphasic mixture. Dilute acetic acid (3% aq., 10 mL) was added to 
lower the pH of the aqueous layer. The layers were separated, and the resulting organic 
layer was extracted with dilute acetic acid (3% aq., 2x 25 mL). The resulting combined 
aqueous layers were extracted with EtOAc (2 x 10 mL) to remove any remaining 
triphenylphosphine oxide. The aqueous layer was saturated with sodium sulfate, and the 
pH of the resulting solution was raised to 12 by the addition of ammonium hydroxide (ca. 
3 mL). The aqueous layer was extracted with EtOAc (2x 10 mL) and the combined 
organic layers were dried over anhydrous sodium sulfate. The organic solution was 
decanted and concentrated under reduced pressure to yield a golden yellow oil (83) (776 
mg, 88%), the structure of which was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) 
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δ 7.25 (s, 1H), 6.47 – 6.39 (m, 2H), 3.78 (d, J = 8.7 Hz, 6H), 3.49 (s, 2H), 2.66 (t, J = 7.0 
Hz, 3H), 2.38 (t, J = 7.5 Hz, 4H), 1.91 – 1.71 (m, 4H), 1.42 (dq, J = 14.0, 7.3 Hz, 4H), 
1.27 (s, 14H). 13C NMR (126 MHz, CDCl3) δ 159.67, 158.79, 130.88, 120.71, 104.00, 
98.40, 55.49, 55.47, 54.17, 51.56, 42.33, 33.83, 29.63, 27.70, 27.16, 27.07. FTIR (thin 
film) λ (cm-1): 3357, 2928, 2854, 1612, 1587, 1505, 1465. HRMS (ESI) C23H43N3O2: 
Calculated for [M+H] C23H44N3O2, 394.3434; found: 394.3448. 
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To a flame-dried round bottom flask, triamine (83) (393 mg, 1.0 mmol, 1.0 eq.), 
4-bromo-7-chloroquinoline156 (13) (535 mg, 2.2 mmol, 2.2 eq.), Pd(OAc)2 (11mg, 
0.05mmol, 0.05 eq.), BINAP (62 mg, 0.1 mmol, 0.1 eq.), K3PO4 (640 mg, 52.92 mmol, 
3.0 eq.) were added. The reagents were placed under an argon atmosphere and dissolved 
in 1,4-dioxane (44mL) to give a 0.4M reaction concentration. The reaction was then 
heated to 105 °C under in a sealed vessel. The reaction was monitored by 1H NMR 
(CDCl3) where the consumption of primary amine-containing linker marks complete 
consumption of the limiting reagent (peak at ~2.7 ppm). The reaction was then cooled to 
23 °C and filtered through Celite™ using EtOAc (10 mL). The solution was concentrated 
under reduced pressure to afford a paste which was dissolved in CH2Cl2 (20 mL). Water 
(10 mL) and 1N HCl (3 mL) were added to the CH2Cl2 and stirred for 60 minutes to form 
the tris-HCl salt of the product. The layers of the biphasic mixture were separated, and 
the resulting aqueous layer was washed with CH2Cl2 (3 x 10 mL) to ensure the removal 
excess ligand and bromo-quinoline starting materials. The pH of the aqueous solution 
was adjusted to 12 with 2N NaOH (6 mL). The resulting aqueous layer was extracted 
with CHCl3 (3 x 25 mL), and the combined aqueous layers were dried over anhydrous 
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sodium sulfate. The organic solution was decanted and concentrated under reduced 
pressure to afford a paste which was purified by column chromatography (SiO2, 35 mm x 
120 mm, 5:94:1, MeOH: CH2Cl2:NH4OH, gradient to 7:93, MeOH: CH2Cl2). The product 
was isolated as a golden solid-foam (84) (512 mg, 72%), the structure of which was 
verified by 1H NMR. TLC (Rf= 0.45, 7:93, MeOH: CH2Cl2). 
1H NMR (500 MHz, CDCl3) 
δ 8.50 (dd, J = 5.4, 2.2 Hz, 2H), 7.93 (t, J = 2.3 Hz, 2H), 7.69 (dd, J = 8.9, 2.2 Hz, 2H), 
7.32 (dt, J = 8.9, 2.3 Hz, 2H), 7.28 (dd, J = 8.3, 2.1 Hz, 1H), 6.48 – 6.34 (m, 4H), 5.16 (s, 
2H), 3.76 (d, J = 2.3 Hz, 6H), 3.55 (s, 2H), 3.26 (dt, J = 7.3, 4.9 Hz, 4H), 2.50 – 2.36 (m, 
4H), 1.75 – 1.65 (m, 4H), 1.55 – 1.21 (m, 18H). 13C NMR (126 MHz, CDCl3) δ 159.97, 
158.86, 152.15, 149.95, 149.29, 134.95, 131.14, 128.89, 125.34, 121.20, 117.32, 104.17, 
99.17, 98.43, 55.53, 55.49, 53.96, 51.56, 43.36, 29.31, 28.91, 27.44, 27.21, 26.87. FTIR 
(thin film) λ (cm-1): 2926, 2851, 1611, 1578, 1537, 1504, 1455,1370,1329, 
1288,1207,1133.1037. HRMS (ESI) C41H51Cl2N5O2: Calculated for [M+H] 
C41H52Cl2N5O2, 716.3498; found: 716.3497. 
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 Compound 84 (42 mg, 0.06 mmol 1.0 equiv.) was added to a microwave vial and 
dissolved in TFA (2 mL), water (350 uL), and triisopropylsilane (350 uL). The reaction 
was sealed and placed under an atmosphere of argon. The sealed reaction was heated to 
130 °C under microwave irradiation for 3 hours. The reaction was considered complete 
when starting inhibitor was consumed as observed by LC-MS. The reaction was cooled to 
room temperature and the solvent was removed under reduced pressure. The crude paste 
was dissolved in CHCl3 (10 mL) and washed with NH4OH (2 x3 mL) to create the free 
base of the crude product. The organic layer was dried over anhydrous sodium sulfate 
and concentrated under reduced pressure to yield a crude paste. The crude material was 
then purified by column chromatography (SiO2, 15 x 130 mm, 10:90:1, MeOH: 
CH2Cl2:NH4OH) to afford the product as a film on a vial (85) (24 mg, 72%).  The 
structure of the resulting product was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) 
δ 8.51 (d, J = 5.4 Hz, 2H), 7.93 (d, J = 2.1 Hz, 2H), 7.68 (d, J = 8.9 Hz, 2H), 7.33 (dd, J = 
8.9, 2.2 Hz, 2H), 6.38 (d, J = 5.3 Hz, 2H), 5.13 (t, J = 5.4 Hz, 2H), 3.27 (td, J = 7.2, 5.2 
Hz, 4H), 2.61 (t, J = 7.3 Hz, 4H), 1.72 (p, J = 7.3 Hz, 4H), 1.57 – 1.28 (m, 16H). 13C 
NMR (126 MHz, CDCl3) δ 152.20, 149.90, 149.32, 134.95, 128.96, 125.36, 121.14, 
117.31, 99.21, 50.02, 43.35, 29.87, 29.33, 28.92, 27.36, 27.16. FTIR (thin film) λ (cm-1): 
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3269, 2928, 2854, 1610, 1579, 1540, 1452.HRMS (ESI) C32H41Cl2N5: Calculated for 
[M+H] C32H42Cl2N5, 566.2817; found: 566.2837. 
 
 DC770 (85) (46 mg, 0.08 mmol, 1.0 eq.) was added to a screwcap vial and 
dissolved in CHCl3 (350 uL). Aqueous formaldehyde was added (10 uL, 37% aq, 0.24 
mmol, 1.5 eq.) to the vial, and the reaction was vortexed for 30 seconds. Solid sodium 
triacetoxyborohydride (52 mg, 0.24 mmol. 3.0 eq.) was added to the vial, and the reaction 
was stirred for 48 hours. The reaction was observed to be complete via LC-MS, where 
only a single peak corresponding to the [M+H] for the product (580) was observed. The 
reaction was quenched by first dilution with CH2Cl2 (500 uL), 2N NaOH (500 uL) and 
stirred for 60 minutes. The layers of the resulting biphasic mixture were separated, and 
the resulting aqueous layer was extracted with CHCl3 (3 x 1 mL). The combined organic 
layers were dried over anhydrous sodium sulfate and concentrated to a film (40 mg), 
which was purified by column chromatography (SiO2, 15 mm x 100 mm, gradient 
elution[100% CH2Cl2;7:93:1, MeOH:CH2Cl2:NH4OH; 10:90:1, MeOH:CH2Cl2:NH4OH; 
15:85:1, MeOH:CH2Cl2:NH4OH]) to yield a film (86) (36 mg, 76%). The structure of the 
purified product was verified by 1H NMR. 1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 5.3 
Hz, 2H), 7.93 (d, J = 2.3 Hz, 2H), 7.66 (d, J = 8.9 Hz, 2H), 7.35 – 7.28 (m, 2H), 6.37 (d, 
J = 5.4 Hz, 2H), 5.14 (d, J = 5.2 Hz, 2H), 3.26 (td, J = 7.2, 5.0 Hz, 4H), 2.30 (dd, J = 8.7, 
6.5 Hz, 4H), 2.19 (d, J = 3.7 Hz, 3H), 1.72 (p, J = 7.2 Hz, 4H), 1.51 – 1.26 (m, 16H). 13C 
NMR (126 MHz, CDCl3) δ 152.16, 149.89, 149.30, 134.91, 128.92, 125.32, 121.11, 
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117.30, 99.18, 57.96, 43.35, 42.45, 29.40, 28.93, 27.57, 27.37, 27.21. IR (thin film) λ 
(cm-1): 3277, 2928, 2854, 1608, 1579, 1541, 1454. HRMS (ESI) C33H42Cl2N5: Calculated 
for [M+H] C33H43Cl2N5, 580.2974; found: 580.2976.
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The third generation of dimeric chloroquine inhibitors 
  
Compound75 87 (3.7 g, 28.0 mmol, 1.0 eq.)  was added to a round bottom flask along 
with a stir bar and place under an atmosphere of argon. THF (70 mL) was added to the 
round bottom flask via a syringe. The solution was cooled to 0 °C in an ice bath and 
triphenylphosphine (11.8 g, 45 mmol, 1.6 eq.) was added in one portion. Carbon 
tetrabromide (14.97 g, 45 mmol, 1.6 eq) was added to the reaction in three portions, 
adding the next portion when the first portion has dissolved. All additions performed 
while maintaining the 0 °C bath. The reaction was first clear but becomes increasingly 
brown and opaque through the duration of the reaction. The reaction was stirred for 1 
hour at 0 °C. The reaction was then warmed to 23 °C and stirred for 4 hours. The reaction 
was considered complete when the starting azido alcohol was consumed by TLC (starting 
material Rf = 0.25, 1:3 EtOAc:Hex, KMnO4). The reaction was then concentrated under 
reduced pressure to afford a paste. The paste was triturated with Et2O (300 mL), and the 
resulting solid was washed with Et2O (2 x 100 mL). The combined ethereal fractions 
were dried over MgSO4 and concentrated to a crude oil. The resulting crude product was 
purified by column chromatography (SiO2, 65 mm x 150 mm, 1:5, EtOAc:Hex) to afford 
an oil (3.5 g, 64%). The structure of the product (88) was verified by 1H NMR. TLC (Rf = 
0.6, 3:1, Hex: EtOAc). 1H NMR (500 MHz, CDCl3) δ 3.41 (t, J = 5.0 Hz, 2H), 3.48 (t, J = 
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6.2 Hz, 2H), 3.70 (dd, J = 5.5, 4.6 Hz, 2H), 3.83 (t, J = 6.2 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 71.35, 70.13, 50.89, 30.14. FTIR (thin film) λ (cm
-1): 2867, 2107. HRMS (ESI) 
C4H8BrN3O: Calculated for [M-N2+H] C8H9BrNO, 165.9868; found: 165.9888. 
 
 Compound76 89 (6.16 g, 28.0 mmol, 1.0 eq.)  was added to a round bottom flask 
along with a stir bar and place under an atmosphere of argon. THF (70 mL) was added to 
the round bottom flask via a syringe. The solution was cooled to 0 °C in an ice bath and 
triphenylphosphine (11.8 g, 45 mmol, 1.6 eq.) was added in one portion. Carbon 
tetrabromide (14.92 g, 45 mmol, 1.6 eq) was added to the reaction in three portions, 
adding the next portion when the first portion has dissolved. All additions performed 
while maintaining the 0 °C bath. The reaction was first clear but becomes increasingly 
brown and opaque through the duration of the reaction. The reaction was stirred for 1 
hour at 0 °C. The reaction was then warmed to 23 °C and stirred for 4 hours. The reaction 
was considered complete when the starting azido alcohol was consumed by TLC (starting 
material Rf = 0.25, 1:3 EtOAc:Hex, KMnO4). The reaction was then concentrated under 
reduced pressure to afford a paste. The paste was triturated with Et2O (200 mL), and the 
resulting solid was washed with Et2O (100 mL). The combined ethereal fractions were 
dried over MgSO4 and concentrated to a crude oil. The resulting crude product was 
purified by column chromatography (SiO2, 65 mm x 150 mm, 1:3, EtOAc:Hex) to afford 
an oil (4.49 g, 57%). The structure of the product (90) was verified by 1H NMR. TLC (Rf 
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= 0.25, 1:3, EtOAc:Hex). 1H NMR (500 MHz, CDCl3) δ 3.81 (td, J = 6.3, 1.4 Hz, 2H), 
3.70 – 3.65 (m, 10H), 3.47 (td, J = 6.3, 1.4 Hz, 2H), 3.39 (t, J = 4.6 Hz, 2H). 13C NMR 
(126 MHz, CDCl3) δ 71.12, 70.63, 70.60 (2C), 70.46, 69.97, 50.61, 30.21. FTIR (thin 
film) λ (cm-1): 2868, 2108, 1449, 1352, 1281. HRMS (ESI) C8H16BrN3O3: Calculated for 
[M+Na] C8H16BrN3O3Na, 304.0273; found: 304.0279. 
 
 
To a round bottom flask the azido-bromide 88 was added (3.581 mmol,18.5 
mmol, 3.0 eq), the reaction was placed under an atmosphere of argon, EtOH (14 mL) was 
added to dissolve to form a solution, and anhydrous potassium carbonate was added 
(2.55g, 18.5 mmol, 3.0 eq). The reaction was placed under a reflux condenser, 
benzylamine was added (672 uL, 6.2 mmol, 1.0 eq), and the reaction was heated to reflux 
in an oil bath (75 °C). The reaction was heated until the benzylamine has been completely 
bisalkylated, as observed by 1H NMR. The reaction was concentrated under reduced 
pressure to afford a paste. The reaction was partitioned between EtOAc (20 mL) and 
water (20 mL). The layers were separated, and the water was extracted with EtOAc (25 
mL). The combined organic layers were dried over sodium sulfate and concentrated 
under reduced pressure to afford a crude paste. The paste was purified by flash 
chromatography (SiO2, 55 mm x 150 mm, Hex EtOAc, 4:1) to afford a translucent oil 
(91) (1.33 g, 65%), the structure of which was confirmed by 1H NMR. TLC (Rf = 0.7, 
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2:1, Hex:EtOAc, UV254 nm). 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.28 (m, 4H), 7.23 
(td, J = 7.3, 6.9, 1.5 Hz, 1H), 3.73 (s, 2H), 3.58 (dt, J = 7.2, 5.3 Hz, 8H), 3.35 (t, J = 5.0 
Hz, 4H), 2.79 (t, J = 6.0 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 139.87, 128.92, 128.35, 
127.05, 70.22, 69.88, 60.02, 54.08, 50.98. FTIR (thin film) λ (cm-1):  2864, 2107.HRMS 
(ESI) C15H23N7O2: Calculated for [M+H] C15H24N7O2, 334.1991; found: 334.1991. 
 
 
To a round bottom flask the azido-bromide 90 was added (1.53 g, 5.4 mmol, 3.0 
equiv.) and the reaction was placed under an atmosphere of argon. EtOH (4 mL) and 
anhydrous potassium carbonate were added (749 mg, 5.4 mmol, 3.0 equiv.) to the 
reaction vessel. The reaction was placed under a reflux condenser, benzylamine was 
added (200 uL, 1.8 mmol, 1.0 eq), and the reaction was heated to reflux in an oil bath 
preset to 75 °C. The reaction was heated for 20 hours, until the benzylamine has been 
completely bisalkylated as observed by 1H NMR. The reaction was concentrated under 
reduced pressure to afford a paste and dissolved in CH2Cl2 (10 mL). Water (5 mL) and 
saturated aqueous sodium bicarbonate (5 mL) were added to the crude solution. The 
layers of the biphasic mixture were separated, and the resulting aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to afford a crude 
paste. The paste was purified by flash chromatography (SiO2, 35 mm x 150 mm, Gradient 
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1:1 to 0:1, Hex:EtoAc) to afford a translucent oil (92) (753 mg, 82%) the structure of 
which was verified by 1H NMR. TLC (Rf = 0.6, 99:1, EtOAc:MeOH). 
1H NMR (500 
MHz, CDCl3) δ 7.30 (dt, J = 15.0, 7.7 Hz, 4H), 7.22 (t, J = 7.0 Hz, 1H), 3.75 – 3.51 (m, 
30H), 3.36 (t, J = 5.1 Hz, 4H), 2.75 (t, J = 6.3 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 
139.88, 128.84, 128.17, 126.85, 70.75, 70.72, 70.43, 70.07, 69.98, 59.79, 53.86, 50.73. 
FTIR (thin film) λ (cm-1): 2868, 2106. HRMS (ESI) C23H39N7O6: Calculated for [M+H] 
C23H40N7O6, 510.3040; found: 510.3042. 
 
 
 The tertiary amine (91) (900 mg, 2.7 mmol, 1.0 equiv.) was added to a round 
bottom flask followed by sodium bicarbonate (125mg, 1.5 mmol, 0.6 eq), and was placed 
under an argon atmosphere with a stir bar. The reaction was dissolved in toluene (3.8 
mL) and methylchloroformate (250 uL, 3.2 mmol, 1.2) was added to the reaction 
dropwise while the reaction was stirring. The reaction was then heated to 85 °C in an oil 
bath until the starting tertiary amine was consumed as observed by TLC ((Rf = 0.7, 2:1, 
Hex:EtOAc ,UV 254). The reaction was cooled to 23 °C and concentrated under reduced 
pressure to afford a crude paste. The paste was purified by column chromatography 
(SiO2, 2:1, Hex:EtOAc) to afford a translucent oil (93) (770 mg, 97%). The structure of 
the crude oil was verified by 1H NMR. TLC (Rf = 0.2, 2:1, Hex:EtOAc). The 
13C NMR 
was observed to contain a mixture of rotamers. 1H NMR (500 MHz, CDCl3) δ 3.70 (s, 
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3H), 3.67 – 3.56 (m, 8H), 3.56 – 3.50 (m, 4H), 3.36 (t, J = 5.0 Hz, 4H). 13C NMR (126 
MHz, CDCl3) δ 156.85, 69.98, 69.89, 69.74, 52.67, 52.64, 50.88, 48.41, 47.96. FTIR 
(thin film) λ (cm-1): 2867, 2109, 1702. HRMS (ESI) C10H19N7O4: Calculated for [M+H] 
C10H20N7O4, 302.1577; found: 302.1590. 
 
 The tertiary amine 92 (426 mg, 0.84 mmol, 1.0 equiv.) was added to a round 
bottom flask followed by sodium bicarbonate (40 mg, 0.46 mmol, 0.6 equiv.) and was 
placed under an argon atmosphere with a stir bar. The reaction was dissolved in toluene 
(1.2 mL) and methylchloroformate (80 uL, 1 mmol, 1.2 equiv.) was added to the reaction 
dropwise while the reaction was stirring. The reaction was then heated in an oil bath 
preset to 85 °C until the starting tertiary amine was consumed as observed by TLC (Rf = 
0.2, EtOAc, UV 254). The reaction was then concentrated under reduced pressure to 
afford a crude paste which was purified by flash chromatography (SiO2, 25 mm x 150 
mm, EtOAc). The product was isolated as a clear oil (94) (243mg, 61%), the structure of 
which was verified by 1H NMR. The 13C NMR was observed to contain a mixture of 
rotamers. TLC (Rf = 0.4, EtOAc, KMnO4). 
1H NMR (500 MHz, CDCl3) δ 3.73 – 3.42 
(m, 32H), 3.37 (q, J = 4.8 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 156.86, 70.82, 70.79, 
70.60, 70.50, 70.15, 69.77, 69.60, 52.59, 50.80, 48.22, 47.76. FTIR (thin film) λ (cm-1): 
2868, 2106, 1701. HRMS (ESI) C18H35N7O8: Calculated for [M+Na] C18H35N7O8Na, 
500.2445; found: 500.2455. 
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 The bisazide (93) (540 mg, 1.9 mmol, 1.0 equiv.) was added to a round bottomed 
flask along with a stir bar. The reaction vessel was placed under an atmosphere of argon, 
and the contents of the flask were dissolved in THF (2.8 mL). Triphenylphosphine (992 
mg, 3.8 mmol, 2.0 equiv.) was added to the reaction vessel, and the reaction was stirred at 
50 °C. Water (1 mL, 55 mmol, 29.0 equiv.) was added via a syringe to the reaction vessel 
and the reaction was heated until the all azide containing compounds were reduced as 
observed via LCMS. The reaction was then concentrated to a paste and dissolved in 
CH2Cl2 (10 mL). The organic solution was washed with 1N HCl (4 mL). The organic 
fraction was extracted (2 x 5 mL) with 1N HCl and the aqueous layers were combined. 
The product, now a HCl salt in the aqueous layer, was then back extracted with 
methylene chloride. The water layer was now frozen and lyophilized to obtain the pure 
product as a white HCl salt (95) (518mg, 85 %). The structure of the salt was verified by 
1H NMR. The 13C NMR was observed to contain a mixture of rotamers. MP (Water) 165-
175 °C. TLC (Rf = 0.0, 10:90:1, MeOH:NH4OH:CH2Cl2). 
1H NMR (500 MHz, CD3OD) 
δ 3.73 – 3.63 (m, 12H), 3.59 – 3.51 (m, 4H), 3.16 – 3.10 (m, 4H). 13C NMR (126 MHz, 
CD3OD) δ 158.91, 70.57, 70.02, 67.73, 53.40, 48.74, 48.02, 40.57. FTIR (thin film) λ 
(cm-1): 2971, 1672, 1485, 1246, 1107. HRMS (ESI) C10H23N3O4(HCl)2: Calculated for 
[M+H-2HCl] C10H24N3O4, 250.1767; found: 250.1750. 
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 The bisazide 94 (200 mg, 0.42 mmol, 1.0 equiv.) was added to a round bottomed flask 
along with a stir bar. The reaction vessel was placed under an atmosphere of argon, and the 
contents of the flask were dissolved in THF (0.75 mL). Triphenylphosphine (219 mg, 0.84 mmol 
2.0 equiv.) was added to the reaction vessel, and the reaction was stirred at 50 °C. Water (250 
uL) was added via a syringe to the reaction vessel and the reaction was heated until the all azide 
containing compounds were reduced as observed via 1H NMR. The reaction was then 
concentrated to a paste and dissolved in EtOAc (2 mL). The EtOAc was washed with 1N HCl (6 x 2 
mL) and the aqueous layers were combined. The product, now a HCl salt in the aqueous layer 
was frozen and lyophilized to obtain a solid clear paste as the HCl salt (96) (147mg, 70%). The 
structure of which was determined by 1H NMR and HRMS. The 13C NMR was observed to contain 
a mixture of rotamers. TLC (Rf = 0.0, 10:90:1, MeOH:NH4OH:CH2Cl2). 1H NMR (500 MHz, DMSO-
d6) δ 3.64 – 3.45 (m, 14H), 3.33 (d, J = 3.8 Hz, 24H), 3.16 (s, 1H), 2.94 (s, 1H). 13C NMR (126 MHz, 
CDCl3) δ 155.40, 69.19, 69.13, 66.08, 51.78, 37.93. FTIR (thin film) λ (cm-1): 3390, 1670. HRMS 
(ESI) C18H39N3O4(HCl)2: Calculated for [M+H-2HCl] C18H40N3O4, 426.2815; found: 426.2807. 
 
To the reaction vessel 4-bromo-7-chloroquinoline (13) (290 mg, 1.2mmol, 2.2 
equiv.) was added followed by the diamine (95) (175 mg, 1.0 mmol, 1.0 equiv.), 
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Pd(OAc)2 (6 mg, 0.03 mmol, 0.05 equiv.), BINAP (74 mg, 0.12 mmol, 0.1 equiv.), 
K3PO4 (578 mg, 3.0 mmol, 5.0 equiv.). The reaction vessel was then sealed and placed 
under an atmosphere of argon. 1,4-dioxane was degassed and added to the reaction via a 
syringe (1.4 mL). The reaction was then heated at 105 °C for 20 hours. The reaction was 
cooled to room temperature and was considered to be complete when 4-bromo-7-
chloroquinoline was consumed as observed via TLC (Rf = 0.65, 3 Hexanes :1 EtOAc). 
The reaction was filtered through Celite™ using EtOAc and concentrated to a solid 
(530mg). The reaction was then purified by flash chromatography (SiO2, 25 mm x 130 
mm, gradient: MeOH:NH4OH:CH2Cl2; 1:98:1 (50 mL), 2:97:1 (50 mL), 3:96:1 (50 mL), 
4:95:1 (50 mL), 8:91:1 (50 mL), 10:89:1 (100 mL)). The product was isolated as a yellow 
white solid (97) (266mg, 86%), the structure of which was confirmed by 1H NMR. The 
13C NMR was observed to contain a mixture of rotamers. MP 56 – 60 °C. 1H NMR (500 
MHz, CDCl3) δ 8.50 (d, J = 5.4 Hz, 2H), 7.94 (d, J = 2.2 Hz, 2H), 7.32 (s, 2H), 6.37 (d, J 
= 5.9 Hz, 2H), 5.73 (d, J = 143.3 Hz, 2H), 3.82 – 3.35 (m, 19H). 13C NMR (126 MHz, 
CDCl3) δ 157.32, 151.80, 148.98, 135.18, 128.63, 128.42, 125.60, 125.32, 122.10, 
121.41, 117.44, 99.30, 70.01, 69.44, 68.89, 68.48, 53.07, 53.05, 47.84, 43.18, 42.95. 
FTIR (thin film) λ (cm-1): 2869, 1691, 1611, 1579, 1539. HRMS (ESI) C28H31Cl2N5O4: 
Calculated for [M+H] C28H32Cl2N5O4, 572.1831; found: 572.1823. 
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To a reaction vessel 4-bromo-7-chloroquinoline (13) (119 mg, 1.2mmol, 2.2 
equiv.) was added followed by the diamine (96) (111 mg, 1.0 mmol, 1.0 equiv.), 
Pd(OAc)2 (3 mg, 0.03 mmol, 0.05 equiv.), BINAP (17 mg, 0.12 mmol, 0.1 equiv.), 
K3PO4 (235 mg, 1.10 mmol, 5.0 equiv.). The reaction vessel was then sealed and placed 
under an atmosphere of argon. 1,4-dioxane was degassed and added to the reaction via a 
syringe (560 mL). The reaction was then heated at 105 °C for 20 hours. The reaction was 
cooled to room temperature and considered to be complete when 4-bromo-7-
chloroquinoline was consumed as observed via TLC (Rf = 0.65, 3 Hexanes :1 EtOAc). 
The reaction was filtered through Celite™ using 10% MeOH in CHCl3 (v/v) and 
concentrated to a solid (168 mg). The reaction was then purified by flash chromatography 
(SiO2, 25 mm x 130 mm, gradient: MeOH:NH4OH:CH2Cl2; 3:96:1 (50 mL), 5:94:1 (50 
mL)) The product was isolated as a yellow white paste (98) (167 mg, 72%) the structure 
of which was confirmed by 1H NMR. The 13C NMR was observed to contain a mixture of 
rotamers. 1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 5.3 Hz, 2H), 7.93 (d, J = 2.2 Hz, 
2H), 7.80 (d, J = 8.9 Hz, 2H), 7.32 (dd, J = 8.9, 2.2 Hz, 2H), 6.37 (d, J = 5.4 Hz, 2H), 
5.81 (d, J = 15.2 Hz, 2H), 3.79 (t, J = 5.2 Hz, 4H), 3.70 – 3.34 (m, 33H). 13C NMR (126 
MHz, CDCl3) δ 156.88, 152.09, 150.10, 149.26, 135.01, 128.74, 125.36, 121.74, 117.58, 
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99.30, 70.75, 70.69, 70.62, 70.46, 69.79, 69.47, 68.78, 52.71, 48.18, 47.68, 42.89. FTIR 
(thin film) λ (cm-1): 3380, 2869, 1698, 1610, 1580, 1538. HRMS (ESI) C36H47Cl2N5O8: 
Calculated for [M+H] C36H48Cl2N5O8, 748.2880; found: 748.2894. 
 The carbamate 97 (37 mg, 0.07 mmol, 1.0 equiv.) was added to a screw-cap vial 
followed by solid KOH (150 mg, 3 mmol, 45 equiv.). The reaction contents were placed 
under an atmosphere of argon and dissolved in a 2:1 mixture of methanol and water (600 
uL). The reaction was then heated for 48 hours at 100 °C. The reaction was monitored by 
consumption of the starting material via TLC (Rf = 0.5, 5:95:1, MeOH:NH4OH:CH2Cl2). 
The completed reaction was then concentrated under reduced pressure to remove the 
methanol. The resulting pasted was partitioned between CHCl3 (1 mL) and water (1 mL). 
The layers were separated, and the water layer was extracted with CHCl3 (3 x 1 mL). The 
combined organic layers were dried over anhydrous sodium sulfate and concentrated to a 
crude paste. Purification of the paste by column chromatography (15 mm x 150 mm, 
gradient 3:96:1 to 6:93:1, MeOH:NH4OH:CH2Cl2) yielding a white yellow film (99) (27 
mg, 79%). TLC (Rf = 0.2, 5:95:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) 
δ 8.48 (d, J = 5.3 Hz, 2H), 7.91 (d, J = 2.1 Hz, 2H), 7.70 (d, J = 9.0 Hz, 2H), 7.31 – 7.24 
(m, 2H), 6.33 (d, J = 5.3 Hz, 2H), 5.63 (t, J = 5.1 Hz, 2H), 3.72 (dd, J = 5.7, 4.6 Hz, 4H), 
3.62 – 3.56 (m, 4H), 3.38 (q, J = 5.1 Hz, 4H), 2.84 (t, J = 5.1 Hz, 4H), 1.23 (t, J = 7.0 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 152.19, 149.92, 149.32, 135.00, 128.93, 125.39, 
121.43, 117.50, 99.39, 77.44, 77.19, 76.93, 70.61, 68.82, 49.40, 42.85. FTIR (thin film) λ 
(cm-1): 3269, 2869, 1611, 1580, 1541, 1451, 1429, 1368, 1332, 1280, 1251,1142, 1118. 
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HRMS (ESI) C26H29Cl2N5O2: Calculated for [M+H] C26H30Cl2N5O2, 514.1777; found: 
514.1760. 
 
 The carbamate (98) (50 mg, 0.7 mmol, 1.0 equiv.) was added to a screw-cap vial 
and placed under an atmosphere of argon. The reaction was dissolved in CHCl3 (200 uL). 
TMS-I (60 uL, 0.21 mmol, 3.2 equiv.) was added and the reaction was heated to 65 °C 
for 3 hours. The reaction was observed to be complete by the consumption of starting 
carbamate (TLC Rf = 0.7, 1:10 MeOH:CH2Cl2). The reaction was concentrated under 
reduced pressure to afford a crude paste. The crude product was purified by column 
chromatography (SiO2, 15 mm x 150 mm, 10:90:1, MeOH:CH2Cl2:NH4OH) to yield a 
film on a vial (100) (34mg, 71%). The structure of the product was verified by 1H NMR. 
TLC (Rf = 0.2, 10:90:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.46 (d, 
J = 5.6 Hz, 2H), 8.00 – 7.92 (m, 4H), 7.36 (dd, J = 8.9, 2.2 Hz, 2H), 6.42 (d, J = 5.7 Hz, 
2H), 6.32 (s, 2H), 3.86 – 3.80 (m, 4H), 3.70 – 3.49 (m, 27H), 2.83 (t, J = 5.2 Hz, 4H). 13C 
NMR (126 MHz, CDCl3) δ 150.86, 150.45, 147.56, 135.53, 127.14, 125.51, 122.49, 
117.15, 99.05, 70.50, 70.35, 70.22, 70.14, 69.24, 68.75, 48.65, 42.88. FTIR (thin film) λ 
(cm-1): 3292, 2871, 1610, 1538, 1451, 1426, 1367, 1332, 1281, 1243, 1098. HRMS (ESI) 
C34H45Cl2N5O6: Calculated for [M+H] C34H46Cl2N5O6, 690.2825; found: 690.2844. 
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 The dimeric inhibitor 99 (11 mg, 0.02 mmol, 1.0 equiv.) was added to a screw-
cap vial and placed under an atmosphere of argon. A stock solution was made of CH2O 
(3.5 uL/ 110 uL) in CH2Cl2. The inhibitor was dissolved in CH2Cl2 (110 uL) which 
contained CH2O (3.5 uL, 0.04 mmol, 2.0 equiv.). The reaction was stirred for 2 minutes 
before adding solid sodium triacetoxyborohydride (18 mg, 0.9 mmol, 4.0). The reaction 
was stirred for three hours until the starting material was consumed as observed by TLC 
(Rf = 0.3, 5:94:1, MeOH:CH2Cl2:NH4OH) and LCMS. The excess sodium 
triacetoxyborohydride was quenched by the addition of 2N NaOH (500 uL). CH2Cl2 (500 
uL) was added to the reaction mixture, and the biphasic mixture was separated. The 
aqueous layer was extracted with CH2Cl2, the combined organic layers were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to afford a crude 
paste. The crude paste was then purified by column chromatography (SiO2 (pipet), 
5:94:1, MeOH:CH2Cl2:NH4OH) to afford a film on a vial 101 (9mg, 80%). TLC (Rf = 
0.3, 5:94:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 5.3 Hz, 
2H), 7.94 (d, J = 2.3 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 7.34 – 7.24 (m, 4H), 6.32 (d, J = 
5.3 Hz, 2H), 5.63 (d, J = 5.4 Hz, 3H), 3.71 (t, J = 5.1 Hz, 5H), 3.61 (t, J = 5.4 Hz, 5H), 
3.36 (q, J = 5.1 Hz, 6H), 2.69 (t, J = 5.4 Hz, 5H), 2.34 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 152.23, 149.95, 149.36, 135.00, 128.94, 125.30, 121.55, 117.56, 99.36, 68.88, 
68.43, 57.23, 43.55, 42.78. FTIR (thin film) λ (cm-1): 3265, 2870, 1611, 1578, 1538, 
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1482, 1451, 1428, 1367, 1332, 1280, 1252, 1141, 1120, 1080. HRMS (ESI) 
C27H31Cl2N5O2: Calculated for [M+H] C27H32Cl2N5O2, 528.1933; found: 528.1917. 
 
 The dimeric inhibitor 100 (33mg, 0.048 mmol, 1.0 equiv.) was added to a round 
bottom flask, placed under an atmosphere of argon, and dissolved in CH2Cl2. Aqueous 
formaldehyde (10 uL) was added via a microsyringe, and the reaction was stirred for ten 
minutes. Sodium triacetoxyborohydride (31 mg, 0.14 mmol, 3.0 equiv.) was added to the 
reaction in one portion, and the reaction was stirred for 20 hours. In LC-MS of the crude 
reaction only the mass of the methylated product (704 [M+H]) was observed. Excess 
sodium triacetoxyborohydride was quenched by dilution with CH2Cl2 (2 mL) and the 
addition of 2N NaOH (2 mL). The reaction was vortexed for 60 seconds and the resulting 
emulsion was allowed to settle. The resulting biphasic mixture was separated, and the 
remaining aqueous fraction was extracted with CH2Cl2 (3 x 2 mL). The combined 
organic layers were dried over sodium sulfate, concentrated under reduced pressure to a 
paste, and purified by flash chromatography (SiO2, 15 mm x 125 mm, 10:90:1, 
MeOH:CH2Cl2:NH4OH). The product was isolated as a film on a vial (102) (23 mg, 
68%), the structure of which was verified by 1H NMR. TLC (Rf = 0.2, 10:90:1, 
MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 5.3 Hz, 2H), 7.93 (d, 
J = 2.0 Hz, 2H), 7.86 (d, J = 9.2 Hz, 2H), 7.33 (dd, J = 9.0, 2.2 Hz, 2H), 6.36 (d, J = 5.4 
Hz, 2H), 6.01 (s, 2H), 3.80 (t, J = 5.2 Hz, 4H), 3.69 – 3.58 (m, 12H), 3.56 – 3.43 (m, 
12H), 2.58 – 2.49 (m, 7H), 2.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.14, 150.22, 
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149.39, 134.94, 128.72, 125.28, 122.08, 117.73, 99.20, 70.68 (2C), 70.41, 70.39, 69.24, 
68.84, 57.36, 43.12, 42.98. FTIR (thin film) λ (cm-1): 3308, 2869, 1611, 1579, 1539, 
1451, 1428, 1367, 1332, 1280, 1251, 1200, 1118. HRMS C35H47Cl2N5O6: Calculated for 
[M+H] C35H48Cl2N5O6, 704.2982; found: 704.2995. 
 
Diamine77 103 (197 mg, 0.4023 mmol, 1.0 equiv) aryl halide 13 (215 mg, 0.8851 mmol, 
2.2 equiv), Pd(OAc)2 (4.54 mg, 0.02 mmol, 0.05 equiv), BINAP (25 mg, 0.04 mmol, 0.1 
equiv), and K3PO4 (257 mg, 1.207 mmol, 3.0 equiv) were added to a vial. The vial was 
sealed and placed under an atmosphere of argon. Through the septum, 1,4-dioxane (1 
mL), was added to the reaction vessel. The reaction was heated to 105 °C until the 
consumption of the linker was observed via proton NMR. Protons of the methylene next 
to the primary amine were easily visible (~2.7 ppm CDCl3). When the reaction was 
complete, it was cooled to 23 °C and the reaction was filtered through a pad of celite 
using CHCl3 to remove inorganic salts. The crude reaction mixture was then concentrated 
under reduce pressure and purified via flash chromatography (SiO2, 25 mm X 150 mm, 
eluted via a gradient 2%-5% MeOH with 1% TEA in EtOAc). Isolate the product 92% 
pure by HPLC as a brown solid (115 mg, 32%) 104. The product is a mixture of rotamers 
at 300K. Heating the sample to 340 K causes the mixture of rotamers to coalesce. The 
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structure of the compound was then verified by 1H NMR and HRMS. The 13C NMR 
contained a mixture of rotamers. MP 62 – 64 °C. TLC (Rf = 0.45, 7:93:1, 
MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 5.4 Hz, 2H), 8.25 – 
8.16 (m, 3H), 7.78 (s, 2H), 7.39 (d, J = 9.0 Hz, 2H), 6.48 (s, 2H), 3.34 (d, J = 6.5 Hz, 
4H), 2.86 (s, 5H), 2.68 – 2.59 (m, 27H).13C NMR (126 MHz, CDCl3) δ 157.81, 155.10, 
151.74, 148.77, 134.97, 128.25, 125.28, 121.91, 117.12, 97.98, 81.36, 80.54, 53.39, 
46.29, 45.73, 45.48, 45.06, 43.98, 43.75, 28.37. FTIR (thin film) λ (cm-1): 1673, 1611, 
1579, 1541, 1477, 1465, 1453, 1392, 1366, 1333, 1308, 1279, 1241, 1216, 1156, 1138. 
HRMS (ESI) C41H55Cl2N7O6: Calculated for [M+H] C41H56Cl2N7O6, 812.3669; found: 
812.3665. 
 
The starting carbamate 104 (77 mg, 0.095 mmol, 1.0 equiv.) was added to a vial 
and placed under an atmosphere of argon. The carbamate was dissolved in CH2Cl2 (400 
uL) and TFA was added (400 uL). The reaction was monitored via LC-MS, where after 3 
hours of stirring the reaction was complete. The reaction was concentrated under reduced 
pressure to afford a paste. The paste was partitioned between CHCl3 (5 mL) and 50% 
concentrated NH4OH in water (2 mL). The layers were separated, and the water layer was 
saturated with NaCl. The saturated aqueous solution was then extracted with CHCl3 (2 x 
3 mL). The combined organic layers were then dried over Na2SO4 and concentrated to 
afford a paste (105) (23 mg, 47%). 1H NMR (500 MHz, CDCl3) δ 8.52 – 8.46 (m, 2H), 
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7.92 (t, J = 2.3 Hz, 2H), 7.68 (dd, J = 9.1, 2.1 Hz, 2H), 7.29 (dd, J = 8.9, 2.3 Hz, 2H), 
6.33 (dd, J = 5.7, 2.0 Hz, 2H), 5.84 (s, 2H), 3.30 – 3.24 (m, 4H), 3.00 – 2.94 (m, 4H), 
2.74 (q, J = 2.3 Hz, 8H), 1.62 (bs, 3H). 13C NMR (126 MHz, CDCl3) δ 152.24, 150.00, 
149.29, 134.91, 128.87, 125.27, 121.45, 117.52, 99.36, 49.55, 49.04, 47.63, 42.24. 
FTIR (thin film) λ (cm-1): 3280, 2938, 2840, 1611, 1579, 1533, 1450, 1428, 1367, 1330, 
1280, 1246, 1215, 1137, 1080. HRMS (ESI) C26H31Cl2N7: Calculated for [M+H] 
C26H32Cl2N7, 512.2096; found: 512.2105. 
 To a screw cap vial the DC inhibitor 105 (50 mg, 0.1 mmol, 1.0 equiv.) was 
added and placed under an atmosphere of argon. The vial contents were dissolved in 
HCOOH (500 uL) and aqueous formaldehyde (74 uL, 1.0 mmol, 10 equiv.) was added. 
The reaction was heated at 105 °C for four hours, until LCMS showed tris-methylated 
product and no mass for the bis- or mono-methylated species was observed. The reaction 
contents were concentrated under reduced pressure to afford a paste. The resulting paste 
was then dissolved in water (3 mL), CHCl3 (4 mL), and concentrated NH4OH (1 mL). 
The resulting biphasic mixture was separated, and the resulting aqueous layer was 
extracted with CHCl3 (3 x 3 mL). The combined organic layers were then dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to yield a crude paste. 
The crude material was purified by flash chromatography (SiO2, 15 mm x 150 mm, 
5:94:1 to 10:90:1, MeOH:NH4OH:CH2Cl2) to yield the product as film on a vial (106) 
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(33 mg, 60%). The structure of the product was confirmed by 1H NMR. 1H NMR (500 
MHz, CD3OD) δ 8.53 – 8.37 (m, 4H), 7.90 (d, J = 2.5 Hz, 2H), 7.73 – 7.62 (m, 2H), 7.05 
– 6.98 (m, 2H), 4.07 (s, 4H), 3.64 – 3.53 (m,4H), 3.44 (s, 4H), 3.05 – 2.95 (m, 9H), 2.40 
(d, J = 2.5 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 157.82, 144.40, 141.30, 140.01, 
129.02, 126.16, 120.41, 117.17, 100.13, 55.11, 54.34, 53.06, 41.31, 40.99, 39.56. FTIR 
(thin film) λ (cm-1): 1674, 1614, 1457, 1200, 1131, 720. HRMS (ESI) C29H37Cl2N7: 
Calculated for [M+H] C29H38Cl2N7, 554.2566; found: 554.2589. 
Piperaquine Dimeric Inhibitors 
 
To a screw-cap vial the secondary amine78 107 (248 mg, 1.0 mmol, 2.0 equiv.) 
and potassium carbonate (166 mg, 1.2 mmol, 2.4 equiv.) were added as solids and placed 
under an atmosphere of argon. DMF (1 mL) was added to the reaction mixture followed 
by 1,2-dibromoethane 108 (45 uL, 0.5 mmol, 1.0 equiv.). The reaction was heated until 
107 was consumed by TLC (Rf = 0.3, 10:90:1, MeOH:CH2Cl2:NH4OH, UV254). The 
reaction was cooled to room temperature and diluted with water (1 mL). The crude 
mixtures were all purified specific to each reaction. The reaction was poured onto water 
(20 mL) and a white-brown precipitate is observed. Vacuum filtration and washing with 
water (20 mL) allowed collection of the product as a brown solid (109) (214 mg, 82%), 
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the structure of which was verified by 1H NMR. MP (DMF/Water) 193-195 °C. TLC (Rf 
= 0.25, 7:92:1, MeOH:CH2Cl2:NH4OH, UV254). 
1H NMR (500 MHz, CDCl3) δ 8.69 (d, 
J = 5.0 Hz, 2H), 8.07 – 7.98 (m, 2H), 7.93 (d, J = 8.8 Hz, 2H), 7.44 – 7.37 (m, 2H), 6.81 
(d, J = 5.1 Hz, 2H), 3.30 – 3.19 (m, 8H), 2.88 – 2.64 (m, 10H). 13C NMR (126 MHz, 
CDCl3) δ 157.03, 152.06, 150.27, 134.99, 129.01, 126.23, 125.31, 122.04, 109.09, 56.07, 
53.69, 52.29. FTIR (thin film) λ (cm-1): 2947, 2827, 1606, 1574, 1497, 1459, 1424, 1381, 
1333, 1299, 1253, 1234, 1193, 1134, 1072. HRMS (ESI) C28H30Cl2N6: Calculated for 
[M+H] C28H31Cl2N6, 521.1987; found: 521.2007. 
 
To a screw-cap vial the secondary amine78 107 (100 mg, 0.4 mmol, 2.0 equiv.) 
and potassium carbonate (66 mg, 0.48 mmol, 2.4 equiv.) were added as solids and placed 
under an atmosphere of argon. DMF (1 mL) was added to the reaction mixture followed 
by 1,7-dibromoheptane (34 uL, 0.2 mmol, 1.0 equiv.). The reaction was heated until 107 
was consumed by TLC (Rf = 0.3, 10:90:1, MeOH:CH2Cl2:NH4OH, UV254). The reaction 
was cooled to room temperature and diluted with water (10 mL). The resulting aqueous 
mixture was extracted with EtOAc (3 x 10 mL) and the resulting organic fractions were 
collected. The combined organic layers were washed with water (2 x 10 mL), brine (1 x 
10 mL) and the resulting organic layers were dried over anhydrous sodium sulfate. The 
271 
 
dried organic layer was concentrated under reduced pressure to a crude paste. The paste 
was purified by column chromatography (SiO2, 20 x 150 mm, 5:95:1, 
MeOH:CH2Cl2:NH4OH) resulting in a brown paste (110) (35 mg, 29%). The structure of 
the product was verified by 1H NMR. TLC (Rf = 0.5, 10:90:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.68 (d, J = 5.0 Hz, 2H), 8.02 (d, J = 2.1 Hz, 2H), 7.92 (d, 
J = 8.9 Hz, 2H), 7.39 (dd, J = 9.0, 2.1 Hz, 2H), 6.81 (d, J = 5.0 Hz, 2H), 3.29 – 3.19 (m, 
8H), 2.78 – 2.66 (m, 8H), 2.46 (dd, J = 9.1, 6.4 Hz, 4H), 2.21 (s, 4H), 1.56 (t, J = 7.5 Hz, 
4H), 1.42 – 1.30 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 157.14, 152.02, 150.21, 135.00, 
128.93, 126.21, 125.35, 122.04, 109.07, 58.85, 53.27, 52.29, 29.66, 27.66, 26.98. FTIR 
(thin film) λ (cm-1): 3373, 3066, 297, 2885, 2822,1606,1575, 1497, 1458, 1424,1379, 
1357, 1334, 1298, 1252, 1233, 1192, 1159, 1142, 1072, 1020. HRMS (ESI) C33H40Cl2N6: 
Calculated for [M+H] C33H41Cl2N6, 591.2770; found: 591.2770. 
 
 
To a screw-cap vial the amine78 107 (242 mg, 1.0 mmol, 2.0 equiv.) and potassium 
carbonate (161 mg, 1.2 mmol, 2.4 equiv.) were added as solids and placed under an 
atmosphere of argon. DMF (1 mL) was added to the reaction mixture followed by 1,8-
dibromooctane 35 (82 uL, 0.44 mmol, 1.0 equiv.). The reaction was heated until 107 was 
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consumed by TLC (Rf = 0.3, 10:90:1, MeOH:CH2Cl2:NH4OH, UV254). The reaction was 
cooled to room temperature and diluted with water (1 mL). The crude mixtures were all 
purified specific to each reaction. The reaction was poured onto water (20 mL) and a 
white-brown precipitate is observed. The water and DMF was decanted and discarded. 
The resulting precipitate (247 mg) was purified by flash chromatography (SiO2, 25 x 150 
mm, 4:96:1 then 6:94:1, MeOH:CH2Cl2:NH4OH) resulting in a brown paste (111) (176 
mg, 65%). TLC (Rf = 0.5, 10:90:1, MeOH:CH2Cl2:NH4OH).
1H NMR (500 MHz, CDCl3) 
δ 8.68 (dd, J = 5.2, 2.0 Hz, 2H), 8.01 (d, J = 2.2 Hz, 2H), 7.91 (dd, J = 9.0, 2.0 Hz, 2H), 
7.38 (dt, J = 9.0, 2.2 Hz, 2H), 6.80 (dd, J = 5.0, 2.0 Hz, 2H), 3.23 (t, J = 4.6 Hz, 8H), 2.79 
– 2.64 (m, 8H), 2.45 (td, J = 7.6, 2.0 Hz, 4H), 1.60 – 1.48 (m, 4H), 1.34 (t, J = 5.1 Hz, 
9H). 13C NMR (126 MHz, CDCl3) δ 157.11, 152.04, 150.26, 134.95, 128.97, 126.16, 
125.36, 122.05, 109.05, 58.87, 53.27, 52.31, 29.67, 27.66, 27.02. FTIR (thin film) λ (cm-
1): 2930, 2851, 2820, 1606, 1574, 1497, 1458, 1424, 1380, 1357, 1335, 1297, 1252,1233, 
1191, 1161, 1139, 1071, 1020. HRMS (ESI) C34H42Cl2N6: Calculated for [M+H] 
C33H43Cl2N6, 605.2926; found: 605.2946. 
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Dimeric ferroquine inhibitors 
 
 Ferroquine (6) (20 mg, 0.046 mmol, 1.0 eq) was added to a screw cap vial under 
an atmosphere of argon. In a separate vial a mixture of 3:1 CHCl3:MeOH is made (1.2 
mL), and methyl iodide (50 uL) is added to the solution. The methyl iodide, CHCl3, and 
method solution (400 uL, 0.27 mmol of MeI, 5.8 equiv.) is added to the screw cap vial, 
and the vessel is sealed. The reaction mixture is heated at 40 °C for four hours until the 
starting material is consumed as observed by LC-MS. The solvent is removed from the 
reaction vessel under reduced pressure, and the reaction is placed under high vacuum for 
one hour to ensure all excess methyl iodide is removed. The amine82 107 (46 mg, 0.19 
mmol, 4.0 equiv.) is added to the reaction vessel in a mixture of CHCl3:MeOH (300 uL). 
The reaction is sealed and stirred at 56 °C for four days. The reaction is then concentrated 
under reduced pressure to afford an orange-yellow paste. The paste is then purified by 
flash chromatography (SiO2, 15 x 150 mm, 3:94:1, MeOH:CH2Cl2:NH4OH) yielding an 
orange yellow film which contained a coeluted impurity. The film was recrystallized 
from methanol boiling methanol to yield the product as orange crystals (113) (11 mg, 
37%). The structure of the product was verified by 1H NMR. TLC (Rf = 0.4, 8:92:1, 
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MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3) δ 8.78 (d, J = 4.9 Hz, 1H), 8.58 (d, 
J = 5.4 Hz, 1H), 8.06 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.90 (d, J = 9.0 Hz, 
1H), 7.80 (d, J = 8.9 Hz, 1H), 7.42 (dd, J = 8.9, 2.2 Hz, 1H), 7.19 (dd, J = 8.9, 2.2 Hz, 
1H), 6.71 (d, J = 5.0 Hz, 1H), 6.56 (d, J = 5.3 Hz, 1H), 6.22 (s, 1H), 4.44 – 4.32 (m, 2H), 
4.32 – 4.15 (m, 8H), 3.86 (d, J = 12.7 Hz, 1H), 3.25 – 3.06 (m, 5H), 2.83 (s, 2H), 2.64 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 156.85, 152.27, 150.37, 135.21, 129.23, 126.54, 
125.56, 125.13, 122.90, 122.08, 117.33, 109.19, 99.41, 83.72, 82.83, 72.01, 70.77, 
69.59(5C), 69.43, 66.95, 57.44, 53.29, 51.94, 51.14, 42.57. FTIR (thin film) λ (cm-1): 
2929, 2847, 1606, 1578. HRMS (ESI) C34H31Cl2FeN5: Calculated for [M+H] 
C34H32Cl2FeN5, 636.1384; found: 636.1394. 
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Ferroquine (6) (20 mg, mmol, 1.0 eq) was added to a screw cap vial under an 
atmosphere of argon. In a separate vial a mixture of 3:1 CHCl3:MeOH is made (1.2 mL), 
and methyl iodide (50 uL) is added to the solution. The methyl iodide, CHCl3, and 
method solution (400 uL, 0.27 mmol of MeI, 5.8 equiv.)  is added to the screw cap vial, 
and the vessel is sealed. The reaction mixture is heated at 40 C for four hours until the 
starting material is consumed as observed by LC-MS. The solvent is removed from the 
reaction vessel under reduced pressure, and the reaction is placed under high vacuum for 
one hour to ensure all excess methyl iodide is removed. The secondary amine,82 114 ( 49 
mg, 0.19 mmol, 4.0 equiv.) is added to the reaction vessel in a mixture of CHCl3:MeOH 
(400 uL). The reaction is sealed and stirred at 40 °C for four days. The reaction is then 
concentrated under reduced pressure to afford an orange-yellow paste. The reaction is 
then concentrated under reduced pressure to afford an orange-yellow paste. The paste is 
then purified by flash chromatography (SiO2, 15 x 150 mm, 3:94:1, 
MeOH:CH2Cl2:NH4OH) yielding an orange yellow film which contained a coeluted 
impurity (13 mg). The paste is then recrystallized from methanol boiling methanol to 
yield orange crystals (6 mg). The remaining supernatant was purified by RPHPLC (C18, 
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19 mm x 250 mm, 10-45% MeCN in water (0.1% TFA) over 40 minutes). The combined 
products resulted in an orange film on a vial (150) (9 mg, 30%), the structure of which 
was verified by 1H NMR. TLC (Rf = 0.4, 8:92:1, MeOH:CH2Cl2:NH4OH). 
1H NMR (500 
MHz, CDCl3) δ 8.59 (d, J = 5.3 Hz, 1H), 8.52 (d, J = 5.3 Hz, 1H), 7.98 (dd, J = 7.5, 2.2 
Hz, 2H), 7.82 (d, J = 8.9 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.45 (dd, J = 8.9, 2.2 Hz, 1H), 
7.32 (dd, J = 8.9, 2.2 Hz, 1H), 6.56 (d, J = 5.4 Hz, 1H), 6.41 (d, J = 5.4 Hz, 1H), 6.36 (d, 
J = 7.7 Hz, 1H), 4.72 (d, J = 7.0 Hz, 1H), 4.40 – 4.31 (m, 2H), 4.23 (dd, J = 2.5, 1.4 Hz, 
1H), 4.17 (s, 7H), 3.80 (d, J = 12.9 Hz, 1H), 3.53 (s, 1H), 3.07 (d, J = 12.8 Hz, 1H), 2.99 
(d, J = 11.6 Hz, 1H), 2.86 (s, 1H), 2.34 (s, 1H), 2.13 (d, J = 13.3 Hz, 1H), 2.00 (d, J = 
13.8 Hz, 2H), 1.45 (q, J = 8.5, 5.3 Hz, 2H), 1.25 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 
152.33, 151.92, 150.20, 149.36, 148.50, 135.32, 135.09, 129.08, 128.90, 125.94, 124.56, 
123.07, 120.84, 117.85, 117.28, 99.69, 99.58, 84.08, 83.33, 71.90, 70.64, 69.50, 66.73, 
57.32, 53.60, 50.93, 49.37, 42.46, 31.74, 31.51, 29.89. FTIR (thin film) λ (cm-1): 2925, 
1609, 1578, 1530, 1448. HRMS (ESI) C35H33Cl2FeN5: Calculated for [M+H] 
C35H34Cl2FeN5, 650.1541; found: 650.1519. 
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Chapter 3: Synthesis of photoaffinity analogs 
 
 (4-hydroxyphenyl)(4-(prop-2-yn-1-yloxy)phenyl)methanone105 (compound 142) 
(1.02g, 4.05 mmol) was added to a round bottom flask, under an argon atmosphere, 
followed by K2CO3 (Fisher Scientific) (1.10g, 8.1 mmol, 2.0 eq.). 2-(2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate104 (compound 143) 
(1.55g, 4.46 mmol, 1.1 eq.) was dissolved in absolute ethanol (8 mL) and added to the 
reaction vessel.  The reaction was heated to reflux under a condenser for 16 hours. The 
reaction was halted upon consumption of the tosylate starting material as determined by 
TLC (Rf = 0.2, EtOAc). The reaction was concentrated under reduced pressure to remove 
ethanol. The crude paste was dissolved in 30 mL of a 1:1 mixture of water and EtOAc. 
The layers were separated, and the aqueous layer was washed with EtOAc (2 x 25 mL). 
The combined organic layers were washed once with brine and dried over anhydrous 
Na2SO4. Evaporation under reduced pressure yielded a yellow clear paste (2.06g). The 
crude material was purified by column chromatography (45mm x 150mm, SiO2, EtOAc) 
which yielded a translucent paste (141) (1.314g, 76%), the structure of which was 
verified by 1H NMR to match the reported literature.3 TLC (Rf = 0.2, EtOAc) 
1H NMR 
(500 MHz, CDCl3): δ 2.56 (1H, s, CH), 3.76-3.61 (m, 12H, CH2), 3.90 (2H, t, J= 4.84, 
CH2), 4.22 (2H, t, J=4.81, CH2), 4.78 (2H, d, J=2.4 Hz, CH2), 6.98 (2H, d, J= 8.7 Hz, 
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ArH), 7.04 (2H, d, J= 8.7 Hz, ArH), 7.80-7.77 (4H, m, ArH). 13C NMR (126 MHz, 
CDCl3): δ 194.47, 162.27, 160.77, 132.35, 132.22, 131.68, 130.85, 114.49, 114.24, 78.05, 
76.27, 71.00, 70.81, 70.73, 70.48, 69.70, 67.75, 61.87, 56.00. FTIR λ (neat/cm-1): 2873, 
1644, 1600, 1507. HRMS (ESI) Calculated for [M+H] C24H29O7 ,429.1913; found: 
429.1933. 
279 
 
 
 
 
In a flame-dried round bottom flask under an argon atmosphere, a solution of 
freshly distilled oxalyl chloride (0.31 mL, 3.6 mmol, 1.2 eq.) in dichloromethane (20 
mL), was cooled to -78°C. Anhydrous DMSO (Acros Organics) (0.51 mL, 7.2 mmol, 2.4 
eq.) was added to the flask, causing the evolution of gas. The reaction mixture was stirred 
for 30 min at -78°C, then a solution of the alcohol 141 (1.28g, 3.0 mmol, 1.0 eq.) in 
CH2Cl2 was added slowly.  Prior to addition, the alcohol was dried azeotropically with 
benzene and then placed under high vacuum for 16 hours to remove water.  The resulting 
solution was stirred at -78°C for 1 hour, at which time freshly distilled triethylamine 
(Acros Organics) (2.0 mL, 15.0 mmol, 5.0 eq.) was added to the reaction. The resulting 
mixture was slowly warmed to 23 °C and stirred for 16 hours. The progress of the 
reaction was determined via TLC by consumption of the starting alcohol (TLC Rf = 0.18, 
EtOAc) and the appearance of a new TLC spot for the aldehyde product (Rf = 0.6, 
EtOAc). Upon completion, the reaction mixture was then washed with saturated aqueous 
NH4Cl (3 x 20 mL), brine (1 x 20 mL), and the resulting organic solution dried over 
anhydrous Na2SO4. The filtrate was concentrated under reduced pressure yielding a crude 
paste, the presences of the product was verified by 1H NMR to match the literature 
precedent.3 Due to stability concerns, the crude aldehyde 144 was used without further 
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purification in the next reaction. TLC (Rf = 0.6, EtOAc). 
1H NMR (500 MHz, CDCl3): δ 
2.56(1H, s, CH), 3.76-3.61, (10H, m, CH2), 3.87 (2H, t, J= 3.86, CH2), 4.13 (2H, s, CH2), 
4.18 (2H, t, J= 4.35, CH2), 4.75 (2H, d, J= 2.0 Hz, CH2), 6.98 (2H, d, J=8.0 Hz, ArH), 
7.04 (2H, d, J= 9.0 Hz, ArH), 7.8-7.5 (4H, m, ArH), 9.69 (1H, s, CHO). 
  
DC661-Alkyne 
To a round bottom flask, solid DC660 inhibitor (66) was added (307 mg, 0.57 
mmol, 1.0 eq.). The solid was then placed under an atmosphere of argon. The crude 
aldehyde (123) (505mg, 1.2 mmol, 2.1 eq.) was then dissolved in CH2Cl2 (7mL). The 
aldehyde solution was then added to the reaction vessel via a syringe to give a reaction 
concentration of 0.1 M. The reaction was stirred at 23 °C for 10 minutes. Next, sodium 
triacetoxyborohydride was added to the reaction as a solid (483mg, 2.4 mmol, 4.0 eq.). 
The reaction was stirred for 22 hours at 23 °C, when the starting DC660 (66) was 
consumed as observed via TLC (Rf = 0.10 (EtOAc:MeOH:TEA; 80:15:5). Upon 
completion of the reaction, CH2Cl2 was added (10 mL) to the reaction, and an equal 
volume of 2N sodium hydroxide was added (10 mL). The biphasic solution was stirred 
for 60 min to quench the remaining sodium triacetoxyborohydride. After stirring, the 
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layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL), and 
the resulting organic layers were combined. The combined organic layers were washed 
once with an equal volume of brine (50 mL) and dried over anhydrous Na2SO4. The 
organic phase was concentrated under reduced pressure to afford a crude paste (580 mg), 
which was purified by flash chromatography (SiO2, gradient starting 3:1:96 
MeOH:triethylamine:EtOAc, moving to 3:1:50:44  MeOH:triethylamine:EtOAc:CHCl3 ) 
to afford the pure product (118) as a yellow paste (200mg, 51%), the structure of which 
was verified by 1H NMR. TLC (Rf = 0.25, 5:1:50:44, 
MeOH:triethylamine:EtOAc:CHCl3,UV 254 nm) 
1H NMR (500 MHz, CDCl3): δ 1.27 – 
1.50 (m, 12H), 1.72 (p, J = 7.2 Hz, 4H), 2.44 (t, J = 7.4 Hz, 4H), 2.56 (t, J = 2.3 Hz, 1H), 
2.65 (t, J = 6.4 Hz, 2H), 3.28 (td, J = 7.1, 5.3 Hz, 4H), 3.49 – 3.73 (m, 10H), 3.83 – 3.89 
(m, 2H), 4.17 (t, J = 4.8 Hz, 2H), 4.76 (d, J = 2.3 Hz, 2H), 5.15 (s, 2H), 6.39 (d, J = 5.4 
Hz, 2H), 6.91 – 6.98 (m, 2H), 7.03 (d, J = 9.0 Hz, 2H), 7.34 (dd, J = 8.9, 2.2 Hz, 2H), 
7.69 – 7.80 (m, 7H), 7.95 (d, J = 2.1 Hz, 2H), 8.52 (d, J = 5.4 Hz, 2H). 13C NMR (126 
MHz, CDCl3): δ 194.50, 162.27, 160.82, 151.90, 150.10, 149.08, 135.00, 132.34, 132.22, 
131.59, 130.83, 128.62, 125.31, 121.46, 117.31, 114.51, 114.21, 99.08, 78.01, 76.29, 
71.02, 70.82, 70.75, 70.54, 69.68, 67.76, 56.02, 54.70, 53.43, 43.29, 28.81, 27.21, 27.10, 
26.98. FTIR (thin film) λ (cm-1):  2921.63, 2848.35, 1756.83, 1719.23, 1627.63, 1594.84, 
1558.2. HRMS (ESI) C54H63Cl2N5O6: Calculated for [M+H] C54H64Cl2N5O6, 948.4234; 
found: 948.4229. 
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DC221-Alkyne 
To a round bottom flask, solid DC220 (8) was added (95 mg, 0.22 mmol, 1.0 eq.). The 
solid was then placed under an atmosphere of argon. The crude aldehyde (144) (189mg, 
0.44 mmol, 2.0 eq.) was then dissolved in CH2Cl2 (2.2 mL). The aldehyde solution was 
then added to the reaction vessel via a syringe, to give a total reaction concentration of 
0.1 M. The reaction was stirred at 23 °C for 10 minutes. Next, sodium 
triacetoxyborohydride was added to the reaction as a solid (190mg, 0.89 mmol, 4.0 eq.). 
The reaction was stirred for 22 hours at 23 °C, when the starting DC inhibitor was 
consumed as observed via TLC (Rf = 0.2, 10:89:1, MeOH:CH2Cl2;NH4OH, UV 254 nm). 
Upon completion of the reaction, CH2Cl2 was added (10 mL) to the solution, and an 
equal volume of 2N sodium hydroxide was added (10 mL). The biphasic solution was 
stirred for 60 min to quench the remaining sodium triacetoxyborohydride. After stirring, 
the layers were separated, and the aqueous layer was extracted with CH2Cl2 (2 x 15 mL), 
and the resulting organic layers were combined. The combined organic layers were 
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washed once with an equal volume of brine (40 mL) and dried over anhydrous Na2SO4. 
The organic phase was concentrated under reduced pressure to afford a crude paste (185 
mg), which was purified by flash chromatography (SiO2, 25 mm x 150 mm, 7.5:1:92, 
MeOH:NH4OH:CH2Cl2) to yield the product as a yellow paste (145) (55 mg, 38%), the 
structure of which was verified by 1H NMR. TLC (Rf = 0.5, 7.5:1:92, 
MeOH:NH4OH:CH2Cl2, UV 254 nm). 
1H NMR (500 MHz, CDCl3): δ 2.57 (d, J = 2.4 
Hz, 1H), 2.84 (t, 2H), 2.97 (dd, J = 6.6, 4.4 Hz, 4H), 3.23 – 3.28 (m, 4H), 3.44 – 3.53 (m, 
4H), 3.55 – 3.59 (m, 2H), 3.64 – 3.73 (m, 6H), 4.04 (t, 2H), 4.77 (d, J = 2.4 Hz, 2H), 6.19 
(s, 2H), 6.24 (d, J = 5.4 Hz, 2H), 6.75 (dd, J = 8.9, 2.2 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 
7.03 (d, J = 8.9 Hz, 2H), 7.55 (d, J = 8.9 Hz, 2H), 7.74 (dd, J = 17.5, 8.8 Hz, 3H), 7.87 
(d, J = 2.2 Hz, 2H), 8.41 (d, J = 5.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 194.50, 
162.15, 160.82, 151.63, 150.05, 148.65, 135.17, 132.34, 132.25, 131.56, 130.85, 128.28, 
125.29, 121.70, 117.26, 114.52, 114.14, 99.10, 78.03, 76.30, 70.82, 70.63, 70.58, 70.23, 
70.12, 69.61, 67.60, 56.03, 53.30, 53.04, 41.08. FTIR (thin film) λ (cm-1): 3435.56, 
2871.49, 1644.98, 1600.63, 1581.34. HRMS (ESI) C46H47 Cl2N5O6:  Calculated for 
[M+H] C46H48Cl2N5O6, 836.2982; found: 836.2982. 
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In a flame dried round bottom flask under an argon atmosphere, a suspension of 
DQ660 (56) (320mg, 0.458 mmol) in 2 mL of dichloromethane was reacted with a 
solution of aldehyde (144) (558mg, 1.31 mmol, 2.9 eq) in 3.5 mL of dichloromethane, 
bringing the reaction to a final concentration of 0.08 M. The two components were stirred 
for 15 minutes at 23°C and the resulting orange mixture became homogeneous. 
NaBH(OAc)3 (388mg, 1.832 mmol, 4.0 eq) was added as a solid to the reaction mixture 
and the resulting mixture was stirred for 16 hours at 23°C, until the DQ 660 (56) was 
consumed as observed by TLC. The reaction mixture was then diluted with 
dichloromethane (50 mL) and stirred with an equal volume of 2N NaOH (50 mL) for 1 
hour at 23°C. The layers were separated, and the aqueous layer was washed with 2 x 20 
mL of dichloromethane. The combined organic layers were washed once with brine and 
dried over anhydrous Na2SO4. Evaporation under reduced pressure afforded an orange 
paste, which was purified by column chromatography (35mm x 150mm, SiO2, 5% 
MeOH:94% EtOAc:1%TEA) to yield an orange paste (146) (200mg, 39%). 1H NMR 
(500 MHz, CDCl3/CD3OD): δ 8.05 (2H, s, ArH), 8.00 (4H, t, J= 9.0  Hz, ArH), 7.77-7.74 
(4H, m, ArH), 7.42 (2H, dd, J=9.2 Hz, J= 2.5 Hz, ArH), 7.30 (2H, dd, J=9.3  Hz, J=2.5 
144 
146 
56 
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Hz, ArH), 7.23 (2H, d, J=2.6 Hz, ArH), 7.03 (2H, d, J=8.9 Hz, ArH), 6.94 (2H, d, J=8.3, 
ArH), 4.75 (2H, d, J= 2.4 Hz, CH2), 4.17 (2H, t, J=5.0 Hz, CH2), 3.95 (6H, s, OMe), 3.85 
(2H, t, J=3.8 Hz, CH2), 3.70-3.56 (14H, m, CH2) 2.59 (2H, t, J=6.5 Hz, CH2), 2.55 (1H,s, 
CH), 2.36 (4H, t, J= 7.0 Hz, CH2), 1.72 (4H, m, CH2), 1.39 (8H, m, CH2), 1.27 (4H, m, 
CH2). 
13C NMR (126 MHz, CDCl3): δ 194.23, 162.03, 160.57, 155.88, 149.712, 148.187, 
134.67, 132.108, 131.99, 131.39, 130.62, 128.11, 124.36, 124.32, 123.99, 117.80, 115.70, 
114.26, 113.97, 99.21, 77.80, 76.02, 70.80, 70.58, 70.32, 69.71, 69.45, 67.52, 55.78, 
55.45, 54.58, 53.21, 50.54, 31.65, 27.08, 26.98, 26.77. IR λ (neat/cm-1): 2921, 2848, 
1756, 1719, 1627, 1594, 1558, 1254. HRMS (ESI) C64H71N5O8Cl2: Calculated for [M + 
H] C64H72N5O8Cl2 1108.4758; found: 1108.4749. 
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Desthiobiotin Azide 
To a flame-dried round bottom flask, d-desthiobiotin (131) (Sigma Aldrich) (200 
mg, 0.94 mmol, 1.0 eq.) was added, followed by TBTU (449mg, 1.4 mmol, 1.5 eq.). The 
reactants were placed under an atmosphere of argon and dissolved in dimethylformamide 
(DMF) (2 mL). The solution was stirred and (2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethan-1-amine)105 (147) (305mg, 1.4 mmol,1.5 eq.) was 
added as a solution in DMF (1mL). Then after stirring for 5 min, DIPEA (490 uL, 3.7 
mmol, 4.0 eq.) was added to the reaction via micro-syringe. The reaction was stirred for 
24 hours until the starting desthiobiotin was consumed, as observed by TLC (Rf = 0.1, 
10:1 CHCl3:MeOH, KMnO4 stain). The reaction was quenched by pouring onto 30 mL of 
brine. The opaque solution was extracted with EtOAc (3 x 30mL). The combined organic 
extracts were then washed with water (5 x 10mL), resulting in a second aqueous fraction. 
TLC analysis (Rf = 0.35, 1:10, MeOH:CHCl3, KMnO4 stain) revealed the product was 
found exclusively in the second aqueous fraction. The second aqueous fraction was then 
extracted with EtOAc (5 x 50mL). The combined organic extracts were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to yield a crude 
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brown oil. The crude product was then purified by column chromatography [SiO2, 20 mm 
x 180 mm, gradient elution of increasing MeOH in CHCl3 (MeOH: 2% for 100 mL, 4% 
for 100 mL, and 6% for 200 mL)]. The product was isolated as a purple-translucent oil 
(140) (163mg, 42%). TLC (Rf = 0.35, 1:10, MeOH:CHCl3, KMnO4 stain). 1H NMR (500 
MHz, CDCl3): δ 1.14 (d, J = 6.5 Hz, 3H), 1.56 – 1.23 (m, 7H), 1.66 (t, J = 7.3 Hz, 2H), 
2.19 (t, J = 7.6 Hz, 2H), 3.50 – 3.36 (m, 4H), 3.74 – 3.54 (m, 13H), 3.91 – 3.82 (m, 1H), 
6.16 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 173.22, 164.19, 70.66, 70.51, 70.50, 70.13, 
70.02, 69.98, 56.09, 51.40, 50.67, 39.14, 35.84, 29.51, 28.56, 25.82, 25.19, 15.72. FTIR λ 
(neat/cm-1): 3287.07, 2 2933.2, 2106.85, 1699.94, 1545.67. HRMS (ESI) C18H35N6O5: 
Calculated for [M+H], C18H36N6O5, 415.2669; found: 415.2666. 
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DC661 Pulldown 
Alkyne 139 (50mg, 0.053 mmol, 1.0 eq.) and desthiobiotin azide 140 (23mg, 
0.080 mmol, 1.5 eq.), were added to a screwcap vial. The vial contents were dissolved in 
500 uL of a 1:2:1 mixture of acetone:water:DMSO and placed under an argon 
atmosphere. CuSO4 was added from a 1M aqueous solution (38uL, 0.05 mmol, 1.0 eq.), 
followed by the addition of solid sodium ascorbate (37mg, 0.2 mmol, 5.0 eq.). The 
reaction was complete after 30 min when the starting alkyne was consumed, as observed 
by TLC (Rf = 0.25, 5:1:50:44, MeOH:triethylamine:EtOAc:CHCl3, UV 254 nm). The 
reaction was concentrated to a paste and partitioned between water (1mL) and CHCl3 (1.5 
mL), which caused a film to deposit on the wall of the vial. The aqueous layer was 
removed, and methanol was added to the organic layer to solubilize the film. The aqueous 
layer was extracted with a 1:3 mixture of 2-propanol:CHCl3 (2 x 2.5 mL). The combined 
organic layers were then dry loaded onto silica for flash chromatography. Crude material 
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was chromatographed (SiO2, 15 mm x 150 mm, 1:10 MeOH:CHCl3 gradient to 10:1:100 
MeOH:NH4OH:CHCl3) to afford the product as a yellow translucent paste (138) (35mg, 
51%), the structure of which was verified by 1H NMR. TLC (Rf= 0.3, 10:1:100 
MeOH:NH4OH:CHCl3). 
1H NMR (500 MHz, CDCl3): δ 1.09 (d, J = 6.5 Hz, 3H), 1.15 – 
1.51 (m, 19H), 1.61 (p, J = 7.2 Hz, 2H), 1.71 (p, J = 7.3 Hz, 4H), 2.14 (t, J = 7.5 Hz, 2H), 
2.42 (t, J = 7.4 Hz, 4H), 2.63 (t, J = 6.3 Hz, 2H), 3.27 (td, J = 7.2, 5.3 Hz, 4H), 3.37 – 
3.74 (m, 28H), 3.75 – 3.82 (m, 1H), 3.87 (dt, J = 15.5, 4.9 Hz, 4H), 4.17 (dd, J = 5.6, 4.0 
Hz, 2H), 4.51 (s, 1H), 4.55 (t, J = 5.0 Hz, 2H), 5.04 (s, 1H), 5.27 (s, 4H), 6.38 (d, J = 5.4 
Hz, 2H), 6.90 – 6.97 (m, 2H), 7.04 (d, J = 8.8 Hz, 1H), 7.32 (dd, J = 8.9, 2.2 Hz, 2H), 
7.69 – 7.78 (m, 6H), 7.85 (s, 1H), 7.93 (d, J = 2.2 Hz, 2H), 8.50 (d, J = 5.4 Hz, 2H). 13C 
NMR (126 MHz, CDCl3): δ 194.60, 173.37, 163.53, 162.28, 161.62, 151.94, 150.18, 
149.08, 143.41, 135.02, 132.37, 131.29, 130.80, 128.58, 125.32, 124.46, 121.57, 117.35, 
114.48, 114.26, 99.07, 70.97, 70.82, 70.72, 70.66, 70.59, 70.49, 70.47, 70.23, 70.15, 
69.67, 69.55, 69.52, 67.74, 62.19, 56.13, 54.66, 53.57, 51.53, 50.53, 43.27, 39.29, 36.21, 
29.59, 28.96, 28.76, 27.22, 27.07, 26.77, 26.10, 25.44, 15.91. FTIR (thin film) λ (cm-1): 
3352.64, 2929.34, 2854.13, 1696.09, 1645.95, 1596.77, 1578.45, 1539.88. HRMS (ESI) 
C67H87 Cl2N11O11: Calculated for [M+2H]/2 C67H89 Cl2N11O11, 646.8060; found: 
646.8046. []D 22 24.1 (c 1.0, CH2Cl2). 
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DC221 Pulldown 
Alkyne 145 (16mg, 0.019 mmol, 1.0 eq.) was added to a screwcap vial, followed by 
desthiobiotin azide 140 (12mg, 0.029 mmol, 1.5 eq.). The contents of the vial were 
dissolved in MeOH (200 uL) to give a 0.1 M reaction concentration. In a separate vial, 
THPTA and CuSO4 dissolved in water to form a dark blue solution (100 mM CuSO4 and 
200 mM THPTA). This aqueous solution was used to deliver THPTA and CuSO4 (0.0036 
mmol and 0.0018 mmol respectively) to the screwcap vial. While stirring, sodium 
ascorbate was added to the vial (20 mg, 0.10 mmol, 5.3 eq.). The reaction was monitored 
by RPHPLC (C18, 4.6 mm x 250 mm, gradient elution: 10% acetonitrile in water (0.1% 
TFA) to 60% acetonitrile in water (0.1% TFA) over 40 min). The reaction was complete 
when no starting alkyne remains. The reaction was concentrated to remove the methanol 
and dissolved in CHCl3 (5 mL). The CHCl3 washed with saturated sodium bicarbonate (3 
x 5 mL). The organic layer was separated and dried over anhydrous Na2SO4. The organic 
layer was then concentrated under reduced pressure to afford a film. The film was then 
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solubilized in MeOH and DMSO (300 uL and 60 uL respectively) and purified by 
RPHPLC (C18, 19 mm x 250 mm, gradient elution: 10% acetonitrile in water (0.1% TFA) 
to 60% acetonitrile in water (0.1% TFA) over 40 min). The pH of the fractions was 
brought to 12 by addition of NH4OH (1 mL), and then saturated with NaCl. The aqueous 
layer was then extracted with CHCl3 (3 x 5 mL).  The CHCl3 was dried over sodium 
sulfate and concentrated under reduced pressure to afford a film on a vial (148) (8mg, 
34%), the structure of which was verified by 1H NMR. TLC (Rf= 0.2, 10:1:100 
MeOH:NH4OH:CHCl3). 
1H NMR (500 MHz, CDCl3): δ 8.44 (d, J = 5.3 Hz, 2H), 7.89 – 
7.85 (m, 3H), 7.73 (dd, J = 14.1, 8.9 Hz, 4H), 7.53 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 8.9 
Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 6.76 (dd, J = 8.9, 2.2 Hz, 2H), 6.31 (s, 1H), 6.26 (d, J = 
5.6 Hz, 2H), 6.06 (s, 2H), 4.95 (s, 1H), 4.57 (t, J = 5.1 Hz, 2H), 4.45 (s, 1H), 4.05 (t, J = 
4.6 Hz, 2H), 3.90 (t, J = 5.1 Hz, 2H), 3.81 (p, J = 6.4 Hz, 1H), 3.73 – 3.39 (m, 27H), 3.27 
(q, J = 5.5 Hz, 4H), 2.98 (t, J = 5.3 Hz, 4H), 2.84 (t, J = 4.7 Hz, 2H), 2.16 – 2.13 (m, 2H), 
1.61 (q, J = 7.1 Hz, 2H), 1.50 – 1.28 (m, 8H), 1.10 (d, J = 6.5 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 194.47, 173.10, 163.27, 162.23, 161.63, 152.00, 149.92, 149.04, 143.48, 
135.09, 132.37, 132.35, 131.34, 130.86, 128.65, 125.30, 124.40, 121.53, 117.36, 114.50, 
114.21, 99.23, 70.85, 70.74, 70.68, 70.64, 70.60, 70.30, 70.28, 70.24, 70.10, 69.63 (2C), 
69.57, 67.67, 62.27, 56.15, 53.15, 51.54, 50.57, 41.12, 39.30, 36.36, 29.66, 29.10, 26.25, 
25.50, 15.97. FTIR (thin film) λ (cm-1): 3350.71, 2933.2, 2865.7, 1697.05, 1684.52, 
1650.77, 1599.66, 1578.45. HRMS (ESI) C64H81 Cl2N11O11: Calculated for [M+2H]/2 
C64H83Cl2N11O11, 625.7825; found: 625.7823. []D 22 20.7 (c 1.0, CH2Cl2). 
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DQ661-P 
To a solution of DQ661-alkyne (146) (58mg, 0.052 mmol) and desthiobiotin-
azide (140) (33mg, 0.08mmol, 1.5 eq) in 250 μL of MeOH in a resealable vial was added 
200 μL of a solution that was 20 mM in CuSO4 (0.65mg, 0.004mmol) and 44 mM in 
THPTA (3.9mg, 0.009mmol; Tris(3-hydroxypropyltriazolylmethyl)amine) which had 
been treated with 2 mg (10 μmoles) of sodium ascorbate to discharge the blue color 
before addition to the reaction mixture.  The resulting mixture was stirred for 20 hours at 
23°C. The reaction mixture was concentrated to a paste under reduced pressure and the 
residue partitioned between chloroform (5mL) and water (5mL). The water was extracted 
6 x 5 mL with 3:1 chloroform: isopropanol, and the combined organic layers were dried 
over anhydrous Na2SO4 and concentrated under reduced pressure to give 94 mg of crude 
product, which was chromatographed (20 mm x 150 mm, SiO2, 10% MeOH: 
90%CH2Cl2). The resulting product required further purification (RP-HPLC). The 
chromatographed product 149 (36mg) was purified as the TFA salt by RP-HPLC (C18, 
gradient elution using 35%-53% acetonitrile in water with 0.1% TFA over 15 min) 
yielded a yellow film (18 mg, 23%). 1H NMR (500 MHz, CD3OD): δ 8.51 (2H, d, J = 9.3 
146
140 
149 
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Hz, ArH), 8.18 (1H, s, ArH), 7.86 (4H, dd, J = 12.5 Hz, J = 2.5 Hz, ArH), 7.81 – 7.77 
(6H, m, ArH), 7.72 (2H, dd, J = 9.0 Hz, J = 2.5 Hz, ArH),  7.57 (2H, dd, J = 9.3, J =2.1 
Hz, ArH), 7.06 (2H, d, J = 8.7 Hz, ArH), 6.94 (2H, d, J = 8.7 Hz, ArH), 4.61 (2H, t, J = 
4.3 Hz, CH2), 4.26 (2H, t, J = 4.5 Hz, CH2), 3.99 (6H, s, OMe), 3.92-3.88 (4H, m, CH2), 
3.85 – 3.78 (4H, m, CH2), 3.73 – 3.56 (18H, m, CH2), 3.49 (2H, t, J = 5.5 Hz, CH2), 3.18 
– 3.13 (4H, m, CH2), 2.92 (4H, t, J= 8.0 Hz), 2.17 (2H, t, J = 8.0 Hz, CH2), 1.97 (4H, q, J 
= 7.6 Hz), 1.72-1.58 (13H, m), 1.50 – 1.29 (14H, m), 1.35 (2H, q, J = 6.5 Hz), 1.10 (3H, 
d, J = 6.5 Hz, CH3).13C NMR (126 MHz, CD3OD): δ 194.32, 174.82, 171.61, 164.75, 
162.33, 161.82, 156.61, 142.74, 140.39, 131.87, 131.82, 130.26, 130.08, 127.25, 125.03, 
123.57, 120.20 ,117.27, 114.03, 113.72, 70.33, 70.09, 70.03, 69.98, 69.82, 69.28, 69.14, 
68.89, 67.61, 65.51, 64.26, 61.09, 60.16, 60.14, 55.96, 55.28, 53.06, 52.54, 52.08, 51.28, 
50.11, 48.90, 38.89, 35.48, 31.36, 29.31, 29.12, 28.80, 25.96, 25.79, 25.42, 23.08, 22.31, 
19.50, 19.47, 14.25, 14.04, 13.06. IR λ (neat/cm-1): 3040, 1652, 1447, 1197, 1123. HRMS 
(ESI) C82H104Cl2N11O13: Calculated for ([M+2H]/2) C82H106Cl2N11O13 761.8713; found: 
761.8740. []D 22 22.1 (c 1.0, CH2Cl2). 
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Tetrahydrofuran (THF) (70 mL) was added to a flame-dried round bottom flask, placed 
under an atmosphere of argon, and cooled to 0°C. Lithium aluminum hydride was added 
(7.09g, 186 mmol, 3.5 eq.) to the reaction vessel, causing the evolution of gas. Ethyl 4-
nitropentanoate107 154 (9.334g, 53.3 mmol, 1.0 eq.) was dissolved in THF (70 mL) and 
added to the reaction mixture using a syringe pump at a rate of 1mL/min.  The reaction 
was stirred for 30 min at 0 °C then allowed to warm to 23 °C. The reaction was then 
stirred at 23°C for 14 hours. The reaction was cooled to 0 °C and quenched by the 
addition of three solutions: First, 8 mL of water were added via a syringe pump at a rate 
of 0.5 mL/min. Second, 8 mL of 15% (w/v) NaOH (aq) were added at rate of 0.5 
mL/min. Third, 24 mL of water were added to the reaction at a rate of 1 mL/min. The 
reaction was then warmed to room temperature and filtered through a pad of Celite™ 
using 100 mL of EtOAc. The combined organic layer was then dried over anhydrous 
sodium sulfate and concentrated to a translucent oil (153) (4.77 g, 87%), the structure of 
which was verified by 1H NMR. TLC (Rf = 0.0, regardless of solvent choice, KMnO4 
stain). 1H NMR (500 MHz, CDCl3): δ 3.66 – 3.56 (m, 2H), 2.98 – 2.90 (m, 1H), 1.77 – 
1.68 (m, 1H), 1.66 – 1.56 (m, 2H), 1.41 – 1.32 (m, 1H), 1.13 (d, J = 6.5 Hz, 3H). NO N-H 
showed up. 13C NMR (126 MHz, CDCl3): δ 25.32, 30.45, 37.77, 47.17, 63.04. FTIR (thin 
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film) λ (cm-1): 3345.89, 2938.98, 2360.44, 1567.84. HRMS (ESI) C5H13NO: Calculated 
for [M+H], C5H14NO, 104.1075; found: 104.1050 
 
 
4-aminopentan-1-ol, 153, (1.00 g, 9.71 mmol, 1.0 eq.), 4-bromo-7-chloroquinoline1 13 
(1.80 g, 7.28 mmol, 0.75 eq.), Pd(OAc)2 (109 mg, 0.485 mmol, 0.05 eq.), BINAP (605 
mg, 0.971 mmol, 0.1 eq.), and K3PO4 (3.10 g, 14.6 mmol, 1.5 eq.) were added to a flame-
dried round bottom flask. The flask contents under a reflux condenser were then placed 
under an argon atmosphere. 1,4-dioxane, which was degassed, was then added to the 
round bottom flask. The reaction was heated to reflux in a bath preset to 105 °C for 2 
hours. After the first 20 minutes, the reaction takes on a deep red color. The reaction was 
complete when the 4-bromo-7-chloroquinoline 13 was consumed as observed by TLC (Rf 
= 0.65, 4:3:1 Hex:CH2Cl2:EtOAc, UV 254 nm). The reaction was then filtered through a 
pad of Celite™ using a 100 mL of a 1:10 mixture, MeOH:CHCl3. Removal of solvent 
under reduced pressure affords a red paste which was then dry loaded on silica gel and 
purified by flash chromatography (SiO2, 5:94:1 MeOH:CH2Cl2:NH4OH (aq)) to afford a 
brown white solid. This solid required triturated with boiling CH2Cl2 to yield a white 
solid which still contains an inseparable impurity (152) (~10% by 1H NMR) (695 mg, 
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36%). TLC (Rf = 0.25, 5:94:1 MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CD3OD): δ 
8.33 (d, J = 5.6 Hz, 1H), 8.17 (dd, J = 9.0, 0.5 Hz, 1H), 7.76 (dd, J = 2.2, 0.5 Hz, 1H), 
7.38 (dd, J = 9.0, 2.2 Hz, 1H), 6.54 (dd, J = 5.7, 0.7 Hz, 1H), 3.81 (h, J = 6.4 Hz, 1H), 
3.59 (t, J = 6.4 Hz, 2H), 1.86 – 1.60 (m, 3H), 1.32 (d, J = 6.4 Hz, 3H). 13C NMR (126 
MHz, CD3OD): δ 150.81, 150.66, 148.26, 134.80, 125.97, 124.31, 122.93, 117.29, 98.34, 
61.23, 47.98, 32.12, 28.76, 18.78. FTIR (thin film) λ (cm-1): 3319, 2937, 1578. HRMS 
(ESI) C14H17 Cl1N2O: Calculated for [M+H] C14H18 Cl1N2O, 265.1108; found: 265.1101. 
 
 
THF (4.7 mL) was added to a flame-dried round bottom flask under an 
atmosphere of argon. Freshly distilled oxalyl chloride (190 uL, 2.3 mmol 1.2 eq.) was 
added to the round bottom flask, and the solution was cooled to -78°C. While stirring at -
78°C, DMSO (320 uL, 4.5 mmol, 2.4 eq.) was added via a syringe, causing the evolution 
of gas. In a separate flame-dried round bottom flask, compound 152, under an argon 
atmosphere was dissolved in THF (20 mL) by heating to reflux and cooling to 25° C. 
After 30 minutes, the solution of 152 was added dropwise via a syringe to the oxalyl 
chloride/DMSO solution. The combined reaction was then stirred for 30 minutes at -78 
°C. At this time, triethylamine (1.3 mL, 9.45 mmol, 5.0 eq.) was added to the reaction via 
a syringe. The reaction was stirred at -78°C for 60 min before being moved to an ice bath 
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at 0°C. The reaction was stirred at 0°C for 4 hours, until the consumption of the starting 
alcohol was observed by TLC (Rf= 0.10, 2:1:1 Hex:THF:CH2Cl2 with 3 drops of 
triethylamine). The reaction was then concentrated under reduced pressure to afford a 
crude paste. The structure of the aldehyde was confirmed by 1H NMR of the crude 
reaction mixture, with ~10% of starting alcohol remaining. Previous experiments 
demonstrated purification the aldehyde caused decomposition. The crude mixture of 155 
was carried on to the next step without further purification. TLC (Rf= 0.15. 2:1:1 
Hex:THF:CH2Cl2 with 1% v/v triethylamine). 
1H NMR (500 MHz, CDCl3): δ 9.74 (s, 
1H), 8.37 (d, J = 5.3 Hz, 1H), 7.82 (d, J = 2.3 Hz, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.28 – 
7.21 (m, 1H), 6.32 (d, J = 5.5 Hz, 1H), 5.48 (d, J = 7.2 Hz, 1H), 3.70 – 3.64 (m, 3H), 1.78 
(t, J = 3.6 Hz, 2H), 1.26 (d, J = 6.4 Hz, 3H).  
 
Crude 155, (450mg, 1.9 mmol, 1.0 eq.) was added to a round bottom flask with a 
stir bar and placed under an atmosphere of argon. The flask was then charged with 
CH2Cl2 (7mL) and allowed to stir at 23°C until the solution was homogenous. A solution 
of ethylamine (70% w/v) (230 uL, 2.8 mmol, 1.5 eq.) was prepared in CH2Cl2 (2 mL) and 
added via a syringe to the reaction vessel. The reaction was stirred at 23°C for 5 minutes, 
and sodium triacetoxyborohydride (1.20 g, 5.63 mmol, 3.0 eq.) was added in one portion. 
The reaction was stirred at 23 °C for two hours until the aldehyde starting material was 
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consumed as observed by TLC (Rf = 0.25, 2:1:1 Hex: CH2Cl2:THF with 2% triethylamine 
(v/v)). The reaction was then diluted with CH2Cl2 (5mL) and an equal volume of 2N 
NaOH (5mL). The reaction was stirred for 60 minutes at 23°C to quench any remaining 
sodium triacetoxyborohydride. The layers were then separated in a separatory funnel, and 
the aqueous layer was extracted with CH2Cl2 (2 x 15 mL). The combined organic layers 
were dried over anhydrous sodium sulfate. The organic layers were then concentrated 
under reduced pressure to afford a translucent green paste (151) (400 mg). The green 
paste was purified by flash chromatography (SiO2, 25mm x 100 mm, 10:90:1 
MeOH:CH2Cl2:NH4OH) to afford (155 mg, 0.53 mmol, 28% over 2 steps) of a green 
paste. TLC (Rf = 0.3, 10:90:1 MeOH:CH2Cl2:NH4OH). 
1H NMR (500 MHz, CDCl3): δ 
8.48 (dd, J = 5.4, 0.8 Hz, 1H), 7.94 – 7.91 (m, 1H), 7.70 (d, J = 8.9 Hz, 1H), 7.31 (ddd, J 
= 8.9, 2.2, 0.9 Hz, 1H), 6.38 (dd, J = 5.5, 0.7 Hz, 1H), 5.54 (d, J = 7.0 Hz, 1H), 3.73 – 
3.64 (m, J = 5.9 Hz, 1H), 2.69 – 2.60 (m, 4H), 1.83 – 1.58 (m, 3H), 1.30 (dd, J = 6.4, 0.9 
Hz, 3H), 1.12 (td, J = 7.2, 0.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 152.13, 149.52, 
149.29, 134.88, 128.88, 125.07, 121.46, 117.54, 99.30, 49.45, 48.50, 44.36, 34.27, 26.64, 
20.29, 15.37. FTIR (thin film) λ (cm-1): 2966, 2927, 1577. HRMS (ESI) C16H22ClN3: 
Calculated for [M+H] C16H22ClN3, 292.1581; found: 292.1575.  
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CQ-Alkyne 
The aldehyde 144 (57 mg, 0.13 mmol, 1.0 eq.) was added to a flame-dried 
screwcap vial, followed by desethyl chloroquine 151 (33mg, 0.1 mmol, 0.8 eq.) in a 
CH2Cl2 solution (500 uL). The reaction was stirred at 23°C for 5 minutes before sodium 
triacetoxyborohydride was added in one portion (85 mg, 0.40 mmol, 3.0 eq.). The 
reaction was complete in 30 minutes when the aldehyde was consumed as observed by 
TLC (Rf = 0.5, EtOAc, UV 254 nm). The reaction was diluted with 1 mL of CH2Cl2, and 
1 mL 2N NaOH. The reaction was vortexed for 1 minute, and the resulting emulsion was 
placed into a freezer set to -20 °C, where after two hours the emulsion had separated. The 
layers were then separated, and the aqueous layer was extracted with CH2Cl2 (2 x 1 mL). 
The combined CH2Cl2 layers were washed with 3 mL of brine. The resulting organic 
layer was then dried over anhydrous sodium sulfate and concentrated under reduced 
pressure to afford a white paste (89 mg). The white paste was dissolved in a solution of 
10:20:70 DMSO:CH2Cl2:MeOH and purified by preparative HPLC (C18, 19 mm x 250 
mm, gradient elution: 10% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water 
(0.1% TFA) over 40 min). Lyophilization of the collected fractions yields a white film on 
a vial (21mg). The vials contents were then dissolved in an immiscible mixture of 
CHCl3:NH4OH (aq), vortexed for 1 min, the layers were separated, and the resulting 
organic layer was dried over anhydrous sodium sulfate. The dried organic solution was 
concentrated under reduced pressure to yield a film on a vial (150) (19 mg, 24%), the 
structure of which was verified by 1H NMR. 1H NMR (500 MHz, CDCl3): δ 8.50 (d, J = 
5.4 Hz, 1H), 7.93 (d, J = 2.1 Hz, 1H), 7.81 – 7.71 (m, 5H), 7.33 (dd, J = 8.9, 2.2 Hz, 1H), 
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7.04 (d, J = 8.9 Hz, 1H), 6.94 (d, J = 8.9 Hz, 1H), 6.40 (d, J = 5.4 Hz, 1H), 5.29 (d, J = 
7.3 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 4.16 (t, J = 4.8 Hz, 2H), 3.83 (t, 2H), 3.72 – 3.51 
(m, 11H), 2.64 (hept, J = 6.6, 6.1 Hz, 2H), 2.58 – 2.51 (m, 3H), 2.48 (t, J = 6.8 Hz, 2H), 
1.78 – 1.53 (m, 4H), 1.29 (d, J = 6.4 Hz, 3H), 0.98 (t, J = 7.2 Hz, 3H). 13C NMR (126 
MHz, CDCl3): δ 11.5, 20.5, 24.1, 34.5, 48.4, 48.5, 52.9, 53.7, 56.0, 67.8, 69.7, 69.9, 70.6, 
70.8, 70.9, 71.0, 76.3, 78.1, 99.4, 114.3, 114.5, 117.5, 121.6, 125.1, 129.0, 130.9, 131.7, 
132.3, 132.4, 134.9, 149.3, 149.6, 152.2, 160.8, 162.3, 194.5. FTIR (thin film) λ (cm-1): 
2922.59, 2869.56, 1646.91, 1599.66, 1576.52, 1538.92 HRMS (ESI) C40H48ClN3O6: 
Calculated for [M+H] C40H49ClN3O6, 702.3310; found: 702.3304. 
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CQ Pulldown 
Alkyne 150 (13mg, 0.019 mmol, 1.0 eq.) was added to a screwcap vial and placed 
under an atmosphere of argon. Desthiobiotin azide 140 was dissolved in MeOH (12 
mg/100uL). The whole solution (100 uL) was added to the reaction vessel. A separate 
aqueous CuSO4 solution was made (100mM) and was used to dissolve the copper (I) 
ligand THPTA (10mg/100 uL). An aliquot of the CuSO4/THPTA solution (20uL, 0.0018 
mmol of Cu and 0.0036 mmol of THPTA) were added to the reaction vessel. Sodium 
ascorbate (10mg, 0.05 mmol ,2.7 eq.) was then added to the reaction vessel as a solid, and 
the reaction was stirred for 16 hours at 23 °C.  The reaction was monitored by HPLC and 
was complete when consumption of the alkyne containing starting material was observed 
(C18, 19 mm x 250 mm, gradient elution: 10% acetonitrile in water (0.1% TFA) to 60% 
acetonitrile in water (0.1% TFA) over 40 min). The completed reaction was then diluted 
in 1 mL of methanol and filtered through a 0.45 uM filter. The reaction was then 
concentrated under reduced pressure to afford 33 mg of a brown film. The film was 
dissolved in 300 uL of methanol and purified by HPLC (C18, 19 mm x 250 mm, gradient 
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elution: 10% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water (0.1% TFA) 
over 40 min, retention time = 21.7 min). The product containing fractions were combined 
and their pH was brought to 12 by the addition of NH4OH (aq) (1 mL). NaCl was then 
added to saturate the aqueous solution. The aqueous solution was then extracted with 
CHCl3 (3 x 5 mL).  The CHCl3 extracts were dried over anhydrous sodium sulfate and 
concentrated under reduced pressure to afford a film on a vial 156 (8mg, 39%), the 
structure of which was confirmed by 1H NMR. 1H NMR (500 MHz, CDCl3): δ 0.98 (t, J 
= 7.1 Hz, 3H), 1.11 (d, J = 6.5 Hz, 3H), 1.21 – 1.52 (m, 6H), 1.60 (dt, J = 22.0, 7.1 Hz, 
4H), 1.76 (d, J = 22.5 Hz, 8H), 2.15 (t, J = 7.5 Hz, 2H), 2.48 (t, J = 6.8 Hz, 2H), 2.55 (q, J 
= 7.1 Hz, 2H), 2.58 – 2.71 (m, 2H), 3.42 (q, J = 5.3 Hz, 2H), 3.48 – 3.74 (m, 20H), 3.78 – 
3.85 (m, 3H), 3.87 – 3.92 (m, 2H), 4.13 – 4.18 (m, 2H), 4.38 (s, 1H), 4.54 – 4.60 (m, 2H), 
4.86 (s, 1H), 5.29 (s, 2H), 5.38 (d, J = 7.4 Hz, 1H), 6.26 (s, 1H), 6.40 (d, J = 5.5 Hz, 1H), 
6.94 (d, J = 8.8 Hz, 1H), 7.06 (d, J = 9.0 Hz, 1H), 7.33 (dd, J = 9.0, 2.2 Hz, 1H), 7.73 – 
7.80 (m, 4H), 7.86 (s, 1H), 7.92 (d, J = 2.2 Hz, 1H), 8.49 (d, J = 5.4 Hz, 1H). 13C NMR 
(126 MHz, CDCl3): δ 194.53, 173.11, 163.24, 162.32, 161.58, 152.16, 149.56, 149.34, 
143.50, 134.90, 132.39, 131.41, 130.82, 128.86, 125.10, 124.39, 121.70, 117.54, 114.47, 
114.26, 99.35, 71.02, 70.85, 70.77, 70.73, 70.64, 70.61, 70.59, 70.30, 70.11, 69.78, 69.69, 
69.57, 67.76, 62.26, 56.14, 53.70, 52.90, 51.54, 50.57, 48.54, 48.43, 39.30, 36.36, 34.52, 
29.65, 29.11, 26.26, 25.49, 24.09, 20.46, 15.98, 11.49. FTIR (thin film) λ (cm-1): 
3433.64, 1644.98, 1604.48, 1578.45. HRMS (ESI) C58H82ClN9O11: Calculated for 
[M+2H]/2 C58H84ClN9O11, 558.7977; found: 558.7990. []D 22 20.3 (c 1.0, CH2Cl2). 
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Chapter 4: Methods 
 
Acid141 189 (306mg, 0.64 mmol, 1.0 eq.) was added to a round bottom flask, 
followed by EDC*HCl (185 mg, 0.96 mmol, 1.5 eq.), and HOBT (130mg, 0.96 mmol, 
1.5 eq.). In a separate flask, amine159 204 (102mg, 0.706 mmol, 1.1 eq.) was dissolved in 
DMF (1.5 mL). Triethylamine (90 uL, 0.64 mmol, 1.0 eq.) was added to the DMF 
solution. The DMF solution was then added to the reaction vessel via a syringe. The 
reaction was stirred for 2.5 hours, until the acid was no longer detected by LC/MS. The 
reaction was concentrated to an oil, which was diluted with Et2O (10 mL). The solution 
was washed with water (2 x 5 mL) to remove any remaining DMF. The organic layer was 
dried over anhydrous MgSO4 and concentrated under reduced pressure to a yield a crude 
white foam (384 mg). The foam was then purified via column chromatography (SiO2, 25 
mm x 120 mm, gradient of increasing MeOH, 3%-5%, in CH2Cl2, maintaining a constant 
1% of NH4OH (aq)). The product was isolated as a white foam 205 (259 mg, 67% yield), 
the structure of which was verified by 1H NMR. TLC (Rf = 0.5, 5:94:1; 
MeOH:CH2Cl2:NH4OH).
 1H NMR (500 MHz, CDCl3) δ 1.45 (s, 9H), 1.59 (m, 2H), 2.36 
(m, 7H), 2.58 (s, 3H), 2.74 (s, 1H), 3.16 – 3.34 (m, 2H), 3.69 (s, 4H), 4.32 (d, J = 94.4 
Hz, 1H), 6.55 (d, J = 55.6 Hz, 1H), 7.17 – 7.23 (m, 3H), 7.24 – 7.31 (m, 6H), 7.40 – 7.45 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 144.77, 129.75, 128.09, 126.86, 66.88, 53.85, 
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30.50, 28.53. FTIR (thin film) λ (cm-1): 3434.6, 1662.34.  HRMS (ESI) C35H45N3O4S: 
Calculated for [M+H] C35H46N3O4S, 604.3209; found: 604.3205. 
 
The carbamate 205 (195 mg, 0.32 mmol, 1.0 eq.) was added to a round bottom 
flask and dissolved in CH2Cl2 (1.2 mL). Trifluoroacetic acid (230 uL) was added to the 
flask, and the reaction was stirred for 24 hours until the starting carbamate was consumed 
as observed via TLC (Carbamate Rf = 0.45, 5:1:94 MeOH:NH4OH:CH2Cl2) (Product Rf = 
0.35, 5:1:94 MeOH:NH4OH:CH2Cl2). The reaction is diluted with CH2Cl2(10 mL) then 
concentrated under reduced pressure to afford a viscous yellow oil. The oil was flashed 
through a plug of SiO2 (5:1:94, MeOH:NH4OH:CH2Cl2) and the filtrate was concentrated 
to a viscous white paste 206 (153 mg, 94%), the structure of which was verified by 1H 
NMR. The 1H NMR of the molecule presents as a mixture of rotamers at a temperature of 
300 K. However, 1H NMR at an elevated temperature observes the coalescence of the 
rotameric mixture. TLC (Rf = 0.35, 5:1:94 MeOH:NH4OH:CH2Cl2). 
1H NMR (500 MHz, 
CDCl3); δ 1.64 (ddt, J = 9.7, 6.9, 3.0 Hz, 2H), 2.16 (s, 3H), 2.32 – 2.43 (m, 6H), 2.49 (dd, 
J = 12.3, 8.2 Hz, 1H), 2.63 – 2.74 (m, 2H), 3.20 – 3.35 (m, 2H), 3.69 (t, J = 4.7 Hz, 4H), 
7.18 – 7.24 (m, 3H), 7.29 (dd, J = 8.5, 6.9 Hz, 6H), 7.40 – 7.47 (m, 6H), 7.57 (t, J = 5.8 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 172.31, 144.64, 129.67, 128.06, 126.88, 67.01, 
66.92, 63.50, 57.39, 53.88, 38.28, 35.26, 34.99, 25.83. FTIR (thin film) λ (cm-1): 
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2929.34, 1669.09, 1508.06. HRMS (ESI) C30H37N3O2S: Calculated for [M+H] 
C30H38N3O2S, 504.2685; found: 504.2695. 
 
 
The amine160 211 (388 mg, 3.1 mmol, 1.0 eq.) and aldehyde161 202 (953 mg, 4.7 
mmol, 1.5 eq.) were added to a round bottom flask. The two compounds were dissolved 
in CH2Cl2 (16 mL) and were stirred at 23 °C for 10 minutes. Sodium 
triacetoxyborohydride was added to the flask in one portion and the reaction was stirred 
for 48 hours. The reaction was quenched by dilution with CH2Cl2 (20 mL), and 2N 
NaOH (aq) (30 mL). The biphasic mixture was stirred for 60 minutes. The layers of the 
biphasic mixture were separated, and the aqueous layer was extracted with CH2Cl2 (2 x 
20 mL). The combined organic fractions were dried over anhydrous sodium sulfate and 
concentrated under reduced pressure to afford a crude paste (1.12g). The crude paste was 
then purified by column chromatography (SiO2, 35 mm x 130 mm, 3:1:96, 
MeOH:NH4OH:CH2Cl2) to afford a solid 212 (820 mg, 84%), the structure of which was 
verified by 1H NMR. MP (CH2Cl2) 153-155 °C. TLC (Rf = 0.5, 4:95:1, 
MeOH:NH4OH:CH2Cl2).
 1H NMR (500 MHz, CDCl3 δ 7.83 (dd, J = 5.4, 3.0 Hz, 2H), 
7.70 (dd, J = 5.5, 3.0 Hz, 2H), 3.76 (t, J = 6.9 Hz, 2H), 3.19 (d, J = 2.5 Hz, 2H), 2.42 (t, J 
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= 6.9 Hz, 8H), 2.18 (t, J = 2.4 Hz, 1H), 1.86 (p, J = 6.9 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 168.63, 133.97, 132.50, 123.32, 79.01, 73.23, 56.15, 53.11, 51.96, 46.93, 36.82, 
25.45. FTIR (thin film) λ (cm-1): 3272.61, 2937.06, 2814.60, 2369.48, 1771.30, 1706.69. 
HRMS (ESI) C18H21N3O2: Calculated for [M+H] C18H22N3O2, 312.1728; found: 
312.1719. 
 
Phthalimide 212 (820 mg, 2.64 mmol, 1.0 eq.) was added to a screwcap vial, and 
placed under an atmosphere of argon. The phthalimide was dissolved in EtOH (4 mL), 
and hydrazine (190 uL, 4.0 mmol, 1.5 eq.) was added via a syringe. The reaction was 
sealed and heated to reflux in an oil bath preset to 94 °C. The reaction was heated for 2 
hours, where after 30 minutes a white precipitate begins to form. The reaction was 
observed to be complete by the loss of phthalimide starting material, as observed via 
LC/MS. The reaction was cooled to 23 °C and diluted with EtOH (4 mL). The reaction 
was filtered through a pad of Celite™. The white solid removed by filtration was washed 
with EtOH (2 mL), and the combined filtrate was concentrated under reduced pressure to 
yield a paste (213) (429 mg, 90%), the structure of which was verified by 1H NMR. MP 
(EtOH) 100-105 °C TLC (Rf = 0.0, compound immobile on silica). 1H NMR (500 MHz, 
CDCl3) δ 3.29 (d, J = 2.5 Hz, 2H), 2.74 (t, J = 6.8 Hz, 2H), 2.69 – 2.35 (m, 10H), 2.23 (t, 
J = 2.4 Hz, 1H), 1.63 (dd, J = 16.1, 9.0 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 79.02, 
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73.32, 56.58, 53.31, 52.10, 46.99, 41.00, 30.69. FTIR (thin film) λ (cm-1): 2923, 2851, 
2822, 1577, 1460, 1335,1314, 1147. HRMS (ESI) C10H19N3: Calculated for [M+H] 
C10H20N3, 182.1657; found: 182.1658.  
 
 
N-Methyl-N-Boc-S-Trt-Cys-OH141 189 (250 mg, 0.52 mmol, 1.0 eq.) was added to a 
round bottom flask, followed by EDC (150 mg, 0.79 mmol, 1.5 eq.) and HOBT (105mg, 
0.79 mmol, 1.5 eq.). The flask was placed under an atmosphere of argon. In a separate 
flask, the amine 213 (107 mg, 0.58 mmol, 1.1 eq.) was placed under an argon atmosphere 
and dissolved in DMF (1.5 mL). Triethylamine (70 uL, 0.52 mmol, 1.0 eq.) was added to 
the DMF solution, and vortexed for 30 seconds. The DMF solution was then added via a 
syringe to the original reaction vessel. The reaction was stirred for 3 hours until the acid 
was consumed as observed by LC-MS. The reaction was then quenched by pouring onto 
water (20 mL). Upon addition to the water, a white precipitate was observed. Addition of 
EtOAc (20 mL) was added to solubilize the precipitate. The biphasic solution was 
separated, and the aqueous fraction was extracted with EtOAc (2 x 20 ml). The combined 
organic fractions were washed with water (2 x 20 mL) and brine (1 x 60 mL). The 
organic layer was then dried over anhydrous sodium sulfate and concentrated under 
reduced pressure yielding crude white foam. The crude product was then purified by 
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column chromatography (SiO2, 35 mm x 150 mm, gradient elution 2%, 3%,4%, and 5% 
MeOH in CH2Cl2, increased every 100 mL), yielding a white foam (214) (279 mg, 83%), 
the structure of which was verified by 1H NMR. The 1H NMR of the molecule presents as 
a mixture of rotamers at a temperature of 300 K. However, 1H NMR at an elevated 
temperature observes the coalescence of the rotameric mixture. TLC (Rf = 0.4, 4:95:1, 
MeOH:NH4OH:CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 8.22 (s, 1H), 7.33 (d, J = 6.5 Hz, 
12H), 7.28 – 7.21 (m, 3H), 4.28 (s, 1H), 3.67 (s, 2H), 3.23 (d, J = 2.4 Hz, 2H), 3.11 – 
2.88 (m, 9H), 2.68 (dd, J = 12.3, 5.4 Hz, 1H), 2.61 (s, 3H), 2.48 – 2.21 (m, 11H), 1.53 (d, 
J = 8.8 Hz, 2H), 1.39 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 144.71, 129.68, 128.02, 
126.80, 79.06, 73.26, 66.82, 57.67, 56.69, 56.13, 53.20, 52.00, 46.90, 38.10, 36.55, 31.12, 
30.37, 28.50, 26.37. FTIR (thin film) λ (cm-1): 2933.20, 1683.55, 1507.1. HRMS (ESI) 
C38H48N4O3S: Calculated for [M+H] C38H49N4O3S, 641.3525; found: 641.3510. 
 
The carbamate 214 (200 mg, 0.31 mmol, 1 eq.) is added to a round bottom flask 
and placed under an atmosphere of argon. CH2Cl2 (3 mL) is added to the flask via a 
syringe to dissolve the carbamate. While stirring, TFA (3 mL) is added to the flask via a 
syringe, and the reaction is stirred at 23 °C until the carbamate starting material has 
disappeared as observed via LC-MS. Once the reaction was complete, the solvent was 
removed under reduced pressure to afford a crude paste. The paste was dissolved in 
CH2Cl2 (10 mL) and conc. NH4OH (2mL) was added. The reaction was vortexed for 30 
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seconds, and brine (10 mL) was added to the reaction mixture. The now biphasic mixture 
was separated, and the resulting aqueous phase was extracted with CH2Cl2 (2 x 10 mL). 
The resulting organic layers were combined and dried over anhydrous sodium sulfate. 
The organic layer was then concentrated under reduced pressure to afford the product as a 
translucent gel (215) (152mg, 90%). TLC (Rf = 0.1, 4:95:1, MeOH:NH4OH:CH2Cl2). 1H 
NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.44 – 7.39 (m, 6H), 7.28 (dd, J = 8.4, 6.8 Hz, 
6H), 7.24 – 7.19 (m, 3H), 3.34 – 3.20 (m, 4H), 2.72 – 2.41 (m, 12H), 2.26 (d, J = 2.4 Hz, 
1H), 2.15 (s, 3H), 1.68 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 172.42, 144.70, 129.74, 
128.12, 128.08, 126.93, 73.46, 66.97, 63.51, 56.78, 53.18, 51.68, 46.92, 38.23, 35.27, 
35.04, 26.03. FTIR (thin film) λ (cm-1): 3302.5, 2936.09, 2359.48, 1669.09, 1519.63. 
HRMS (ESI) C33H40N4OS: Calculated for [M+H] C33H41N4OS, 541.3001; found: 
541.3026 
 
 
CyOH139 (173) (50 mg, 0.1 mmol, 1.0 equiv). is added to a round bottom flask 
and placed under an atmosphere of argon. In a separate flame dried round bottom flask 
solid trisphosgene (30 mg, 0.1 mmol, 1.0 equiv.) is added and placed under an 
atmosphere of argon. The trisphosgene containing flask is cooled in an ice bath, and 
CH2Cl2 (1 mL) is added via a syringe. CH2Cl2 (4 mL) is added to the flask containing 
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CyOH (173), and triethylamine (14 uL, 0.19 mmol, 1.0 equiv.) is added as a solution in 
CH2Cl2. The solution of compound CyOH (173) and triethylamine is vortexed until the 
solution becomes homogeneous. A syringe pump is used to add the solution of CyOH 
(173) to the flask of triphosgene over 30 min. The solvent is then removed via a stream of 
argon and a 40 °C oil bath. The resulting crude mixture is then carried forward to the 
acylation reaction. The crude reaction mixture is dissolved in CH2Cl2 and stirred in an ice 
bath. The amine 206 (54mg, 1.0 mmol, 0.5 equiv.) is dissolved in CH2Cl2 and 
triethylamine (14 uL, 0.19 mmol, 1.0 equiv.) is added to the solution. The amine 
containing solution is then added dropwise to the crude reaction, while stirring in an ice 
bath. The reaction is then stirred for 30 minutes and monitored via LC-MS, where 
consumption of the crude triphosgene reaction intermediates can be monitored. Once the 
reaction is complete, the solvent is removed under reduced pressure to afford a crude 
mixture containing acylated intermediate as observed via LC-MS. The solvent is removed 
under reduced pressure to afford a crude purple paste. 
Crude intermediate (0.095 mmol, 1.0 eq.) was dissolved with CH2Cl2 (5mL) in 
round bottom flask under an atmosphere of argon. To the reaction TFA(1.5 mL), and 
triisopropylsilane (31 uL, mmol, 5.0 eq) were added to the reaction with a syringe. The 
reaction was stirred for ten minutes and verified complete via LC/MS (Mass -243 for loss 
of trityl). The reaction was then concentrated under reduced pressure to remove excess 
TFA. The crude reaction mixture was then dissolved in CH2Cl2 (5 mL) and stirred at 23 
°C. Palmitoyl chloride was added to the flask via a syringe, and the reaction was stirred 
for two hours and monitored via LC/MS. Observe the product mass, the starting dye 
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CyOH, and palmitoylated CyOH, therefore the reaction was quenched and worked up. 
The reaction was concentrated under reduced pressure to a blue paste and dissolved in 
CH2Cl2 (20 mL). The organic solution was washed with 50% saturated NaHCO3 (20 
mL). The layers are separated, and organic layer is collected. The remaining aqueous 
phase is extracted with CH2Cl2 (1x20 mL). The combined organic layers were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to afford a blue 
purple solid (240 mg). The blue solid was triturated with diethyl ether, which removes the 
palmitoylated CyOH side product from the crude reaction mixture. The remaining solid 
was solubilized in methanol and 50% MeCN: 50% Water (0.1% TFA). The solution is 
filtered through a 0.22 um filter, and purified via HPLC (RPHPLC, C18, 19 mm X 250 
mm, 45%MeCN to 99% MeCN in water (0.1% TFA) over 30 minutes). Pure product is 
obtained as a purple film (198) (22 mg, 20% over three steps). The structure of which 
was verified by 1H NMR and HRMS. The compound is a mixture of rotamers at 300 K 
which coalesce at 350 K. 1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 15.2 Hz, 1H), 8.15 
(s, 1H), 7.73 (t, J = 7.9 Hz, 2H), 7.62 – 7.48 (m, 3H), 7.42 (s, 1H), 7.34 (s, 1H), 7.15 (d, J 
= 8.4 Hz, 1H), 6.67 (d, J = 15.2 Hz, 1H), 4.71 (s, 1H), 4.43 (d, J = 7.3 Hz, 2H), 3.79 (s, 
4H), 3.61 – 3.31 (m, 12H), 3.28 – 3.16 (m, 10H), 3.10 – 2.65 (m, 7H), 2.59 (s, 2H), 1.95 
– 1.74 (m, 13H), 1.58 (s, 2H), 1.34 – 1.13 (m, 29H), 1.02 (d, J = 8.3 Hz, 3H), 0.91 – 0.80 
(m, 3H).13C NMR (126 MHz, MeOD) δ 200.55, 180.55, 172.00, 161.59, 156.07, 154.97, 
154.56, 147.73, 143.92, 142.98, 132.78, 131.40, 130.54, 129.50, 129.27, 124.01, 121.15, 
120.70, 116.11, 114.74, 110.96, 106.85, 65.15, 62.56, 56.04, 53.24, 52.59, 48.09, 44.93, 
37.42, 35.22, 33.23, 30.95, 30.92, 30.63, 30.45, 30.12, 28.41, 28.39, 27.09, 25.15, 25.07, 
23.89, 22.64, 21.66, 14.60, 11.71.  FTIR (thin film) λ (cm-1): 2925, 2853, 1719, 1685, 
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1578, 1535, 1458, 1371, 1285, 1255, 1205, 1186, 1173, 1122, 1064. HRMS (ESI) 
C56H81N4O6S: Calculated for [M
+] C56H81N4O6S
+, 937.5877; found: 937.5887. 
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CyOH139 (173) (100mg, 0.2 mmol, 1.0 equiv). is added to a round bottom flask and 
placed under an atmosphere of argon. In a separate flame dried round bottom flask solid 
trisphosgene (60 mg, 0.2 mmol, 1.0 equiv.) is added and placed under an atmosphere of 
argon. The trisphosgene containing flask is cooled in an ice bath, and THF (1 mL) is 
added via a syringe. A 1:1 mixture of CH2Cl2:THF (8.5 mL) is added to the flask 
containing CyOH(173), and triethylamine 28 uL, 0.4 mmol, 2.0 equiv.) is added as a 
solution in THF. The solution of compound CyOH (173) and triethylamine is vortexed 
until the solution becomes homogeneous. A syringe pump is used to add the solution of 
CyOH (173) to the flask of triphosgene over 2 hours. The solvent is then removed via a 
stream of argon and a 40 °C oil bath. The resulting crude mixture is then carried forward 
to the acylation reaction.  
The crude reaction mixture is dissolved in CH2Cl2 and stirred in an ice bath. The 
amine (215) (54mg, 1.0 mmol, 0.5 equiv.) is dissolved in CH2Cl2 and triethylamine (14 
uL, 0.19 mmol, 1.0 equiv.) is added to the solution. The amine containing solution is then 
added dropwise to the crude reaction, while stirring in an ice bath. The reaction is then 
stirred for 30 minutes and monitored via LC-MS, where consumption of the crude 
triphosgene reaction intermediates can be monitored. Once the reaction is complete, the 
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solvent is removed under reduced pressure to afford a crude mixture containing acylated 
intermediate as observed via LC-MS. The solvent is removed under reduced pressure to 
afford a crude purple paste. 
Crude intermediate is dissolved in CH2Cl2 (2 mL). Trifluoroacetic acid (2 mL) is 
then added to the reaction mixture, and triisopropylsilane (100 uL, 0.5 mmol, 5.0 equiv.) 
is added as well. The reaction mixture is stirred for 30 minutes, and monitored via LC-
MS. Once the trityl-protected intermediate is consumed, the reaction is diluted with 
CH2Cl2 (10 mL) and concentrated under reduced pressure to afford a crude purple paste. 
The paste is dissolved in CH2Cl2 (1.5 mL) and stirred in at room temperature. To the 
solution, palmitoylchloride (2.5 mL) is added via a syringe, and the reaction is stirred 
until the free thiol is mostly consumed after stirring for 16 hours. The reaction is diluted 
with methanol and stirred for 30 minutes to quench excess palmitoyl chloride. The 
reaction is then concentrated to a crude purple solid. Trituration of the purple solid with 
Et2O removed methyl palmitate and CyOH which reacted with palmitoyl chloride. The 
remaining solid (125 mg) is then dissolved in acetonitrile (500 uL), diluted in half with a 
solution of (50% acetonitrile, 50% water, containing 1% TFA) and filtered through a 0.45 
um filter. This mixture is then purified via RPHPLC (C18, 19 mm x 250 mm, 45% 
MeCN to 99%MeCN over 30 minutes). The product 218 is isolated as a purple film (25 
mg, 19% over 3 steps), the structure of which was determined by NMR and HRMS.  The 
molecule is observed by NMR as a mixture of rotamers, which coalesce at 350 K. 1H 
NMR (500 MHz, DMSO) δ 8.64 (d, J = 15.2 Hz, 1H), 8.13 (s, 1H), 7.72 (t, J = 6.8 Hz, 
2H), 7.57 (dd, J = 11.1, 8.1 Hz, 2H), 7.50 (t, J = 7.5 Hz, 1H), 7.41 (s, 1H), 7.33 (d, J = 
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2.2 Hz, 1H), 7.15 (dd, J = 8.4, 2.2 Hz, 1H), 6.67 (d, J = 15.1 Hz, 1H), 4.71 (s, 1H), 4.43 
(t, J = 7.3 Hz, 2H), 3.52 (dd, J = 14.0, 5.4 Hz, 1H), 3.45 – 3.34 (m, 3H), 3.31 – 3.15 (m, 
6H), 3.10 – 2.94 (m, 6H), 2.87 – 2.68 (m, 8H), 2.60 (t, J = 7.3 Hz, 2H), 2.09 (s, 2H), 1.91 
(q, J = 7.5 Hz, 6H), 1.80 (s, 6H), 1.59 (q, J = 7.4 Hz, 2H), 1.35 – 1.15 (m, 25H), 1.04 (t, J 
= 7.4 Hz, 3H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 200.44, 180.43, 
171.94, 162.58, 161.41, 155.92, 154.82, 154.43, 154.41, 147.59, 143.80, 142.85, 132.64, 
131.27, 130.42, 129.40, 129.16, 123.89, 121.03, 120.51, 119.26, 115.98, 114.63, 110.89, 
106.77, 77.99, 76.02, 66.93, 62.50, 60.97, 55.36, 53.02, 52.48, 47.95, 46.65, 44.79, 37.33, 
35.21, 33.10, 30.83, 30.80, 30.75, 30.60, 30.55, 30.51, 30.32, 30.00, 28.25, 26.96, 26.11, 
25.39, 25.01, 23.76, 22.52, 21.53, 15.46, 14.47, 11.58. FTIR (thin film) λ (cm-1): 3308, 
2924, 2853, 1716, 1682, 1534, 1458, 1442, 1426, 1371, 1285, 1254, 1206, 1186, 
1286,1064. HRMS (ESI) C59H84N5O5S: Calculated for [M
+] C59H84N5O5S, 
974.6193.5877; found: 974.6185. 
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 The alkyne 218 (8 mg, mmol, 1.0 equiv.) was added to a screwcap vial with a stir 
bar. BHQ3 221 (6mg, mmol, 1.5 equiv.) was added to the screwcap vial. The vial 
contents were placed under an atmosphere of argon and dissolved in DMSO (200 uL). 
Water was added to the screwcap vial, and the vial contents were vortexed for 30 
seconds. Cu(II)SO4 (40 uL of 0.1 M aqueous solution, mmol, 0.2 equiv.) was added via 
the use of a pipet. Sodium ascorbate (40 uL of 0.1 M aqueous solution, mmol, 0.2 equiv.)  
was added to the reaction via a pipet and the screwcap vial was vortexed for 30 seconds. 
The reaction was stirred for two hours until the alkyne was consumed as observed by LC-
MS. The reaction was diluted 1:1 with a mixture of water and acetonitrile (1 mL). The 
resulting solution was filtered through a 0.45 um filter, and purified by reverse phase 
HPLC (C18, 19 mm x 250 mm, 30 min gradient of increasing MeCN in water (0.1% 
TFA): 45%-99% over 30 minutes, 13 mL/min flow rate). The product 222 was isolated as 
a purple-blue film, the structure of which was determined by 1H NMR. The molecule at 
300 K, as observed by NMR, was found to be a mixture of rotamers, which coalesce at a 
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temperature of 340 K. 1H NMR (500 MHz, DMSO-d6) δ 8.62 (d, J = 15.2 Hz, 1H), 8.43 
(d, J = 9.0 Hz, 1H), 8.25 – 8.09 (m, 3H), 8.06 – 7.85 (m, 6H), 7.82 – 7.68 (m, 6H), 7.57 
(t, J = 8.8 Hz, 2H), 7.49 (t, J = 7.4 Hz, 1H), 7.41 (s, 1H), 7.30 (t, J = 4.2 Hz, 2H), 7.13 (d, 
J = 8.5 Hz, 1H), 6.81 (d, J = 8.9 Hz, 2H), 6.67 (d, J = 15.1 Hz, 1H), 5.80 (s, 1H), 4.64 (t, 
J = 6.1 Hz, 3H), 4.43 (t, J = 7.4 Hz, 2H), 4.00 (t, J = 6.2 Hz, 2H), 3.80 (s, 2H), 3.62 (s, 
3H), 3.51 – 3.42 (m, 1H), 3.33 (dd, J = 14.0, 9.8 Hz, 1H), 3.15 (d, J = 6.5 Hz, 2H), 3.08 – 
2.66 (m, 19H), 2.58 (d, J = 7.2 Hz, 2H), 1.90 (dt, J = 13.8, 7.1 Hz, 4H), 1.79 (s, 9H), 1.56 
(s, 2H), 1.34 – 1.11 (m, 39H), 1.02 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, CD3CN) δ 199.95, 179.81, 169.61, 161.33, 157.23, 156.36, 154.96, 154.35, 
154.33, 153.96, 147.37, 145.51, 144.62, 143.49, 143.47, 142.64, 140.55, 139.33, 136.95, 
135.52, 135.15, 133.79, 133.69, 132.78, 132.75, 132.58, 132.38, 131.03, 130.07, 129.10, 
128.95, 128.70, 128.54, 127.26, 126.75, 125.25, 123.66, 121.20, 120.96, 120.59, 120.32, 
120.03, 115.76, 115.61, 114.32, 112.53, 112.42, 112.37, 110.63, 106.16, 92.93, 92.89, 
62.35, 60.51, 52.36, 52.05, 49.88, 48.58, 47.85, 44.67, 44.55, 38.35, 36.76, 35.31, 32.68, 
30.44, 30.41, 30.37, 30.35, 30.22, 30.20, 30.12, 30.11, 30.08, 29.95, 29.53, 28.28, 28.16, 
28.10, 28.05, 26.57, 26.38, 24.85, 23.44, 22.06, 21.06, 14.45, 13.95, 11.59, 11.57. FTIR 
(thin film) λ (cm-1): 2921, 1680, 1535, 1460, 1284, 1186. HRMS (ESI) C90H116N14O5S: 
Calculated for [M2++H+] C90H117N14O5S
3+, 501.9684; found: 501.9672. 
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